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i SUMMARY  
Osteogenesis imperfecta (OI) is an inherited disorder characterized by increased bone fragility, with 
severity ranging from very mild to lethal. Mutation in COL1A1 and COL1A2, which code for type I 
collagen, are identified in the majority (~85%) of patients. 
Research to identify the cause of OI in individuals without identified mutations has focused on severe 
and lethal forms of the disease. By focusing on patients not fulfilling the current definition of “severe” 
adopted by the NHS funded Highly Specialised OI Service for children with severe, complex and 
atypical OI, we aimed to contribute to the current knowledge of the molecular basis of OI.  
We employed a number of sequencing strategies to achieve this: targeted exome, Sanger and whole 
exome analysis. Results in this thesis have established that these approaches, together with 
appropriate functional analysis, can identify novel causes of OI and bone fragility.  
We identified four patients with variable presentation and mutations in BMP1 and, importantly, 
highlight a risk of causing delayed healing, increased stiffness or atypical fractures by anti-resorptive 
treatment. We report the third occurrence of a c.1178A>G;p.Tyr393Cys P4HB mutation and describe 
what appears to be an emerging, distinctive radiological phenotype: meta-diaphyseal fractures with 
metaphyseal sclerosis.  
We have expanded the clinical spectrum associated with NBAS mutations to include bone fragility 
that may present as atypical OI. Submission of a UKGTN gene dossier has ensured rapid transition of 
this research finding into the patient diagnostic pathway.  
In addition, we have identified a number of novel genes and pathways that warrant further 
investigation, namely SLC38A10, SRCAP, UGGT1, UBASH3B, SULF2-POSTN, and voltage-gated 
sodium channel genes. Future work will focus on elucidating the significance of these findings and the 
development of tools to facilitate analysis and interpretation of genetic data as whole genome 
sequencing becomes more readily available for OI patients. 
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ii INTRODUCTION 
ii.i Function of Bone: 
Bone has several functions within the human body. The skeleton provides structural support, protects 
vital organs and allows movement. Bones provide an environment for the bone marrow to enable 
haemopoesis and act as a reservoir for minerals such as calcium, phosphorus and magnesium.  
Bone also acts as a reservoir for growth factors and cytokines such as insulin-like growth factors 
(IGF), transforming growth factor-β (TGFβ) and bone morphogenetic proteins (BMP). Bone also helps 
maintain the body’s acid–base balance. 
Bone strength depends largely on bone mass (50-70% of bone strength), but material properties, 
geometry and microstructure are also important.   
ii.ii Bone structure: 
Bones consist of two tissue types:  the cortical (compact) bone which is dense and tough and 
surrounds the marrow space and the trabecular (cancellous) bone which is composed of a 
honeycomb-like network of trabeculae. The boundary between the cortical and trabecular bone is 
generally difficult to define, particularly in the metaphyses where the trabeculae merge to form the 
cortex (Figure 1). 
A dense connective tissue layer, the periosteum, surrounds the outer surface of cortical bone except 
at joints where bone is lined by cartilage. The periosteal attachment to bone is stronger towards the 
ends of the bone, around the metaphyses and growth plates, than it is in the diaphyseal (mid-shaft) 
region. In relation to OI, this difference in immediate local support may help explain why metaphyseal 
fractures are rare compared to those in the diaphysis, despite the bone being relatively fragile. 
The periosteum is vascular, contains nerves, and is rich in osteoblasts and osteoclasts. It plays an 
important role in bone formation, growth and fracture repair.  
Bone is composed of three cell types (osteoblasts, osteocytes and osteoclasts), collagen and 
noncollagenous structural proteins (including proteoglycans, sialoproteins, gla-containing proteins and 
the 2HS-glycoprotein, a plasma protein synthesized in the liver that is enriched in bone matrix), called 
osteoid, and inorganic mineral salts containing calcium and phosphate that are deposited within the 
bone matrix and give the bone its hardness and rigidity. There is also increasing evidence that 
haemopoietic lineage cells, in particular macrophages and lymphocytes act within the bone 
environment and cross-talk with cells that directly regulate bone mass and structure (Weitzmann 
2017) 
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Figure 1 Bone cross-section diagram. (Pbroks13, CC BY 3.0) 
https://commons.wikimedia.org/w/index.php?curid=5188772) 
ii.iii Osteoblasts  
Osteoblasts originate from mesenchymal stem cells (MSC) and are responsible for bone matrix 
synthesis and subsequent mineralisation. Differentiation of MSCs to osteoblasts is regulated by the 
expression of a number of genes including Runt-related transcription factor 2 (RUNX2), distal-less 
homeobox 5 (DLX5) and Osterix (OSX). RUNX2 is generally described as a master gene in 
osteoblast differentiation and has been shown to upregulate other osteoblast-related genes such as 
those encoding alkaline phosphatase (ALP), osteocalcin (OCN), bone sialoprotein (BSP) and type I 
collagen (COL1A1/1A2) (Bruderer, Richards et al. 2014). Expression of bone morphogenic proteins 
(BMPs) and Wingless (Wnt) signalling pathway proteins also regulate the commitment of MSCs 
towards osteoblasts. 
Osteoblasts synthesise bone matrix in two main steps, the first step being secretion of an organic 
matrix consisting of collagens (mainly type I collagen), non-collagenous proteins (such as osteocalcin, 
osteonectin, bone sialoprotein II and osteopontin) and proteoglycans including decorin and biglycan. 
Subsequently, matrix mineralization by hydroxyapatite, a crystalline complex of phosphate and 
calcium ions, occurs. Osteoblasts that become embedded in the newly forming matrix give rise to 
osteocytes.  
ii.iv Osteocytes  
During the osteoblast/osteocyte transition morphological and ultra-structural changes occur.  In 
addition, down-regulation of genes such as BSPII, OCN, ALP and COL1A1/1A2 occurs. In contrast 
sclerostin (SOST) and dentine matrix protein (DMP1) are highly expressed. 
In the osteocyte, organelles such as rough endoplasmic reticulum (ER) and Golgi apparatus are 
reduced in number and the nucleus to cytoplasmic ratio is increased when compared to osteoblasts. 
A network of plasma membrane extensions (filopodia) develop and radiate into microscopic canals in 
the ossified bone called canaliculi. These filopodia facilitate communication of osteocytes with each 
other and also with other cells types, such as osteoblasts, via the transport of small signalling 
molecules such as prostaglandins. Cell-cell communication is also achieved by the flow of interstitial 
fluid between the osteocytes filopodia and the bone canaliculi. It is through this process that 
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osteocytes are thought to act as mechanosensors and direct bone resorption or formation processes, 
although the exact mechanisms by which this is achieved have not been identified (Florencio-Silva, 
Sasso et al. 2015). 
ii.v Osteoclasts  
Osteoclasts are multinucleate cells that originate from haemopoetic stem cells. A critical 
osteoclastogenesis regulator is RANK ligand (RANKL). RANKL is secreted by osteoblasts, osteocytes 
and stromal cells and is itself regulated by osteoprotegerin (OPG). OPG binds RANKL and prevents it 
binding to its receptor, RANK, hence inhibiting osteoclastogenesis (Florencio-Silva, Sasso et al. 
2015). 
Osteoclasts function in the resorption of mineralised bone and are found in resorption cavities called 
Howship’s lacunae. Here they secrete hydrogen ions, creating an acidic pH that dissolves the 
mineralized bone matrix. Hydrolytic enzymes such as cathepsin K and matrix metalloproteases are 
also released in order to digest the organic matrix components. 
ii.vi Bone Modelling  
Modelling is the process by which bones respond to physiologic or mechanical influences. The 
process is responsible for changes to bone size and shape and ensures the appropriate gain in 
skeletal mass during growth. For modelling to occur there needs to be independent action of 
osteoblasts and osteoclasts on separate bone surfaces.  Bone modelling is less frequent than 
remodelling in adults.  
ii.vii Bone Remodelling 
This process ensures there is bone turnover while maintaining bone mass in the mature skeleton. It 
requires the coordination of bone resorption and formation by osteoblasts and osteoclasts 
respectively. Remodelling is influenced by many local and systemic factors including cytokines, 
hormones, chemokines and mechanical stimulation. It involves the continuous resorption of small 
compartments of old bone, replacement with newly synthesized matrix (osteoid), and subsequent 
mineralization of the matrix to form new bone (Figure 2). Known local control factors influencing 
remodelling include the RANK/RANKL regulation of osteoclast formation, sclerostin (SOST) 
production in osteocytes inhibiting bone formation, and Wnt signalling in bone and immune cells, 
including macrophages and lymphocytes (Martin 2017). 
The remodelling process controls the repair of bone following injuries like fractures and also prevents 
accumulation of micro-damage that occurs during normal activity, possibly through changes in fluidic 
shear stress stimulating osteocyte signalling. Remodelling responses due to mechanical loading 
ensure that bone is added where needed and removed where it is not required, a process that helps 
to maintain bone strength as well as mineral homeostasis.  
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Figure 2 Bone remodelling. 
Different cell types originate from either the hematopoietic or mesenchymal lineages. Osteocytes regulate both 
resorption by osteoclasts and formation by osteoblasts. Bone-lining cells and mesenchymal stromal cells can 
differentiate into osteoblasts or adipocytes. HSC, hematopoietic stem cell; MSC, mesenchymal stromal cell. Figure 
and legend adapted from Lee et al (Lee, Guntur et al. 2017) 
 
ii.viii Regulation of Bone Metabolism 
Ninety nine percent of the body’s calcium and 85% of phosphorus is contained within the bones. 
Regulation of bone mineral metabolism results from the interaction of parathyroid hormone (PTH), 
calcitonin and vitamin D in the gastrointestinal (GI) tract, the kidneys and in bone by osteoblasts and 
osteoclasts. 
ii.viii.i Parathyroid Hormone (PTH) 
Parathyroid hormone, an 82 amino acid protein, is secreted from the parathyroid glands in response 
to low levels of serum calcium which is monitored through cell surface calcium sensing receptors 
(CSR). PTH regulates both serum calcium and phosphorus levels through its action on bone, kidneys 
and the GI tract. In bone, PTH exhibits its effects through osteoblasts and thus indirectly the 
stimulation of osteoclastic bone resorption via the RANK-OPG pathway, releasing calcium (and 
phosphate) from mineralised bone tissue.  
In the kidneys, PTH increases the reabsorption of calcium and inhibits reabsorption of phosphate. 
PTH also increases the absorption of calcium in the GI tract by increasing production of activated 
vitamin D in the kidneys through up-regulation of 25-hydroxyvitamin D 1-alpha-hydroxylase and 
subsequent absorption of calcium via calbindin. 
 
 
6 
 
ii.viii.ii Calcitonin 
Calcitonin is secreted from the thyroid gland in response to hypercalcaemia. Its main function is to 
inhibit osteoclast-mediated bone resorption and also results in reduced resorption of calcium and 
phosphorus in the kidneys. 
ii.viii.iii Vitamin D 
The active metabolite of Vitamin D, 1,25 dihydroxyvitamin D, increases calcium and phosphate 
absorption in the GI tract, providing mineral substrate for the mineralization of osteoid. It also acts with 
PTH to increase osteoclast activity. In addition vitamin D also regulates transcription of several bone 
proteins, most notably osteocalcin, type I collagen and alkaline phosphatase. 
ii.viii.iv Other Factors 
In addition to the hormones described above, many other hormones play a role in bone metabolism. 
These include gonadal steroids, such as oestrogen and testosterone that influence skeletal 
development and help maintain bone mass; growth hormones, insulin and androgens that promote 
skeletal growth and maturation; and thyroid hormones that can stimulate both synthesis and 
mineralisation of osteoid by osteoblasts and increase the number of osteoclasts.  
 Stimulate bone formation 
Decrease Bone 
formation 
Stimulate bone 
resorption 
Inhibit bone 
resorption 
Growth 
factors 
BMP-2, BMP-4, BMP-6, 
BMP-7,IGF-I, IGF-II, TGF-
β, FGF, and PDGF 
 
TNF, EGF, PDGF, 
FGF, M-CSF, and 
GM-CSF 
 
Cytokines IL-4,IL-13, IFN, and OPG  
IL-1, IL-6, IL-8, IL-11, 
PGE 2, PGE1, PGG2, 
PGI2,and PGH2 
IFN-y IL-4 
Hormones 
Growth hormone 
Vitamin D metabolites 
Androgens 
Insulin 
Low-dose PTH/PTHrP 
Progestogens 
Glucocorticoids 
PTH/PTHrP 
Glucocorticoids 
thyroid hormones 
High-dose vitamin D 
Calcitonin 
Estrogens 
Table 1 Hormones, growth factors and cytokines that influence bone metabolism and remodelling. 
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ii.ix Local Regulation of Bone Remodelling 
Bones also contain many growth factors, including BMP and TGF-β, which are not only vital for bone 
development but play an important role in the local regulation of bone remodelling. These additional 
regulators of bone metabolism are summarised in Table 1.  
The major signalling pathways in bone formation are: 
Insulin-like Growth Factor I and II (IGF1 & IGFII) 
Insulin-like Growth Factor I and II (IGF1 & IGFII) are polypeptides that are synthesised in the liver and 
osteoblasts. They increase collagen production in the bone by increasing osteoblast numbers and 
function. IGFBII in particular is important during embryogenesis. The expression of IGFI and IGFII is 
regulated by growth hormone, oestrogen, progesterone (which increase expression) and 
glucocorticoids (which inhibits expression). IGF1 & IGFII are linked to their respective binding proteins 
(IGFBP) which themselves can influence bone remodelling activity (Conover 2008).  
Transforming growth factor beta (TGFβ) and Bone morphogenic protein (BMP) 
TGFβ/BMP signalling has a fundamental role in both embryonic skeletal development and in bone 
homeostasis. TGFβ/BMP signalling inhibits bone degrading enzymes such as metalloproteinase 
(MM), reduces osteoclast differentiation and activity, and strongly promotes osteoblast differentiation 
(Wu, Chen et al. 2016) 
Platelet derived growth factor (PDGF) 
PDGF stimulates osteoblast or osteoprogenitor cell (MSC) activity and is known to be up regulated 
following bone fracture. The current view is that PDGF contributes to bone repair by enabling 
osteoclasts to control osteoblast chemotaxis, however the exact mechanism by which this occurs 
remains to be elucidated (Caplan and Correa 2011). 
 
 
Figure 3 The role of FGFR1-3 in osteoblast differentiation.  
The effect of FGFR3 on osteogenesis is unclear (marked by dotted lines).Figure adapted from (Su, Jin et al. 2014) 
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Fibroblastic growth factor (FGF) 
The FGF/fibroblast growth factor receptor (FGFR) signalling pathway is essential for bone 
development, maintenance of homeostasis and regulation of phosphate levels. Multiple FGFs and 
FGFRs are also expressed during fracture repair (Su, Jin et al. 2014). 
FGFR1 is believed to promote the differentiation of mesenchymal progenitors into pre-osteoblasts, but 
inhibit the proliferation of MSCs. It also inhibits the maturation and mineralization of osteoblasts. 
FGF2 is thought to positively modulate osteoblast differentiation and bone formation, whereas there is 
conflicting data concerning the effects of FGF3 signalling (Figure 3). 
ii.x Bone Matrix 
The bone matrix is an organized frame-work of organic and inorganic material that provides 
mechanical support and has a key role in the regulation of bone cell activity. It consists of 65-70% 
inorganic material (mineral) and around 5-10% water, the remainder being organic material such as 
type I collagen (90%) and non-collagenous proteins such as proteoglycan, glycoproteins and 
sialoproteins.  
Type I collagen, the major protein component in bone, is secreted by osteoblasts and self-assembles 
into overlapping crosslinked groups of five. Each collagen molecule is ~ 1.5nm wide and 300nm in 
length (Streeter and de Leeuw 2011) and is staggered from its neighbour by approximately a quarter 
of its length, with a small gap between itself and the successive molecule. It is this gap that gives rise 
to the recognised banded appearance (known as D-periodic spacing, Figure 4) of collagen fibrils on 
electron microscopy (Fang, Goldstein et al. 2012).  As the collagen molecules in each group coil 
around each other small pockets are created that act as binding sites for other matrix proteins and 
adhesion molecules and are important for mineralisation. Adhesion molecules, particularly integrins, 
are involved in the interaction between the matrix and bone cells. 
 
 
Figure 4 Electron microscopy of longitudinal cross section of dermal collagen. 
Characteristic banding appearance (D-periodic spacing) caused by overlapping collagen molecules are seen (original 
magnification 12000X). 
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Collagen molecules are joined together by both enzymatic and non-enzymatic crosslinking. Lysyl 
oxidase and lysyl hydroxylase form enzymatic divalent crosslinks that in some mature to trivalent 
crosslinks. Measurement of pyridinoline and pyrrole crosslinks, which are cleaved during collagen 
degradation, can be used as an indication of bone turnover. Enzymatic crosslinks are considered to 
contribute positively to bone strength. In contrast non-enzymatic cross links, formed between sugars 
and exposed amino acids, are thought to have a negative effect on bone material properties, causing 
increased brittleness.  
Crystalline hydroxyapatite is deposited along the collagen fibres in highly ordered stacks of mineral 
platelets. There is no current consensus as to how the location and spatial arrangement between 
these mineral platelets and the collagen fibres affects the material properties of bone in health and 
disease. However, it is known that changes in the bone matrix alter both the structure and function of 
bone tissue. 
ii.x.i Collagen structure 
Type I collagen is a heterotrimer consisting of two pro-α1 chains and one pro-α2 chain that are 
assembled into a triple helical structure.  The pro-α1 and pro-α2 chains are encoded by the COL1A1 
and COL1A2 genes respectively. Both pro-α1 and  pro-α2 chains consist of  a large central  domain 
of 1014 amino acids containing repeated Gly-X-Y triplets, known as the ‘triple helix’ domain, which is 
flanked by short non-helical telopeptide domains and globular carboxyl and amino terminal 
propeptides (the C- and N- propeptides).  
The Gly-X-Y triplets are key to the integrity of the type I collagen protein as glycine residues have the 
smallest side chain of any amino acid, consisting of a single hydrogen atom, allowing the three alpha 
chains to come together to form a tightly folded right-handed coil structure, the alpha helix.  The X-
position in the Gly-X-Y triplet is most often occupied by a proline residue, with hydroxyproline in the Y-
position.  
Along each alpha chain are regions that are important for interaction with other collagen molecules or 
extracellular matrix proteins, in particular proteoglycans. There are three of these regions, known as 
major ligand binding regions (MLBR) (Figure 5). Severe dominant OI mutations are thought to cluster 
in these regions, supporting the importance of proteoglycan-collagen interactions for normal bone 
homeostasis (Marini, Forlino et al. 2007).  
Type I collagen is first synthesised as a soluble precursor protein called procollagen and undergoes 
several stages of processing and trafficking before fibrillogenesis occurs. 
ii.x.ii Collagen Biosynthesis 
The chains of type I collagen are first synthesized as procollagen molecules and the growing protein 
chains are translocated into the lumen of the rough endoplasmic reticulum (ER). 
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Figure 5 The structure of type I collagen. 
Type I collagen consists of two pro-α1 and  pro-α2 chains that each consist of  a large central  domain of 1014 amino 
acids containing repeated Gly-X-Y triplets, known as the ‘triple helix’ domain. This is flanked by short non-helical 
telopeptide domains and globular carboxyl and amino terminal propeptides (the C-terminal and N-terminal 
propeptides). The X-position in the Gly-X-Y triplet is most often occupied by a proline residue, with hydroxyproline in 
the Y-position. Along each alpha chain are regions that are important for interaction with other collagen molecules or 
extracellular matrix proteins, known as major ligand binding sites (MLBR). Figure adapted from (Marini, Forlino et al. 
2017) 
ii.x.iii Rough Endoplasmic Reticulum 
Here the chain recognition sequence within the C-propeptide domains enable two pro-α1and one pro-
α2 chains to align (Khoshnoodi, Cartailler et al. 2006, Bourhis, Mariano et al. 2012). The alignment 
and stabilisation of the interactions between the three C- propeptides is facilitated by interchain 
disulphide bonds (Canty and Kadler 2005). The two pro-α1 chains and one pro-α2 chain then 
assemble in a carboxyl to amino direction leading to propagation of the triple helix. The telopeptides 
stabilise the newly synthesised collagen fibrils by means of intermolecular cross-links. 
During chain assembly modification of lysine and proline residues by hydroxylation occurs. Specific 
3’-hydroxylation of proline 1164 (also referred to as proline 986 using alternate nomenclature) is 
undertaken by the three protein complex formed by prolyl 3-hydroxylase 1 (P3H1), cartilage-
associated protein (CRTAP), and cyclophilin B (CypB), (Ishikawa, Wirz et al. 2009)  which are 
encoded by the CRTAP, P3H1 and PPIB genes respectively. This 3’-hydroxylation is thought to allow 
binding of collagen chaperone molecules as well as having an effect on triple helix stability 
(Makareeva, Aviles et al. 2011).  
Hydroxylation of lysine residues in the telopeptide is performed by lysyl hydroxylase 2 (LH2), encoded 
by the PLOD2 gene (van der Slot, Zuurmond et al. 2003, Hyry, Lantto et al. 2009), whereas 
hydroxylation of two sites in the helical domain is undertaken by lysyl hydroxylase 1 (LH1), encoded 
by PLOD1. 
In addition to hydroxylation processes, glycosylation of hydroxylysyl residues also occurs during helix 
formation. When propagation of the triple helix is complete this processing, known as post-
translational modification, stops. 
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The ATP-independent heat shock protein HSP47, encoded by SERPINH1, is a further protein 
required for procollagen folding and is thought to help maintain triple helix stability (Christiansen, 
Schwarze et al. 2010). HSP47 is known to accompany procollagen from the ER to the golgi, where it 
dissociates and then returns to the ER for recycling (Canty and Kadler 2005). The precise function of 
HSP47 is still unknown although its pattern of expression suggests that it is collagen-specific rather 
than a general ER chaperone (Makareeva, Aviles et al. 2011).  
A further ER-resident chaperone protein, FKBP65, encoded by FKBP10, also interacts with type I 
procollagen (Ishikawa, Vranka et al. 2008). FKBP65 is thought to be important for procollagen 
trafficking as well as molecular folding through interaction with the PLOD2 protein. In addition it forms 
a complex with CRTAP/P3H1/CyPB  to facilitate hydroxylation of proline 1164 (Marini, Forlino et al. 
2017). It has also been shown to co-operate with HSP47 during post translational modification 
(Duran, Nevarez et al. 2015). 
 
 
Figure 6 Steps in Type I Collagen Biosynthesis.  
Figure modified from (Van Dijk and Sillence 2014) 
ii.x.iv Golgi Apparatus 
The type I procollagen protein exits the ER when it has achieved a stable folded configuration and is 
transported through the secretory pathway of the Golgi apparatus and plasma membrane into the 
extracellular matrix. 
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ii.x.v Extracellular Matrix 
In the extracellular matrix procollagen is processed into collagen by the removal of the globular N and 
C propeptides by C-proteinases,  such as bone morphogenetic protein 1, BMP-1, (Hartigan, Garrigue-
Antar et al. 2003), and by the N-proteinase activity of the ADAMTS family of enzymes (Le Goff, 
Somerville et al. 2006). This results in spontaneous aggregation of collagen molecules to form fibrils, 
which is facilitated by the formation of intra- and inter-molecular crosslinks. These fibrils grow by 
lateral and end-to-end fusion to form type I collagen fibres (Figure 6).  
ii.xi Osteogenesis Imperfecta 
Osteogenesis Imperfecta (OI) is a rare inherited condition thought to affect approximately 6–7 in 
100,000 individuals (Folkestad, Hald et al. 2016) and is characterised by low bone mass and an 
increased tendency to fracture, often with minimal or no apparent trauma.  There is considerable 
variation in both severity and age of onset, which ranges from death in the perinatal period to very 
mildly affected individuals with few or no fractures.  
The clinical features of OI can include fractures, short stature with bone deformities, hyperlaxity of 
joints and skin, and Wormian bones. Extraskeletal symptoms such as blue sclerae, progressive adult 
hearing loss and dentinogenesis imperfecta may also be evident. Other important features are bone 
pain and impaired mobility. 
ii.xii Genotype/Phenotype Correlation in OI 
Genetic characterisation of families affected with OI has shown that autosomal dominant mutations in 
the genes that encode the alpha chains of type I collagen, COL1A1 and COL1A2 can be identified in 
~85% of affected individuals (Rohrbach and Giunta 2012). The recurrent autosomal dominant IFITM5 
mutation, c.-14C>T, is reported to account for an additional 4-5% of OI cases (Shapiro, Lietman et al. 
2013). 
Recessive mutations in a variety of genes are known to account for a further ~5% of cases (Forlino, 
Cabral et al. 2011). The contribution of each recessive gene is population dependent. In North 
American and European populations those encoding the components of the 3’-hydroxylation complex, 
CRTAP, P3H1 and PPIB are the most common (Forlino, Cabral et al. 2011) whereas in Arabian 
populations SERPINF1 and FKBP10 are the more frequent (Shaheen, Alazami et al. 2012). In 
addition several recurrent mutations in P3H1 have been identified, c.232delC;p.Gln78Serfs*30 in Irish 
travellers (Baldridge, Schwarze et al. 2008) and c.1080+1G>T in those of African descent (Bodian, 
Chan et al. 2009). 
Considerable effort has been applied in an effort to define the relationship between genotype and 
phenotype in OI with the hope of improving prognostic information and genetic counselling/risk 
assessment for families with an affected individual. 
ii.xii.i Defects in Collagen Molecule  
ii.xii.i.i COL1A1 and COL1A2  
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Autosomal dominant mutations in COL1A1 and COL1A2 are described throughout the genes and 
there are currently over 1,200 unique OI variants reported (http://www.le.ac.uk/genetics/collagen). 
Mutations broadly fall into two categories, those resulting in a quantitative reduction in normal protein 
and those causing a qualitative defect.  
Quantitative mutations causing a reduction in the amount of normal type I collagen 
(haploinsufficiency) are associated with milder OI phenotypes and are most commonly caused by 
heterozygous variants in COL1A1 that lead to mRNA instability and nonsense mediated decay (‘null’ 
allele). Small deletions and duplications causing a frameshift and nonsense mutations are a common 
cause of ‘null’ alleles, although splice site changes resulting in intronic inclusion or activation of cryptic 
splice sites are also reported.  Rarely whole gene deletions are also described (van Dijk, Huizer et al. 
2010). Heterozygous ‘null’ alleles in COL1A2 have yet to be described and are thought to result in a 
phenotype that cannot be distinguished from normal. 
A rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from 
homozygous ‘null’ mutations in the COL1A2 gene (Schwarze, Hata et al. 2004), suggesting that type I 
collagen comprising of three pro-α1 chains can assemble and maintain bone integrity in a near 
normal fashion in the absence of pro-α2 chains. The lack of reported phenotypes for homozygous 
COL1A1 ‘null’ mutations may indicate that this is incompatible with life. 
Qualitative defects are associated with a wide phenotypic spectrum ranging from mild to lethal and 
are characterized by assembly of type I collagen comprising of mutant and normal alpha chains 
resulting in production of an abnormal protein (dominant-negative effect). Qualitative defects disrupt 
fibrillogenesis and generally have a greater phenotypic impact than quantitative changes due to their 
increased influence on the bone matrix.  
The most frequent qualitative defect is the substitution of a glycine residue in a Gly-X-Y triplet in the 
triple helix domain that disrupts folding, slows chain propagation and results in over-modification of 
the protein. Splice site changes resulting in exon skipping, in frame deletions/insertion and changes in 
the C-terminal propeptide (Figure 8) also cause qualitative changes.  
A key challenge in OI is the prediction of phenotypic severity from genotype. Early characterisation of 
glycine substitutions led to the development of a position-dependent gradient model for phenotypic 
severity for the  pro-α1 chain  which was later refined to include the pro-α2  chain (Lund, Aström et al. 
1999). The model proposed that mutations affecting glycine residues towards the C-terminus are 
likely to be more clinically severe than those towards the N-terminus. This reflects the direction of 
chain propagation as mutations earlier in chain propagation are proposed to result in greater over-
modification of the protein. However, it became apparent that this model required modification to 
incorporate the nature of the substituting amino acid, as those with larger and/or charged side chains 
have a greater impact on the folding of the triple helix.   
Substitution of glycine residues with amino acids that have a charged side chain (aspartic acid, 
glutamic acid and arginine) as well as valine, which has a branched nonpolar side chain, leads to a 
severe phenotype more often than alanine which has smaller methyl group side chain (Figure 7). 
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Figure 7 Gradient-dependent Severity Model for Glycine Substitutions in the Helical Domain of 
Type I collagen 
Further refinement of this model was undertaken as the number of independent mutations grew 
(Marini, Forlino et al. 2007) resulting in the development of a regional model. There are two regions in 
the α1 chain where only lethal mutations have been described (amino acid positions 691-823 and 
910-964) and these correspond to major ligand binding regions suggesting a role in intermolecular 
cross linking and fibril-chain interaction. Lethal regions in the α2 chain, of which there are eight, occur 
in clusters that correspond to the domains necessary for proteoglycan binding, further supporting the 
importance of fibril-matrix interaction (Bodian, Madhan et al. 2008). 
In addition to glycine substitutions in the helical domain leading to disruption of chain assembly, splice 
site changes resulting in exon skipping and in frame deletions/insertion have also been shown to 
result in delayed chain assembly and subsequent over-modification of the procollagen trimer (Pace, 
Atkinson et al. 2001).  
The phenotypic effect of non-glycine substitutions in the helical domain is more difficult to predict, and 
it can be hard to attribute pathogenicity to many changes. However, arginine residues when 
substituted by cysteine have been reported to be causative of classical Ehlers-Danlos Syndrome 
(EDS) (Nuytinck, Freund et al. 2000), infantile cortical hyperostosis (Caffey disease) (Cho, Moon et al. 
2008) and EDS with a susceptibility to arterial rupture in early adulthood (Malfait, Symoens et al. 
2007). 
Mutations outside the helical domain have been described in a range of phenotypes (Figure 8). C-
propeptide domain mutations have been demonstrated to delay chain assembly and result in reduced 
secretion of over modified but stable procollagen molecules. Mutations in this domain have been 
reported in mild OI (Pace, Kuslich et al. 2001) and in a variant of OI characterised by high bone mass 
(Takagi, Hori et al. 2011).  
Retention of the C-propeptide due to mutations in either the pro-α1 or pro-α2 cleavage recognition 
sites have also been described to be associated with high bone mass (Lindahl, Barnes et al. 2011). 
The exact mechanism by which mutations in this region cause a high bone mass variant of OI is still 
to be determined. However, it has been hypothesised that both retention of the C-propeptide and the 
presence of overmodified molecules caused by mutations in this region support increased 
mineralisation density of the bone, which exceeds those of classical OI, because the C-propeptide 
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domains also act as signalling molecules within the extracellular matrix, hence influencing 
mineralisation. Alternatively, increase mineralization may be triggered by the physical effect of 
increased inter-molecular spacing due to retention of the globular C-propeptide moiety. 
Mutations in the N-propeptide, other than those resulting in a ‘null’ allele, have not yet been described 
with the exception of a mutation affecting the signal peptide cleavage site (Pollitt, McMahon et al. 
2006) and therefore the phenotype associated with mutations in this domain remains unknown.  
Mutations affecting the protease cleavage site located in exon 6, which result in reduced cleavage 
efficiency and retention of the N-propeptide, are associated with the arthrocholasic type of EDS. An 
overlapping EDS/OI phenotype is linked to mutations in the first 90 amino acid of the pro-α1 chain 
due to their effect on both the secondary structure of the adjacent N-propeptide cleavage site and 
triple helix propagation. These patients exhibit bone fragility as well as symptoms of EDS (Cabral, 
Makareeva et al. 2005). Dermatosparatic EDS is caused by non-cleavage of both the pro-α1 and pro-
α2 N-propeptides due to mutations in the N-proteinase enzyme gene, ADAMTS2. 
The broad spectrum of phenotypes reported to be associated with mutations in the type I collagen 
genes illustrates the difficulty in predicting phenotypic outcome from genotype in this disorder.  
 
 
Figure 8 Different clinical phenotypes are linked to mutations at specific positions along the type I 
procollagen protein.  
Those in the triple helical and C-propeptide domains are associated with Osteogenesis Imperfecta (OI).  An 
OI/Ehlers-Danlos syndrome overlapping phenotypic variant is caused by amino acid substitutions in the N-anchor 
domain. Mutations in the N-propeptide cleavage site cause arthrocholasic Ehlers-Danlos (EDS VII). High bone mass 
variants of OI have been described in association with mutations at the C-propeptide cleavage site and for missense 
mutations within the C-propeptide domain.  
Hexagons = hydroxyl lysine linked sugar molecules OH–=hydroxyl group linked to proline or lysine residues.  
Figure adapted from Forlino et al (Forlino and Marini 2016). 
 
ii.xii.ii Defects in Collagen post translational Modification 
The identification of autosomal recessive mutations in the prolyl 3-hydroxylation complex genes 
(CRTAP/P3H1/PPIB), responsible for the hydroxylation of proline 1164 in the α1 chain, led the way in 
new gene discovery for OI. These mutations were thought to confirm that post-translational 
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modification and subsequent correct folding of type I collagen is essential to maintain bone strength. 
However, there is still uncertainty as to whether the lack of prolyl 3-hydroxylation or the loss of 
chaperone activity or both is the key mechanism. There is also evidence that the 3-hydroxlation site 
affects collagen protein interaction with SLRPs, such as biglycan and decorin, that are known to be 
important for fibrillogensis (Kalamajski and Oldberg 2010). 
ii.xii.ii.i CRTAP 
CRTAP is a helper protein for the 3’ hydroxylation complex. There is evidence that matrix 
disorganization as well as overmodification of the type I collagen protein contributes to the disease 
mechanism in CRTAP deficient OI, supporting an independent role as a matrix component for this 
protein (Valli, Barnes et al. 2012).  
The description of a consanguineous family from Quebec with a distinct form of OI, termed type VII, 
(Ward, Rauch et al. 2002), and the subsequent identification of CRTAP as the causative gene, was 
key to expanding our knowledge of genes in OI (Morello, Bertin et al. 2006). The most prominent 
clinical features in this family were the presence of severe rhizomelia and coxa vara. No 
dentinogenesis imperfecta, ligamentous laxity or hearing impairment was noted and the sclerae were 
described as being minimally bluish. Affected individuals were confirmed to be homozygous for a 
c.472-1021C>G CRTAP variant in intron 1 that creates a cryptic splice site and the inclusion of a 
73bp cryptic exon.  
The majority of CRTAP mutations now reported result in a functional null allele with a consequent 
absence or significant reduction in levels of the protein. The spectrum of phenotypes associated with 
CRTAP deficiency range from severely deforming to lethal with rhizomelic shortening, bowing of long 
bones and grey/white sclerae. Skeletal abnormalities are often evident in the prenatal and early 
neonatal period. Relative macrocephaly may also be present (van Dijk, Nesbitt et al. 2009). 
ii.xii.ii.ii P3H1 
P3H1 encodes prolyl 3-hydroxylase1 (P3H1), the enzymatic component of the collagen 3-
hydroxylation complex and is mutually stabilising with CRTAP (Chang, Barnes et al. 2010).  
Mutations usually result in a null allele and are associated with moderately deforming to lethal 
phenotypes (van Dijk, Cobben et al. 2011) that overlap with CRTAP-related OI. There is usually 
severe under mineralisation of the bone, growth deficiency and extreme bone fragility. 
A founder mutation, c.1080+1G>T in P3H1 has been described at a frequency of 1.5% in West 
Africans and 0.4% in African Americans (Cabral, Barnes et al. 2012). The frequency of the common 
c.232delC;p.Gln78Serfs*30 mutation in Irish travellers is not reported. 
ii.xii.ii.iii  PPIB 
PPIB encodes the cyclophilin B protein (CyPB), the third protein in the P3H1/CRTAP/CyPB complex. 
A limited number of mutations have been reported in this gene but have been described to result in 
decreased 3’-hydroxylation of proline 1164 and overmodification of type I collagen (van Dijk, Nesbitt 
et al. 2009).  
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Clinical presentation for PPIB-associated OI can range from perinatal lethality to moderate severity 
without rhizomelia or severe deformity of the long bones (Pyott, Pepin et al. 2011). 
Interestingly, although mutations leading to OI have been identified in all three genes encoding the 3’ 
hydroxylation complex, variants affecting proline 1164 itself have yet to be identified. 
ii.xii.iii Defects in collagen processing/cleavage 
ii.xii.iii.i BMP1 
Bone morphogenetic protein 1 (BMP1) is a member of the astacin family of multidomain 
metalloprotease whose functions include activation of growth factors, degradation of polypeptides, 
and processing of extracellular proteins. The function of BMP1 includes the proteolytic removal of the 
C-propeptide from procollagen type I. This processing promotes self-assembly of collagen fibrils, 
thereby influencing fibre formation and matrix integrity. BMP1 is also described as influencing dorsal-
ventral patterning through the indirect activation of some TGFβ superfamily proteins (Asharani, Keupp 
et al. 2012). 
BMP1/mTLD also removes the N-terminal peptides from the small leucine rich proteoglycans (SLRPs) 
biglycan, decorin and osteoglycan which themselves activate precursor forms of lysyl oxidase and 
lysyl oxidase-like, regulating intermolecular covalent cross-linking and influencing collagen fibril size 
and shape. 
A mutation in the signal peptide of the BMP1 gene has been reported in recessive OI presenting with 
bone fragility associated with an increase in bone mineral density. This mutation, p.Gly12Arg, causes 
markedly reduced post-translational N-glycosylation, impaired secretion and compromises BMP1 
activity in zebra fish (Asharani, Keupp et al. 2012, Syx, Guillemyn et al. 2015). 
In contrast, a missense mutation in the protease domain, p.(Phe249Leu), has been described as 
leading to mild OI with recurrent fractures, generalized bone deformity, osteopenia and Wormian 
bones. The mutant protein has been shown to have reduced proteolytic activity in-vivo (Martinez-
Glez, Valencia et al. 2012).  
It can be hypothesized that the described phenotypic variability between these reported cases may 
result from different functional consequences of the two mutations, particularly as the signal peptide 
mutation has a high bone mass phenotype similar to that reported in individuals with mutation in the 
type I collagen C-propeptide that cause delayed secretion. As further mutations are identified the 
relationship between mutations in this gene and those in the type I collagen C-propeptide, and their 
functional consequence, may become clearer. 
ii.xii.iv Defects in collagen cross-linking and folding 
ii.xii.iv.i SERPINH1 
The ATP-independent heat shock protein HSP47, encoded by SERPINH1, is an ER resident 
multifunctional protein that acts downstream of the CRTAP/P3H1/CyPB 3-hydroxylation complex. 
HSP47 is believed to be required for procollagen folding, triple helix stability and quality control of the 
helix at the ER/Golgi boundary and is commonly referred to as a collagen ‘chaperone’. Loss of 
function of the protein causes increased transit of type I collagen from ER to the Golgi (Van Dijk, Pals 
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et al. 2010). There is also evidence from an Hsp47−/− mouse model that ER stress is increased 
leading to apoptosis, possibly contributing to the OI phenotype (Ito and Nagata 2017).  
Two cases of recessive OI caused by missense mutations in SERPINH1 have been reported with 
clinical features that include triangular face, relative macrocephaly, blue sclerae, micrognathia, short 
bowed limbs, thin ribs and multiple fractures (Christiansen, Schwarze et al. 2010, Duran, Nevarez et 
al. 2015). A third reported case of severe OI associated with a homozygous frameshift has been 
reported with the additional feature of hydranencephaly (Marshall, Lopez et al. 2016).  
ii.xii.iv.ii PLOD2 
Crucial for maintaining stability of the collagen protein in bone is the formation of lysyl and 
hydroxylysyl cross-links between molecules at the telopeptides and two sites located in the triple helix 
at position Lys87 and Lys930.  
The enzyme lysyl hydroxylase 2 (LH2) is responsible for hydroxylation of telopeptide lysine and is 
encoded by PLOD2. This gene is alternatively spliced to produce two isoforms, LH2 long which is 21 
amino acids longer than LH2 short. LH2 long is ubiquitously expressed whereas LH2 short has been 
detected only in spleen, cartilage, liver and placenta. Loss of function mutations affecting only the 
LH2 long isoform result in Bruck syndrome which is characterised by congenital contractures as well 
as susceptibility to low trauma fracture (Puig-Hervás, Temtamy et al. 2012).  
Evidence that mutations in this gene can give rise to highly variable phenotypes, with and without 
contractures, and overlapping with mild to severe forms of recessive OI has been presented (Puig-
Hervás, Temtamy et al. 2012). 
ii.xii.iv.iii FKBP10 
The FKBP10 gene encodes the FKBP65 protein, an ER resident collagen chaperone, which is a 
member of the family of prolyl cis-trans isomerases. Recent evidence has been presented to indicate 
that FKBP65 also interacts with LH2, possibly resulting in misfolding of LH2 and thereby influencing 
telopeptide lysyl hydroxylation, which is reduced in individuals with FKBP10 mutations (Schwarze, 
Cundy et al. 2013). 
Novel mutations in the FKBP10 gene were first identified by Alanay et al who described a cohort of 
five consanguineous Turkish families with moderately severe OI and a Mexican family with severe 
progressively deforming OI (Alanay, Avaygan et al. 2010). In contrast, those described by other 
groups are characteristic of Bruck syndrome (Kelley, Malfait et al. 2011, Schwarze, Cundy et al. 
2013).  
Marked intrafamilial variation has also been reported for mutations in this gene, with some members 
of the same family described as having Bruck syndrome and others OI (Shaheen, Al-Owain et al. 
2011).  
The broad inter- and intra-familial spectrum of phenotypes for FKBP10 and PLOD2 mutations, and 
the overlap between Bruck syndrome and OI phenotypes in these individuals supports that Bruck 
syndrome is a subtype of OI and does not represent a distinct clinical entity. In addition, the 
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overlapping phenotype between individuals with FKBP10 and PLOD2 mutations may be the 
consequence of their linked functional mechanism which influences telopeptide lysyl hydroxylation.  
A further finding supporting a continuum of phenotypes is the p.(Tyr293del) founder mutation in Yup’ik 
Eskimos. This mutation causes an autosomal dominant congenital contracture disorder, Kuskokwin 
syndrome. In addition to contractures, which particularly affect the lower body and are progressive, 
affected individuals have short stature with osteopenic or osteoporotic vertebrae and many are 
reported to have low impact fractures. (Barnes, Duncan et al. 2013). 
Of note is that mutations in PLOD1, affecting lysyl hydroxylation in the helical domain, are associated 
with kyphoscoliotic Ehlers Danlos Syndrome. This condition is characterized by hyperextensible and 
fragile skin, easy bruising, hypermobile joints, muscular hypotonia and progressive scoliosis. Scleral 
fragility with increased risk of optical globe rupture is also evident, although bone fragility is not 
present. 
 
ii.xii.v Defects in osteoblast development and function 
ii.xii.v.i SP7 
The first gene discovered to cause recessive OI that is not involved in the type I collagen biosynthesis 
pathway was SP7, which encodes the Osterix protein (Osx). Osterix is a transcription factor 
expressed by osteoblasts and contains three Cys2-His2 zinc-finger DNA-binding domains. In mice, 
Osx has been shown to be essential for osteoblast differentiation and bone formation during 
development as well as postnatal bone growth and homeostasis. Mice that are deficient in Osx have 
perinatal lethal bone deformities similar to those seen in OI patients and show deficient osteoblast 
differentiation and proliferation (Nakashima, Zhou et al. 2002). 
Until recently a single case of recessive OI had been reported in association with a homozygous 
frameshift mutation in SP7 that results in loss of the last 81 amino acids, including the third zinc-finger 
motif of the protein. The affected individual is described as having moderately severe OI with 
fractures, mild bone deformities and white sclerae and it is speculated that the mutant protein must 
retain sufficient residual function to prevent this being a lethal phenotype (Lapunzina, Aglan et al. 
2010).  
The recent description of a c.946C>T;p.(Arg316Cys) in a sibship with short stature, osteoporosis and 
low impact fractures has suggested that hearing loss, that can be moderate to profound, could be a 
distinguishing feature of SP7- associated OI (Fiscaletti, Biggin et al. 2018).  
ii.xii.v.ii WNT1 
Recessive OI is now described in association with WNT1, a member of the WNT gene family. WNT 
proteins function as regulatory ligands for the frizzled transmembrane receptor family (FZD) and low 
density lipoprotein receptor-related proteins (LRP5/6), which trigger WNT signalling. WNT signalling is 
essential for many developmental and regulatory processes including cell proliferation, migration, 
differentiation and maintenance of bone, heart, muscle, and other tissues. 
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Historically WNT signalling has been divided into three main branches, the canonical β-catenin 
pathway, the non-canonical planar cell polarity pathway and the WNT-calcium pathway. The 
canonical β-catenin pathway, which has been identified as the dominant metabolic pathway regulating 
bone homeostasis, is activated by the binding of WNT ligands to the transmembrane receptor 
complex consisting  of frizzled (FZD) and either LRP5 or LRP6  (Baron and Kneissel 2013). There is 
also increasing evidence that non-canonical WNT signalling has a role in controlling bone metabolism 
and interacts with other pathways affecting bone mass.  
Mutations identified in WNT signalling proteins which affect bone mass have so far only been 
identified in those targeting the canonical WNT pathway (Figure 9), although genome wide 
association studies have identified common single nucleotide polymorphisms in both canonical and 
noncanonical WNT ligand genes as candidates for osteoporosis susceptibility. 
Mutations in WNT1 have been identified in 4 individuals from three families with a previous clinical 
diagnosis of OI type IV. The phenotype of these individuals includes numerous long bone fractures, 
multiple vertebral compression fractures and short stature. Severe abnormalities in brain development 
are described in the Wnt1 knockout mouse and, although neurological problems were not observed in 
this cohort, two siblings from a consanguineous family were noted to have muscle hypotonia 
(Fahiminiya, Majewski et al. 2013).  
Further WNT1 mutations have been identified in seven affected individuals from four families 
described as having moderately severe, progressive phenotypes which are indistinguishable from OI 
type III. Affected individuals presented with recurrent fractures, bone deformity and short stature, 
although hearing and teeth formation are reported to be unaffected. In three of these families affected 
individuals are reported to have developmental delay, although whether this is entirely attributed to 
mutations in WNT1 is unclear (Pyott, Tran et al. 2013). 
Functional confirmation of the role of WNT1 in the canonical WNT signalling pathway has been 
provided by Keupp and colleagues (Keupp, Beleggia et al. 2013) using expression vectors and dual 
luciferase reporter assays. Homozygous loss of function mutations, identical to those identified in 
individuals with moderate to progressively deforming OI, have been shown to result in almost 
complete failure of activation of the WNT-β-catenin signalling cascade.  
The key role of WNT1 in bone homeostasis is also supported by the recent studies of Joeng et al 
(Joeng, Lee et al. 2017) who developed both loss and gain of function mouse models. Their results 
demonstrated that loss of function mutations in mice results in reduced bone mass and low-impact 
fractures that are primarily associated with decreased osteoblast activity. In contrast, gain of function 
mutations (over expression) increases osteoblast numbers via activation of the mTORC1 signalling 
pathway. 
Of particular interest is that autosomal dominant early-onset osteoporosis has been reported in a 
number of families with heterozygous WNT1 loss of function mutations. Clinical features of affected 
individuals include low BMD and fragility fractures (Keupp, Beleggia et al. 2013, Laine, Joeng et al. 
2013, Palomo, Al-Jallad et al. 2014).  
This confirms that mutations in the WNT signalling pathway give rise to variable bone fragility 
phenotypes dependent on whether the mutation is inherited in a dominant or recessive manner. It 
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also emphasises that OI causative genes can have implications for other bone fragility disorders, such 
as osteoporosis. 
ii.xii.vi Defects in bone mineralisation 
ii.xii.vi.i SERPINF1 
SERPINF1 encodes the 50-kDa protein pigment-epithelium-derived factor (PEDF), a multifunctional 
protein that is a strong inhibitor of angiogenesis as well as having involvement in bone formation and 
remodelling (Becker, Semler et al. 2011).  The specific clinical phenotype associated with mutations in 
SERPINF1, causing loss of PEDF function, is OI type VI (Homan, Rauch et al. 2011).  
Although the exact pathological mechanism underlying OI type VI is unknown, mouse studies have 
demonstrated that in normal mouse bone Pedf is localized to osteoblasts and osteocytes. The Pedf 
null mouse shows reduced trabecular bone volume, unmineralised bone matrix and increase bone 
fragility, mimicking findings in OI type VI and therefore providing a good model for investigation of the 
role of PEDF in this disorder (Bogan, Riddle et al. 2013). 
 
 
Figure 9 Regulation of bone formation and mineralization in osteogenesis imperfecta 
WNT1 stimulates the transcription of genes involved in osteoblast differentiation via LRP5/6, Frizzled and the 
canonical β-catenin signalling pathway.  The endopeptidase S2P (MBTPS2) is located in the Golgi and cleaves 
regulatory proteins, such as OASIS, via regulated intramembrane proteolysis (RIP) in times of ER stress. 
TMEM38B/TRIC-B regulates calcium flux within the ER. 
Pigment epithelium-derived factor (PEDF encoded by SERPINF1), a strong inhibitor of angiogenesis, is involved in 
bone formation and remodelling. It cross talks with bone-restricted interferon-induced transmembrane protein-like 
protein (BRIL) to regulate mineralization.  
Dashed lines represent unknown pathways. *Mutations identified in osteogenesis imperfecta. Figure adapted from 
Marini et al (Marini, Forlino et al. 2017) 
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Individuals with OI type VI appear healthy at birth with fractures of long bones, severe vertebral 
compression fractures and significantly low bone mineral density becoming evident between age 4 -
18 months (Glorieux, Ward et al. 2002, Wang, Liu et al. 2017). Characteristic histological findings are 
gross under mineralization of the osteoid and disorganized bone matrix with a distinct "fish-scale" 
appearance. 
ii.xii.vi.ii IFITM5  
Type V OI is characterised by hyperplastic callus formation following fracture or surgery, calcification 
of the interosseous membranes of the forearm and mesh-like appearance of lamellae under polarised 
light (Glorieux, Rauch et al. 2000). Affected individuals present with moderate to severe skeletal 
deformity (Lazarus, McInerney-Leo et al. 2014).   
Inheritance was known to be autosomal dominant although the genetic aetiology remained unknown 
until linkage analysis and whole-exome sequencing identified a single causative mutation in the 5’-
untranslated region of the IFITM5 gene (alternatively known as Bone-restricted interferon induced 
transmembrane protein-like protein, BRIL). This single mutation, c.-14C>T, has been confirmed by 
transfection construct studies to create a novel in-frame start codon adding a string of five amino 
acids (Met-Ala-Leu-Glu-Pro) to the amino terminus of the BRIL protein. It is proposed that, as gene 
expression and protein localisation are restricted to skeletal tissue, this mutation presumably leads to 
dysregulation of bone formation (Cho, Lee et al. 2012, Semler, Garbes et al. 2012). In particular, a 
‘gain of function’ is proposed, which leads to the formation of hyperplastic callus and ossification of 
membranes, although the exact mechanism requires further study.  
A study of 42 individuals with OI type V reported considerable phenotypic variability even for this 
single mutation (Rauch, Moffatt et al. 2013). These finding have been confirmed in a further cohort of 
17 individuals from 12 families where marked phenotypic variation was observed both within and 
between affected families (Shapiro, Lietman et al. 2013). 
A second mutation in the IFITM5 gene, c.119C>T, leading to a p.(Ser40Leu) substitution has been 
identified in association with atypical severe OI. Phenotypic and histological findings are suggestive of 
OI type VI, although SERPINF1 analysis is negative. Protein expression studies carried out using 
patient osteoblasts suggest the p.(Ser40Leu) mutation stimulates intracellular SERPINF1 regulation 
hence leading to the apparent impairment of mineralization (Farber, Reich et al. 2014). This supports 
the idea that BRIL and PEDF interact during osteoblast development, bone formation and 
mineralization (Figure 9). 
ii.xii.vi.iii SPARC  
Secreted protein, acidic, cysteine rich (SPARC, also known as Osteonectin) is a glycoprotein that 
binds extracellular matrix proteins including type I collagen within the extracellular space. It is 
expressed mainly in cells with high rates of extracellular matrix production, including osteoblasts in 
bone, and is required for collagen in bone to become calcified. Knock-out mice have defective bone 
formation leading to progressive osteoporosis along with intervertebral disc degeneration and reduced 
muscle mass (Delany, Amling et al. 2000).   
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Autosomal recessive OI caused by mutations in the SPARC gene have been identified by whole-
exome sequencing in two female patients. Their phenotype is described as resembling OI type VI 
(associated with SERPINF1 mutations) in that neither individual had any obvious skeletal abnormality 
at birth but developed progressive severe bone fragility (Mendoza-Londono, Fahiminiya et al. 2015). 
No further cases of SPARC-related OI have been reported to date. 
 
ii.xii.vii ER Related Proteins 
ii.xii.vii.i CREB3L1   
Another gene exhibiting variable bone fragility dependent on mode of inheritance is CREB3L1. The 
gene encodes the ER-stress protein OASIS that is involved in the unfolded protein response (UPR).  
OASIS protein has a leucine zipper domain and a transmembrane domain that anchors it in the ER. 
During ER stress, the protein is released from the ER, transported to the Golgi and cleaved by 
S1P/MBTPS1 and S2P/MBTPS2 through regulated intramembrane proteolysis (RIP) (Figure 9). 
OASIS is also known to be a requirement for TGFβ activation of genes involved in collagen matrix 
assembly (Chen, Lee et al. 2014) and OASIS-/- mice have severe osteopenia and are susceptible to 
spontaneous fractures (Murakami, Saito et al. 2009).  
The first report of mutations in this gene being associated with OI is the description of two siblings 
with a homozygous deletion encompassing the entire CREB3L1 gene (Symoens, Malfait et al. 2013). 
The siblings are described as being severely affected with intrauterine fractures. 
More recently a c.934_936delAAG;p.(Lys312del) CREB3L1 mutation has been identified in members 
of a consanguineous family.  The mutation disrupts the DNA-binding site of the OASIS protein and 
prevents activation of SEC24D, a component of the COPII complex that moves secreted proteins 
between the ER and Golgi (Keller, Tran et al. 2018). 
Individuals homozygous for the c.934_936delAAG;p.(Lys312del) mutation had multiple intrauterine 
fractures and reduced skull mineralisation whereas heterozygous individuals have blue sclerae, 
osteopenia and recurrent fractures. 
ii.xii.vii.ii MBTPS2 
A second gene involved in the RIP pathway, MBTPS2, has been identified in an X-linked form of 
moderate to severe OI in 2 extended pedigrees with missense mutations in the gene. Bone from 
affected individuals shows reduced hydroxylation of lysine 87 of α1 and α2 chains along with 
disorganised collagen crosslinking and reduced bone strength (Lindert, Cabral et al. 2016). The 
phenotype of obligate carrier females is not described but their LP/HP ratio is normal, suggesting 
minimal impact on bone metabolism. 
The substrates of site-2 metalloprotease (S2P), encoded by MBTPS2, include activating transcription 
factor 6 (ATF6), a component of the unfolded protein response pathway and sterol regulatory element 
binding protein (SREBP), involved in cholesterol synthesis. S2P is located in the Golgi and, along with 
OASIS, cleaves these regulatory proteins during times of ER stress (Figure 9). 
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ii.xii.vii.iii TMEM38B 
The identification of causative mutations in the TMEM38B gene in consanguineous Israeli Bedouin 
and Saudi families (Shaheen, Alazami et al. 2012, Volodarsky, Markus et al. 2013) further expanded 
the biochemical pathways associated with recessive OI.  
The TMEM38B protein (TRIC-B) forms part of a trimeric cation channel which is known to regulate 
intracellular calcium levels in the ER (Figure 9) and is perinatally lethal in the knockout mouse model 
(Shaheen, Alazami et al. 2012, Volodarsky, Markus et al. 2013). Disruption of calcium flux caused by 
loss of TMEM38B/TRIC-B causes ER stress, increased BiP and dysregulation of collagen synthesis 
(Cabral, Ishikawa et al. 2016).  
ii.xii.vii.iv SEC24D 
The protein encoded by the SEC24D gene is part of the COPII complex. Proteins, including collagen 
molecules, are packaged into COPII transport vesicles as they exit the ER. Depletion of this COPII 
component has been shown to result in an autosomal recessive form of OI that has phenotypic 
overlap with Cole-Carpenter syndrome in some individuals (Garbes, Kim et al. 2015). It has been 
suggested that disturbed ossification of the skull and a specific facial appearance, that includes down-
slanting palpebral fissures, ear dysplasia, and micrognathia, may be a characteristic feature of OI 
associated with SEC24D mutations (Zhang, Yue et al. 2017).  
ii.xii.vii.v P4HB 
A single autosomal dominant c.1178A>G;p.Tyr393Cys mutation in the P4HB gene has been identified 
in two individuals with Cole Carpenter Syndrome. The protein encoded by the gene, prolyl 4-
hydroxylase beta subunit (also known as PDI), is abundant in the ER and acts as a chaperone 
preventing aggregation of the procollagen alpha chains and is involved in hydroxylation of prolyl 
residues in procollagen.  The mechanism by which this specific mutation causes severe bone fragility 
remains to be confirmed but is proposed to result from interaction with two active site cysteines, 
Cys397 and Cys400, which normally form a reversible disulfide bond (Rauch, Fahiminiya et al. 2015). 
ii.xii.viii OI-like phenotype 
As well as the OI genes described above additional genes that cause bone fragility have been 
described and are sometimes referred to as causing an OI-like phenotype. 
ii.xii.viii.i PLS3  
The first report of X-linked inheritance of an OI-like phenotype was given by van Dijk et al who 
describe mutations in the actin-binding protein plastin 3 gene (PLS3) in five families with osteoporosis 
and fractures manifesting in childhood (van Dijk, Zillikens et al. 2013) . A further two families have 
been described where four males with a history of long bone fractures and mild vertebral compression 
fracture were found to have mutations in the PLS3 gene. One of the carrier mothers was found to 
have low bone mass at the distal radius although without a history of fractures (Fahiminiya, Majewski 
et al. 2014). 
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The mechanism by which mutations in the PLS3 gene cause osteoporosis and fractures is unknown 
although it is hypothesised that these mutations may lead to dysregulation of bone 
modelling/remodelling through mechano-sensing pathways in osteocytes.  
Generally it is now considered that mutations in PLS3 cause an X-linked form of osteoporosis rather 
than OI as it does not seem to be associated with generalized bone dysplasia, changes in bone 
shape or structure. Clinical presentation is mostly apparent in middle-aged adults, although onset in 
childhood with recurrent fractures, low (BMD) and vertebral compression fractures is also reported. 
Carrier females are reported to be mildly affected (Laine, Wessman et al. 2015). 
ii.xii.viii.ii TAPT1 
Exome sequencing following genome-wide homozygosity mapping has identified a homozygous 
splice site mutation in TAPT1, c.1108-1G>C, in a family with three affected individuals with a complex 
lethal osteochondrodysplasia syndrome. Multiple intrauterine fractures, incomplete ossification of the 
skull and severe undermineralisation of the skeleton are described along with abnormalities of the 
brain, kidney and lungs (Symoens, Barnes et al. 2015).  
A further consanguineous family with three affected individuals is also described with multiple 
fractures and generalized undermineralisation of the entire skeleton. Additional findings in this family 
included cardiomegaly, hydrops fetalis, lung hypoplasia, and abnormalities of the umbilical arteries. 
The mutation in this family, c.1058A>T;p.(Asp353Val) lies within the same putative protein domain as 
c.1108-1G>C, namely the second extracellular/luminal loop of this transmembrane protein, although 
the function of this domain is still unclear. 
TAPT1 encodes transmembrane anterior posterior transformation-1 protein and null mice show 
posterior to anterior transformation in the axial skeleton and do not survive. TAPT1 mutant cells from 
one of the affected individuals have been shown to have delayed secretion of type I collagen which is 
overmodified. Knockdown of tapt1b in zebra fish causes craniofacial cartilage malformations, delayed 
ossification and aberrant differentiation of cranial neural crest cells (Symoens, Barnes et al. 2015). 
ii.xii.ix Classification of OI 
The classification of OI is based on the numerical scheme proposed by Sillence (Sillence, Senn et al. 
1979) which suggested that there are four distinct syndromes within the OI spectrum:  
 Type I    mild disease with blue sclera and dominant inheritance 
 Type II    prenatally lethal with beaded ribs and crumpled long bones 
 Type III    progressively deforming with normal sclera and 
 Type IV  moderately deforming  
Autosomal dominant inheritance was initially proposed for types I and IV and recessive inheritance for 
types II and III. 
The subsequent identification of dominant mutations in all four types of OI in the genes encoding type 
I collagen (COL1A1 and COL1A2) lead to the acceptance that OI is predominantly an autosomal 
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dominant disorder. Recurrence of severe OI (type II/III) in some families was attributed to germ line 
mosaicism and a risk of less than 10% was proposed (Pepin, Atkinson et al. 1997).  
More recent evidence confirms that most cases of severe OI are caused by de-novo dominant 
mutations in either COL1A1 or COL1A2, with somatic mosaicism reported in 16% of couples with an 
affected child. This is associated with a 27% recurrence risk for future pregnancies (Pyott, Pepin et al. 
2011). 
In the early 21st century the Sillence classification was extended to include three further distinct 
clinical groups of moderate to severe phenotypes, named as types V, VI and VII (Glorieux, Rauch et 
al. 2000, Glorieux, Ward et al. 2002, Ward, Rauch et al. 2002). These types were described in 
association with distinct clinical/histological findings and/or unknown genetic aetiology: 
 Type V - moderate/severe, calcification of the interosseous membrane and hyperplastic 
callus formation 
 Type VI - moderate/severe with accumulation of osteoid due to a mineralization defect 
 Type VII - moderate/severe with autosomal recessive inheritance 
The identification of homozygous loss of function mutations in the gene encoding cartilage-associated 
protein, CRTAP, (Barnes, Chang et al. 2006, Morello, Bertin et al. 2006) confirmed the recessive 
inheritance in OI type VII.  
This triggered the subsequent identification of recessively inherited loss of function mutations in the 
other two proteins in the prolyl-3-hydroxylase complex, namely P3H1 and PPIB (Cabral, Chang et al. 
2007, van Dijk, Nesbitt et al. 2009, Barnes, Carter et al. 2010).  OI associated with mutations in the 
P3H1 and PPIB genes were assigned OI type VIII and IX respectively. 
The number of genes to date associated with OI is seventeen and these now encompass additional 
genes involved in type I collagen biosynthesis as well those involved in mineralisation and osteoblast 
development and bone homeostasis (Table 2) 
 
 
OMIM 
number 
Locus 
Gene 
symbol 
Sillence 
type 
Main 
location 
Bone 
deformity 
Collagen synthesis 
      
Autosomal dominant 166200 17q21.33 COL1A1 I-IV 
Extracellular 
matrix 
Mild to very 
severe 
Autosomal dominant 166200 7q21.3 COL1A2 I-IV 
Extracellular 
matrix 
Mild to very 
severe 
Collagen 
processing/cleavage       
Autosomal 
recessive 
614856 8p21.3 BMP1 XIII 
Extracellular 
environment 
Mild to 
severe 
Collagen 
modification       
Autosomal 
recessive 
610682 3p22.3 CRTAP VII 
Endoplasmic 
reticulum 
Severe 
rhizomelia 
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Autosomal 
recessive 
610915 1p34.2 P3H1 VIII 
Endoplasmic 
reticulum 
Severe 
rhizomelia 
Autosomal 
recessive 
259440 15q22.31 PPIB IX 
Endoplasmic 
reticulum 
Severe 
Collagen folding and 
cross-linking       
Autosomal 
recessive 
613848 11q13.5 SERPINH1 X 
Endoplasmic 
reticulum 
Severe 
Autosomal 
recessive 
610968 17q21.2 FKBP10 XI 
Endoplasmic 
reticulum 
Mild to 
severe 
Autosomal 
recessive 
609220 3q24 PLOD2 
 
Endoplasmic 
reticulum 
Moderate to 
severe 
Bone mineralisation 
      
Autosomal dominant 610967 11p15.5 IFITM5 V 
Plasma 
membrane 
Variable 
Autosomal 
recessive 
613982 17p13.3 SERPINF1 VI 
Extracellular 
matrix 
Moderate to 
severe 
Autosomal 
recessive 
182120 5q33.1  SPARC XVII Extracellular 
matrix 
Moderate to 
severe 
Osteoblast 
development       
Autosomal 
recessive 
613849 12q13.13 SP7 XII Nucleus Severe 
Autosomal 
recessive 
615220 12q13.12 WNT1 XV Extracellular 
matrix 
Severe 
ER-Related       
Autosomal 
recessive 
616229 11p11.2 CREB3L1 XVI 
Endoplasmic 
reticulum 
Severe 
X-linked 300294 Xp22.12 MBTPS2 XVIII 
Endoplasmic 
reticulum 
Moderate to 
severe 
Autosomal 
recessive 
615066 9q31.2 TMEM38B XIV 
Endoplasmic 
reticulum 
Severe 
Autosomal 
recessive 
607186 4q26 SEC24D  
Endoplasmic 
reticulum 
Cole–
Carpenter  
Autosomal 
recessive 
176790 17q25.3 P4HB  
Endoplasmic 
reticulum 
Cole–
Carpenter  
Table 2 Summary of Genes Associated with OI and their numerical classification.   
OMIM=Online Mendelian Inheritance in Man 
There is some debate in the literature concerning how to incorporate newly acquired genetic 
knowledge into the OI classification. One proposal (Barnes, Carter et al. 2010) is that these genes are 
added to the current classification as X, XI, and XII etc and this has been adopted by some groups 
including OMIM (Online Mendelian Inheritance in Man ®). However, as the number of genes 
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increases, there is growing support for the classification to remain clinically focused, without reference 
to genetic aetiology although it could be argued that reference to genetic cause is vital if this has the 
potential to influence subsequent treatment or management of affected individuals. 
A further difficulty in classification is posed by Bruck syndrome type 1 and type 2 which are 
characterised by bone fragility and joint contractures (Breslau-Siderius, Engelbert et al. 1998, van der 
Slot, Zuurmond et al. 2003).  Autosomal recessive mutations in FKBP10 and PLOD2 have been 
identified in some affected individuals with these conditions (Ha-Vinh, Alanay et al. 2004, Hyry, Lantto 
et al. 2009, Setijowati, van Dijk et al. 2012). However, it is becoming apparent that the phenotype 
associated with FKBP10 and PLOD2 mutations overlaps with recessive OI (Puig-Hervás, Temtamy et 
al. 2012, Schwarze, Cundy et al. 2013). Indeed, there is some debate as to whether Bruck syndrome 
could be considered as a further OI variant, although it is not listed as such in the International 
Nomenclature group for Constitutional disorders of the Skeleton proposal (Warman, Cormier-Daire et 
al. 2011).  
Similarly, Cole Carpenter syndrome is a skeletal dysplasia characterized by features of OI, such as 
frequent fractures and bone deformity, along with a distinctive facial appearance, craniosynostosis, 
ocular proptosis and hydrocephalus. Mutations in P4HB (Rauch, Fahiminiya et al. 2015), SEC24D 
(Garbes, Kim et al. 2015, Zhang, Yue et al. 2017) and CRTAP (Balasubramanian, Pollitt et al. 2015) 
have all been described to be causative. 
The most recent proposal for OI nomenclature (Van Dijk and Sillence 2014) includes current genetic 
knowledge but is focused on clinical description. The new classification has five main categories:  
 Type 1   Non-deforming OI with blue sclerae 
 Type 2  Perinatally lethal OI 
 Type 3   Progressively deforming 
 Type 4   Common variable OI with normal sclerae 
 Type 5   OI with calcification in interosseous membranes 
The nomenclature is supported by a Severity Grading Scale designed to allow international agreed 
criteria to be established for classification of affected individuals. It is hoped this will help to inform 
clinical utility of treatments, development of new therapies and provide valuable information of likely 
prognosis for families. However, it seems reasonable to speculate that reference to genetic aetiology 
will be a requirement as personalised treatments become available. 
 
ii.xiii OI pathogenesis 
Identifying the genetic cause of OI has enabled considerable advances in our understanding of OI. 
However, there is still uncertainty about the underlying pathophysiology and the contribution that each 
proposed mechanism makes to clinical severity. 
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ii.xiii.i Bone characteristics 
The main feature of OI is low bone mass and increased bone fragility. Bone tissue 
hypermineralisation, that leads to the characteristic ‘brittleness’, is a key feature of OI and 
differentiates it from other early onset bone fragility disorders. 
At the macro level, OI bone from individuals with collagen defects shows cortical thinning and 
decreased trabecular bone. Increased osteoblasts and osteoclasts and a subsequent increase in 
bone turnover is observed, although at the osteoblast level deposited bone is reduced and is not 
compensated for by increased osteoblast numbers, resulting in reduced bone mass.  
At the fibril level, increased or variable fibril diameter, as a result of defects in collagen assembly, and 
increased susceptibility to fibril ‘kinking’ leads to a disorganised matrix that is associated with 
increased mineral and water content. Mineral platelets, that are usually smaller in OI bone, are closely 
packed, overall resulting in hypermineralization. At the molecular level an increase in non-enzymatic 
cross linking of collagen molecules, adding to tissue stiffness, is also observed (Bishop 2016). 
These multi level changes affect the ability of the OI bone to absorb normal mechanical stresses and 
to dissipate impacts that may result in fracture. This in turn will impact on the presence of growth 
factors and cytokines influencing the proliferation and differentiation of bone cells and matrix 
mineralisation. 
ii.xiii.ii ER stress 
As well as changes in bone architecture, a further proposed mechanism of OI pathogenesis is through 
the activation of ER stress mechanisms caused by misfolded protein molecules (Boot-Handford and 
Briggs 2010). This ER stress response activates synthesis of chaperone proteins designed either to 
help in protein folding or increase mutated protein degradation. There are three known pathways that 
are referred to as the unfolded protein response (UPR). 
Increased unfolded protein in the ER activates three membrane receptors: protein kinase R (PKR)-
like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 
(ATF6). These are normally bound to an HSP70 molecular chaperone located in the ER called 
binding immunoglobulin protein (BiP), which suppresses their activity. Disassociation of BiP from 
PERK, IRE1 and ATF6, when BiP is needed to promote protein folding, triggers these ER stress 
receptors and activates the downstream ER stress pathways (Figure 10).   
Activation of PERK causes dimerisation and phosphorylation of eukaryotic translation initiation factor-
α (eIF2α), which induces more effective assembly of functional 80S ribosomes and translation of the 
transcription factor ATF4. This in turn upregulates transcription of genes involved in the UPR, 
including the transcription factor CCAAT/enhancer-binding protein homologous protein (CHOP) that 
induces apoptotic cell death.  
In response to ER stress, the IRE1 protein degrades mRNA in the ER in a process called regulated 
IRE1-dependent decay (RIDD) that decreases protein biosynthesis. IRE1 also induces 
unconventional splicing of the mRNA that encodes X-box-binding protein 1 (XBP1), upregulating 
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genes encoding mediators for protein folding and those for controlling ER-associated degradation 
(ERAD). 
Activation of ATF6, a transcription factor anchored in the ER membrane, causes its translocation to 
the Golgi. Here it is cleaved by the sequential action of site 1 protease (S1P) and site-2 proteases 
(S2P), releasing the cytoplasmic 50-kDa domain (ATF6-50). This enables translocation to the nucleus 
and upregulation of UPR target genes, including components of the ER-associated degradation 
(ERAD) pathway. 
  
 
Figure 10 The unfolded protein response (UPR). 
Unfolded proteins trigger disassociation of BiP from PERK, IRE1 and ATF6 triggering downstream ER stress 
responses. These activate synthesis of chaperone proteins designed either to help in protein folding, increase 
mutated protein degradation or induce apoptotic cell death. Figure adapted from (Celli and Tsolis 2015). 
 
Mutations in the procollagen C-propeptide, that inhibit collagen chain assembly and cause propeptide 
misfolding, has been shown to activate the conventional unfolded protein response (UPR) leading to 
upregulation of BiP and subsequent ERAD (Chessler and Byers 1993, Makareeva, Aviles et al. 2011). 
A mouse model with a mutation in the C-propeptide domain of COL1A1, that causes exon skipping, 
provided evidence for ER stress–associated apoptosis of osteoblasts as a key component of OI 
pathogenesis (Lisse, Thiele et al. 2008). 
In contrast, procollagen with triple helix mutations that cause misfolding does not trigger the 
conventional UPR but is removed by autophagy and lysosomal degradation, mainly through the 
PERK pathway (Besio, Iula et al. 2018). This pathway is not yet fully elucidated but is often referred to 
as the aggregated protein response (APR). Aggregates that accumulate due to lack of HSP47 
(SERPINH1) also trigger APR. 
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In the α2(I)-G610C mouse model misfolded procollagen has been shown to cause altered expression 
of ER chaperones αB crystalline and HSP47, as well as upregulation of the general stress response 
protein CHOP. Significantly, deficient osteoblast differentiation and maturation as well as abnormal 
response to signalling molecules such as WNT and TGFβ and deposition of abnormal bone matrix 
was also demonstrated (Mirigian, Makareeva et al. 2016).  
The ER-stress mechanism of pathogenesis is further supported by the identification of severe OI in 
individuals with loss of OASIS, a tissue-specific ER-stress transducer that alters gene transcription 
during mild ER-stress. Mutations in the MBTPS2 gene, encoding S2P that cleaves regulatory proteins 
during times of ER stress have also been reported in individuals with OI. 
 
ii.xiii.iii TGFβ signalling 
Transforming growth factor-beta (TGFβ) signalling is known to be fundamental to both skeleton 
development and bone homeostasis, coupling resorption and formation to maintain bone mass (Lim, 
Grafe et al. 2017). TGFβ is synthesised as a noncovalently bound complex with latency-associated 
protein (LAP). Osteoclast bone resorption results in the cleavage of LAP, releasing active TGFβ 
inducing Smad-dependent and Smad-independent signalling (Figure 11). 
In Smad-dependent signalling, TGFβ binds to membrane-bound serine/threonine receptors (TβRI and 
TβRII) and, in a sequential phosphorylation cascade, leads to phosphorylated R-Smad (Smad2 or 3). 
R-Smads dissociate from their receptors and complex with Smad4, migrating to the nuclei where they 
regulate gene expression.  
The Smad-dependent signalling pathway is negatively regulated by Smad7 that prevents R-Smad 
phosphorylation. Smad 7 itself is targeted by Arkadia with the resulting upregulation of Smad-
dependent signalling. 
TGFβ–Smad signalling can locally attract osteoblast precursor cells, stimulating proliferation and 
differentiation. However, it also inhibits osteoblast maturation and transition into osteocytes as well as 
inhibiting osteoclast differentiation by reducing RANKL/OPG secretion. 
In the non-Smad-dependent pathway, phosphorylated TAK1 recruits TAB1 initiating the MKK-p38 
MAPK or MKK–ERK1/2 signalling cascade. The downstream target of both the Smad-dependent and 
the Smad-independent pathways is RUNX2, a key transcription factor associated with osteoblast 
differentiation. Continuous TGFβ signalling can result in inhibition of osteoblast function, increasing 
the relative density of osteocytes and resulting in low bone mass. 
Increased TGF-β signalling has been demonstrated in both the Crtap-/- and Col1a2tm1.1Mcbr mouse 
models of OI. Smad2 phosphorylation and increased TGF-β target gene expression were also 
observed in both mice. (Grafe, Yang et al. 2014) In addition, treatment with 1D11, a TGF-β antibody, 
resulted in normalization of osteocyte numbers and improved bone strength.  
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Figure 11 TGFβ signalling in bone.  
In Smad-dependent signalling, TGFβ binds to TβRI and TβRII receptors leading to phosphorylated R-Smad (Smad2 
or 3). R-Smads dissociate from their receptors and complex with Smad4, regulating gene expression. This pathway 
is negatively regulated by Smad7 that prevents R-Smad phosphorylation. Smad 7 itself is targeted by Arkadia with 
the resulting upregulation of Smad-dependent signalling. TGFβ–Smad signalling stimulates proliferation and 
differentiation of osteoblast precursor. However, it also inhibits osteoblast maturation and transition into osteocytes 
as well as inhibiting osteoclast differentiation by reducing RANKL/OPG secretion. In the non-Smad-dependent 
pathway, phosphorylated TAK1 recruits TAB1 initiating the MKK-p38 MAPK or MKK–ERK1/2 signalling cascade. The 
downstream target of both the Smad-dependent and the Smad-independent pathways is RUNX2, a key transcription 
factor associated with osteoblast differentiation. Figure modified from (Wu, Chen et al. 2016) 
Similarly altered TGF-β signalling was also observed in Brtl+/− mice, where the degree of TGF-β 
upregulation correlates with phenotypic severity (Bianchi, Gagliardi et al. 2015). These findings 
suggest that increased TGF-β signalling may be a common mechanism in both dominant and 
recessive forms of OI. 
ii.xiv Treatment 
Treatment for OI is not curative and requires a multidisciplinary approach, including rehabilitation 
(physical and occupational therapy), surgical interventions and medical treatment (Marr, Seasman et 
al. 2017) 
The main pharmacological treatment for OI is bisphosphonates, antiresorptive agents that can 
improve bone architecture and increase bone mass by reducing osteoclastic bone resorption. 
However, the efficacy of this treatment in terms of fracture rate reduction and bone pain is not 
completely clear (Marini, Forlino et al. 2017).  
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A further treatment option is denosumab, a RANKL antibody that also inhibits osteoclast maturation. A 
limited number of studies have reported an increase in lumbar spine aBMD but without subsequent 
mobility improvements in children treated with denosumab (Hoyer-Kuhn, Franklin et al. 2016). 
Teriparatide, a human recombinant parathyroid hormone with known osteoanabolic effect, has also 
been shown to be effective at increasing BMD in mildly affected adults (Orwoll, Shapiro et al. 2014) 
without a clear effect on fracture risk. 
Emerging therapies: 
Sclerostin, is a negative regulator of bone formation and acts by inhibition of Wnt signalling, thus 
down-regulating osteoblast development and function. Treatment of post-menopausal osteoporosis 
by romosozumab, an anti-sclerostin antibody, results in increases in bone mineral density and 
reduced fracture risk (Cosman, Crittenden et al. 2016). Studies in Wnt1sw/sw mice showed significant 
improvements in bone quality and quantity when treated with anti-sclerostin antibody and suggest that 
this could be an effective gene specific treatment for WNT1-related OI (Joeng, Lee et al. 2017). 
Expanded studies in different mouse models would be useful to inform the likely efficacy in other 
genotypes. 
Raloxifene, a selective oestrogen receptor modulator (SERM) is also used to reduce fracture risk in 
post-menopausal osteoporosis. The mechanism of action is thought to be via a combination of 
reduction in bone resorption and altered skeletal hydration. These findings have been duplicated in 
bone from the oim mouse that also had reduced fracture rate following treatment (Berman, Wallace et 
al. 2016). 
Another potential emerging therapy is anti TGFβ antibodies that have been shown to increase bone 
maximum load and strength in recessive (Crtap-/-) and dominant (Col1a2+/P.G610C) mice. Response in 
these models is genotype dependent with the Crtap-/- model exhibiting greater response to 1D11, a 
pan TGFβ antibody. However this treatment did not appear to rescue the reduced collagen or 
increased brittleness in either of these OI models (Bi, Grafe et al. 2017). A study with fresolimumab, a 
human polyclonal antiTGFb antibody, is underway in adults with OI in the USA. 
Mutant allele specific silencing has been achieved in fibroblasts from Brtl mouse using small 
interfering RNAs targeting the 3'UTR of the gene opening the possibility of bespoke mutation specific 
treatment (Lindahl, Kindmark et al. 2013, Rousseau, Gioia et al. 2014). 
Fetal stem cell transplantation has been reported in two human cases of OI; efficacy is hard to assess 
due to variable assessment of severity at baseline (Le Blanc, Götherström et al. 2005, Götherström, 
Westgren et al. 2014). 
ii.xv Novel Molecular Mechanisms in OI 
Understanding both the genetics and underlying mechanism of OI pathogenesis is vital for the 
development of new and improved treatments. 
Despite the recent proliferation of genes associated with OI, as a consequence of the recent 
advances in gene discovery technology, there remain ~5% of OI individuals in whom a causative 
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mutation has not been identified. Within this group is a cohort of families with mild/moderate OI 
without a mutation in the type I collagen genes. However, research to identify new OI genes has 
largely focused on severely affected individuals, often from large consanguineous families, where 
recessive inheritance is implicated.  
Historically a number of strategies have been employed to identify causal genes in inherited 
disorders. Linkage analysis, using families with multiple affected members, and positional cloning 
were traditionally used to support gene identification, the most well known examples being the 
identification of the loci for Huntington disease (Gusella, Wexler et al. 1983) and discovery of the 
cystic fibrosis gene (Riordan, Rommens et al. 1989). Linkage analysis was traditionally employed in 
OI to identify which type I collagen gene was causal within an individual family.  
More recently, the emergence of ‘next generation’ high through-put sequencing platforms and high 
density arrays has enabled rapid identification of more than 100 genes associated with Mendelian 
disorders (Rabbani, Mahdieh et al. 2012, Study 2015), including many of the newly described OI 
genes. High density single nucleotide variant (SN) arrays to identify homozygosity regions in three 
consanguineous OI families followed by targeted exome sequencing lead to the identification of the 
TMEM38B gene (Shaheen, Alazami et al. 2012, Volodarsky, Markus et al. 2013). Similarly, SP7 was 
identified as the causative gene in a single affected individual from a consanguineous family using a 
combination of homozygosity mapping and a subsequent candidate gene sequencing approach 
(Lapunzina, Aglan et al. 2010). Linkage analysis and whole exome sequencing in a four-generation 
family has also been employed to identify the dominant mutation in IFITM5 responsible for OI type V 
(Cho, Lee et al. 2012). 
However, for non-consanguineous families where the number of affected individuals is small, or for 
apparently de-novo cases, the identification of the causal gene can be more problematic, particularly 
in disorders with genetic and phenotypic heterogeneity such as OI.  The number of variants identified 
by whole exome sequencing can be large, averaging more than 80,000, dependent on ethnic origin 
(Belkadi, Bolze et al. 2015). Filtering and analyzing this data is challenging and interpretation of whole 
exome sequencing can therefore be difficult.  
Even when data is filtered to remove common polymorphisms, several hundred potentially pathogenic 
variants can remain, dependent on study design and filtering strategy employed. For sporadic cases 
analysis of trios (proband and parents) may help to detect de-novo variants, although the presence of 
a de-novo variant is not considered sufficient to confirm causality as there is an estimated de-novo 
mutation rate of one in 108 bases per haploid genome per generation (Lynch 2010).  Commonly, 
variants in genes already reported to be associated with the condition are analysed as a first step in 
exome data analysis.  
The use of a targeted candidate gene approach to identify causative mutations, rather than whole 
exome sequencing, has the advantage that it is focused on existing knowledge of the condition and 
its possible biological origin. Candidate genes are generally those whose function directly or indirectly 
influences the developmental or regulatory processes of the trait under investigation. In OI this would 
be biological pathways known to be involved in skeletal development and homeostasis. Variants 
identified in an appropriate pathway can be more confidently interpreted than those outside, although 
ideally functional studies are required to confirm the effect of any variant on protein function. 
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Mutations in genes involved in pathways influencing bone development and homeostasis are known 
to be associated with a variety of conditions and some show inheritance in both an autosomal 
recessive and autosomal dominant manner for example LRP5 and ALPL.  
ii.xv.i.i  LRP5  
The LRP5 gene encodes the low density lipoprotein receptor-related protein 5, a transmembrane co-
receptor that participates in the WNT–β-catenin signalling pathway with Frizzled (FZD4 gene) and 
LRP6. As previously discussed WNT signalling is involved in the development and maintenance of 
several tissues, influencing cell proliferation, adhesion and migration, and in particular plays a key role 
in skeletal homeostasis and eye development and function. Mutations in LRP5 give rise to several 
conditions, which reflect the involvement of the protein in the affected tissue, and can be inherited in 
either a dominant or recessive manner.  
Heterozygous loss of function mutations in LRP5 result in familial exudative vitreoretinopathy (FEVR) 
a condition that is characterised by disruption to early eye development, abnormal blood supply to the 
retina and resulting loss of vision. As LRP5 also plays a role in bone formation, individuals with FEVR 
may also have reduced bone mineral density (Qin, Hayashi et al. 2005).  
Homozygous loss of function mutations are associated with the severe osteoporotic disorder 
Osteoporosis Pseudoglioma (OPPG) where severe low bone mineral density results in multiple 
fractures. Individuals with OPPG also have eye abnormalities. LRP5 has also been linked to 
Idiopathic Juvenile Osteoporosis (IJO) and reduced bone mass in the heterozygous carriers of OPPG 
(Ferrari, Deutsch et al. 2005). 
In contrast heterozygous gain of function mutations are associated with high bone mass conditions 
such as autosomal dominant osteopetrosis type 1 and endosteal hyperostosis (Little, Carulli et al. 
2002).   
ii.xv.i.ii ALPL 
Hypophosphatasia is caused by loss or reduced function of tissue non-specific alkaline phosphatase 
(TNSALP). The functional mechanism of the TNSALP enzyme is not completely understood, but it is 
known to be essential for mineralization of bone and teeth and has been shown to increase 
concentrations of phosphate, which promotes mineralization, and decreased pyrophosphate, which is 
an inhibitor of mineral formation (Hessle, Johnson et al. 2002).  
Hypophosphatasia is characterized by defective mineralization of bone and/or teeth caused by 
mutations in the ALPL gene which encodes TNSALP. In a similar manner to OI, there is considerable 
variation of clinical severity ranging from stillbirth without mineralized bone to mildly affected adults 
with early loss of dentition and few fractures. There are six recognized forms of the condition based 
on severity and age of onset (Table 3).  
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Type Inheritance 1 Cardinal Features 
Dental 
Features 
Clinical Diagnosis 
Perinatal (lethal) AR 
Hypomineralisation, 
osteochondral spurs 
N/A 
Radiographs, 
prenatal 
ultrasound 
examination 
Perinatal (benign) AR or AD 
Long-bone bowing, 
benign postnatal course 
± 
Prenatal 
ultrasound 
examination, 
clinical course 
Infantile 2 AR 
Craniosynostosis, 
Hypomineralisation, 
rachitic ribs, 
hypercalciuria 
Premature 
loss, 
deciduous 
teeth 
Clinical course, 
radiographs, 
laboratory 
findings 
Childhood AR or AD 
Short stature, skeletal 
deformity, bone 
pain/fractures 
Premature 
loss, 
deciduous 
teeth 
(incisors) 
Clinical course, 
radiographs, 
laboratory 
findings 
Adult 3 AR or AD 
Stress fractures: 
metatarsal, tibia; 
chondrocalcinosis 
± 
Clinical course, 
radiographs, 
laboratory 
findings 
Odontohypophosphatasia AR or AD Alveolar bone loss 
Exfoliation 
(incisors), 
dental caries 
Clinical course, 
dental panorex, 
laboratory 
findings 
Table 3 Classification of Hypophosphatasia  
Modified from National Center for Biotechnology Information (NCBI; http://ncbi.nlm.nih.gov). 
The inheritance of the most severe forms, perinatal and infantile, is in an autosomal recessive manner 
whereas milder forms may be inherited in an autosomal recessive or autosomal dominant. Parents of 
infants with the recessive perinatal form of the disease may, on investigation, be shown to have 
undiagnosed mild symptoms. The differing inheritance patterns and marked phenotypic heterogeneity 
in this condition is related to the variable levels of residual enzyme activity caused by missense 
mutations that predominantly affect the functional domains of the TNSALP protein (Mornet 2000). 
The examples of LRP5 and ALPL show that genes encoding proteins participating in pathways 
influencing skeletal development may be associated with marked phenotypic variability and/or 
different inheritance patterns. This is further supported by the reports of heterozygous dominant 
WNT1 and CREB3L1 mutations in families with early onset osteoporosis and fractures as well as in 
families with moderately severe recessive OI (Keupp, Beleggia et al. 2013, Laine, Joeng et al. 2013, 
Palomo, Al-Jallad et al. 2014, Keller, Tran et al. 2018) 
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The prevalence and range of phenotypes associated with mutations in many of the severe autosomal 
recessive OI genes is currently unclear and the phenotype of heterozygous carriers is not well 
documented.  These genes are therefore good candidates for further investigation. 
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ii.xvi Project Objective 
The overall aim of this research was to contribute to the current knowledge of the molecular basis of 
Osteogenesis Imperfecta (OI) by investigation of patients with a mild/moderate clinical presentation 
without a causative mutation in the type I collagen genes being identified. This is important to be able 
to deliver personalised medicine for these patients in the future. 
ii.xvi.i Objective 1.  
The first objective of this study was to identify a cohort of families with mild/moderate OI without a 
mutation in the type I collagen genes.  
This involved a comprehensive review of the molecular and phenotypic data obtained in a large 
cohort of OI patients referred to the Sheffield Diagnostic Genetics Service connective tissue disorder 
service. Those without a likely pathogenic mutation in the type I collagen genes were invited to 
participate. 
ii.xvi.ii Objective 2. 
The second objective was to elucidate the genetic aetiology in this cohort. A number of different 
strategies have been employed to achieve this: 
 An initial study where all participants were screened for variants in genes 
previously describe in severe OI using a custom designed targeted Next 
Generation Sequencing exome panel (NGS) was undertaken. 
 All participants without a pathogenic mutation in any of these genes were then 
screened by Sanger sequencing for mutations in the TRAM2 gene. This gene was 
identified by the Sanger mouse phenotyping consortium as a strong candidate 
gene for OI. 
 A small subset of participants who screened negative for all known OI genes and 
TRAM2 were investigated using whole exome sequencing.  
 Follow on studies to investigate potential pathogenicity and mechanisms of novel 
sequence variants identified using additional techniques such as examination of 
dermal collagen and fibroblasts, methylation studies and protein expression 
analysis, where appropriate. 
ii.xvi.iii  Objective 3 
The third objective of this study was to explore a broader dataset of variants from patients who have 
clinical features relating to bone health, including fractures. This part of the study involves analysis of 
data from whole exome sequencing and array CGH analysis through a collaborative complementary 
analysis project (CAP) with the ‘Deciphering Developmental Disorders’ (DDD) study.  
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iii METHODS AND MATERIALS 
iii.i Funding and Ethical Approval 
iii.i.i Targeted Exome Study 
The first element of this research project was to study autosomal recessive genes in a cohort of 
patients previously tested negative for the type I collagen genes. To achieve this I wrote an 
application to obtain funding from the Sheffield Children’s Charity (Protocol Number: SCH/11/062). 
The application included development of the study design (Figure 12), preparation of age appropriate 
patient information sheets, consent forms and patient eligibility criteria (Appendix pages 277, 283 and 
298). 
Following the successful funding application, I gained ethical approval for the project from the 
Yorkshire and Humber NRES committee (Reference Number: 12/YH/0021). R&D approval was 
obtained from the Clinical Research Facility at Sheffield Children’s NHS Foundation Trust and at each 
host organisation prior to the start of patient recruitment, in accordance with NHS research 
governance procedures.  
iii.i.ii Whole Exome Sequencing 
A subsequent application for funding to support whole exome sequencing in a smaller cohort of 
patient was developed in collaboration with Dr Balasubramanian, Dr Dalton and Prof Bishop to The 
Children’s Hospital Charity (TCHC) grant number CA15001.  
iii.i.iii Deciphering Developmental Delay 
In collaboration with Dr Balasubramanian, a project application was submitted and successfully 
registered with Deciphering Developmental Delay study (CAP12, Appendix page 296) 
iii.ii Patient Recruitment 
iii.ii.i Participant Identification 
Potential participants were initially identified for this study by a review of all patient records held at 
Sheffield Diagnostic Genetics Service to identify patients referred for analysis of the type I collagen 
genes. A total of 655 patients were identified. Patients with either a confirmed pathogenic mutation or 
a variant of uncertain significance in these genes were excluded. Presenting phenotypic details were 
reviewed for all remaining patients. Further exclusion criteria were subsequently applied as follows. 
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iii.ii.ii Exclusion Criteria 
Individuals without a clear clinical phenotype were excluded as were those where analysis had been 
performed to exclude a diagnosis of OI in cases of suspected non-accidental injury (medico-legal 
testing).  
Patients with a lethal (type II) phenotype or fulfilling the current definition of “severe” adopted by the 
NHS-funded Highly Specialised OI Service for children with severe, complex and atypical OI were 
excluded. 
The “severe” definition criteria are: 
 Neonates with OI who have multiple long bone fractures 
 Children/infants with OI who have: 
 Six or more vertebrae crush-fractured/deformed (more likely to progress to 
scoliosis according to published data) 
 Multiple limb deformities resulting in corrective surgery and attendant frequent 
OT/PT input 
 Intractable bone pain despite intravenous bisphosphonate therapy     
iii.ii.iii Recruitment 
Consultant Clinical Geneticists who had referred individuals eligible for the study were contacted with 
information on the study. Those willing to support the study were asked to discuss the study with 
relevant patients and carers, either directly or through their Genetic counselling team. Patients 
interested in participation were sent an invitation letter and age appropriate patient information sheet 
describing the study and its objective.  Recruitment involved obtaining consent for genetic analysis for 
the purpose of research. 
The majority of participants had DNA stored at the Sheffield Diagnostic Genetics Department (SDGS). 
Where further DNA was required a fresh sample of blood was obtained and automated DNA 
extraction was performed. 
iii.iii DNA Extraction     
The Chemagen Magnetic Separation Module is used for automated extraction of genomic DNA from 
whole blood using the Chemagic DNA blood kit. The extraction is carried out in two stages, the first 
involves mixing and lysing of white blood cells to release DNA, the second involves DNA being bound 
to magnetic beads, from which the DNA is subsequently eluted. The kit contains magnetic beads, 
lysis buffer, binding buffer, wash buffers and elution buffer. The eluted DNA is stable at 4ºC or -20ºC.   
A peripheral blood sample of 1-3ml (in EDTA) is required. The expected DNA concentration is ≥ 40 
ng/l in an elution volume of 0.3 ml (in 1 x TE buffer) which is sufficient for subsequent sequencing by 
either Sanger or Next Generation Sequencing methodologies. 
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Figure 12 Study Workflow 
Study Workflow for targeted exome sequencing showing patient recruitment, sample analysis and reporting. 
iii.iv Targeted Exome Sequencing 
Next Generation Sequencing (NGS) is a broad term used to describe the simultaneous sequencing of 
multiple fragments of DNA. This technology allows multiple genes of interest, or even the whole 
genome, from an individual to be sequenced in parallel.   
The first part of this research was to use a candidate gene approach focused on recently identified 
genes leading to severe OI. To achieve this objective a ‘targeted’ next generation sequencing 
strategy was developed whereby only fragments of DNA from the specific genes of interest were 
‘selected’ for sequencing. This process is referred to as targeted exome sequencing. 
Two methodologies for targeted exome sequencing were assessed; SureSelectXT (Agilent 
Technologies) and Nextera (Illumina). These methods are used to ‘capture’ or ‘enrich’ the DNA 
fragments of interest, in a process called library preparation, prior to sequencing. An overview of 
these two library preparation methods is shown in Figure 13. An Illumina MiSeq sequencing platform 
was then used to sequence the libraries generated for each participant.  
iii.iv.i SureSelectXT Library preparation 
The SureSelectXT system was used to capture genomic regions of interest using a custom designed 
probe set. 
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Custom Probe Design 
A custom probe set was designed using the Agilent web based SureDesign software 
(https://earray.chem.agilent.com/suredesign/) to cover all coding regions and intron/exon boundaries 
of known OI genes (Table 4). 
 
Figure 13 Comparison of SureSelectXT and Nextera Library Capture Methods 
Overview of SureSelect and Nextera Library Capture methods. Figure based on (Samorodnitsky, Datta et al. 2015) 
and is published under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License (CC 
BY NC ND). 
The COL1A1 and COL1A2 genes were included in the design to confirm the absence of mutations in 
these genes in this cohort. The process of probe design involves creating a file (.BED format) 
containing a list of genomic co-ordinates corresponding to each coding region of the genes of interest. 
This file was uploaded to the SureDesign application and the parameters for probe design selected as 
follows: Flanking bases: 25, Density: X5, Masking: Moderately Stringent, Boosting: Max Performance. 
Once the probe design was complete the resulting probe set was downloaded and inspected to 
identify any missed regions, the location of the probes and the gene structure. 
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Gene 
Coding 
cDNA 
length 
Coding 
exons 
Reference Sequence 
Chromosome 
location 
Autosomal Dominant 
COL1A1 4392 52 NM_000088.3 17q21.33 
COL1A2 4098 52 NM_000089.3 7q21.3 
IFITM5 396 2 NM_001025295.1 11p15.5 
Autosomal Recessive 
BMP1 2961 20 NM_006129.4 8p21.3 
BMP1 85  1 NM_007799.3 8p21.3 
CREB3L1 1557 12 NM_052854.3 11q11 
CRTAP 1206 7 NM_006371.4 3p22.3 
FKBP10 1749 10 NM_021939.3 17q21.2 
OSX/SP7 1296 2 NM_152860.1 12q13.13 
P3H1 2211 15 NM_22356.3 1p34.2 
PLOD2 2277 19 NM_182943.2 3q24 
PPIB 651 5 NM_000942.4 15q22.31 
SERPINF1 1254 8 NM_002615.5 17p13.3 
SERPINH1 1257 4 NM_001235.2 11q13.5 
TAPT1 1701 14 NM_153365.2 4p15.32 
TMEM38B 873 6 NM_ 018112.1 9q31.2 
WNT1 1110 4 NM_005430.3 12q13.12 
X-linked 
PLS3 1890 16 NM_005032.6 Xq23 
Table 4 Location, size and reference sequence for genes in the Custom Probe Design 
Any regions not covered by the initial design were processed through SureDesign without masking. 
This provided a further set of probes but with the potential to anneal to additional locations within the 
genome. Web Blat was used to assess how many times and how well each set of probes anneals to 
the genome. The best probe sets were manually selected and added to the initial probe design before 
finalising in SureDesign. For areas of ‘difficult sequence’, such as those with high GC content, the 
number of probe replicates was boosted in order to maximise the likelihood of probe capture of those 
regions. A summary of the SureSelect probe design work flow is given in Figure 14  
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Figure 14 SureSelect Custom Probe Design Workflow 
Summary of the workflow for custom probe design for Sureelect library preparation showing stepwise refinement to 
include regions of high GC content and regions masked during initial design process. 
 
 
A completed probe design is listed in a tab delimited text file format as illustrated in Table 5 below. 
 
TargetID ProbeID Sequence Strand Coordinates 
chr11:27695606-
27695831 BA_134634_000028 TTACTCACCTT… + 
chr11:27695599-
27695718 
chr11:27695606-
27695831 BA_134634_000029 TCAGGGATCAG… + 
chr11:27695623-
27695742 
chr11:27695606-
27695831 BA_134634_000030 ACTGAAACGTG… + 
chr11:27695647-
27695766 
chr11:27695606-
27695831 BA_134634_000031 CAGCCCTTCTT… + 
chr11:27695671-
27695790 
chr11:27695606-
27695831 BA_134634_000032 TCATGCCATAC… + 
chr11:27695695-
27695814 
chr11:27695606-
27695831 BA_134634_000033 TAGACGCCAA… + 
chr11:27695719-
27695838 
chr11:27720928-
27720952 BA_134634_000034 TGCCCGTCAG… + 
chr11:27720868-
27720987 
chr11:27720928-
27720952 BA_134634_000035 ATCCTCAGCTA… + 
chr11:27720892-
27721011 
chr11:27722517-
27722583 BA_134634_000036 AGCACCCAAG… + 
chr11:27722466-
27722585 
chr11:27722517-
27722583 BA_134634_000037 GCGTGCGTTT… + 
chr11:27722490-
27722609 
Table 5 Example of a completed probe design for SureSelect library preparation. 
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SureSelectXT Library Construction 
DNA (>3µg) from each participant was ‘normalised’ to a concentration of 26.7ng/µl. The normalised 
DNA was then sonically sheared using a Covaris E220 sonicator to produce fragments between 150-
200bp.  Lastly end repair, adapter ligation and amplification were performed. 
Successful library preparation was confirmed by electrophoresis to confirm a band of ~300bp and a 
smooth peak of fragments sizes was seen on scanning (Figure 15 and Figure 16). 
 
 
Figure 15 Gel image of DNA samples following library preparation 
Each lane, marked A4-H4 and A5-H5, represents an individual patient sample. A size ladder is positioned in lane A0. 
Two standard markers are included at 1500bp (purple) and 25bp (green). Successful library preparation should 
produce a clear band of DNA at ~300bp. 
 
 
Figure 16 Scanned image of individual patient DNA following library preparation 
The DNA was fragmented to ~300bp and standard markers are shown at 25bp and 1500bp 
 
 
An average yield of half the input amount, eg for 2µg you would expect 1µg in total, was achieved. A 
minimum of 750ng was used for hybridisation/capture.  
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SureSelect XT Hybridisation / capture 
The SureSelect XT target enrichment protocol combines the prepared DNA library with hybridisation 
reagents and the SureSelect Capture library consisting of the custom designed probes for the specific 
genes of interest. The samples were hybridised for 20 hours, then captured using magnetic beads. 
The final enriched library contained 10000-20000 pmol/l DNA with a maximum fragment size of 
~300bp. 
iii.iv.ii Nextera Library Preparation 
Custom Probe Design 
A custom probe set was developed using the Illumina DesignStudio Sequencing Assay Designer. In a 
similar process to the SureSelect design, genomic coordinates of each region of interest (coding 
regions and intron/exon boundaries) were used by the DesignStudio algorithm to optimize probe set 
design. Regions of poor coverage or those with high GC content are highlighted and these were 
manually reviewed and refined. An illustration of the completed design, as a tab delineated file, is 
shown in Table 6 below.  
 
Probe 
ID 
Chr Start Stop Labels Sequence Design 
Warnings 
720478 17 1674370 1674449 SERPINF1_4 GACTTGATCAGCAGCCCAGACATCCATGGTACC
TATAAGGAGCTCCTTGACACGGTCACTGCCCCC
CAGAAGAACCTCAA 
 
722847 17 1678493 1678572 SERPINF1_6 AGGTCTGTAGGGATAGGGGCAGGGTGGGGGGT
GGATGGAGGGAGAGGATAGAGAAGCAAAACAG
GGTAGTGGGAATAAAA 
Low 
Specificity 
722082 17 1678393 1678472 SERPINF1_6 GAGGATTTCTACTTGGATGAAGAGAGGACCGTG
AGGGTCCCCATGATGTCGGACCCTAAGGCTGTT
TTACGCTATGGCTT 
 
720243 8 22022896 22022975 BMP1_15UTR TCCCTCGCCGCCGCCCCGCCAGCATGCCCGGC
GTGGCCCGCCTGCCGCTGCTGCTCGGGCTGCT
GCTGCTCCCGCGTCCC 
Poor GC 
Content 
722793 8 22022836 22022915 BMP1_15UTR TCGCGATCGAGCAAGCAAGCGGGCGAGAGGAC
GCCCTCCCCTGGCCTCCAGTGCGCCGCTTCCCT
CGCCGCCGCCCCGCC 
 
723648 8 22031091 22031170 BMP1_2 CCTGGCTTCTTCTTTTCTCTTTAGCTGCCTTTCTT
GGGGACATTGCCCTGGACGAAGAGGACCTGAG
GGCCTTCCAGGTA 
 
Table 6 Completed probe design for part of the SERPINF1 and BMP1 genes for Nextera Library 
preparation 
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Nextera Library Preparation 
Extracted DNA (>3µg) from each participant was cleaned (Ampure DNA clean up) and titrated down 
to a concentration of 5ng/µl. The library preparation consists of a tagmentation reaction, PCR 
amplification using known dual indices, library hybridisation to the custom designed oligos for the 
targeted regions and a second PCR amplification, with bead clean up between steps. Tagmentation is 
where the Nextera transposome fragments and tags the DNA with adapter sequences 
simultaneously, ready for the following PCR steps.  
Following tagmentation there should be a broad distribution of DNA fragment size, ideally between 
200-400bp . This was checked on an Agilent Technologies 2200 Tapestation using a High Sensitivity 
D1K tape. An example of successful tagmentation is given below in Figure 17: 
 
 
Figure 17 Tapestation analysis of DNA library preparation 
The size of the tagmented DNA template should be between 200-400bp. An optimal profile would have a wide peak 
(as seen in above picture). A narrow peak would indicate that the DNA has been overly tagmented. Sample intensity 
appears low in comparison to SureSelect library preparation but this increases after subsequent PCR amplification. 
 
 
Nextera Hybridization 
The prepared DNA library was mixed with the custom designed capture probes and incubated at 
58°C for between 90 minutes and 24hours. Streptavidin beads were then used to capture probes 
hybridized to the targeted regions of interest. This enriched library is washed and a second round of 
hybridization performed, which ensures high specificity for the captured regions. Following a sample 
clean up, the captured library was amplified via a 12 cycle PCR process. The library insert size was 
checked using the Tapestation to ensure it lies between 250-300bp. 
iii.iv.iii Sequencing on the Illumina MiSeq.  
Sequencing was performed on an Illumina MiSeq™ platform using the MiSeq™ Reagent Kit v2 
performing 150bp paired-end reads.  Sequencing using paired-end reads (sequencing both ends of a 
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DNA molecule) improves alignment to the genome particularly over repetitive regions. The detection 
of insertions or duplications is also improved.  
The ‘sequencing by synthesis’ method used by Illumina uses fluorescently labelled dNTPs that are 
incorporated during each sequencing cycle. Imaging after each cycle allows base calling of the DNA 
molecule.  
iii.v NGS analysis pipeline 
Raw DNA sequence files obtained from the Illumina MiSeq™ platform were analysed through the 
pipeline developed at Sheffield Diagnostic Genetics Service (SDGS). This pipeline broadly adheres to 
the ‘Best Practices’ workflow by the Broad Institute ( http://www.broadinstitute.org/gatk/guide/best-
practices), but with some additional analysis and data-filtering steps added, some of which have been 
customised to accommodate local needs at SDGS. 
The pipeline aligns reads to human genome build hg19, performs various QC checks, including the 
analysis of percent aligned reads and reads on target (i.e. reads that contain sequence that overlap 
the region of interest), and also depth of coverage. A minimum threshold of 30-fold read depth was 
set for exonic sequences and intronic sequences up to and including 5bp from the intron/exon 
boundary. A minimum threshold of 18-fold read depth was set for intronic sequences from 6bp to 
25bp from the exon.  
Variants were subsequently identified using HaplotypeCaller and annotated with Human Genome 
Variation Society (HGVS) nomenclature. Variants were filtered against a common polymorphism list 
which was compiled using NCBI dbSNP (Single Nucleotide Polymorphism Database), which contains 
data from large sequencing projects such as the NHLBI Exome Sequencing Project and 1000 
Genome Project. In house reference files such as the polymorphism lists and preferred transcript list 
were also used. 
The SDGS NGS analysis pipeline (v3.1.3) was used to take fastq files generated by the Illumina 
HiSeq through accepted best practices and produce filtered annotated variants for review, in the form 
of a Variant Call Format (VCF), a text file format containing a header followed by variant calls. The 
header contains information about the variant data and relevant reference sources (e.g. genome build 
version etc.) and defines the annotations used in the variant calls contained in the VCF file. In 
addition, the pipeline produces a number of QC files that allow assessment of the quality of the data. 
The pipeline was contained within one script which handles the calling of other software required to 
process and analyse the sequencing data (sdgs_ngs_gene_panel_analysis.sh). The pipeline was run 
as a ’job’ in the sun-grid-engine high performance computing environment using hg19 from NCBI as 
the reference genome. 
The following steps were taken by the pipeline for analysis of patient’s sequencing data. 
Check input arguments for validity 
Make output directory and start analysis log 
Run bwa align, sample, and sort into 2 bam files which are then merged 
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Clip overlapping reads  
Make regions of interest bed file  
Count total and failed reads 
Picard mark duplicates 
Calculate Duplicate stats 
GATK Indel realignment restricted to bed file  
GATK Haplotype Caller 
Filter VCF by bed file 
SnpSift annotation from dbSNP, COSMIC & HGVS 
Format the files required for annovar 
Run annovar (annotate variants with respect to functional consequences) 
Combine annotations 
Remove low quality calls and polymorphisms 
A number of files were created by the pipeline, both results and QC files, which were used to check 
the quality of the run.   
The bioinformatics pipeline uses open source software to align and call variants within the sequencing 
data. The versions of open source software used are listed in Table 7 below. 
 
Software Use Version 
bwa Alignment v0.7.15 
samtools Bam/Sam processing v1.3.1 
GATK Indel realignment & Variant calling v3.6 
picard Marking duplicates v1.101 
sambamba Coverage calculations v0.6.3 
bedtools Processing & manipulating bed files v2.17.0 
annovar Annotating variants 2013-08-23 11:32:41 -0700  
SnpSift Annotating variants 3.3h (build 2013-08-20) 
Table 7 Versions of open source software used in the bioinformatics pipeline (v3.1.3). 
The SDGS bioinformatics pipeline is used to call and annotate sequence variants prior to analysis 
Quality Control 
A quality control report was generated by taking the temp_run_report.txt file that was generated for 
each sample and combining with others in the run to produce a run report.  This file was used in 
determining the quality of the data for all samples in the run. The report contains the following 
columns for each sample: 
tot_reads – Total number of reads 
%_run – Percent of the run that is from that sample 
Fail – Number of failed reads 
PCR_dups & %PCR_dups  – Total and percentage PCR duplicates 
opt_dups & %opt_dups – Total and percentage Optical duplicates 
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lib_size – Estimated library size 
med_read_length & 1st_quart_read_length & 3rd_quart_read_length – Median 1st and 
3rd read length of non-failed non dups 
Mapped & %mapped - Total mapped reads and percent mapped 
proper_pairs & %proper_pairs - Total proper pairs and percent proper pairs 
correct_orient & %correct_orient – Total correct orientation and percent correct orientation 
med_insert & 1st_quart_insert & 3rd_quart_insert – Median insert size & 1st & 3rd quartiles. 
small_insert & %small_insert - Number and % of read pairs with insert size below the 
expected insert size minus 50. The expected insert size for SureSelect libraries is 200 and 
for TruSight is 300. 
large_insert & %large_insert - Number and % of read pairs with insert size above the 
expected insert size plus 50 
broad_panel on_target & %on_target - Number and % of not PCR duplicate reads 
mapping in the broad panel (strictly this is the number of not failed, not PCR duplicate 
mapped reads minus the number of not PCR duplicate reads that mapped off target) (% of 
reads in mapped category) 
broad_panel_%5x ..10x ..15x ..20x ..25x ..30x ..35x ..40x ..45x ..%50x ..100x - % of broad 
panel covered by not failed not PCR duplicate reads at range of depths 
A sample was flagged as poor quality if it failed any of the following criteria: 
%mapped   ≥80 
%proper_pairs   ≥70 
%on_target   ≥40 
%30x    =100 
Samples defined as poor quality were either rerun to obtain more sequence data or, if unlikely to 
generate sufficient sequencing data, a repeat blood sample and DNA extraction was performed. 
iii.vi Mouse Models - TRAM2 Analysis 
iii.vi.i Primer Design 
Primer pairs for PCR amplification of coding regions of the TRAM2 gene were designed using 
Primer3 software (http://frodo.wi.mit.edu/primer3/) (Table 8 below). All primers were checked to 
ensure that there are no common single nucleotide polymorphisms under the primer binding site, 
which can prevent primer annealing, using the Manchester National Genetics Reference Laboratory 
tool provided at URL https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck.htm. 
M13-tails were added to the 5’ end of each primer to allow PCR by a standard sequencing protocol: 
  M13F1 (forward) - CAC GAC GTT GTA AAA CGA C         
  M13R (reverse) - CAG GAA ACA GCT ATG ACC 
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Exon  Forward Primer Reverse Primer2 GC content 
1 CCAGCGGCTAGAGGGTTAAG AGGGGTACAGTGCACAAAGC 73.04% 
2 ATGTAAAAGGGGCGGTTAGC TGTACACAGATGGGGAAAAGG 44.21% 
3 CTGAGGCTATAGCAAACGGG GAGCTGCAGTTTCCTCCAAG 50.00% 
4 ATGTTCAACCCTTCTGTGGG GGGTCCTTTGCAGTCATTTG 44.63% 
5 TTTCTGTCAGGTGGGGACTG CATCCACAATAGGCTCAGGG 59.41% 
6 AGCTCCTCACAGGCAGAGTC AGGAAGGGAGGTACCCCTG 55.76% 
7 TGTGTGTTAAAGCAGCCCAG TGCTAGGCACACAGAGGATG 48.01% 
8 AAAGTGGGAGTGGAAAGCAG AAAATAACGGGAGGGCACC 58.77% 
9 CCCTTGAATCCTCTTCCCAC GGCTGCTATCTCTTCTCCCC 52.83% 
10 CTTGTTCTCCCCTGCACAAC CACCCATCCCAGACAGACTT 63.00% 
11 TCCATGTATAGCAGCTGGGC CCCATTGCAAGACAGGTTTC 58.33% 
Table 8 Primers designed for Sanger sequencing of the TRAM2 gene 
iii.vi.ii PCR reaction 
PCR of TRAM2 was undertaken using OneTaq® Quick-Load® 2X Mastermix which contains taq 
polymerase, dNTPs, MgCl2 and buffers. There are two versions of the mastermix containing either 
standard or GC buffer. Standard buffer was used where the GC content of the primer was below 55%. 
For GC content 55-65% the GC buffer was used and for higher GC content an enhancer was added 
to improve annealing and amplification. The GC content of the TRAM2 primers is listed in Table 8 
 
 Standard exons YELLOW exons RED exons 
 Vol (µl) 
OneTaq + Standard buffer 10   
OneTaq + GC buffer  10 10 
GC Enhancer   3 
Water 7 7 4 
Primer @ 5pmol/μl 1 1 1 
DNA @ 10ng/ μl 2 2 2 
Table 9 Reagents used for TRAM2 amplification by PCR 
Each DNA sample was diluted to a concentration of 10ng/µl in water. Reagents were prepared for 
PCR amplification of TRAM2 depending on GC content of primer sequences (Table 9).  PCR cycling 
was undertaken according to Table 10.  
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Temp (C) Time (min) Cycles 
94 1 x1 
94 0.5  
60 0.5 x33 
68 1  
68 5 x1 
15 10 x1 
Table 10 PCR Cycling Conditions for TRAM2 amplification by PCR 
PCR products were visualised using on a 1.5% agarose gel using 5µl OneTaq PCR product run at 
120V for 15 minutes. 
The TRAM2 primers were initially validated using two control DNA samples to ensure that PCR was 
successful and produced fragments of the expected size. A negative control, with all reagents but no 
DNA, was also included (Figure 18).  
 
 
Figure 18 Electrophoresis of PCR products for the TRAM2 gene 
PCR products from normal control DNA (Cont 1 and Cont 2) and water blank (NTC) are shown.  
iii.vi.iii Sanger Sequencing 
DNA sequencing of PCR-amplified fragments of TRAM2 was carried out using an ABI 3730 
automated sequencer and Big Dye Terminator Sequencing protocol (Applied Biosystems, Foster City, 
USA; http://www.appliedbiosystems.com (Table 11) 
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Mastermix 
Reagents 
PCR Cycling conditions 
BigDye Ready React v1.1 
Terminator Mix 
1μl  
Temp. Time Cycles 
95oC 1 min 1 cycle 
95oC 15s 
25 
cycles 
55oC 10s 
60oC 4min 
Better Buffer 7μl 
H2O 3.8μl 
Sequencing primer  1pmol/μl 3.2μl  
Total 15μl 
PCR product 5μl 
Table 11 Reagents and cycling condition for Sanger Sequencing of TRAM2 PCR products 
iii.vi.iv Analysis of Sanger Sequencing using Mutation Surveyor 
Mutation Surveyor®, a DNA Sequencing software tool, was used for the analysis of Sanger 
sequencing generated by the ABI3730.  
The software provides base calling, sequence alignment and assembly. The package includes 
automated download of annotated GenBank reference files and looks for non-correlation between the 
input sequence and the reference sequence allowing variant identification and annotation using 
Human Genome Variation Society nomenclature (HGVS).  
iii.vii DDD Complimentary Analysis Project 
The required subset of patient data was identified by searching the DDD database using Human 
Phenotype Ontology (HPO) terms. HPO provides a standard vocabulary to describe phenotypic 
information. The terms are developed with reference to Online Mendelian Inheritance in Man (OMIM), 
Orphanet, DECIPHER (DatabasE of genomiC varIation and Phenotype in Humans using Ensembl 
Resources) and medical literature. There are currently more than 11,000 terms.  
The following terms and their HPO numbers were used in this study:  
 Abnormal susceptibility to fractures; Increased susceptibility to fractures 
(HP:0002659) 
 Fractures of the long bones (HP:0003084) 
 Fractures of vertebral bodies; Vertebral compression fractures (HP:0002953) 
 Increased fracture rate; Recurrent fractures; Spontaneous fractures; Generalized 
osteopenia with pathologic fractures (HP:0002757) 
 Pathologic fractures (HP:0002756) 
 Generalized osteopenia; Osteopenia (HP:0000938) 
 Severe osteoporosis (HP:0005897) 
 Generalised osteoporosis with pathological fracture (HP:0005744) 
The data returned for each patient included a list of potential candidate variants as identified by the 
DDD study, a complete list of unfiltered variants (VCF) and details of family structure and phenotypes 
(Table 12). In addition, the referring clinician details were provided for each patient.  
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File type Description 
CAP FILE latest version of the proposal submission form. 
SEARCH FILE: list of updated HPO terms used to perform the searches 
FAMILY ID FILE maps DECIPHER IDs on to the person stable IDs for the proband, mother 
and father.  
FAMILY RELATIONSHIPS FILE: IDS for the proband, father and mother 
CLINICAL FILE all of the clinical observations, growth parameters and ontology term 
annotations that are available for each patient. 
VARIANT FILES VCF files for each patient and their parents (where applicable). 
CANDIDATE VARIANTS: high quality candidate variants in the proband across all genes in the 
relevant patient subset. 
REPORTED SNV & INDEL FILE: a flat text file containing SNVs and indels reported back to clinicians via 
DECIPHER 
a flat text file containing SNVs 
and indels reported back to 
clinicians via DECIPHER 
flat text file containing CNVs reported back to clinicians via DECIPHER 
RESEARCH TRACK VARIANTS: flat file containing variants of unknown significance, may contain additional 
variants of interest not present in the candidate file, such as low quality 
variants 
Table 12 Data fields returned by the Deciphering Developmental Delay study for Complimentary 
Analysis Projects. 
The candidate and research variants for each individual were first assessed at the gene level by 
looking at the function of the protein with emphasis on a potential role in bone disease. The sources 
of information interrogated for each gene is listed in Table 13. 
Those with function related to bone metabolism were further assessed along with the provided clinical 
phenotypes of the patient and their family members. Finally, the full list of variants supplied in the VCF 
for each proband was interrogated. Any variants identified were assessed using the prioritisation 
strategies listed in section iii.ix below. 
 
Source Feature 
GeneAtlas Protein – function, cellular processes and pathways 
 Associated disorders (if any) 
 Cellular expression (tissue) 
UniProt Protein function 
 GO terms for molecular and biological function 
 Pathology and Biotech for involvement in disease 
OMIM Disease phenotype (if any) 
 Gene description, function, molecular genetics and animal models. 
Table 13 Source of terms used to assess the function of candidate genes. 
 Terms used to target genes with a potential role in bone metabolism  
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iii.viii Whole Exome Sequencing 
iii.viii.i Personalis 
Three participants were commercially sequenced by Personalis using their ACE ExomeTM Assay. The 
Personalis pipeline uses the Burrows-Wheeler Aligner (BWA, version number 0.7.5a-r405) for 
alignment, the Broad Institute Genome Analysis Tool Kit (GATK) UnifiedGenotyper for variant calling 
and Variant Quality Score Recalibration (VQSR) to provide a quality score. AnnoL, a Personalis tool, 
is used to annotate variants. The annotation includes population frequencies from 1000 genomes and 
the NHLBI GO Exome Sequencing Project (ESP), those with a frequency of >1% in any of the 
populations are excluded.  Further annotation includes data from dbSNP; predicted mutational impact 
using tools such as including SIFT and Polyphen2; known disease associations from databases such 
as OMIM and ClinVar; and data from pathway and network tools including Reactome (a database of 
reactions, pathways and biological processes) and the Molecular INTeraction database (MINT). 
Clinical information for each patient was provided to Personalis and this was used to rank variants, 
taking into account the similarity between presenting clinical features and known disease-gene 
associations.  
Personalis returned a full data set of variants and this was further investigated at SDGS. Quality 
control was carried out, as recommended by the GATK best practice guidelines, using the following 
hard filters:  
Values used for: SNVs Indels 
QualByDepth (QD) < 2 < 2 
RMSMappingQuality (MQ) < 40  
FisherStrand (FS) > 60 > 200 
HaplotypeScore > 13  
MQRankSum < -12.5  
ReadPosRankSum < -8 < -20 
Table 14 Quality Control filter settings used in analysis of Personalis sequence data 
 
Population frequencies from the Exome Aggregation Consortium (gnomAD, version 0.3) were used in 
filtering and those with a frequency >5% in any subpopulation (excluding the ‘other’ population), or of 
>1% with a total allele count >1000 were removed. Variants with a reported frequency >1% in any of 
the 1000 genomes, NHLBI ESP or UK10K cohort populations were also excluded. After frequency 
filtering, variants were prioritised using the methods detailed in section iii.ix. 
iii.viii.ii In house whole exome sequencing 
The remaining participants, were sequenced at SDGS using QXT library preparation method and 
SureSelect Human All Exon V6 baits for target enrichment. The laboratory method for this is identical 
to that used for targeted exome sequencing of candidate genes using the custom designed probe set 
(section iii.iv.i and iii.iv.iii). Sequencing data from all exome participants and, when available, both 
parents was generated using a HiSeq 2500, using paired-end sequencing 2x100bp. The Human All 
Exon V6 probe set is designed to capture all protein coding regions of the genome and covers 99% of 
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sequence listed in the RefSeq, CCDS, GENCODe, HGMD_cds and OMIM_cds databases at an 
average coverage depth of 20x. Bcl2fastq (v1.8.4) was used to convert sequencing data to fastq files 
ready for mapping to the human genome.  Fastq files were uploaded to Sapienta (v1.5.0) for mapping 
and variant calling.  
 
 
Figure 19 Depth of sequence coverage across all chromosomes for patient E using SureSelect 
Human All Exons V6r2 
An average depth of 103x (standard deviation 62.1) and a median of 94x was obtained. The patient is female. 
 
 
 
Sapienta does not provide a whole exome coverage summary; however, after mapping with BWA-
MEM (a BWA algorithm recommended for high quality sequence queries, version 0.7.15) to GRCh37 
a mean exonic coverage was obtained. Bases contribute to coverage if their quality is >= 30 and 
mapping quality is at least 10 for the read within which they are contained. Duplicate reads are 
excluded. “SureSelect Human All Exon V6 r2” design files were used to restrict coverage calculations. 
The coverage across each chromosome was assessed to ensure read depth was sufficient to allow 
confident variant calling, an example is given in Figure 19. 
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iii.ix Prioritisation of Sequence Variants from WES 
The number of variants identified by whole exome sequencing can be large, averaging approximately 
80,000, dependent on ethnic origin (Belkadi, Bolze et al. 2015). Filtering, analysis and interpretation 
of this data are challenging. An initial step for variant filtering in rare diseases was to exclude those 
found with significant frequency in the general population. In this study, information available in public 
databases from the following projects was used to remove variants with a minor allele frequency 
(MAF) above 1%: 
 Exome Aggregation Consortium (gnomAD, http://gnomAD.broadinstitute.org/) 
 NHLBI Exome Sequencing Project (ESP, http://evs.gs.washington.edu/EVS/)  
 Genome of the Netherlands (GoNL, http://www.nlgenome.nl/) 
Even when data was filtered to remove common polymorphisms, several hundred potentially 
pathogenic variants remained. Three different but overlapping strategies have been employed in this 
study to further filter and prioritise variants to identify the most interesting candidates. 
iii.ix.i Strategy 1: An inheritance hypothesis 
Variants were filtered using an inheritance hypothesis-based approach; this could be an autosomal 
recessive, autosomal dominant, X-linked or Y-linked model. Analysis of trios (proband and parents) 
was particularly useful for this approach and allowed detection of de-novo variants, which if present in 
a gene of interest can be indicative of pathogenicity. 
Filtered variants were then ordered by predicted effect on protein function. Loss of function, including 
nonsense variants and shifts in the protein coding reading frame (frameshift), are in general more 
likely to be damaging than missense variants. Variants that affect the conserved splice donor or splice 
acceptor sites are also likely to have an effect on protein function. For small insertions or deletions, 
these can be ordered on whether they cause splicing disruption, in-frame protein changes or a 
frameshift. 
The resulting list of variants was manually reviewed taking into account published literature, any 
known disease-gene interactions, metabolic and signalling pathways as well as any available gene 
function information and annotations (Figure 20).  
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Figure 20 Variant prioritisation Strategy 1 
Variants identified by exome sequencing are filtered on an inheritance based hypothesis model. 
iii.ix.ii Strategy 2:  Exomizer 
Inheritance driven analysis of trio data as described in strategy 1 is a powerful tool to prioritise 
variants but there may still be many candidate variants remaining. For different pedigree structures, 
such as duos or singletons, inheritance filtering strategies are less useful.  Each genome carries 
approximately 100 loss of function variants (MacArthur, Balasubramanian et al. 2012) requiring the 
use of many different approaches to identify disease-associated genes. One such approach is 
Exomizer, a phenotype driven tool that uses clinical data (in the form of HPO terms), model organism 
phenotype data and random-walk analysis (that uses direct and indirect protein interactions in 
biological networks, protein expression and biological similarities) to prioritise variants generated from 
whole exome analysis (Smedley, Jacobsen et al. 2015).  
Exomizer is a Java program that uses VCF files to first filter then prioritise variants. The filtering steps 
include variant annotation relative to the University of California Santa Cruz (UCSC) reference 
genome hg19, removal of variants above a user defined MAF, removal of variants below a specified 
quality score and pedigree filtering if appropriate.  Prioritisation is undertaken by a number of different 
methods including protein-protein interaction, comparison of patient phenotype and those in human 
disease databases and model organisms, and predicted effect on protein structure. Exomizer 
calculates both variant and gene based scores and combines these to generate a final combined 
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score that is used to rank the variants (Figure 21). The top 20 variants ranked by Exomizer were 
subsequently manually reviewed. 
 
 
Figure 21 Variant Prioritisation Strategy 2 
Strategy 2 uses Exomizer, a phenotype driven tool that uses clinical data (in the form of HPO terms), model 
organism phenotype data and random-walk analysis of protein-protein interactions to prioritise variants generated 
from whole exome analysis 
iii.ix.iii Strategy 3: Targeted Gene Approach 
The hypothesis for this strategy was that new pathways can be established in OI by identifying novel 
variants in genes already established in known diseases or bone phenotypes (Figure 22). A manually 
curated candidate gene list was developed by extensive database and literature review using the 
following search criteria: 
 All genes known to be associated with OI and OI-like phenotypes 
 All genes known to be associated with skeletal dysplasia and/or short stature 
 Genes within BMD loci with genome-level significance detected in Genome Wide Association 
Studies 
 Mouse models with reduced BMD, brittle bones, abnormal mineralization or reduced 
mineralization. 
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Figure 22 Variant prioritisation strategy 3 
An extended list of candidate genes was developed using a combination of those described in association with 
skeletal disorders in man, bone changes in mouse models and those association with reduced bone mineral density 
in GWAS studies 
 
Finally, genes identified using HPO terms related to bone fragility and increased fractures (Table 15) 
were also added. The final list of 635 targeted genes is given in the appendix, page 250.  
 
HP:0003023 Bowing of limbs due to multiple fractures 
HP:0005744 Generalized osteoporosis with 
pathological fracture 
HP:0002757 Recurrent fractures 
HP:0002659 Increased susceptibility to fractures 
Table 15 HPO terms used to generate an extended target gene list used in variant prioritisation 
The lists generated from strategies 1-3 above were combined to give a final list of prioritised variants. 
Variants in HLA and Mucin genes were removed from the variant list and, finally, the whole cohort 
dataset was reviewed, alongside data from the DDD study, to identify potential disease-related genes 
or variants enriched in this cohort in comparison to control populations.  
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iii.x Assessment of sequence variants 
Sequence variants identified in all parts of this project were assessed for potential significance using a 
number of web based resources that explore possible modes of pathogenicity and sources of 
information where the variant may have been previously documented. The assessment tools used 
include: 
iii.x.i Population Frequency 
The population frequency in the following datasets was interrogated.  
 Exome Aggregation Consortium (gnomAD) http://gnomAD.broadinstitute.org/ 
 NCBI dbSNP build 144 through Ensembl e83 https://www.ncbi.nlm.nih.gov/projects/SNP/ 
 NCBI ClinVar https://www.ncbi.nlm.nih.gov/clinvar/ 
 NHLBI GO Exome Sequencing Project (ESP) http://evs.gs.washington.edu/EVS/ 
 The Genome of the Netherlands Consortium (GoNL) http://www.nlgenome.nl/ 
Variants listed as present in >1% of any population were excluded from further analysis  
iii.x.ii Web-based Literature Search 
Resources used for the literature search included Google, Google Scholar, PubMed and the following 
Locus Specific Databases:  
 The Human Gene Mutation Database (HGMD) (http://www.hgmd.cf.ac.uk/ac/index.php 
 Osteogenesis Imperfecta and Ehlers Danlos Syndrome Variant Databases 
http://www.le.ac.uk/ge/collagen/ 
Where a variant was identified as being previously reported, the available evidence for that 
classification was reviewed. This included assessment of in-silico variant predictions, any supplied 
pedigree/segregation data, population frequency data and any available functional studies.  
iii.x.iii Variant Effect Predictors: 
There are a number of tools available that predict the effect of missense changes on protein structure 
and function. These can be broadly assigned to one of three categories depending on the strategies 
used for prediction: machine learning, evolutionary conservation and protein sequence and structure. 
An outline of the tools used from each category is as follows. 
 
Machine learning tools:  
Machine Learning methods – learn patterns that can be applied to new scenarios. Some combine 
predictions from different sources and match the variant to the best fitting category. The quality of 
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their predictions is dependent on the information that the programs learn from and can be a source of 
false pattern recognition particularly if the program over trains. 
SNPs&Go (http://snps.biofold.org/snps-and-go/snps-and-go.html) Trained on the effect of any 
substitution in association with adjacent residues and uses functional gene ontology.  
MutPred  (http://mutpred.mutdb.org/) This tool trains on HGMD and Swiss-Prot data. It gives an 
overall probability of a variant being deleterious based on 14 properties relating to protein structure 
and dynamics along with predicted functional properties alongside evolutionary conservation score. 
HANSA (http://www.cdfd.org.in/HANSA/) Trained on combination of position specific, structural and 
amino acid features (10 properties) 
Evolutionary Conservation based tools: 
These use multiple sequence alignments to assess the conservation of specific amino acid residues 
across species. Analysis against at least 5 mammals from different orders, plus chicken, frog and fish 
(zebra/fugu) was used where available.  
Panther (http://www.pantherdb.org/tools/csnpScoreForm.jsp) Aligns sequence to protein subfamilies 
within its own library collection and calculated a probability of being pathogenic based on variation 
with the alignment 
PROVEAN http://provean.jcvi.org/genome_submit_2.php?species=human retrieves scores from a 
pre-computed database that clusters sequences to give a predicted effect on protein translation and 
effect on function. 
SIFT http://provean.jcvi.org/genome_submit_2.php?species=human Uses multiple sequence 
alignments generated from a BLAST search for similar sequences to calculate a probability score. 
Mutation Assessor http://mutationassessor.org/r3/Uses multiple sequence alignments based on 
functional specificity. 
Protein sequence and structure based tools: 
The predictions from these tools are based on the severity of the amino acid substitution and the 
potential structural implications based on the surrounding residues. 
PolyPhen2 http://genetics.bwh.harvard.edu/pph2/ This is a supervised learning tool that assess 
evolutionary conservation and impact on functional region. The HumVar output is recommended in 
assessment for Mendelian diseases as this algorithm is trained on the differences between human 
disease-causing and neutral non-synonymous variants. 
iii.x.iv Potential Splice changes  
Intronic, synonymous and missense variants were assessed for their potential effect on splicing using 
the following tools:  
63 
 
 SpliceSiteFinder (http://www.umd.be/HSF/) 
 MaxEntScan (http://genes.mit.edu/burgelab/maxent/)  
 NNSplice  (http://www.fruitfly.org/seq_tools/splice.html)  
 GeneSplicer  (http://cbcb.umd.edu/software/GeneSplicer 
 Human Splicing Finder (http://www.umd.be/HSF/) 
Interpretation was based upon the consensus of at least three of the above programs and generally 
needs these to show a change of +/-10% in splicing efficiency to be considered to be of potential 
significance. 
iii.x.v Severity of Amino Acid substitution 
For missense variants data from Russell, the Grantham distance and BLOSUM scores from Alamut 
were used to give an overall idea of the difference in properties between the wildtype and mutant 
amino acids. Those with greater differences are most likely to be pathogenic. 
Although there are a number of tools available to aid interpretation of variants, it was important to note 
that these are only predictions. Further studies, such as segregation and/or functional analysis may 
be required to draw a definite conclusion as to the significance of the variant. 
iii.xi Method for Electron Microscopy  
Punch biopsies of non-lesional skin were obtained from the upper inner arm. Each biopsy was cut into 
4 columns and immediately fixed using 3% glutaraldehyde in 0.1M phosphate buffer at pH7.4. 
Samples were post-fixed in 2% aqueous osmium tetroxide, dehydrated through alcohol and acetone 
and then embedded in 812 epoxy resin in a flat bottomed BEEN® specimen embedding capsule. 
Semi-thin sections (0.6um) were produced on an Ultracut E ultramicrotome using a Diatome 
Histoknife. These were stained with 1% Toluidine blue in 1% sodium tetraborate at 120°C. Mid gold 
interference coloured sections were produced using a Diatome ultraknife and staining with uranyl 
acetate and Reynold’s lead citrate.   
Sections were photographed at step magnifications on a Philips 400 transmission electron 
microscope using an AMT 16 megapixel mid mount camera. Each section was screened for the 
presence of collagen ‘flowers’. Collagen fibril diameters in the reticular dermis were measured 
manually (20000X magnification) using the camera software and mouse (Figure 23).  
The mean diameter of 200 fibres was compared to the expected measurement for the age of the 
individual (Table 16). Fibroblasts and elastic fibre morphology were initially assessed at low 
magnification. The presence or absence of ER dilation, a feature providing evidence of stress, was 
assessed for each fibroblast identified (up to 20,000X magnification). 
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Figure 23 Electron microscopy of med-reticular dermis (20,000X magnification) 
The mean diameter of collagen fibres (nm) was assessed by measuring 200 fibres at a magnification of 20,000. 
 
 
 
Life Stage Expected collagen fibre 
diameter (nm) 
Fetus 70 
Child/Adult 80-90 
Elderly 70 
Table 16 Expected diameter of collagen fibres in each life stage 
Figures taken from Stewart et al (Stewart 1995) 
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iv RESULTS: TARGETED EXOME SEQUENCING 
iv.i Patient recruitment 
Eighteen families were recruited for targeted exome analysis (participant ID 001-018).  Eight further 
families were recruited for whole exome sequencing (participant ID A-H).  An additional cohort of 
BMP1 patients were identified during the course of this study (patients I-K) following introduction of 
BMP1 gene analysis into the diagnostic pathway following results for the NGS target panel part of this 
project. The presenting clinical details for each recruited participant are listed in Table 17 
 
Participant ID Clinical History 
Targeted Exome  
001 Crush fracture of spine and generalised osteopenia 
002 Family history of early onset osteopenia and osteoarthritis. Hypermobile 
003 Multiple fractures and osteopenia 
004 Dislocations, fractures, hearing loss in one ear. ?Blue sclerae. Other family 
members clinically affected. 
005 Two fractures, one with no obvious trauma 
006 Skull fracture, blue sclerae, Wormian bones. 
007 Severe vertebral fracture and collapse, short stature, facial features 
suggestive of OI. Mother has similar features. 
008 Numerous scars, history of >10 fractures 
009 Hypermobile, fractures. 
010 Clinically has OI type I, >30 fractures 
011 Fractures, osteopenia 
012 Antenatal fractures, autism, severe developmental delay 
013 Atypical OI, severe scoliosis, grey sclerae, very hypermobile, no tissue 
fragility.  
014 Recurrent fractures and osteopenia, characteristic facies of OI 
015 Hypermobile. Metabolic bone disease. ? Osteopetrosis 
016 OI type I 
017 Fractures. Dysmorphic, developmental delay, 
018 Multiple dislocations, easy/spontaneous bruising, blue sclerae, fractures, 
dental problems. 
Whole Exome  
A Cystic hygroma/increased nuchal translucency, moderate intellectual 
disability/mental retardation, fractures, flat or prominent occiput, dysmorphic 
facies, low rotated ears, downslanting palpebral fissures, thin upper lip, 
squint, atrial septal defect, ventricular septal defect. Wormian bones. 
B Multiple fractures, proximal shortening, scoliosis, possible contractures 
C Prematurity - 32 weeks, severe intellectual disability/developmental delay, 
fine motor delay, gross motor delay, speech delay, autism spectrum 
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disorder/autistic features, scoliosis, failure to thrive, fractures - vertebral and 
tibial fractures, frontal bossing/prominent forehead, dysmorphic facies, 
low/posteriorly rotated ears, abnormality of hairline, hypertelorism, upslanting 
palpebral fissures, myopia, optic atrophy, hair hypoplasia, low 
immunoglobulin levels, short stature, bilateral optic pallor. 
D Dysmorphic, developmental delay, hypotonic, muscle weakness, short 
stature, osteopenia, fractures, high arched palate, frontal bossing, bilateral 
club feet, low posteriorly rotated ears. 
E Sparse falling out hair, blue sclerae, hypertelorism, delayed fontanel closure, 
club foot, crush fracture vertebrae, rib fracture, bone fragility. 
F Multiple fractures, blue sclerae, dentinogenesis imperfecta, hypermobile 
joints. 
Mother is hypermobile with fractures following insignificant trauma. 
G Failure to thrive, macrocephaly, persistent large anterior fontanelle, multiple 
fractures, dysmorphic features. 
Heterozygous mutation in P3H1 c.1080+1G>T 
H Clinically osteogenesis imperfect with crush fracture vertebrae and multiple 
long bone fractures, scoliosis 
BMP1  
I Ten low trauma long bone fractures, white sclerae, normal hearing. No 
evidence of dentinogenesis imperfecta. 
J Three low impact fractures, grey sclerae, hypermobile fingers and no 
evidence of dentinogenesis imperfecta 
K High bone mass phenotype 
Table 17 Clinical Details provided for recruited individuals 
Eighteen families were recruited for targeted exome analysis (participant ID 001-018).  Eight families were recruited 
for whole exome sequencing (participant ID A-H).  A further cohort of BMP1 patients were identified during the 
course of this study (patients I-K) 
 
 
There have been no participant withdrawals during this research project.  
 
iv.ii Validation of Targeted Exome NGS Panel 
To assess the relative merits of SureSelect vs Nextera panel design and library capture 
methodologies for targeted exome sequencing, the sequence coverage for each region of interest 
was assessed for each method. To achieve this, five DNA samples were run on both the SureSelect 
and Nextera panels. The number of region without adequate sequence for each method is shown in 
Table 18 
67 
 
 
 Number of regions without adequate sequence coverage. 
Sample Number SureSelect Nextera 
1 2 17 
2 0 14 
3 0 13 
4 0 5 
5 0 15 
Table 18 Comparison of regions without adequate sequence coverage for SureSelect vs Nextera 
library preparation in five control DNA samples. 
Overall coverage for the Nextera panel was considerably lower than SureSelect for all samples. 
Visualisation of coverage for each method was undertaken and clearly demonstrated poorer 
sequence coverage across the entire panel. An example is shown in Figure 24. 
  
 
Figure 24 Visualisation of sequence coverage for SureSelect and Nextera methodologies  
The number of sequence reads for the COL1A1 gene for a single control sample is shown. The top panel indicates 
the gene with exons coloured blue. The middle and bottom panels show the number of reads in each location 
combined to form peaks (coloured grey). The middle panel shows coverage with Nextera, the bottom with 
SureSelect. 
 
One explanation for the reduced coverage of the Nextera panel in comparison to SureSelect is the 
difference in the number of probes produced for each region by the two design methodologies. 
SureSelect creates a number of overlapping probes for each region, increasing the likelihood that this 
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region will be captured whereas in comparison, the number of probes designed by Nextera is more 
limited, as illustrated in Figure 25. 
The conclusion was that SureSelect gave superior coverage for the genes of interest in this study and 
was chosen as the method to evaluate further. The next step was to look at the ability of the 
SureSelect panel and bioinformatics analysis pipeline to correctly identify variants within the 
sequence generated. 
 
 
Figure 25 Comparison of the number of probes designed by SureSelect and Nextera  
Coverage of four exons of the COL1A1 gene is shown.  
SureSelect probe= black solid line          Nextera Probe =black dashed line           COL1A1 exon = blue rectangle 
Variant lists from seven control samples that had been previously analysed using Sanger sequencing, 
the ‘gold standard’ method of sequencing, were compared for 14 genes. A total of 164 variants were 
available and the number in each gene are summarised in Table 19 below. 
 
Gene Variants Gene Variants Gene Variants 
COL5A1 49 ALPL 14 PLOD1 1 
COL1A1 21 CRTAP 5 COL5A2 14 
COL1A2 24 COL3A1 12 SERPINH1 4 
SP7 2 PPIB 1 P3H1 5 
SERPINF1 11 FKBP10 1   
Table 19 List of genes and number of variants used to validate SureSelect targeted exome panel. 
 
A wide region of interest (ROI) of 150bp+/- from each exon was employed to maximise the number of 
variants included in the process. All variants were identified in the targeted exome NGS results. No 
false positives or false negatives were identified. The SureSelect and MiSeq platform were 
considered to be performing well compared to Sanger sequencing and were therefore chosen as 
methods for the targeted exome sequencing of patient samples. 
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iv.iii SureSelect Targeted Exome Patient Results 
All participants were screened for known OI genes using the targeted exome panel. Each identified 
variant was compared against the manually developed and curated database containing details of 
known common benign polymorphisms. Variants listed in the database are considered unlikely to 
cause OI, primarily due to their frequency in the general population (allele frequency >1%). Those 
listed in the database were excluded from further analysis. 
Additional manual assessment of variants to remove further polymorphisms not listed in the database 
was undertaken. Regions of homopolymer, that can give false positive variant calls, were also 
removed. A total of 21 variants requiring pathogenicity assessment remained (Table 20). 
 
Patient 
ID Gene Variant Zygosity dbSNP ref 
Read 
count Conclusion 
1 TMEM38B c.113-7A>G het rs186864213 1997 SNV 
1 COL1A1 c.1350G>T;p.(E450D) het . 15 False Positive 
1 CREB3L1 c.1194C>T;p.(S398S) het rs199639528 6929 SNV 
2 TAPT1 c.837G>T;p.(M279I) het . 20 False Positive 
3 FKBP10 c.590A>G;p.(K197R) het rs34764749 4526 SNV 
3 P3H1 c.1322A>G;p.(D441G) het rs113593896 10705 SNV 
3 TAPT1 c.613-3delT het . 33 False Positive 
3 BMP1 c.2134G>A;p.(G712S) het rs117159093 6824 ? UV  
4 COL1A1 c.4070T>C;p.(L1357P) het  5515 ? UV  
4 CREB3L1 c.962+18G>A het rs2288249 4077 SNV 
4 CREB3L1 c.1231G>A;p.(A411T) het rs35652107 8155 SNV 
5 IFITM5 c.80G>C;p.(G27A) het rs57285449 1309 SNV 
5 COL1A2 c.71-17dupT hom rs144776919 2147 SNV 
6 P3H1 c.1720+3G>A het  1404 No splice effect 
predicted 
8 BMP1 c.1112G>A;p.(R371H) hom rs145284541 5480 SNV 
10 SERPINF1 c.85-13T>G hom rs199735427 1428 
No splice effect 
predicted 
11 PPIB c.170T>C;p.(V57A) het  1770 Likely SNV 
12 COL1A1 c.1111G>T;p.(G371C) het  4427 N:# 
13 CRTAP c.471+1G>A het  46 False Positive 
15 BMP1 c.1148G>A;p.(R383Q) het  3888 ?UV 
15 BMP1 c.1293C>G;p.(Y431*) het  2021 ?UV 
Table 20 Variants identified in participants 001-018 using targeted exome analysis 
Each variant was manually assessed for likely pathogenicity and the results of this analysis are listed in the final 
conclusion column of the table. 
SNV=single nucleotide variant (likely benign); UV=unclassified variant; N;#=likely pathogenic mutation; 
Het=heterozygous; Hom=homozygous 
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Four variants, COL1A1 c.1350G>T;p.(E450D), TAPT1 c.613-3Tdel, TAPT1 c.837G>T;p.(M279I), and 
CRTAP c.471+1G>A were considered to be false positive calls due to their low read count, which 
indicates poor quality sequencing. Nine were classified as likely polymorphisms following evaluation 
as described in section iii.x due to their frequency in the general population and/or the lack of in-silico 
evidence to support a deleterious effect on protein structure or function.  
A highly likely pathogenic mutation, c.1111G>T;p.(Gly371Cys) in the COL1A1 gene, was identified in 
patient 12. This mutation affects a glycine residue in a Gly-X-Y triplet within the helical domain of the 
protein, a mutational mechanism well reported to be causative in OI. A different mutation affecting the 
same amino acid, c.1111G>A;p.(Gly371Ser), has previously been reported in a patient with type III OI 
(Marini, Forlino et al. 2007). No other variants of interested were identified in patient 12. It is likely that 
the c.1111G>T;p.(Gly371Cys) mutation was not detected by the original analysis of this patient due to 
the presence of a rare variant under a primer binding site, a known disadvantage of Sanger 
sequencing. 
Four variants of particular interested remained: BMP1 c.2134G>A;p.(Gly712Ser); COL1A1 
c.4070T>C;p.(Leu1357Pro);  BMP1 c.1293C>G;p.(Tyr431*)  and BMP1 c.1148G>A;p.(Arg383Gln).  
These variants were all confirmed by Sanger sequencing (Figure 26 and Figure 29). 
 
 
Figure 26 Sanger sequencing confirmation of BMP1 mutations. 
c.2134G>A;p.(Gly712Ser),participant 003 and COL1A1 c.4070T>C;p.(Leu1357Pro) 
participant 004. 
iv.iii.i Investigation of COL1A1 variant 
The COL1A1 p.(Leu1357Pro) variant is located in the C propeptide domain of the alpha 1 chain of 
type I collagen, a region that is essential for chain to chain recognition and subsequent assembly of 
the protein. Although this particular change has not been reported in the literature, three other 
variants affecting leucine residues in the C-propeptide, p.(Leu1464Pro), p.(Leu1437Gln) and 
p.(Leu1388Arg) have previously been published (Chessler, Wallis et al. 1993, Oliver, Thompson et al. 
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1996, Rugolotto, Monti et al. 2007) and are reported to be pathogenic. The p.(Leu1464Pro) variant 
affects the final amino acid before the termination codon in the protein and appeared de-novo in the 
affected individual.  Analysis of collagen secretion from cultured fibroblasts from this individual 
showed a poorly secreted and overmodified protein supporting pathogenicity. Similarly, the 
p.(Leu1388Arg) appears to be de-novo in an individual with lethal OI and delayed secretion and 
extensive over modification of the type I collagen protein were again observed.  No data is provided in 
the literature report in support of a pathogenic role for the p.(Leu1437Gln) change. 
Initially four family members were available for analysis of the COL1A1 c.4070T>C;p.(Leu1357Pro) 
variant in our family (participant 004). The variant was not detected in the proband's reportedly 
affected aunt or cousin but was present in the heterozygous state in her reportedly unaffected father. 
These findings suggested that this variant was not segregating with the features of OI in this family 
(Figure 27).   
 
 
Figure 27 Segregation analysis for the COL1A1 c.4070T>C;p.(Leu1357Pro) variant in 
family 004.  
The filled shapes represent family members who were reported to be clinically affected. Females are 
represented by a circle, males by a square. The arrow indicates the family member initially recruited to 
the study.   
However, the reportedly unaffected father was subsequently reviewed by a different consultant 
following the birth of a clinically affected second child from a different relationship. His clinical history 
was revealed to include numerous fractures during childhood and was highly suggestive of a 
diagnosis of OI. The second affected child was confirmed to be heterozygous for the c.4070T>C 
variant in COL1A1. Clinical review of the proband’s aunt and cousin only identified features that would 
be consistent with normal bone mineralisation.  This new information suggests that this variant is 
segregating with the OI symptoms in this family. 
Each alpha chain of fibrillar collagens contains a unique sequence within the C-propeptide domain 
that allows correct recognition and assembly of the collagen molecule. The p.(Leu1357Pro) variant 
lies within the chain-chain recognition region of the alpha 1 chain but does not affect one of the chain 
specific amino acids (Figure 28). Comprehensive in-silico analysis of the c.4070T>C;p.(Leu1357Pro) 
variant, along with segregation with clinical features of OI and literature review, indicates likely 
pathogenicity and suggests that the physical properties of proline differ from leucine sufficiently to 
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interfere with chain recognition. This is likely to prevent or delay chain alignment and assembly 
resulting in over modification of the collagen molecule.  
 
 
Figure 28 Chain-chain recognition sequences for type I and III collagen molecules 
The blue highlighted amino acids indicate the unique sequence for each chain that allow correct recognition 
and assembly of the collagen molecules. Leucine 1357 is highlighted in red. 
 
The c.4070T>C;p.(Leu1357Pro) COL1A1 variant is therefore likely to be an OI-causing mutation and 
adds to the number of C-propeptide domain mutations reported. Interestingly mutations in this region 
of the gene have been described in both mild OI (Pace, Kuslich et al. 2001) and a high bone mass 
variant (Takagi, Hori et al. 2011). None of the affected members of this family are reported to have 
features of high bone mass. 
These results highlight the importance of phenotypic data in the interpretation of genetic findings.  
iv.iii.ii Investigation of BMP1 variants  
The BMP1 gene (OMIM 112264) is alternatively transcribed to produce two proteins, mammalian 
Tolloid (mTLD; NM_006129) and its shorter isoform bone morphogenic protein-1 (BMP1; 
NM_001199). The functions of the shorter BMP1 protein include the proteolytic removal of the 
carboxyl-terminal propeptide from procollagen type I, II and III and the amino-terminal propeptide from 
types V and XI procollagen. It also influences dorsal-ventral patterning through the indirect activation 
of some TGFβ superfamily proteins (Asharani, Keupp et al. 2012) and has a role in extracellular 
matrix assembly by proteolytic activation of lysyl oxidase (LOX). This is known to be essential for 
collagen cross-linking and processing of small leucine rich proteoglycans (SLRPs) (von Marschall and 
Fisher 2010).  
mTLD has an alternative exon 16 to BMP1 and a subsequent additional four exons encoding 256 
amino acids. This isoform circulates at increased levels in the plasma during acute bone fracture and 
is known to have an important role in bone repair (Grgurevic, Macek et al. 2011).  
Studies in BMP1/mTLD deficient patients with OI have demonstrated delayed cleavage of type I 
collagen C-propeptide (Martinez-Glez, Valencia et al. 2012, Valencia, Caparrós-Martin et al. 2014) 
and disorganization of type I/V collagen fibrils as well as impaired processing of the SLRP prodecorin 
(Syx, Guillemyn et al. 2015). 
In vivo study of the BMP1/mTLD protein to elucidate the mechanisms by which mutations in the 
BMP1 gene give rise to an OI phenotype has been hampered by the early lethality of Bmp1/Tll1 
knockout mice. However, postnatal ablation of the gene using floxed Bmp1 and Tll1 alleles have 
73 
 
produced models with reduced processing of procollagen and dentin matrix protein 1, increased bone 
turnover, decreased expression of sclerostin and induction of canonical Wnt signalling (Muir, Ren et 
al. 2014). These conditional knockout mice have weak brittle bones that are susceptible to 
spontaneous fractures. Studies in the frilly fins zebra fish Bmp1a mutant have shown delayed larval 
ossification progressing to relatively high bone mineral content in adults with malformation and 
evidence of fracture that has been shown to be independent of osteoblast maturation (Asharani, 
Keupp et al. 2012). 
At the time of this study less than 20 individuals with OI have been identified with mutations in the 
BMP1 gene. These patients have been described as having highly variable clinical presentations 
ranging from mild to severe progressively deforming OI. The majority, but not all, have presented with 
bone fragility associated with an increase in bone mineral density. It has been hypothesized that the 
described phenotypic variability between reported cases may result from different functional 
consequences of the BMP1 mutations, although no clear genotype/phenotype correlation has yet 
emerged. 
BMP1 c.2134G>A;p.(Gly712Ser) : Participant 003 
The heterozygous BMP1 c.2134G>A;p.(Gly712Ser) variant in participant 003 changes protein coding 
only in the longer BMP1/mTLD transcript, (mTLD; NM_006129). It affects a highly conserved 
nucleotide and amino acid and is situated in an EGF-like calcium-binding domain of the protein. In the 
shorter transcript (NM_001199) this variant, c.*626G>A, is downsteam of the 3’UTR that finishes at 
c.*280. 
In-silico protein conservation analysis of the p.(Gly712Ser) change using SIFT, PolyPhen2, Align 
GVGD, SNPs3D, Panther and Mutation Taster all suggest that this variant may have a deleterious 
effect on protein structure and/or function, although the severity of the amino acid substitution is 
considered to be neutral.  
However, the available allele frequency data for this change states that it is present in the 
heterozygous state at a frequency of 0.16% in European (Non-Finnish) alleles in the gnomAD 
database (sample size 63042); no homozygous individuals are recorded. This data suggests that, in 
the heterozygous state, this variant is unlikely to be responsible for the symptoms of OI in this patient. 
In addition, there are no literature reports that suggest that variants only affecting protein coding in the 
longer mTLD isoform are associated with increased bone fragility, although a role in bone repair 
cannot be completely excluded. 
BMP1 c.1293C>G;p.(Tyr431*) and c.1148G>A;p.(Arg383Gln) : Participant 015 
Two variants in the BMP1 gene were identified in patient 015, c.1293C>G;p.(Tyr431*) and 
c.1148G>A;p.(Arg383Gln), that affect both isoforms of the protein. Segregation analysis showed that 
the c.1293C>G;p.(Tyr431*) is present in the mother and c.1148G>A;p.(Arg383Gln) in the father, 
confirming that these changes are on different alleles in participant 015. 
The c.1148G>A;p.(Arg383Gln) missense variant is found within the highly conserved CUB1 domain of 
the protein and SIFT, PolyPhen, Align GVD and Mutation Taster analysis all support pathogenicity, 
although the severity of the amino acid substitution is favoured. There is very low frequency data 
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within the gnomAD population database, four alleles out of 121,292. No homozygous indiviudals are 
reported. 
Investigation of the nonsense change identifed in this individual , 1293C>G;p.(Tyr431*) , indicates 
that variants leading to a ‘null’ allele within BMP1 are associated with OI phenotypes. Two such 
changes, c.925del;p.(Asp309fs) and c.1839del;p.(Asn614fs) are recorded on the LOVD database 
(https://oi.gene.le.ac.uk/home.php?select_db=BMP1) associated with OI type III and type IV 
respectively. The 1293C>G;p.(Tyr431*) variant is not reported in the general population. Taken 
together, the available evidence for the two variants identifed in this individual, suggest that they are 
highly likely pathogenic. So far, similar compound heterozygous changes that result in a ‘null’ allele 
and a mutation in a CUB domain have been reported to be associated with severe OI phenotypes. 
 
 
Figure 29 Targeted exome results for patient 015 
A: NGS sequence data highlighting the c.1293C>G;p.(Ty431*) mutation in BMP1. B. 
Sanger sequence confirmation of the c.1293C>G;p.(Tyr431*) and 
c.1148G>A;p.(Arg383Gln) BMP1 mutations 
 
 
Patient 015 is a 7 year old female, the only child of healthy non-consanguineous parents of North 
European origin. There is no family history suggestive of a connective tissue disorder.  She was born 
following IVF treatment at 39 weeks gestation with a birth weight of 2.976 kg. She was considered to 
be well immediately after birth and her early developmental assessment was normal. At age 17 
months, she was noted to be non-weight bearing and was referred for physiotherapy. She was 
diagnosed as being hypermobile and provided with orthopaedic footwear. At 20 months of age, she 
was found to have congenital bilateral hip dislocation. Corrective surgery on both hips was 
undertaken, initially unsuccessful on the right side and further pinning was required.  
The patient began to walk unaided at 2 years 10 months and her first fracture, of the right fibula, 
occurred a month later. She has sustained further fractures including a spiral fracture of the tibia and 
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three metatarsal fractures in the left foot (Figure 30). Following her fracture history, she was 
commenced on treatment with Pamidronate at 3.8 years of age. She remained on treatment for 12 
months before raised BMD was identified by DXA resulting in cessation of treatment (Figure 30). A 
provisional diagnosis of osteopetrosis was suggested.  
At her most recent clinical review aged 7 years, her weight was 24.35kg (>50th centile) and height 
122cm (50-70th centiles). On examination, she has white sclerae and normal teeth, hearing and 
spine.  She has a bossed forehead and has previously been noted to have a mild left sided ptosis. 
Scarring was minimal but haemosiderin deposits were noted on her lower limbs. 
 
 
 
 
 
Age in years 3.2 5.5 6.5 7 
Distal radial 
total 
volumetric 
BMD 
Not 
measured 
+8.7 +7.1 +7.2 
Distal radial 
trabecular 
volumetric 
BMD 
Not 
measured 
+9.2 +6.9 +6.6 
LS BMAD 
(L1 –L4) 
+4.2 +4.3 +3.1 +3.4 
LS 
volumetric 
trabecular 
BMD (L1 –
L3) 
Not 
measured 
+0.35 
Not 
measured 
Not 
measured 
Left: Chalk stick’ fractures through right mid-tibia & mid-fibula 
(arrowed), with soft tissue swelling.  Note dense & thickened 
cortices. Three ‘Pamidronate lines’ are visible at proximal and 
distal tibial metaphyses  
Above: Volumetric Bone Mineral Density Z-scores measured 
by peripheral quantitative computed tomography (distal 
radius), DXA (lumbar spine) and quantitative computer 
tomography (lumbar spine).  
Figure 30 Patient 015: X-Ray of lower leg and sequential BMD measurements. 
See inserted captions for more detailed description. BMD – Bone mineral density, LS – lumbar spine, BMAD - bone 
mineral apparent density 
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BMP1 c.2188dupC;p.(Gln730fs): participants I and J 
Following identification of the BMP1 likely pathogenic mutations in patient 015, the BMP1 gene was 
added to the routine diagnostic NGS panel at SDGS and a further two individuals with OI associated 
with BMP1 mutations (patients I and J) were identified. The clinical features of these patients were 
assessed and available BMD data gathered to produce the manuscript (Appendix page 226): 
Phenotypic variability in patient with osteogenesis imperfecta caused by BMP1 mutations. Pollitt RC 
et al Am J Med Genet A. 2016 ;170(12):3150-3156.  
In addition to the phenotypic variability described in the manuscript, an important finding that is 
highlighted is the potential risk of causing delayed healing, increased stiffness, atypical fractures or 
even iatrogenic osteopetrosis by treatment with anti-resorptive therapy in BMP1-related OI. In 
particular, careful monitoring of response to bisphosphonate therapy is indicated in these patients. 
BMP1 c.355C>T;p.(Arg119Trp) : participant K 
Following publication of the manuscript, a further patient (K), again with a high bone mass phenotype, 
and a novel homozygous c.355C>T;p.(Arg119Trp) mutation in the pro-domain of the BMP1 gene was 
identified.  
It is not clear why some mutations are associated with increased BMD whereas others are reduced.    
Published functional studies have largely focused on the C-propeptide cleavage activity of BMP1 
mutations but BMP1/mTLD is also involved in processing of additional extra cellular matrix 
components. In particular BMP1 deficiency has been shown to influence the processing of the SLRP 
prodecorin by impaired removal of the prodomain (Syx, Guillemyn et al. 2015).  
Decorin is known to influence both collagen assembly and matrix mineralization (Mochida, 
Parisuthiman et al. 2009). Decorin also participates in intracellular and extracellular signalling 
including binding and inhibition of TGF-β. Reduced decorin levels cause increased levels of ‘free’ 
TGF-β that bind to the TGF-βRI and TGF-βRII receptors, inducing Smad dependent and Smad 
independent signalling (Markmann, Hausser et al. 2000, Lim, Grafe et al. 2017). As excessive TGF-β 
signalling is thought to be a common mechanism in OI pathogenesis (Grafe, Yang et al. 2014), it 
seems reasonable to propose that reduced decorin prodomain removal is contributing to the 
increased mineralization in these patients, by influencing downstream TGF-β signalling.  
One possible explanation for the variable phenotypic presentation in this small cohort of BMP1 OI 
patients is that the degree of increased mineralization is a direct result of the ‘severity’ of the mutation, 
the level of residual C-propeptide cleavage activity that remains and the resulting disruption to 
collagen assembly and matrix mineralisation.  
To explore this idea further, collaboration with Dr. Cecilia Giunta, (University of Zurich) was 
established to examine collagen processing in dermal fibroblasts from patient 015, J, and K to see if 
variability in C-propeptide cleavage activity could be demonstrated.  
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Collagen Biochemical Analysis in patients 015, J and K. 
To look at collagen biochemical processing, dermal fibroblasts are cultured in medium containing 
14C-proline which labels procollagen and collagen proteins. These proteins are subsequently isolated 
and analysed using 5% sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Gels are dried, fixed and exposed to an X-ray film before visualisation. 
. 
 
Figure 31 SDS-PAGE of the pepsinized procollagens in the medium. 
Normal controls (C) and patients 015, J and K (P1, P2 and P3 respectively). No evidence of 
abnormal procollagens in the patient’s samples was detected. 
 
 
Figure 32 SDS-PAGE of the untreated procollagen in the presence of 0.05M 
dithiodthreitol, (DTT) 
Patients 015, J and K (P1, P2 and P3 respectively).  
* Accumulation of pCα1(I) procollagen species (those retaining the C-terminal propeptide) in 
patient sample when compared to normal controls. 
The isolated procollagen can be treated with pepsin to cleave the terminal non-helical regions 
allowing more specific examination of the triple helical portion of the protein. The SDS-PAGE of the 
pepsinized procollagens present in the medium is normal for all three patients (Figure 31). This 
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suggests that a defect in the type I collagen triple helical protein structure or processing is not 
responsible for the symptoms in these individuals SDS-PAGE of the untreated procollagen in the 
presence of dithiodthreitol, (DTT, a reducing agent) clearly shows the accumulation of pCα1(I) 
procollagen species in all three patients (those retaining the C-terminal propeptide) and a decreased 
production of pNα1(I) and pNα2(I), which is more evident on the pNα2(I) band (Figure 32). These 
results support that the BMP1 mutations in these patients result in reduced cleavage activity. 
However, there is no indication that any specific mutation is more detrimental to collagen processing 
than the others. The cause of the variable phenotypic severity in these patients remains unclear. 
Electron Microscopy of reticular dermis in patients 015, J and K 
Electron microscopy (EM) of skin in OI patients with type I collagen mutations has shown increased 
variation in collagen fibril diameter, variation from the expected mean diameter and the presence of 
collagen ‘flowers’ (Balasubramanian, Sobey et al. 2016). A limited number of EM studies in BMP1 
positive patients have also shown variable collagen fibril diameter and irregular fibril outlines although 
collagen flowers have not been reported (Syx, Guillemyn et al. 2015). The morphology of dermal 
fibroblasts in BMP1 mutation positive patients has not been described. 
To further explore the functional effect of the BMP1 mutations identified in this study, examination of 
dermal collagen fibrils and fibroblasts from patients 015, J and K was undertaken. These were 
compared against a normal control and a known pathogenic COL1A2 mutation.  
Normal Control 
Collagen bundle packing was regular and collagen fibrils were within the expected range for life stage 
(85nm). Elastic fibres were peripherally irregular in outline but did not appear to be increased or 
decreased in number or diameter. Collagen fibrils were regular with only an occasional fibril with an 
irregular outline. No collagen ‘flowers’ or variability in fibril diameter were evident (Figure 33). 
 
 
Figure 33 Normal control collagen and elastic fibres 
A. Elastic fibres are peripherally irregular in outline but do not appear, to be increased or decreased in number or 
diameter. Collagen bundle packing is normal (9200X).  B. Collagen fibrils are regular with only occasional fibrils with 
an irregular profile. No collagen ‘flowers’ or variability of fibril diameter was observed (20000X). C. Longitudinal 
section of collagen fibrils showing the classical D-period banding pattern.(9200X) 
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Examination of dermal fibroblasts showed normal cell morphology without any expansion of the ER or 
any protein ‘aggregates’ (Figure 34). 
 
 
Figure 34 Normal control dermal fibroblast  
The nucleus, mitochondria, golgi and ER are as labelled. The ER is not expanded (5500X). 
Positive control 
Fibroblasts from a patient with OI (type III) and a c.3269G>A;p.(Gly1090Asp) pathogenic mutation in  
COL1A2 were examined as a positive control. These fibroblasts had grossly expanded ER that was 
protein-filled, supporting aberrant processing of the collagen molecule and subsequent ER stress 
(Figure 35). The presence of collagen flowers and variability in fibril diameter are known features of OI 
(Balasubramanian, Sobey et al. 2016) and were confirmed in this positive control sample. 
 
Figure 35 Ultra structure of dermal fibroblast from a patient with OI type III with a 
c.3269G>A;p.(Gly1090Asp) COL1A2 pathogenic mutation. 
The fibroblasts showed grossly expanded ER that was protein filled suggesting aberrant processing and ER 
stress.(2600X) 
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Patient 015 
Some fibrils showed irregular contours similar to those previously described (Syx, Guillemyn et al. 
2015). Variation in collagen fibril diameter is within normal limits, with a standard deviation of 8nm. 
Occasional small collagen flowers were also identified. Longitudinal sections showed the presence of 
twisted and disorganised fibrils (Figure 36). Collagen bundle packing appeared normal. 
 
 
Figure 36 Ultra structure of collagen fibrils in reticular dermis from patient 015 
A. Some fibrils show irregular contours similar to those previously described (Syx, Guillemyn et al. 2015) and there 
is mild fibril diameter variability. An occasional small cauliflower-like collagen fibrils was also identified (arrowed, 
20000X) B. Longitudinal sections show the presence of twisted and disorganised fibrils (12000X) 
Examination of fibroblasts identified only mildly expanded ER. Elastic fibres were unremarkable 
(Figure 37). 
 
 
Figure 37 Ultrastructure of dermal fibroblasts from patient 015. 
Gross morphology is normal with only mildly expanded ER. Elastic fibres unremarkable. (3300X)  
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Patient J 
Collagen bundle packing was normal. A single fibroblast was identified with moderately expanded and 
protein-filled rough endoplasmic reticulum (Figure 38). Fibroblasts were otherwise unremarkable. 
Collagen fibril diameter variation from the mean ranged from 5.8 to 9.4nm. Mean collagen fibril 
diameter, at 96nm, was in excess of expected for age (85nm). No collagen flowers were observed. 
Elastic fibre ultra structure appeared normal. 
 
 
Figure 38 Ultra structure of collagen and fibroblast from reticular dermis of Patient J 
A: A single fibroblast was identified with mildly expanded ER. All other fibroblasts were unremarkable (3300X) B: 
Mean collagen fibril diameter (96nm) was in excess of that expected for age (85nm). No collagen flowers were 
observed (20000X). 
Patient K 
Collagen bundle packing was unremarkable. Mean collagen fibril diameter at 97nm was slightly in 
excess of expected for age (87nm). Variation in collagen fibril diameter was not excessive at a root 
mean squared deviation of 5.6 to 12.1nm. A few collagen fibrils with an irregular outline and an 
occasional collagen flower were observed (Figure 39). 
The rough endoplasmic reticulum was very slightly expanded and protein filled in occasional 
fibroblasts (Figure 39). Elastic fibres appeared unremarkable.  
Cleavage of the type I collagen C-propeptide is extracellular and therefore it would not be anticipated 
that fibroblasts from BMP1 mutation positive patients, where C-propeptide cleavage is disrupted, 
would show significant signs of ER stress. Rather, it might be expected that collagen fibrils would 
show features suggestive of disrupted fibril assembly.  
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Figure 39 Ultra structure of collagen and fibroblast from reticular dermis of Patient K  
A. Occasional fibroblast with mildly expanded and protein filled ER was observed (3300X). B. A few 
collagen fibrils with an irregular outline and an occasional collagen flower were observed (20000X) 
 
The observations in our patient cohort support this idea and are concordant with previously described 
collagen fibril architecture (Syx, Guillemyn et al. 2015), but with the addition feature of an occasional 
collagen flower in some patients (015 and K).  
Fibroblast morphology was generally unremarkable in this cohort. The mildly expanded ER identified 
in an occasional fibroblast in all three patients was in contrast to the gross expansion seen in the 
COL1A2 mutation positive control. The significance of the mild expansion is unclear. 
Summary 
This group of patients demonstrated the importance of inclusion of BMP1 gene analysis in the 
diagnostic investigation of patients with a clinical diagnosis of OI. This gene analysis should not be 
confined to patients with a noticeable high bone mass phenotype as bone mass in BMP1-related OI 
has been demonstrated to be highly variable (Pollitt, Saraff et al. 2016).  
In addition, careful consideration should be given to anti-resorptive therapy in this ultra rare form of OI 
and close monitoring of response to treatment is recommended. 
Functional exploration of the patients in this study by biochemical collagen analysis, and 
characterisation of collagen fibril and fibroblast ultra structural features has given no clues as to the 
mechanism responsible for the variable phenotypic severity in this group. The exact mechanism by 
which BMP1 mutations cause bone fragility remains to be elucidated. 
  
A B 
Collagen 
‘flower’ 
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v RESULTS: MOUSE MODELS (TRAM2 Gene Analysis) 
The advances in genetic technology have considerably improved our ability to sequence and 
annotate the human genome. However, despite this, the function of many genes and their role in 
disease is still poorly understood.  The mouse is considered the mammalian model of choice to study 
the function of genes and a large scale comprehensive mouse phenotyping consortium has been 
established (International Mouse Phenotyping Consortium, IMPC, www.mousephenotype.org) to try 
and address the questions about gene function (Ayadi, Birling et al. 2012). Some of these mouse 
models have already been valuable in assessing candidate genes associated with OI, for example in 
TAPT1, SP7 and SPARC. 
The IMPC consortium is focused on generating mutations in protein-coding genes of the mouse 
genome. Mutant mouse strains undergo comprehensive high-throughput phenotyping and the data 
generated from this phenotyping pipeline is made available through the web portal 
www.knockoutmouse.org. This functional gene annotation resource allows us to target investigation of 
genes of interest in rare diseases such as OI.  
The phenotypic assessment performed by the Mouse Genetics Project (MGP) includes measurement 
of DEXA scores to provide an indication of bone mineral density (BMD) in their knock-out mouse 
models. BMD is currently used as a predictor of fracture risk, although correlation is poor. 
Approximately 160 knock-out mice are assessed per year, with an approximate 4% hit rate for DEXA. 
This data is useful in targeting further genes for analysis in our cohort, although mouse models can 
only point towards genes where knock-out, rather than gain of function or dominant-negative, 
mutations are causative.  
Nine genes affecting bone strength have been published by the consortium so far (Bassett, Gogakos 
et al. 2012). Three of these, Prpsap2, Slc38a10 and Sparc, are reported to result in bones that are 
described as weak and brittle. The Prpsap2 and Slc38a10 genes are thought to be important in bone 
development, whereas Sparc is a glycoprotein found in the extracellular matrix and is thought to have 
a role in bone mineralization. SPARC mutations have subsequently been identified in autosomal 
recessive OI, as described in section ii.xii.vi.iii, confirming the potential of mouse models to identify 
genes associated with bone fragility. The human homologue gene, SLC38A10, will be discussed 
further in section viii.vi. 
Collaboration with the Sanger Mouse Genetics Project (Sanger MGP), a partner in the IMPC, 
highlighted a novel gene associated with skeletal abnormalities, the Tram2 gene (Figure 42). Primary 
data in a Tram2 -/- knockout mouse indicated reduced viability of homozygous pups (38/274 pups = 
14%, expected 25%), with normal weight at birth but with post-weaning growth retardation (Figure 
40). 
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Reduced bone mineralisation parameters were also recorded, including reduced bone mineral density 
in both males and females (Figure 41).  
 
 
Figure 41 Measure bone mineral density in Tram2 -/- knockout mouse 
using the DEXA analyser (g/cm2).  
Data provided by Chris Lelliot, Sanger MGP 
 
Tram2 -/- knockout mouse also have substantial hearing impairment demonstrated by abnormal 
response to auditory stimulus (click box) measured by signal detection threshold in brainstem 
response. These mice are not completely deaf but require “louder” noise to produce a detectible 
electrical trace. 
 
 
Figure 40 Male and Female weight curves for the Tram2-/- mouse model. 
Both sexes show reduced bone weight when compared with wildtype age and sex 
matched controls 
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Figure 42 X-ray of adult mouse knee joint at 16wks.  
A Normal control B Tram2 -/- knockout mouse with abnormal patella morphology highlighted. Images kindly 
provided by Chris Lelliot Sanger MGP 
 
The translocation-associated membrane protein 2 gene (TRAM2) is cytogenetically located at 6p12.2 
and encodes an ER multi-pass membrane protein.  The function of TRAM2 in humans is not 
completely clear at present. It has been shown to interact with RUNX2, a major transcription factor in 
osteoblasts, in a BMP-dependent manner (Pregizer, Barski et al. 2007) and is known to be required 
for type I collagen synthesis, most probably by interaction with SERCA2b, the calcium pump of the 
ER. This interaction may increase Ca(2+) concentration at sites of collagen synthesis and facilitate 
the functioning of chaperones involved in collagen folding (Stefanovic, Stefanovic et al. 2004). 
TRAM2 is also thought to mediate translocation of M4SF20 (transmembrane 4 L6 family 20), a 
polytropic membrane protein that inhibits proteolytic processing of CREB3L1/OASIS, in the absence 
of ceramide (Chen, Denard et al. 2016).  
Taken together, the phenotype of the Tram2 -/- knockout mouse and the proposed protein function, 
suggested that TRAM2 is a candidate gene for bone fragility. To explore this further the TRAM2 gene 
was analysed by either Sanger sequencing or by interrogation of whole exome data in all patients in 
our cohort.  
Sanger sequencing covered all coding sequence and intron/exon boundaries up to +/-25bp. Where 
deeply intronic variants were identified in exome data these were discounted if they were described 
with an allele frequency of >1% in population datasets. Analysis of the remaining variants identified 
two recurring changes c.627-5C>T and c.470+5_470+6 dup (Table 21 and Figure 43).  
The c.627-5C>T variant is listed on NCBI dbSNP with an average heterozygosity of 0.17. In the 
gnomAD cohort (121,004 chromosomes) 320 individuals are reported as being homozygous. This 
variant can therefore be classed as a benign polymorphism and is highly unlikely to result in 
symptoms of OI.  
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Participant 
ID 
Variant Zygosity dbSNP ID 
001 c.627-5C>T het rs9688915 
002 c.627-5C>T het rs9688915 
004 c.470+5_470+6 dup het rs57120044 
007 c.627-5C>T het rs9688915 
008 c.470+5_470+6 dup het rs57120044 
014 c.470+5_470+6 dup het rs57120044 
A c.470+5_470+6 dup homo rs57120044 
Table 21 Variants identified in the TRAM2 gene in participants 001-018 and A-H 
 
 
Figure 43 Sanger Sequence of two common variants in the TRAM2 
gene identified in our cohort.  
A c.627-5C>T and B c.470+5_470+6 dup 
Frequency data for the c.470+5_470+6 dup is comprehensive. Average heterozygosity is stated as 
0.264 in NCBI dbSNP, although there is no data for the number of individuals that this data is derived 
from. However, gnomAD, ESP and GoNL datasets all show that this variant is common in the general 
population, with allele frequencies ranging from 6.24% to 49.41% depending on ethnicity. This variant 
is therefore also highly unlikely to result in symptoms of OI. 
The results from this analysis suggest that sequencing single genes of interest is a poor strategy for 
identifying novel genes in OI cohorts. 
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vi RESULTS: WHOLE EXOME SEQUENCING (Personalis)  
Three patients (participant ID: A, B and C) were commercially sequenced by Personalis® using their 
ACE ExomeTM Assay. Personalis® returned all raw sequence data as well as a report highlighting 
‘significant’ findings. This report used the HPO terms submitted for each patient to target genes 
potentially responsible for the patient’s clinical symptoms.  
Parental samples were also submitted for sequencing for patient B.  
vi.i Patient A: 
Two variants of uncertain significance were reported by Personalis: c.4136C>T;p.(Thr1379Met) in the 
MYH6 gene and c.3660G>A;p.(Met1220Ile) in the ARID1A gene. These findings were assessed at 
the gene and variant level to clarify if they were likely to be responsible for the phenotypic features in 
this individual. 
vi.i.i MYH6 c.4136C>T;p.(Thr1379Met) 
The MYH6 gene has been described in association with familial hypertrophic cardiomyopathy. This 
particular variant is present in multiple healthy genome datasets including NHLI ESP and gnomAD, It 
is recorded in 72 heterozygous individuals (in 66714 alleles) in the gnomAD European (non-Finnish) 
population and at a frequency of 0.2% in the Dutch (GoNL) population. This variant is therefore likely 
benign, although a contributing role in the cardiac abnormality in this patient (ventricular septal defect) 
cannot be completely excluded. 
vi.i.ii ARID1A c.3660G>A;p.(Met1220Ile) 
Nonsense, frameshift and microduplication mutations in the ARID1A gene are reported in association 
with an autosomal dominant mental retardation syndrome, Coffin-Siris type 2 (Kosho, Okamoto et al. 
2014, Bidart, El Atifi et al. 2017). The c.3660G>A missense variant is novel in that it is not recorded in 
any population genome datasets. In-silico conservation analysis is inconclusive with multiple 
packages, including SIFT and Polyphen, producing conflicting predictions as to likely effect. In 
addition, although the amino acid is conserved among vertebrate species, the amino acid substitution 
is predicted to be neutral. Without further supporting evidence the clinical significance of this finding is 
unclear. However, although this variant has the potential to be contributing to this patient’s symptoms 
of intellectual disability, it seems unlikely to be responsible for his bone fragility.  
Further exploration of the Personalis sequence data was undertaken. In the absence of parental 
samples we searched for all LOF variants in this patient’s dataset. A total of 123 high quality variants 
were identified and each one was manually assessed for likely contribution to patient’s phenotype. 
Strategy 2 (exomizer) and strategy 3 (target gene list) variants were also explored. No OI or bone 
fragility candidate variants/genes were identified in this individual. 
Segregation analysis in the parents of this individual would help to further explore the sequence data 
for this individual using inheritance patterns (strategy 1). This may also clarify the significance of the 
88 
 
MYH6 variant identified in this individual. The patient and his parents have been enrolled in the DDD 
project to facilitate this analysis.  
 
vi.ii Patient B 
A heterozygous variant, c.6427G>A;p.(Gly2143Arg) in the COL6A3 gene was reported by Personalis. 
vi.ii.i COL6A3 c.6427G>A;p.(Gly2143Arg)  
This gene is associated with autosomal dominant and autosomal recessive collagen VI related 
myopathy including Bethlem and Ullrich myopathies and is reported at very low frequency in the 
general population (2/121290 alleles). Glycine 2143 lies within the triple helical domain of the protein 
and similar heterozygous variants in this region have been reported in association with Bethlem 
myopathy (Lampe and Bushby 2005). However, as collagen VI is a non-fibrillar collagen this variant 
cannot be presumed to be pathogenic, although in-silico analysis would support this. The variant is 
inherited from this individual’s unaffected mother, and this could indicate non-penetrance, reduced 
expressivity or recessive inheritance. However, neither the child nor his mother has clinical features 
suggestive of a type VI related myopathy, indicating that this is most likely a rare benign sequence 
variant. 
vi.ii.ii SRCAP c.9029C>A;p.(Pro3010His)  
Exploration of this patient’s sequencing data using strategies 1, 2 and 3 identified a de-novo 
c.9029C>A;p.(Pro3010His) variant in the SRCAP gene (NM_006662.2) that was not reported by 
Personalis. These findings were confirmed by Sanger sequencing (Figure 44). 
This SRCAP gene maps to 16p11.2 and encodes the multifunctional SNF2-related chromatin-
remodelling factor. The SRCAP protein is the catalytic component of a complex that mediates the 
ATP-dependent exchange of histone H2AZ/H2B dimers for nucleosomal H2A/H2B leading to 
transcriptional regulation of genes by chromatin remodelling.  
Independently to its role in chromatin remodelling, SRCAP is a coactivator for the CREB-binding 
protein (CREBBP, also known as CBP). CREBBP regulates gene expression via mediating the 
interaction between transcription factors and transcription machinery (Monroy, Ruhl et al. 2001).  In 
particular CREBBP acts with EP300 via the transcription factor cAMP-responsive element-binding 
protein (CREB) to regulate the transcription of a number of bone-related genes (Gordon, Stein et al. 
2015). EP300 itself is associated with Rubinstein-Taybi syndrome 2 where patients have 
characteristic facial features, short stature, and moderate to severe learning disability (Gordon, Stein 
et al. 2015). 
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Figure 44 Sanger sequence confirmation of de-novo c.9029C>A;p.(Pro3010His) SRCAP variant  in 
patient B. 
Top = patient B, middle = maternal, lower = paternal 
Truncating mutations in SRCAP are associated with Floating Harbor Syndrome (FHS), a condition 
characterized by short stature, delayed bone age and delayed speech (Messina, Atterrato et al. 
2016). A characteristic facial appearance that includes, deep set eyes, short philtrum, thin lips, wide 
columnella and long eyelashes is described. 
The c.9029C>A variant in our patient lies in exon 34 of the SRCAP gene, a region that is known to be 
a ‘hotspot’ for FHS mutations (Hood, Lines et al. 2012). These heterozygous truncating mutations are 
predicted to abolish the three C-terminal AT-hook DNA-binding motifs while leaving the CBP-binding 
and ATPase domains intact (Figure 45).  It is proposed that these mutations act in a dominant 
negative manner either by competing with wildtype protein in binding to its partners in the SRCAP 
chromatin remodelling complex and CREBBP or alternatively by interacting directly with wildtype 
SRCAP protein to form inactive heterodimers that are unable to bind DNA targets or chromatin 
partners (Messina, Atterrato et al. 2016).  
A single case has been described of a de-novo 186kb microdeletion on chromosome 16p11.2 that 
encompasses the SRCAP gene. The patient is reported to have global developmental delay, speech 
impairment and behavioural problems (ADHD). Deep set eyes, bulbous nose with broad nasal bridge, 
and thin upper lip were also identified which could be considered as features that overlap with FHS, 
however it was felt that a diagnosis based on facial gestalt was not possible (Gerundino, Marseglia et 
al. 2014). The authors suggest that this patient might represent the first reported case of 
haploinsufficiency of SRCAP in association with a clinical phenotype, although acknowledge that 
further evidence is required. It is worth noting that this individual is not reported to have a skeletal 
phenotype. 
To date, no missense variants in SRCAP have been reported in association with a clinical phenotype.  
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Figure 45 Locations of Floating Harbour Syndrome-Causing Mutations within SRCAP. 
 (A) Intron-exon structure of SRCAP. The mutation cluster in exon 34 is indicated by a red arrow. 
(B) SRCAP domain structure. The amino acid positions of recognized domains are given below. The positions of 
heterozygous FHS mutations are shown in red.  
Key: HSA = Helicase-SANT-associated domain. Modified from Hood et al.(Hood, Lines et al. 2012) 
 
 
The c.9029C>A missense variant lies within the AT hook 3 domain and affects a moderately 
conserved amino acid. The physiochemical difference between proline and histidine are moderate 
and the amino acid substitution is predicted to be disfavoured (Unclassified Variant evaluation form, 
Appendix page 190). Review of variants listed in the dbSNP database did not identify any missense 
changes in the AT hook domains of the SRCAP gene with any frequency data in the normal 
population. In addition, search of the decipher database did not identify any further missense changes 
in this region of the gene. GnomAD constraint metrics for this gene are pLI=1.00 (pLI>=0.9 indicates 
an extreme loss of function intolerant gene) and the Z score for missense mutations is 2.23 (a positive 
Z score indicates increased constraint/intolerance). 
Methylation Status 
One mechanism for the potential pathogenicity of this variant could be via changes in chromatin 
remodelling and subsequent changes in DNA methylation status. A recent study looking at the 
methylation profile associated with FHS suggests that truncating mutations of SRCAP result in locus 
specific DNA methylation changes which in turn may regulate the expression of specific genes (Hood, 
Schenkel et al. 2016). It is possible that the c.9029C>A variant also has an impact on methylation 
status of genes, particularly those associated with bone metabolism.  
To explore this hypothesis Prof Sadikovic (Western University, London, Canada) kindly undertook 
DNA methylation status analysis for patient B. They used an EPIC array (Illumina) that detects 
cytosine methylation at CpG islands and allows interrogation of methylation patterns at the genome-
wide level, covering more than 850,000 methylation sites. 
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The results for patient B were compared against a large range of control samples from individuals of 
different ages (to counteract any bias in age related methylation status) and a cohort of patients with 
FHS. Multiple approaches from hierarchical clustering to support vector machine were employed. 
Patient B clustered with the normal control cohort (Figure 46 and Figure 47). 
 
 
 
Figure 46 Hierarchical clustering of methylation status. 
Patient B (green), patients with Floating Harbour syndrome (blue) and normal controls (red) using an Illumina EPIC 
methylation array. Patient X clusters with the normal control cohort. 
In addition, multiple genomic regions with altered methylation specific to patients with SRCAP 
nonsense mutations were also examined and clearly demonstrated that this patient does not have the 
characteristic methylation profile previously identified in patients with FHS.  
These results confirm that this patient does not have a phenotypic variant of FHS but does not 
exclude his SRCAP variant being associated with his clinical presentation. To further explore the 
methylation data from our patient, bump-hunter, a bioinformatic tool that removes batch effects and 
detects regions of interest and attaches statistical uncertainty (Jaffe, Murakami et al. 2012) was used 
to look for regions with differential methylation from the normal control cohort. A maximum Gap was 
set to 500bp and the patient was compared with 30 controls. Chromosomes X and Y were excluded. 
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Regions with more than 15% methylation difference were reported back along with images of each 
region. 
 
 
Figure 47 Methylated CpG island at chr6:33282867-33283184 
 Red:= FHS patients with SRCAP mutations, Blue:= Controls; Yellow = : Patient B c.9029C>A;p.(Pro3010His) 
 
A total of 171 regions with altered methylation status were identified and manually assessed in turn. 
Several of the reported regions did not appear to be significant as there was overlap between our 
patient and control patients; these regions were discounted from further analysis.  
Patient B appears to have regions that are both hyper and hypo methylated in comparison to controls 
(for examples see Figure 48 and Figure 49 respectively). Each of these genomic regions was 
interrogated for genes with a function that could be associated with the patient’s phenotype. 
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Figure 48 An example of a hypermethylation region plot. 
Chromosome 4 genomic coordinates 108852555-108852651 (P value = 7.84E-06). Black = patient, Red = controls. 
This genomic region is within the promoter region of the CYP2U1 gene. The protein catalyzes the hydroxylation of 
arachidonic acid, docosahexaenoic acid and other long chain fatty acids. Mutations in this gene are known to be 
associated with Spastic paraplegia 56 (SPG56), an autosomal recessive neurodegenerative disorder characterized 
by progressive weakness and spasticity of the lower limbs but with no skeletal features reported. 
 
 
 
Figure 49 An example of a hypomethylation region plot. 
Chromosome 16 genomic coordinates 68679556-68680117 (P value =.0.001248939). Black = patient, Red = controls 
This genomic region covers of the 5’ end of Cadherin 3 (CDH3), a gene associated with autosomal recessive 
ectodermal dysplasia, ectrodactyly and macular dystrophy (EEMS and hypotrichosis congenital with juvenile macular 
dystrophy (HJMD). The protein is a calcium dependant cell-cell adhesion glycoprotein and not usually expressed in 
blood. 
Two genes of interest were identified, PCOLCE and LOXL3, both of which are hypomethylated in 
patient B compared to normal controls (P= 0.006932885 and P=0.011544351 respectively).  
PCOLCE encodes a protein that binds the C-terminal propeptide of type I procollagen and enhances 
procollagen C-proteinase activity. There is no known phenotype associated with mutations in this 
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gene. Methylation of the gene promoter region was reduced in patient B (Figure 50), perhaps 
representing upregulation of the gene.  
 
 
Figure 50 Methylation pattern for the PCOLCE gene region (chr7 100199826-100199982). 
Patient B compared to normal controls. Black = patient, Red = controls 
This region is hypomethylated when compared to controls (P= 0.006932885) 
 
 
 
Figure 51 Methylation pattern for the LOXL3 gene region (chr2 74775965-74775979). 
Patient B compared to normal controls. Black = patient, Red = controls 
This region is hypomethylated when compared to controls (P=0.011544351) 
 
The LOXL3 gene encodes lysyl oxidase-like 3. The lysyl oxidase family are known to have both 
enzymatic and non-enzymatic functions in bone (Trackman 2016). LOXL3 null mice exhibit perinatal 
lethality and have cleft palate and spinal deformities (Zhang, Yang et al. 2015) and a homozygous 
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missense mutation has been described in a family with autosomal recessive Stickler syndrome. 
(Alzahrani, Al Hazzaa et al. 2015). LOXL3 is hypomethylated in patient B (Figure 51). 
It is not clear whether the altered methylation status of PCOLCE and LOXL3 is a response to, rather 
than being the primary cause of, altered bone metabolism in this patient. 
Activation of CREB-mediated transcription 
Another mechanism for the potential pathogenicity of the c.9029C>A variant is through SRCAPs 
interaction with CREBBP/EP300 and activation of CREB-mediated transcription. Potential pathways 
include cAMP/CREB signalling pathways in osteoblasts such as mediation of PTH and/or BMP2 
signalling. Osteoblast specific deficiency of CREB in mice causes reduced bone mass and decreases 
BMP2 expression, supporting that BMP2 is a critical transcriptional target for CREB in osteoblasts 
(Zhang, Edwards et al. 2011).  
To investigate this hypothesis further, downstream targets of BMP2 were explored (Figure 52). One 
target of particular interest is RUNX2, a gene that is essential for osteoblast differentiation and bone 
development. Haploinsufficieny of RUNX2 is associated with Cleidocranial dysplasia (CCD), an 
autosomal dominant skeletal dysplasia. Clinical features in CCD are hypoplastic or aplastic clavicles, 
dental abnormalities and delayed closure of the fontanels. A small subset of patients with severe CCD 
is reported to have severe osteopenia, absence of the clavicles, marked calvarial hypomineralization 
and progressive kyphoscoliosis (El-Gharbawy, Peeden et al. 2010).   
Clinical presentation of our patient was reviewed to try to identify any features that would be 
consistent with this mechanism. Severe skeletal dysplasia was identified antenatally and he was born 
with limb deformities and fractures of the femurs and ribs. At 8 months of age he had developed 
multiple crush fractures of the vertebrae and went on to develop mild scoliosis by age 15 months. On 
X-ray he was noted to have ‘dimpling’ over both thighs and upper arm. A possibility of joint 
contractures was raised. 
At age 18 months he was again noted to have deep pits (dimples) in his lateral thigh compartments 
but there was no evidence of contractures. It was thought that he was rhizomelic in appearance. Mild 
hypogammaglobulinaemia was identified and he was non-responsive to pneumococcal vaccination. 
Facially he has a wide midface but no other features consistent with FHS. No bone biopsy is available 
for review. He has no radiographic features to support cleidocranial dysplasia. These findings suggest 
that the SRCAP variant is not acting via CREBBP/EP300 to reduce downstream transcription of target 
genes such as BMP2.  
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Figure 52 Downstream targets of BMP2. 
BMP2 activates the canonical BMP/Smad signalling pathway and non-canonical MAPK pathways to regulate 
osteoblast differentiation of progenitor cells. Figure modified form Huang et al. (Huang, Yuan et al. 2014). 
Electron Microscopy Ultra Structure Evaluation 
In the search for further clues as to the cause of patient’s B symptoms, electron microscopy 
examination of a skin biopsy was undertaken. Collagen bundle packing appeared normal, fibre 
diameter was as expected for age and there was minimal diameter variation. No collagen flowers 
were seen.  
 
 
Figure 53 Ultra structure of collagen and fibroblast from reticular dermis of Patient B 
Cross section of a fibroblast showing only slightly expanded ER. Collagen fibrils appeared normal and no collagen 
flowers were seen in this patient (3300X). 
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The majority of fibroblasts appeared normal. A single fibroblast with slightly expanded ER was 
identified (Figure 54).  
 
 
Figure 54 Proteoglycan wrapping around collagen fibres in dermis from patient B (20000X). 
The significance of this observation is unclear   
An interesting feature was the presence of proteoglycan wrapping around collagen fibres (Figure 54). 
The significance of this is unclear but this was also identified in patient E, who has a mutation in the 
P4HB gene (see Figure 68). In light of this finding Patient B’s sequence data was further interrogated 
for variants in P4HB and other genes in the prolyl 4-hydroxylase complex. No candidate variants were 
identified. 
 
vi.ii.iii TAPBP c.1169C>T;p.(Pro390Leu)  
An additional finding of interest, given the mild hypogammaglobulinaemia and non-response to 
pneumococcal vaccination in this individual, is a de-novo c.1169C>T;p.(Pro390Leu) variant in the 
TAPBP gene (NM_003190) identified by exploration of this patient’s sequence dataset. This gene 
encodes the Tapsin protein that mediates the association of the MHC class I with the transporter 
associated with antigen processing protein complex (TAP). Tapsin is highly expressed in neutrophils 
and is essential for the transport of antigenic peptides across the ER (Figure 55).  
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Figure 55 Transport of antigenic peptides across the ER. 
Simplified diagram of cytoplasmic protein degradation by the proteasome, transport into endoplasmic reticulum by 
TAP complex, loading on MHC class I, and transport to the surface for presentation. 
Figure By Scray, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=6251017 
 
Bi-allelic loss of function mutations in TAPBP are associated with Type I Bare Lymphocyte Syndrome, 
a condition characterised by chronic bacterial infection that is usually confined to the respiratory tract 
and manifests in the first decade of life.  The c.1169C>T;p.(Pro390Leu) variant is predicted to be 
possibly damaging by Polyphen but tolerated by SIFT. The probability of this gene being loss of 
function intolerant in gnomAD is given as pLI=0.00 and therefore without a second likely pathogenic 
variant being identified in this patient the clinical significance of this finding is unclear. 
This patient was subsequently entered into the DDD study (DDD patient number 136) and the de-
novo SRCAP variant was reported back to the clinician as a candidate gene for the symptoms in this 
individual. The TAPBP variant was confirmed in the DDD data and listed in their candidate gene list 
but was not reported back to the clinician.  
However, further evidence for the putative causative role of this SRCAP missense variant is needed. 
It should be noted that a reported frequency of de-novo point mutations per generation is in the region 
of 70-175, of which approximately 3 would be expected to cause changes in protein coding (Nachman 
and Crowell 2000, Conrad, Keebler et al. 2011). It therefore follows that a de-novo missense variant 
may not necessarily be associated with a deleterious clinical phenotype. 
vi.iii Patient C 
Personalis reported 4 heterozygous variants that were potentially related to the clinical presentation of 
patient C: c.1041_1043dupGGC;p.(Ala350dup) in ARID1B, c.3404T>C;p.(Ile1135Thr) in SKIV2L, and 
c.5741G>A;p.(Arg1914His) and c.3010C>T;p.(Arg1004*) both in the NBAS gene. 
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vi.iii.i ARID1B c.1041_1043dupGGC;p.(Ala350dup)  
ARID1B (NM_020732.3) is associated with autosomal dominant Coffin-Siris syndrome (CSS) 
characterized by varying degrees of developmental delay, hypotonia, hirsutism/hypertrichosis, and 
sparse scalp hair. Congenital anomalies may include cardiac malformations, gastrointestinal, 
genitourinary, and central nervous systems abnormalities. Patient C is described as having severe 
intellectual disability, abnormality of the hair line and hair hypoplasia, symptoms which overlap with 
those described in CSS. 
Previously reported pathogenic mutations in ARID1B included nonsense, frameshift and microdeletion  
(Hoyer, Ekici et al. 2012) mutations predicted to result in haploinsufficiency. The variant in patient C 
results in the addition of one extra alanine within the 11 Ala repeat region of exon 1 of the gene. 
Variants in this polyalanine tract have not been reported in association with disease and this particular 
copy number variant is reported in 1.17% of individuals in HGVD dataset. This variant therefore is 
most likely benign. 
vi.iii.ii SKIV2L c.3404T>C;p.(Ile1135Thr) 
Nonsense mutation in the SKIV2L gene have been reported in association with autosomal recessive 
trichohepatoenteric syndrome, a condition characterised by intractable diarrhoea,  facial 
dysmorphism, intrauterine growth retardation, immunodeficiency, and hair abnormalities  (Fabre, 
Charroux et al. 2012).  In-silico conservation analysis of this variant did not support a likely deleterious 
effect on protein function and it was considered unlikely to be contributing to the symptoms of patient 
C.  
vi.iii.iii NBAS c.5741G>A;p.(Arg1914His) and c.3010C>T;p.(Arg1004*) 
The NBAS gene is reported in an autosomal recessive condition characterised by growth retardation, 
abnormal shaped neutrophil nuclei and optic atrophy with resulting loss of visual acuity. This is known 
as Short stature, optic nerve atrophy, and Pelger-Huet anomaly syndrome (SOPH) and was first 
described in an isolated Yakut population in Siberia (Maksimova, Hara et al. 2010). Additional clinical 
features include fine hair, facial asymmetry, long face with small features and narrow forehead, 
hypermobility of small joints and muscle hypotonia.  
Compound heterozygous mutations in NBAS have more recently been described in acute liver failure 
(ALF)(Haack, Staufner et al. 2015) and further reports have suggested that this represents a multi-
system disorder (Staufner, Haack et al. 2016) with phenotypic variability ranging from isolated ALF to 
a broader spectrum including short stature, osteopenia, optic atrophy, immunological abnormalities, 
and minor syndromic features such as hypotelorism. Many of these features were consistent with the 
clinical presentation in patient C. However, bone fragility severe enough to need bisphosphonate 
therapy, as was the case for patient C, had not been reported. 
To explore this finding further the full set of variants reported by Personalis was investigated, primarily 
to try to identify any unreported variants that could be responsible for the bone fragility in this patient. 
Firstly, the sequence coverage was assessed to identify any potential regions of low coverage. The 
average depth in the target region was 115X which was considered adequate. The total number of 
variants was 189,298. After quality and frequency filtering 19,772 remained. 
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After filtering, loss of functions variants, i.e. those annotated as frameshift, splice site acceptor, splice 
site donor, or stop gained were extracted. There were 89 of these variants, and after manual review, 
none were considered to be in genes with an apparent function in bone. Finally, a larger group of 
missense variants identified using strategy 2 and 3 (exomizer and targeted gene panel) was 
compiled. There were 23 of these targeted missense variants all of which were considered to be likely 
benign following in-silico conservation analysis and manual review. 
The presence of the NBAS variants in the patient was confirmed by Sanger sequencing. Subsequent 
sequencing of the parents showed that c.3010C>T;p.(Arg1004*)  is present in the mother and 
c.5741G>A;p.(Arg1914His) in the father (Figure 56). 
The c.5741G>A;p.(Arg1914His) variant has previously been described in the homozygous state in 
patients with SOPH syndrome (Maksimova, Hara et al. 2010) and in a single case with an overlapping 
SOPH and ALF phenotype who is heterozygous for this variant and a p.(Glu943*) nonsense mutation 
(Kortum, Marquardt et al. 2017).  
The c.3010C>T;p.(Arg1004*) variant has been reported in an individual compound heterozygous for 
this variant and a c.3164T>C;p.(Leu1055Pro) variant in association with acute liver failure (Haack, 
Staufner et al. 2015, Staufner, Haack et al. 2016).  
 
 
Figure 56 Sanger sequence confirmation of heterozygous NBAS variants in the parents of patient 
C. 
The c.3010C>T;p.(Arg1004*) is present in the mother (bottom left) and c.5741G>A;p.(Arg1914His) in the father 
(bottom right). Normal control sequences are shown top right and top left respectively. 
 
Western blot analysis of NBAS protein levels (performed by Dr S Brown, Sheffield RNAi Screening 
Facility, University of Sheffield) showed reduced levels in the patient’s cultured fibroblasts compared 
to normal controls (Figure 57) and examination of peripheral blood film confirmed the presence of 
Pelger Huët anomaly (Figure 58) both further supporting that these two variants are pathogenic. 
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Figure 57 Western blot of cultured fibroblasts showing reduced NBAS protein levels compared to 
controls. 
HPF: human primary fibroblasts 
 
 
Figure 58 Peripheral blood film showing the presence of Pelger Huët anomaly in patient C. 
Stained using May Grunwald Giemsa. 
Electron Microscopy Ultra structure Evaluation 
Electron microscopy showed normal collagen bundle packing. The mean collagen fibril diameter 
(75nm) was very mildly reduced for age (normal range 80-90nm (Stewart 1995)) There was no 
marked increase in diameter variability, apart from a small area near a vessel that showed variable 
diameter, the significance of which is unclear (Figure 59). Occasional medium sized collagen flowers 
(~200nm in diameter) were seen (Figure 60). 
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Figure 59 Electron microscopy of collagen fibrils in patient C 
Electron microscopy showed normal collagen bundle packing.  Collagen fibre diameter was within expected range for 
age (A) apart from a small area near a blood vessel that showed variable diameter (B) the significance of which is 
unclear (20,000X magnification). 
 
Figure 60 Electron microscopy of collagen fibrils showing occasional collagen flowers in patient C 
(~200nm in diameter). 
 A-B 9200X magnification, C-D 20,000X magnification 
Ultra structure examination of fibroblasts showed grossly expanded protein filled ER (Figure 61). This 
protein has formed ‘aggregates’ within the ER of some fibroblasts and the golgi appears swollen 
(Figure 62).  
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Figure 61 Electron microscopy of dermal fibroblasts from patient C showing markedly expanded 
protein filled ER. 
A: 15600X magnification, and B 9200X magnification 
 
 
Figure 62 Electron microscopy of dermal fibroblast from patient C showing the presence of protein 
aggregates within the expanded ER. 
A The ER is expanded and protein filled and the golgi appears swollen (9200X magnification). B The presence of 
protein aggregates within the ER is shown (20000X magnification). 
Also noted within some fibroblasts were electron dense bodies in the lysosomes (Figure 63). While it 
is normal to accumulate these electron dense bodies with age, it is not expected in a child of this age. 
This may represent autophagy within the cell. 
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The NBAS gene encodes the neuroblastoma-amplified sequence protein and is a component of a 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. SNAREs 
facilitate the docking and fusion of transport vesicles with target membranes, via membrane bound 
proteins on transport vesicles (v-SNARE) and target membranes (t-SNARE). The NBAS protein 
interacts with t-SNARE p31 and, along with other components, forms the syntaxin 18 complex that is 
involved in golgi to ER retrograde transport (Aoki, Ichimura et al. 2009). The disruption to this golgi-
ER transport mechanism is supported by the EM findings in patient C.  
Functional studies in fibroblasts from 14 patients with ALF and NBAS mutations demonstrated that 
decreased NBAS protein was mirrored by reduction in p31 supporting the role of NBAS in the SNARE 
complex (Staufner, Haack et al. 2016). Thermal instability of syntaxin 18, evidenced by compromised 
growth and further reduction of both NBAS and p31 in temperature-challenged fibroblasts, and 
subsequent ER stress induced apoptosis, has been suggested to be the fever-dependent mechanism 
by which ALF is triggered in NBAS patients (Staufner, Haack et al. 2016).  
 
 
Figure 63 Electron microscopy of dermal fibroblast from patient C showing electron dense bodies 
within lysosomes. 
A 2600X magnification. B 20000X magnification 
Studies in zebrafish and C.elegans have also identified that the NBAS protein plays an important role 
in the nonsense mediated (NMD) decay pathway, a surveillance mechanism that targets mRNAs 
harbouring premature termination codons, preventing accumulation of shortened proteins that 
potentially interfere with normal cellular function.  NMD is also known to regulate gene expression and 
NBAS has been shown to act, along with core NMD factors, to regulate expression of genes 
associated with bone mineralisation, osteoblast differentiation and bone development. In particular, 
NBAS-depletion has been demonstrated to result in upregulation of the MGP gene (Matrix Gla 
Protein) which acts as an inhibitor of bone formation (Longman, Hug et al. 2013). 
 
105 
 
As NBAS is proposed to function in both Golgi-ER transport and the NMD pathway, the mechanism 
by which the mutations identified in patient C result in bone fragility could be attributed to either 
pathway or to a combination of both. Interestingly, although our patient has had abnormal liver 
function tests since a young age, he has never had any episodes of ALF. 
Patient C is the second child of healthy, non-consanguineous North European parents. He was born 
at 33 weeks gestation by spontaneous breech delivery following a normal pregnancy weighing 1.75kg 
(9th centile). He needed continuous positive airway pressure (CPAP) ventilation for 24 hours and 
phototherapy for jaundice. He had recurrent infections and significant feeding problems, requiring 
percutaneous gastrostomy insertion. He was diagnosed with a horizontal nystagmus, bilateral optic 
atrophy and myopia, but his hearing is normal.  
His growth parameters remain below the 0.4th centile and at 7 years of age he weighed ~13.1kg 
(<0.4th centile), with height ~ 88cms (<0.4th centile) and head circumference ~ 49.5cms (0.4th-2nd 
centile), A skeletal survey showed multiple Wormian bones, slender tubular bones and osteopenia. 
Following recurrent fractures, a transiliac bone biopsy was taken and showed osteoporosis with high 
bone turnover with marked periosteal bone resorption, which was not consistent with a classical OI 
phenotype. He has moderate intellectual disability and a high-pitched voice. ArrayCGH (60K), FRAX, 
UPD7 and 11p15 methylation genetic testing were all negative. 
On examination at 9-years of age, he was dysmorphic with proptosis, had a progeroid skin 
appearance, bilateral low-set ears, dentinogenesis imperfecta, and bilateral 5th finger clinodactyly. On 
lateral spine radiograph he has loss of vertebral height and a low lumbar bone BMAD Z-score of -3.5. 
Marked improvement of his bone health was achieved with Pamidronate treatment.   
A second patient with biallelic NBAS mutations was highlighted by analysis of the CAP DDD data 
(Chapter viii) due to the HPO term ‘Recurrent fractures’ (HP:0002757). This patient had the same 
missense variant as patient C, c.5741G>A;p.(Arg1914His) inherited from the mother and a novel 
nonsense mutation, c.2032C>T;p.(Gln678*), inherited from the father. This patient was also described 
as having elevated hepatic transaminases in his DDD phenotypic data. 
We concluded that mutations in NBAS result in a variable clinical presentation and that these two 
patients show that symptoms can include a skeletal phenotype with bone fragility. Vertebral and long 
bone fractures can result, potentially requiring treatment with bisphosphonates.  
To facilitate rapid transition of NBAS gene testing into the diagnostic pathway for patients with 
appropriate clinical features, a gene dossier was prepared and submitted to the UK Genetic Testing 
Network (UKGTN). The UKGTN provides a mechanism for national evaluation of proposed new tests 
for NHS patients. The gene dossier covers characterises of the disorder/condition, testing strategies, 
clinical utility and testing criteria (see Appendix M, page 303). The gene dossier was accepted and is 
now published: 
https://ukgtn.nhs.uk/uploads/tx_ukgtn/NBAS_related_Disorder_GD_Sept_2017.pdf  
Sequence analysis of the NBAS gene has been introduced as a diagnostic test for inherited bone 
fragility at SDGS.   
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These two NBAS patients are presented in the co-authored manuscript ‘Compound heterozygous 
variants in NBAS as a cause of atypical osteogenesis imperfecta’ (Balasubramanian, Hurst et al. 
2017), (Appendix G page 240)  
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vii RESULTS: WHOLE EXOME SEQUENCING (SDGS) 
Five patients (participant ID D, E, F, G and H) were sequenced at SDGS using the SureSelect Human 
All Exon V6 baits for target enrichment. Parental samples were also sequenced with the exception of 
patient D where only maternal DNA was available. The total number of variants identified for each 
patient is illustrated in Figure 64 below. 
 
 
 
108 
 
 
 
 
Figure 64 Distribution of variants identified in patients D-H using whole exome sequencing. 
Sequencing performed using the SureSelect Human All Exon V6 probe set and the Illumina HiSeq platform. The total 
number of variants identified in each chromosome is illustrated. 
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The total variants for each patient was first filtered against frequency in the general population, those 
with a minor allele frequency (MAF) above 1% were excluded. Variants were then filtered using 
inheritance (strategy 1, section iii.ix.i page 57) and using the candidate gene list (strategy 3, section 
iii.ix.iii page 59). A number of variants requiring manual assessment remained (Table 22). In addition, 
the total variants identified were prioritized using strategy 2 (Section iii.ix.ii, page 58) and the top 
twenty candidates were manually assessed.  
 
 
Table 22 Variants identified in patient D-H. 
Total variants and those remaining after filtering for minor allele frequency (MAF), mode of inheritance (strategy 1) and 
against the candidate genes list (strategy 3).  
Filtering for inheritance was not possible for patient E as a paternal sample was not available. 
Variant filtering Patient D  Patient E Patient F Patient G Patient H 
Total variants  244836 306063 278239 297609 286512 
<1%MAF  438 498 507 594 486 
Inheritance 
(strategy 1)  
167 _ 68 61 77 
Candidate genes 
(strategy 3)  
2 23 3 2 2 
 
vii.i Patient D 
vii.i.i NBAS c.6971G>A;p.(Arg2324His) and c.4358G>A;p.(Cys1453Tyr) 
The clinical features of patient D are described as being developmental delay, hypotonia, muscle 
weakness, short stature, osteopenia, fractures, high arched palate, frontal bossing, bilateral club feet 
and low posteriorly rotated ears. Interrogation of his whole exome data identified compound 
heterozygous variants in the NBAS gene: a paternal c.6971G>A;p.(Arg2324His) and a maternal 
c.4358G>A;p.(Cys1453Tyr).  
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The c.6971G>A;p.(Arg2324His) is located in exon 52 and is only 28 amino acids upstream from the 
final termination codon. It affects a highly conserved amino acid but there is a small physiochemical 
difference between arginine and histidine. The variant is reported at low frequency in the general 
population (17/246192 alleles; rs150030912) but no homozygous individuals are recorded. In silico 
conservation analysis is inconclusive. 
The c.4358G>A;p.(Cys1453Tyr) is located in exon 37 and again affects a highly conserved amino 
acid. There is a large physiochemical difference between cysteine and tyrosine but this amino acid is 
not within a known functional domain of the protein. A population frequency of 146/276780 alleles is 
recorded in gnomAD (rs148644578) and a single homozygous individual from the Latino population 
(34412 alleles) is reported. In-silico analysis is inconclusive. 
Apart from these two variants of unclear significance in the NBAS gene, no other candidate variants 
were identified. The patient and his family have been invited for further follow up investigation, 
including detailed phenotyping to include an FBC to look for PHA and liver function tests. To date, the 
family have declined this invitation. 
 
vii.ii Patient E 
vii.ii.i P4HB c.1178A>G;p.(Tyr393Cys)   
Inheritance driven analysis of data from patient E (strategy 1) was limited as a sample of DNA from 
the patient’s father was not available. Using strategies 2 and 3, a heterozygous 
c.1178A>G;p.(Tyr393Cys) variant in exon 9 of the P4HB gene (NM_000918.3) was identified. This 
variant is predicted to replace the tyrosine at position 393 with a cysteine. Sanger sequencing of the 
patient confirmed this result and the maternal sample showed no evidence of the variant (Figure 65). 
This particular variant in P4HB has been described in Cole-Carpenter syndrome 1 (CLCRP1), an 
autosomal dominant condition characterized by bone fragility, craniosynostosis, ocular proptosis, 
hydrocephalus, and distinctive facial features (Rauch, Fahiminiya et al. 2015). Craniofacial features 
include frontal bossing, mid-facial hypoplasia and micrognathia. 
Patient E is the first child of healthy, non-consanguineous parents with no significant family history. 
The pregnancy was unremarkable with no suggestions of antenatal bone fragility and she was born at 
term with a birth weight of 3710 grams (75th centile and Z score 0.6). She was diagnosed with 
positional talipes, for which she received physiotherapy. At aged 6 months, she presented with a 
fracture of the left distal tibia. On clinical examination she was noted to have a large head with a wide 
open anterior fontanelle, a broad face with small nose and flat nasal bridge, blue sclerae, long fingers, 
and broad thumbs and toes. Her weight Z score had reduced to -1.4.  
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Figure 65 Sanger sequence of exon 9 of the P4HB gene in patient E. 
Patient E (bottom) is heterozygous for the c.1178A>G;p.(Tyr393Cys) variant associated with Cole-Carpenter 
Syndrome. Her mother (top) showed no evidence of the variant. 
A skeletal survey showed diffusely osteopenic bones with multiple vertebral body compression 
fractures in the thoracic and lumbar spine. Fractures of the anterior left 8th, 9th and 10th ribs were 
identified and historic fractures of both radial shafts were noted. Her long bones of both upper and 
lower limbs showed crumpling fractures with widening and sclerosis of the distal metaphyses. 
Wormian bones were seen in the skull. A clinical diagnosis of osteogenesis imperfecta (OI) was made 
and she commenced intravenous bisphosphonate (pamidronate) infusion therapy. 
She continued to have non-traumatic fractures of upper and lower limb long bones until aged 2 years 
and 8 months of age when she had corrective tibial osteotomies and bilateral tibial roddings with 
Fassier–Duval lengthening rods. There has been a significant improvement of vertebral fractures with 
remodelling of all vertebral bodies while on bisphosphonate infusions, which she continues to receive. 
At clinical review at aged 3 years, she had not sustained any fractures in the previous 18 months. She 
had a broad face with frontal bossing, flat nasal bridge, prominent eyes and bilateral low-set ears. Her 
growth parameters were, weight 12.2 kilograms (2nd-9th centile), height 77 cms (<0.4th centile) and 
head circumference 54 cms (99.6th centile). Bilateral limb deformities were evident and she is 
currently awaiting surgical correction and rodding procedures of her bilateral femur and upper limb 
bones. Although her gross motor development has been delayed due to limb deformities, her speech, 
language and social skills have progressed well and she attends a mainstream nursery.  
P4HB encodes the beta subunit of prolyl 4-hydroxylase, an abundant multifunctional enzyme 
belonging to the protein disulfide isomerase (PDI) family that catalyzes the formation, breakage and 
rearrangement of disulfide bonds in polypeptide chains, therefore having a key role in protein folding. 
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The P4HB protein also functions as a chaperone that inhibits aggregation of procollagen alpha chains 
and forms a tetramer with the prolyl 4-hydroxylase alpha subunit, consisting of 2 α and 2 β-subunits. It 
is thought that the β-subunit is required to maintain the solubility of the α subunit and keep the 
complex within the ER where it hydroxylates many of the proline residues within the triple helical 
domain of type I collagen.  
 
 
Figure 66 Schematic representation of the P4HB protein and the coding exons of P4HB cDNA 
(NM_000918.3). 
The locations of the exons are aligned relative to the regions of the protein that each exon encodes. The domains of 
the protein are represented by a, b, b’, a’ with an ER motif (KDEL) present at the C terminus. The location of the 
c.1178A>G;p.(Tyr393Cys) mutation identified in patient E is indicated. Figure adapted from Rauch et al (Rauch, 
Fahiminiya et al. 2015) 
 
The P4HB protein contains four TRX-like (thioredoxin-like) domains and a C-terminal extension 
domain. Two of these domains have disulphide isomerase activity, termed a and a’ and are separated 
by the enzymatically inactive b and b’ domains (Figure 66) 
The cysteine residue created by the c.1178A>G substitution lies close to two key residues, p.Cys397 
and p.Cys400, in the C terminal catalytic site (Figure 67). The p.Cys397 residue interacts with 
cysteines of many proteins and this is released by p.Cys400 (Wilkinson and Gilbert 2004). 
Immunoblotting experiments have suggested that p.Cys393 may interfere with this mechanism by 
forming more stable disulphide bridges (Rauch, Fahiminiya et al. 2015). 
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Figure 67 Protein structure model of P4HB indicating potential impact of the p.Tyr393Cys mutation 
in patient E. 
The mutated p.Cys 393 is physically close to p.Cys 397 and p.Cys 400. These residues form the active site of the 
protein and normally form a disulfide bond that is disrupted by the mutated p.Cys 393 amino acid. Figure adapted 
from Rauch et al (Rauch, Fahiminiya et al. 2015) 
 
As P4HB also plays a significant role in modification of type I collagen alpha chains it might be 
expected that at least part of the mechanism by which this variant acts would be via aberrant type I 
collagen processing. However, studies in fibroblasts from patients with Cole Carpenter have failed to 
demonstrate significant disruption to modification or secretion of type I procollagen. However, 
increased expression of heat shock protein 47, another collagen chaperone molecule, suggesting 
increased ER stress has been observed (Rauch, Fahiminiya et al. 2015). Immunofluorescence 
studies in patient E also demonstrated no major difference in extracellular type I collagen deposition 
in fibroblasts (data presented in our manuscript) (Balasubramanian, Padidela et al. 2017).   
The potential for ER stress to be a pathogenic mechanism in this patient was investigated further by 
studying dermal fibroblasts. Elastic tissue, collagen bundle packing and fibroblasts appeared normal. 
The mean collagen fibril diameter is 74nm, with diameter variability ranging from deviation RMS 7.0 to 
10.4nm. No collagen flowers were seen. 
The EM data for our patient suggests that there is little to no effect on assembly of collagen fibres or 
significant fibroblast ER stress. This does not support the hypothesis of ER stress being the main 
mechanism by which the recurrent P4HB mutation causes bone fragility (Rauch, Fahiminiya et al. 
2015).  
We were also unable to demonstrate any major variation in extracellular type I collagen deposition in 
our patient’s fibroblasts when compared to a normal control (immunofluoresence analysis performed 
by Dr J McCaughey and Dr D Stephens, School of Biochemistry, University of Bristol, Bristol). It is 
possible that aberrant PDI protein causes disorganisation of the ECM rather than directly affecting 
secretion of type I collagen.  It would be interesting to see if we could demonstrate altered distribution 
of the PDI protein in our patient’s fibroblasts or increased HSP47 protein as previously reported 
(Rauch, Fahiminiya et al. 2015). However, currently the mechanism by which the p.Tyr393Cys single 
amino acid substitution results in bone fragility is still to be resolved. 
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One previously undescribed observation is the presence of four small collections of individual 
collagen fibrils surrounded by proteoglycans (Figure 68); the significance of this feature is unclear. As 
discussed previously, we have also identified this feature in patient B (Section vi.ii, page 88). 
 
 
Figure 68 Electron microscopic ultra structure of collagen in patient E 
Four small collections of individual collagen fibrils surrounded by proteoglycans were observed. The significance of 
this is unclear (9200X magnification) 
 
Following confirmation of the molecular finding in patient E, reverse phenotyping confirmed that this 
patient has features that are consistent with a diagnosis of Cole-Carpenter syndrome. This patient 
also highlights what appears to be an emerging, distinctive radiological phenotype for these patients:  
meta-diaphyseal fractures with metaphyseal sclerosis. This finding is uncommon in patients with 
classical OI and should stimulate targeted mutation analysis in individuals with this radiological 
feature.  
Patient E is the third case of Cole Carpenter Syndrome caused by a defect in P4HB and suggests the 
possibility of a recurrent P4HB mutation as a cause of this syndrome. This is an important finding 
considering the rare occurrence of such patients. Follow up of the patient after bisphosphonate 
therapy indicated a positive outcome on vertebral compression fractures supporting the current 
therapeutic approach of anti-resorptive therapy in patients with a proven P4HB mutation. 
The patient has been presented in the following co-authored posters and manuscript: 
115 
 
Poster Presentation: International Skeletal Dysplasia Society 2017 Cole Carpenter Syndrome Type 
1 (P4HB Missense Mutation) has a Distinct Skeletal Phenotype. Offiah C A, Padidela R, Pollitt C 
R, Bishop J N, Wagner E B, McCaughey J, Stephens J D, Balasubramanian M. (Appendix page 224 ) 
Poster Presentation: International Conference on Childrens Bone Health 2017: P4HB recurrent 
missense mutation causing ColeCarpenter syndrome: exploring the underlying mechanism. M 
Balasubramanian, R Padidela, R Pollitt, N Bishop, Z Mughal, A Offiah, B Wagner, J Mccaughey, D 
Stephens. (Appendix page 225) 
Manuscript: P4HB recurrent missense mutation causing Cole-Carpenter syndrome Meena 
Balasubramanian, Raja Padidela, Rebecca C Pollitt, Nicholas J Bishop, M Zulf Mughal, Amaka C 
Offiah, Bart E Wagner, Janine McCaughey, David J Stephens.  J Med Genet. 2017 doi: 
10.1136/jmedgenet-2017-104899.  (Appendix page 232)  
 
vii.iii Patient F 
No candidate variants were identified in patient F whose clinical features are described as multiple 
fractures, blue sclerae, dentinogenesis imperfect and hypermobile joints. Interestingly the patient’s 
mother is also described as being hypermobile with fractures following insignificant trauma. A 
maternally inherited variant was also sought in this patient but without success. 
 
vii.iv Patient G 
vii.iv.i P3H1 c.1224-80G>A 
Patient G has failure to thrive, macrocephaly, persistent large anterior fontanelle, multiple fractures 
and dysmorphic features. She was enrolled in this study following identification of a heterozygous 
c.1080+1G>T splicing mutation in P3H1 by diagnostic targeted exome analysis (Figure 69). No 
second likely mutation was identified in this gene and no mutation was identified in any other known 
OI gene. 
The c.1080+1G>T is a common OI mutation in the African population and is reported in association 
with OI type II and III (Cabral, Chang et al. 2007, Baldridge, Schwarze et al. 2008, Pepin, Schwarze et 
al. 2013). Analysis of this patient’s exome data confirmed the presence of the heterozygous 
c.1080+1G>T P3H1 mutation and that this was inherited from her unaffected father.  
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Figure 69 P3H1 c.1080+1G>T splicing mutation in patient G identified by targeted exome 
sequencing. 
The figure shows the structure of the P3H1 gene (top) and the position of patient’s sequence, with the ‘A’ substitution 
in green, below. 
Additionally, a heterozygous c.1224-80G>A variant in intron 7 of the P3H1 gene was identified in the 
exome data. The segregation of this mutation in this family was confirmed by Sanger sequencing to 
be present in the patient’s unaffected mother (Figure 70Figure 71). 
 
 
Figure 70 P3H1 c.1224-80G>A variant identified by whole exome sequencing 
Sanger sequence confirmation of c.1244-80G>A present in patient G (top) and her unaffected mother (bottom). 
There is no evidence of the variant in her unaffected father (middle.) 
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The c.1224-80G>A variant is not reported in the general population and splice site prediction analysis 
suggests that this may create a preferred cryptic donor splice site. Three prediction packages 
predicted the cryptic site to be favoured over the wildtype donor site: MaxEnt (5.30 vs 3.71), NNSplice 
(0.34 vs 0.0) and GeneSplicer (3.49 vs 0.64). Two prediction packages suggested similar splicing 
efficiency: SSF (72.13 vs 75.43) and HSF (82.87 vs 84.57). If the new cryptic splice site was used in 
preference to the wildtype donor site then this could lead to the addition of 92 base pairs to the mRNA 
sequence (Figure 71).  
If this prediction is accurate then a frameshift would result, potentially leading to mRNA decay. Taken 
together with the previous heterozygous c.1080+1G>T P3H1 mutation, this would lead to complete 
loss of P3H1 protein function. Subsequent discussion with the referring clinician confirmed that this 
patient’s clinical presentation would be consistent with P3H1-associated OI.  
 
 
Figure 71 P3H1 c.1244-80G>A splice site prediction analysis 
Wildtype prediction (top) shows the presence of a weak cryptic splice site. The substitution of the ‘A’ for a ‘G’ at 
position c.1244-80 is indicated as a vertical blue line. The presence of an enhanced cryptic splice site caused by this 
substitution is indicated (bottom).The analysis was performed via Alamut using the prediction packages listed on the 
left, splice donor predictions are blue, splice acceptor predictions are green. 
 
As the c.1080+1G>T mutation and the c.1224-80G>A variant are both predicted to result in a 
frameshift, and result in total loss of mRNA, it is not currently possible in our laboratory to confirm the 
RNA splice effect of the c.1224-80G>A variant. This is due to being unable to distinguish between 
total loss of the P3H1 mRNA from any potential RNA splicing assay failure.   
An option to explore this variant further would be to undertake collagen expression analysis in dermal 
fibroblasts. The identification of overmodified protein would support pathogenicity of the c.1224-
80G>A variant. Fibroblasts could also be examined for signs of resulting ER stress. However, the 
patient has so far declined this analysis as they do not wish to undergo a skin biopsy. 
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This case clearly highlights the disadvantage of current targeted exome approaches to diagnosis of 
genetic disease. Generally only coding sequence is captured and important intronic findings may be 
missed. 
vii.v Patient H 
No candidate variants were identified in patient H who has a clinical diagnosis of osteogenesis 
imperfecta with crush fracture vertebrae, multiple long bone fractures and scoliosis. 
  
119 
 
 
viii RESULTS: DDD COMPLIMENTARY ANALYSIS 
The Complementary Analysis Project (CAP12) established with the DDD project identified 49 
individuals with clinical features relating to bone fragility (patient ID 101-149). Twenty seven of these 
are female and twenty two male.  
A total of 939 candidate variants were identified in this cohort. This included three copy number 
variants: a 223Kb duplication in Chr 2, a 114kb deletion in chr X and a 658kb deletion in chr 1. The 
DDD project reported positive findings to the referring clinician in 29 individuals, with the number of 
variants ranging from one to four per individual. The majority of these reported variants are primarily 
associated with developmental disorders. 
All variants were manually evaluated at the gene level focusing on reported function, as described in 
method section iii.x (page 61). After this initial assessment a total of 130 variants remained, with the 
number of variants for each individual ranging from none to nine (appendix R). These were evaluated 
at the variant level with reference to the clinical presentation and family structure. Each patient’s 
complete VCF data was also interrogated as described in section iii.ix (page 57) to identify additional 
variants not highlighted by the DDD pipeline. 
viii.i Osteogenesis Imperfecta Patients 
Nine patients (7 females, 2 males) had a clinical diagnosis of Osteogenesis Imperfecta, one of which 
was noted as being atypical.  The supplied clinical details of the nine OI patients, along with their 
results and family structure details are given in Table 23. No candidate variants have been identified 
in four of these individuals either by the DDD project or this study. 
 
Patient 
ID 
S
ex 
Family 
structure 
Clinical Details Results 
101 F Trio Bowing of limbs due to multiple fractures, 
Fractured hand bones, Pathologic fracture 
No candidate variant 
identified. 
102 F Trio Abnormality of the radius, Blue sclerae, 
Multiple rib fractures, Pathologic fracture, 
Plagiocephaly, Thoracic kyphosis, Vertebral 
compression fractures 
No candidate variant 
identified. 
110 F Singleton Abnormality of the face, Asymmetry of 
spinal facet joints, Increased susceptibility 
to fractures, Joint hypermobility, Pes 
planus, Specific learning disability 
COL1A1 c.4006-1G>T 
112 M Trio Decreased antibody level in blood, Elevated 
hepatic transaminases, Hypoglycemia, IgA 
deficiency, IgG deficiency, Increased 
susceptibility to fractures, Ligamentous 
NBAS patient number 2 in 
our manuscript 
c.5741G>A;p.(Arg1914His) 
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laxity, Nystagmus, Osteopenia, Progeroid 
facial appearance, Progressive cone 
degeneration, Recurrent fractures, Wide 
anterior fontanel 
c.2032C>T;p.(Gln678*) 
113 F Singleton Blue sclerae, Ligamentous laxity, Recurrent 
fractures, OI type V. 
IFITM5 c.-14C>T NOT 
reported. 
136 
 (B) 
M Trio Bowing of limbs due to multiple fractures, 
Congenital contracture, Decreased 
antibody level in blood, Multiple prenatal 
fractures 
SRCAP de novo 
c.9029C>A;p.(Pro3010His)   
137 F Trio Bowing of limbs due to multiple fractures, 
Congenital contracture, Decreased 
antibody level in blood, Multiple prenatal 
fractures 
COL1A2 c.280-2A>C NOT 
reported.  
138 F Trio Disproportionate short stature, Hypoplasia 
of dental enamel, Limited elbow extension, 
Moderate generalized osteoporosis, 
Skeletal dysplasia 
No candidate variant 
identified. 
142 F Trio Bowing of limbs due to multiple fractures, 
Fractures of the long bones, Increased 
susceptibility to fractures, Osteopenia 
No candidate variant 
identified. 
Table 23 Clinical details, genetic results and family structure for DDD CAP 12 patients with a 
clinical diagnosis of Osteogenesis Imperfecta.  
Results in black were reported to the referring clinician by the DDD project. Those in grey were not reported by the 
DDD project. 
Of note is that, although DDD reported the pathogenic c.4066-1G>T COL1A1 mutation in patient 110, 
they did not report the pathogenic c.280-2A>C COL1A2 mutation in patient 137 even though it was 
listed in the supplied candidate gene list. This highlights a potential issue with currently available 
automated curation and reporting pipelines used in large cohort whole exome studies. 
A second patient with a known pathogenic mutation (patient 113) was not reported by DDD. This 
patient had previously been screened at SDGS using the targeted exome NGS panel developed 
during the first part of this study. The c.-14C>T IFITM5 autosomal dominant mutation known to be 
associated with OI type V had been identified and reported to the referring clinician.  
The c.-14C>T mutation was not listed in the DDD candidate gene list for patient 113. Interrogation of 
the complete VCF identified that the c.-14C>T mutation had been identified by sequencing but was 
flagged as being of ‘low quality’ by the analysis pipeline and therefore excluded from further analysis. 
This highlights that regions of the genome where mutations are known to occur are not always reliably 
captured in exome sequencing and that ‘false negatives’ can result.   
Interestingly an SRCAP c.3247C>T;p.Pro1083Ser variant was reported by DDD in this individual. This 
variant is reported in 12/28456 alleles in the South Asian population gnomAD dataset (rs776570251), 
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does not lie within a functional domain of the protein and in-silico conservation analysis supports this 
being a benign variant. 
Patient 112 was reported to be compound heterozygous for a c.5741G>A;p.(Arg1914His) and a 
c.2032C>T;p.(Gln678*) in the NBAS gene and, along with patient C, is presented in the manuscript 
‘Compound heterozygous mutations in NBAS as a cause of atypical Osteogenesis Imperfecta’ 
Bone. 2017 ;94:65-74  (Balasubramanian, Hurst et al. 2017) discussed previously (Section vi.iii, page 
98).  
The de novo c.9029C>A;p.(Pro3010His) SRCAP variant previously identified in patient B by exome 
sequencing was confirmed by the DDD project (patient 136) and reported back to the clinician. The 
c.1169C>T;p.(Pro390Leu) TAPBP variant also previously discussed (section vi.ii.iii page 97) was 
listed in the DDD candidate gene list but not reported to the clinician. 
viii.ii Non Osteogenesis Imperfecta Patients 
For patients without a stated clinical diagnosis of Osteogenesis Imperfecta a total of 19 candidate 
variants for bone fragility were identified in 12 patients, some of which are novel (Table 24) 
 
ID Clinical details Gene Variant Inheritance 
105 2-3 toe syndactyly, Abnormality of 
male external genitalia, Bilateral 
single transverse palmar creases, 
Cleft palate, Gastroesophageal 
reflux, Generalized hypotonia, 
Hemimegalencephaly, 
Hypermetropia, Lumbar 
hemivertebrae, Micrognathia, Mild 
short stature, Optic nerve 
hypoplasia, Osteopenia, Radioulnar 
synostosis, Ventriculomegaly, 
Vertebral compression fractures 
B4GALT7 c.277dupC;p.(His93fs) Paternal 
B4GALT7 c.641G>A;p.(Cys214Tyr) Maternal 
106 Abnormality of taste sensation, 
constipation, hyperhidrosis, 
hyperhidrosis, impaired pain 
sensation, lacrimation abnormality, 
muscle weakness, urticaria and 
painless fractures due to injury, has 
a de novo missense variant, , in 
SCN9A 
SCN9A c.4835T>G;p.(Leu1612Arg) De novo 
107 Abnormality of T cells, Bilateral 
cryptorchidism, Eczema, Glandular 
hypospadias, Hypoplasia of the 
corpus callosum, Intellectual 
ZEB2 c.1212G>T;p.(Met404Ile). Unknown 
UBASH3B c.371Tdel;p.(Phe124fs) Unknown 
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disability, moderate, Low-set ears, 
Microcephaly, Micrognathia, 
Micropenis, Microtia, Osteopenia, 
Osteoporosis of vertebrae, Primary 
adrenal insufficiency, Severe short 
stature, Short foot, Stenosis of the 
external auditory canal 
SULF2 c.2411A>G;p.(Asn804Ser) Unknown 
108 Ataxia, Blue sclerae, Delayed 
speech and language development, 
Global developmental delay, 
Horizontal nystagmus, Joint 
hypermobility, Poor coordination, 
Recurrent fractures 
COL1A1 c.2644C>T;p.(Arg882*) Maternal 
(recurrent 
fracture) 
114 Cafe-au-lait spot, generalized 
dystonia, global developmental 
delay, osteopenia, reduced bone 
mineral density, seizures and status 
epilepticus.   
SCN8A c.5615G>A;p.(Arg1872Gly) Unknown  
117 Abnormal facial shape, 
Constipation, Global developmental 
delay, Increased susceptibility to 
fractures, Microcephaly, 
Polyhydramnios, Sleep disturbance, 
Unilateral deafness 
NBAS c.3776C>T;p.(Ser1259Phe) Unknown 
SULF2 c.587T>C;p.(Ile196Thr) Unknown 
UGGT1 c.371Tdel;p.(Phe124fs) Unknown 
127 Camptodactyly of finger, Dislocated 
wrist, Osteoporosis, Pes cavus, 
Scoliosis, Severe Myopia  
PLOD1 c.153dup;p.(Asn52fs) Paternal 
128 Abnormality of blood circulation, 
aortic regurgitation, asthma, thin 
skin with reticulate pigmentation, 
generalized osteoporosis with 
pathologic fractures, genu valgum, 
glaucoma, migraine, myopia, 
otosclerosis, severe generalized 
osteoporosis, short foot, slender 
build, slender fingers and toes, and 
bronchiectasis 
SLC38A10 c.1A>G;p.(Met1?) Maternal 
(osteoporosis 
otosclerosis, 
abnormal 
kidney) 
129 Dilation of lateral ventricles, 
generalized joint laxity, intellectual 
disability, moderate postnatal 
macrocephaly and recurrent 
fractures. His mother is hypermobile 
but no history of fractures is 
reported 
SCN9A c.5367_5368insGAGAACTC
TAT;p.(Lys1790fs) 
Maternal 
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140 Abnormality of the odontoid 
process, amelogenesis imperfecta, 
cerebral calcification, depressed 
nasal bridge, downslanted palpebral 
fissures, elevated circulating 
parathyroid hormone (PTH) level, 
hypophosphatemia, malar 
flattening, narrow mouth. 
osteoporosis, sagittal 
craniosynostosis, subglottic 
stenosis 
FAM20C c.1225C>T;p.(Arg409Cys) Paternal+ 
Maternal  
LRP6 c.4481dup;p.(Arg1495fs) De--novo 
141 Abnormality of mast cells, 
Autonomic dysregulation, Joint 
hypermobility, Orthostatic 
hypotension, Osteopenia, Seizures, 
Joint dislocations in young adult 
POSTN  c.1108+2T>C;p.(?) Maternal 
BMP6 c.334G>A;p.(Glu112Lys) Maternal 
149 2-3 toe syndactyly, Abnormality of 
dental enamel, Blue sclerae, 
Bruising susceptibility, Constipation, 
Delayed gross motor development, 
Delayed speech and language 
development, Downslanted 
palpebral fissures, Increased 
muscle fatiguability, Intellectual 
disability, severe, Joint 
hypermobility, Malar flattening, 
Recurrent fractures 
COL1A1 c.1299+1G>A;p.(?) De novo 
Table 24 Candidate variants in CAP12 DDD patients following manual assessment of DDD supplied 
candidate list and interrogation of full VCF for patients 101-149.  
All variants were identified in the heterozygous state with the exception of the FAM20C c.1225C>T;p.Arg409Cys 
variant which is homozygous in the proband. The inheritance of variants is stated as unknown if parental samples 
were unavailable. 
viii.iii Type I Collagen Genes 
Two patients without a stated clinical diagnosis of OI were found to have a pathogenic mutation in the 
type I collagen genes (Table 24) 
Patient 108 COL1A1 c.2644C>T;p.(Arg882*) 
Patient 108 has a maternally inherited COL1A1 c.2644C>T;p.(Arg882*) mutation that would be 
expected to result in a mild/moderate OI. The patient’s mother is reported to have recurrent fractures 
which supports that this mutation is segregating with the symptoms of bone fragility in this family. This 
pathogenic mutation has been reported on nine occasions in the locus specific data base 
(https://oi.gene.le.ac.uk) in association with OI ranging in clinical severity of type I to type IV, which is 
consistent with the reported phenotype in the patient and her mother. 
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Patient 149 COL1A1 c.1299+1G>A 
The second patient (149) has a de-novo COL1A1 c.1299+1G>A pathogenic mutation that has been 
reported 11 times in association with OI type 1 (https://oi.gene.le.ac.uk) and is also recorded on 
ClinVar and HGMD as pathogenic. This mutation is predicted to result in the complete loss of the 
wildtype donor site of intron 19 and may be expected to result in exon skipping and hence a 
moderate/severe phenotype. However, splice site analysis reveals that there is a cryptic splice site 
within exon 19 that is likely to be used as an alternate splice site, resulting in the loss of 8bp and a 
frameshift (Figure 72). Frameshift mutations usually result in a ‘null allele’ and are associated with a 
milder clinical phenotype; this is congruent with the phenotype of patient 149 and that of the 
previously reported individuals with type I OI. 
 
 
Figure 72 Predicted effect on splicing of the c.1229+1G>A COL1A1 pathogenic mutation identified 
in patient 149.  
The prediction indicates the completed loss of wildtype donor site in intron 19 and shows the location of the cryptic 
donor site located upstream in exon 19 that is likely to be used as an alternative splice site. 
Top = wildtype splice prediction  Bottom = mutant splice prediction 
viii.iv Ehlers Danlos Syndrome Genes 
Two patients were identified with a potential diagnosis of Ehlers Danlos syndrome. 
 
Patient 127 PLOD1 c.153dup;p.(Asn52fs) 
No likely candidate genes were identified in the DDD variant list for patient 127, however interrogation 
of the entire VCF identified a paternally inherited heterozygous c.153dup;p.(Asn52fs) variant in the 
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procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 gene (PLOD1). This gene is known to cause 
kyphoscoliotic Ehlers Danlos Syndrome (EDS).  
Kyphoscoliotic EDS (previously known as EDS VI) is an autosomal recessive connective tissue 
disorder characterised by hyperextensible skin, atrophic scarring and generalised joint laxity. Scoliosis 
can be present at birth and is progressive. Muscle hypotonia and delay in attainment of gross motor 
milestones are also common features. Scleral fragility, rupture of the globe, marfanoid habitus and 
rupture of medium size arteries may also be present.  
The majority of pathogenic PLOD1 mutations are either small deletions/insertions that result in a 
frameshift or are substitutions that result in a nonsense mutations. However, a common larger 
duplication of 8.9kb, caused by  homologous recombination of Alu sequences in introns 9 and 16, is 
reported to account for ~18% of reported mutations (Yeowell, Walker et al. 2005). The resulting 
deletion of exons 10 to 16 is not readily detectable by the exome sequencing performed in this 
project. However, analysis using Multiplex Ligation-dependent Probe Amplification (MLPA) is 
available as a diagnostic test at SDGD for this mutation (Figure 73). 
The c.153dup PLOD1 mutation has previously been reported (as c.153_154insC, using previous 
nomenclature) in an individual with kyphoscoliotic EDS (Heikkinen, Pousi et al. 1999) who is 
compound heterozygous for this mutation and a c.467-2delA mutation. Functional analysis confirmed 
loss of the lysyl hydroxylase protein in the patient’s fibroblasts. No clinical details are provided for the 
affected individual in this case report. 
The PLOD1 protein forms hydroxylysine residues at collagen Xaa-Lys-Gly amino acid sequences 
(Yeowell, Allen et al. 2000, Walker, Overstreet et al. 2005) which are essential for stable collagen 
crosslinking. Deficiency of hydroxylysine-based pyridinoline cross-links in collagens can be detected 
in urine by an increased ratio of deoxypyridinoline to pyridinoline cross-links and is used as a 
diagnostic test in patients with suspected kyphoscoliotic EDS. 
The clinical symptoms of patient 127 are reported as camptodactyly of the finger, dislocated wrist, 
osteoporosis, pes cavus, scoliosis and severe myopia. A diagnosis of Camptodactyly-arthropathy-
coxa pericarditis syndrome (CACP) or Marfan syndrome was initially considered. Testing for 
mutations in the FBN1 gene for Marfan syndrome was negative. Although the patient is described as 
having osteoporosis, that by ISCD definition requires one or more vertebral compression fractures or 
a clinically significant fracture history and BMD Z score of -2 or less. (https://www.iscd.org/official-
positions/2013-iscd-official-positions-pediatric/), no details of any fracture history are provided 
Interestingly camptodactyly, although not listed in the diagnostic criteria for kyphoscoliotic EDS, has 
been reported in individuals with mutations in FKBP14 and CHST14, genes now identified in 
additional forms of kyphoscoliotic EDS (Malfait, Syx et al. 2010, Giunta, Baumann et al. 2018). 
Patients with EDS have been shown to have reduced BMD and an increased susceptibility to both 
vertebral and non-vertebral fractures (Unnanuntana, Rebolledo et al. 2011, Eller-Vainicher, Bassotti et 
al. 2016, Mazziotti, Dordoni et al. 2016). 
The clinical features of our patient, along with the PLOD1 mutation, suggest that a diagnosis of 
kyphoscoliotic EDS should be considered. The patient’s clinician has been contacted and analysis of 
126 
 
a urine sample, to assess deoxypyridinoline to pyridinoline ratio, has been suggested as an initial 
investigation, followed by MLPA analysis if the ratio is increased.  
 
 
Figure 73 Multiplex Ligation-dependent Probe Amplification analysis of genomic DNA for the 
PLOD1 gene. 
A Normal control. B:Heterozygous duplication of exons 10-16 
 
Patient 105 B4GALT7 c.277dupC;p.(His93fs) and c.641G>A;p.(Cys214Tyr) 
A second patient (105) with pathogenic mutations in an EDS-associated gene was also identified. 
This individual is reported as having bilateral single transverse palmar creases, cleft palate, 
gastroesophageal reflux, generalized hypotonia, lumbar hemivertebrae, pes planus, micrognathia, 
mild short stature, optic nerve hypoplasia, osteopenia, radioulnar synostosis, ventriculomegaly, 
bowing of the long bones and vertebral compression fractures.  
He is compound heterozygous for a paternally inherited c.277dupC;p.(His93fs) frameshift and a 
maternally inherited c.641G>A;p.(Cys214Tyr) missense variant in the B4GALT7 gene. This gene was 
originally associated with ‘progeroid’ EDS (PEDS) but this has recently been reclassified as 
spondylodysplastic EDS (Brady, Demirdas et al. 2017). 
The diagnostic criteria for spondylodysplastic EDS (spEDS) include short stature, skin 
hyperextensibility, facial dysmorphisms, muscle hypotonia and joint laxity. Additional features reported 
include neurosensorial hearing loss, radioulnar synostosis, hypermetropia, and varying degrees of 
developmental delay (Salter, Davies et al. 2016, Ritelli, Dordoni et al. 2017). Low bone mineral 
density has also been reported (Ritelli, Dordoni et al. 2017). 
B4GALT7 encodes β1,4-galactosyltransferase 7, a golgi resident enzyme involved in the synthesis of 
the glycosaminoglycan-protein (GAG) linkage region in proteoglycans. The enzyme catalyzes the 
transfer of the first galactose onto the xylose residue of the proteoglycan GAG linker region. Addition 
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of either N-acetylglucosamine or N-galactosylglucosamine to the linker region leads to the formation 
of heparan sulfate or chondroitin/dermatan sulfate respectively (Figure 74). Mutations in other linker 
protein genes (XYLT1, XYLT2, B3GALT6, and B3GAT3) are associated with skeletal diseases with 
overlapping clinical presentation. In particular XYLT2 mutations are characterized severe childhood-
onset primary osteoporosis (Taylan and Mäkitie 2016) 
 
 
Figure 74 The synthesis of heparin sulphate and chondroitin/dermatan sulfate proteoglycans. 
Sequential action of specific enzymes lead to synthesis of the linker region: Xylosyltransferase I/II (encoded 
by XYLT1 and XYLT2), galactosyltransferase I (encoded by B4GALT7) and galactosyltransferase II (encoded 
by B3GALT6), and glucuronyltransferase I (encoded by B3GAT3). Following completion of the linker region, the 
addition of the following residue, either N-acetylglucosamine or N-galactosylglucosamine, determines which 
proteoglycan is synthesized.  Figure modified from Brady et al (Brady, Demirdas et al. 2017) 
Only a limited number of B4GALT7 mutations have been reported to date, seven missense and two 
frameshift, with c.808C>T;p.(Arg270Cys) being the most common. The c.641G>A;p.(Cys214Tyr) 
variant in patient 105 affects a highly conserved amino acid within the galactosyltransferase  
functional domain of the protein and is predicted to be deleterious to function. The 
c.277dupC;p.(His93fs) is predicted to result in a premature termination codon 72 positions 
downstream and the mRNA is a likely target for nonsense mediated decay. Both the 
c.641G>A;p.(Cys214Tyr) and c.277dupC are reported at low frequency in the general population,  
8/111480 European (non Finish) and 4/4260 African American alleles respectively.  
The clinical features of this patient were considered to be consistent with biallelic mutations in the 
B4GALT7 gene and he is presented by the referring centre in the article by Slater et al (Salter, Davies 
et al. 2016). 
viii.v Sodium Ion Channel Genes  
Defects in two voltage-gated sodium ion channels (Nav1.7 and  Nav1.9)  encoded by the SCN9A and 
SCN11A genes respectively, have been described in association with congenital insensitivity to pain 
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(CIP) and episodic/extreme pain syndromes (Bennett and Woods 2014). Frequent fractures are a 
known feature of insensitivity to pain disorders and lack of pain perception and injury awareness have 
been considered to be the reason for this.  
However, although skeletal problems in CIP are well documented, there is little reported about 
mineral and skeletal homeostasis in affected individuals. Studies in one CIP family with an autosomal 
dominant gain of function mutation in SCN11A report normal biochemical parameters, no radiographic 
evidence of rickets or osteopenia and DXA lumbar spine and total hip BMD within the normal range. 
Bone histology was also unremarkable. However, it was noted that the fractures were often as a 
result of apparent low-trauma and the authors comment on the possibility of ‘poor quality bone’ being 
a contributing factor (Phatarakijnirund, Mumm et al. 2016). 
One recent report presents exome analysis in a consanguineous Egyptian family with a clinical 
presentation of “OI type IV”, where a homozygous nonsense mutation c.570G>A;p.(Trp190*) in 
SCN9A in the proband  and her affected aunt has been identified (Caparros-Martin, Aglan et al. 
2017). The proband, who initially presented at 3 months with three fractures, is described as having 
greyish sclerae and with behaviours retrospectively assessed as being consistent with insensitivity to 
pain. The 14 year old aunt, also with insensitivity to pain, had four fractures during the first year of life 
with subsequent deformities and started to develop bowing of the long bone at age of 6-7 months old 
without fractures, suggestive of underlying bone pathology. Unfortunately, no bone parameters of the 
family are provided in the manuscript. 
A further voltage-gated sodium channel, Nav1.6 encoded by SCN8A, is associated with autosomal 
dominant early-infantile epileptic encephalopathy. Recent studies of bone mass and architecture in a 
child with a loss of function SCN8A-related epileptic encephalopathy using dual energy X-ray 
absorptiometry (DXA) and high-resolution peripheral quantitative computed tomography (HRpQCT) 
revealed altered trabecular and cortical bone parameters showing low bone mass, as well as an 
elevated serum bone resorption markers (Rolvien, Butscheidt et al. 2017). Studies in the Scn8a-
deficient mouse model identified elevated bone resorption due to increased osteoclastogenesis as the 
underlying mechanism behind these altered bone parameters. A marked improvement in bone 
structure and no additional skeletal fractures following anti-resorptive therapy (Neridronate) is 
reported in an individual with SCN8A-related epileptic encephalopathy and severe bone loss with 
multiple fractures, supporting the remodelling pathology of bone fragility in this individual (Rolvien, 
Butscheidt et al. 2017). 
Three patients with heterozygous variants in sodium ion channel genes were identified in the DDD 
data dataset: 
Patient 129 SCN9A c.5367_5368insGAGAACTCTAT;p.(Lys1790fs) 
Patient 129 has a maternally inherited c.5367_5368insGAGAACTCTAT;p.Lys1790fs variant in 
SCN9A. He is reported to have dilation of lateral ventricles, generalized joint laxity, intellectual 
disability, moderate postnatal macrocephaly and recurrent fractures. His mother is hypermobile but no 
history of fractures is reported. No second likely deleterious variant in this gene was identified. 
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Patient 106 SCN9A c.4835T>G;p.(Leu1612Arg) 
A second male, patient 106, with a clinical phenotype of abnormality of taste sensation, constipation, 
hyperhidrosis, impaired pain sensation, lacrimation abnormality, muscle weakness, urticaria and 
painless fractures due to injury, has a de-novo missense variant, c.4835T>G;p.(Leu1612Arg), in 
SCN9A.  Another missense mutation at this codon, p.(Leu1612Pro), has previously been associated 
with autosomal recessive paroxysmal extreme pain disorder. 
Interestingly SCN9A, as well as being associated with autosomal recessive CIP, is also reported in a 
spectrum of autosomal dominant seizure disorders ranging from isolated febrile seizures to more 
generalized epilepsy. 
Patient 114 SCN8A c.5615G>A;p.(Arg1872Gln) 
Patient 114, a singleton, is reported as having Cafe-au-lait spot, generalized dystonia, global 
developmental delay, osteopenia, reduced bone mineral density, seizures and status epilepticus. He 
is heterozygous for a known pathogenic mutation in SCN8A, c.5615G>A;p.(Arg1872Gln). This 
mutation has previously been reported in an individual with repetitive language, macrocephaly, 
generalized hyper reflexia, clumsiness and autistic features (Larsen, Carvill et al. 2015). Other amino 
acid substitutions at this position, p.(Arg1872Leu) and p.(Arg1872Trp), are reported as pathogenic in 
early infantile epileptic encephalopathy type 13 (https://portal.biobase-
international.com/hgmd/pro/all.php). It seems reasonable, given the previously described low bone 
mass in a child with a SCN8A loss of function mutation (Rolvien, Butscheidt et al. 2017), to consider 
the c.5615G>A;p.(Arg1872Gln) as a likely cause of the clinical symptoms and bone features in patient 
114. 
Taken together these findings suggest a potential pathway between pain sensation, epilepsy/seizures 
and bone parameters involving voltage-gated sodium channels, particularly SCN9A. However, a note 
of caution is that anti-convalescent medication and reduced mobility, which may be associated with 
epilepsy/seizures and developmental delay respectively, can both contribute to osteopenia. 
viii.vi SLC38A10 
Patient 128 SLC38A10 c.1A>G;p.(Met1?) 
Manual evaluation of data for patient 128, at both the gene and variant level, identified a 
heterozygous c.1A>G;p.(Met1?) variant of interest in the SLC38A10 gene. This gene is located at 
17q25.3 and is alternatively known as SNAT11 or PP1744. The UniProt Go biological processes 
given for this gene include bone development. Frequency data for this variant in the general 
population is limited but it is listed in the genomAD dataset in 13 of 222,830 alleles with a maximum 
allele frequency in any population of 0.01%. No homozygous individuals are reported.  
The Solute carrier (SLC) superfamily consists of 395 transporters divided into 52 different families 
with differing biochemical properties (Hediger, Clémençon et al. 2013). The SLC38 family has 11 
members (A1-A11) that preferentially favour glutamine as substrate, with the exception of SLC38A4, 
which mainly transports alanine, asparagine, and cysteine (Sugawara, Nakanishi et al. 2000). SLC38 
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transporters are ubiquitously expressed within all cell types of the body and, in addition to their 
transport role, are thought to play an important role in amino acid signalling within many tissues 
including the liver, brain, kidney and intestine (Broer 2014). 
Recently, the structure of the SL38A10 protein, a previously orphan member of the group, has been 
modelled (Figure 75) predicting eleven transmembrane domains, an intracellular N-terminal domain 
and a 722 amino acid C-terminal domain that sits outside the membrane (Hellsten, Hägglund et al. 
2017). 
 
 
Figure 75 The predicted structure of the SLC38A10 protein.  
Each amino acid is represented as a circle. The C-terminal domain (amino acids 398-1119) sit outside the membrane 
and are not depicted (Modified from Hellsten et al (Hellsten, Hägglund et al. 2017)). 
 
Data supporting that the bidirectional transport of glutamine, glutamate, and aspartate by SLC38A10 
is a key function, implicating the protein in neurotransmission, has also been published (Hellsten, 
Hägglund et al. 2017).  
Glutamine is the most abundant amino acid and, together with glucose, is important in many 
metabolic and energy production pathways (Pochini, Scalise et al. 2014). It has emerged as an 
important regulator of osteoblasts, being actively metabolised and essential for matrix mineralization 
(Brown, Hutchison et al. 2011). Glutamine is an anaplerotic precursor (replenishing catalytic 
intermediates) that supplies part of the energy requirement of differentiating osteoblasts during bone 
formation (Karner, Esen et al. 2015). Glutamine anaplerosis into the citric acid cycle (TCA) is 
increased by raised glutaminase (GIs) activity in response to Wnt signalling. The resulting reduction in 
intracellular glutamine leads to activation of Gcn2 and Atf4 stimulating uptake and synthesis of amino 
acids, hence promoting protein synthesis from the target gene (Figure 76). 
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Figure 76 Glutamine signalling in osteoblasts in response to Wnt signalling 
Wnt signalling stimulates glutamine metabolism through the citric acid cycle (TCA). Wnt signaling through Frizzled 
(Fz) and Lrp5/6 activates mTORC1; mTORC1 increases glutaminase (Gls) levels that stimulate glutamine oxidation 
for ATP production. Increased levels of glutamine consumption results in reduced intracellular glutamine, activates 
the Gcn2-Atf4 stress pathway and up-regulates gene transcription.  Gln glutamine, Glu glutamate, α-KG α-
ketoglutarate. Figure modified from Karner et al (Karner and Long 2017). 
 
Slc38a10 knock out mice have a severe skeletal phenotype that includes weak and brittle bones, 
reduced body length and decreased bone mineral density, further supporting an important role for this 
gene in bone metabolism (Bassett, Gogakos et al. 2012). 
The clinical features of patient 128 are given as: abnormality of blood circulation, aortic regurgitation, 
asthma, thin skin with reticulate pigmentation, generalized osteoporosis with pathologic fractures, 
genu valgum, glaucoma, migraine, myopia, otosclerosis, severe generalized osteoporosis, short foot, 
slender build, slender fingers and toes, and bronchiectasis. 
The c.1A>G;p.(Met1?) SLC38A10 variant in patient 128 is maternally inherited. The mother’s clinical 
features are given as osteoporosis, otosclerosis and abnormal kidney. This supports a potential role 
for this variant in the bone phenotype in this family but is not conclusive.  The patient and their family 
have been invited for further clinical review. 
viii.vii Complex Genotypes 
Patient 140 FAM20C c.1225C>T;p.Arg409Cys; LRP6 c.4481dup;p.Arg1495fs 
Two missense variants of interest have been identified in patient 140: a homozygous 
c.1225C>T;p.Arg409Cys in FAM20C and a de-novo heterozygous c.4481dup;p.Arg1495fs in LRP6. 
Only the FAM20C variant was reported back to the referring clinician by the DDD project. 
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Fam20C is a golgi serine/threonine protein kinase that phosphorylates Ser-X-Glu (S-X-E) motifs of 
secretory proteins in the extracellular matrix of bones and teeth, including dentin matrix protein 1 
(DMP1) and osteopontin (OPN), and is essential for mineralization (Cui, Xiao et al. 2015, 
Tagliabracci, Wiley et al. 2015). Autosomal recessive mutation in FAM20C have been described in 
the osteosclerotic bone dysplasia Raine syndrome which has varying clinical presentation ranging 
from an aggressive onset and death during the first few hours or weeks of life (Simpson, Hsu et al. 
2007) to survival into childhood or middle adulthood (Simpson, Scheuerle et al. 2009, Fradin, Stoetzel 
et al. 2011, Acevedo, Poulter et al. 2015).  
Raine syndrome is characterised by generalized osteosclerosis, periosteal bone formation and 
craniofacial dysmorphia that includes midface hypoplasia, depressed nasal bridge and prominent 
forehead. Intracranial ossification is a common feature. Abnormal teeth (small with enamel dysplasia) 
are reported in surviving patients. Hypophospataemia, caused by elevated levels of FGF23, is 
reported in patients with non-lethal Raine syndrome (Simpson, Scheuerle et al. 2009, Fradin, Stoetzel 
et al. 2011, Rafaelsen, Raeder et al. 2013). 
The c.1225C>T;p.(Arg409Cys) FAM20C variant in patient 140 has been reported twice in the 
literature in the homozygous state, the first as part of a gene discovery study in neurogenetic 
disorders using whole-exome sequencing of consanguineous families (Alazami, Patel et al. 2015) and 
the second in a Raine syndrome case report (Seidahmed, Alazami et al. 2015). As both literature 
reports originate from the same research group, it is likely that this represents a single individual.  
The skeletal features of the case report a patient, a male who died shortly after birth, include 
generalised increased density of all bone, particularly in the craniofacial bones. Failure of ossification 
is noted in the sacrum and lumbar vertebrae. The degree of osteosclerosis is noted to be relatively 
mild compared with previously reported Raine syndrome patients. The patient’s chest is described as 
asymmetrical and bell shaped with thin ribs. (Seidahmed, Alazami et al. 2015). 
The clinical features of patient 140 are given as abnormality of the odontoid process, amelogenesis 
imperfecta, cerebral calcification, depressed nasal bridge, downslanted palpebral fissures, elevated 
circulating parathyroid hormone (PTH) level, hypophosphatemia, malar flattening, narrow mouth. 
osteoporosis, sagittal craniosynostosis, subglottic stenosis. The majority of these are consistent with 
Raine Syndrome and were considered to offer a full explanation of phenotype by the referring 
clinician. 
However, the LRP6 de-novo c.4481dup;p.(Arg1495fs) variant was not reported to the referring 
clinician but may also be contributing to the phenotype in this patient. LRP6 is a key transmembrane 
co-receptor in the canonical Wnt/β-catenin signalling pathway, an important regulator of skeletal 
development and maintenance.  Canonical Wnt signalling is triggered by the binding of a given Wnt 
ligand to a frizzled family (Fzd) seven-pass transmembrane receptor and a co-receptor of the 
arrow/Lrp family (such as LRP5 and LRP6). This results in the stabilisation and translocation of β-
catenin, an important activator of gene transcription (Figure 77). 
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Figure 77 Simplified Wnt/β-catenin signaling. 
 (A) Without Wnt, the scaffolding protein Axin assembles a protein complex that contains Apc, Gsk3, Ck1 and β-
catenin. In this complex, β-catenin is sequentially phosphorylated by Ck1 and Gsk3. Phosphorylated β -catenin is 
recognized by β-Trcp, which is a component of an ubiquitin-ligase complex that conjugates β-catenin with ubiquitin. 
Poly-ubiquitinated β-catenin is degraded by the proteosome. (B) In the presence of Wnt, β-catenin phosphorylation 
and degradation is inhibited. Accumulated β-catenin forms a nuclear complex with the DNA-bound TCF/LEF 
transcription factor, and together they activate Wnt-responsive genes. (Figure and legend modified from Xi He et al. 
(He, Semenov et al. 2004). 
 
LRP6 has also been shown to be important in parathyroid hormone (PTH) signalling, which regulates 
osteoblast activity. PTH binds to its receptor, PTH1R, inducing the PTH-PTH1R-LRP6 protein 
complex, leading to increased bone formation in rat (Wan, Yang et al. 2008).  
LRP5 and LRP6 have similar structures comprising of four YMTD β-propellar domains followed by 
EGF-like domains that bind the extracellular ligands, and five intracellular PPP(S/T)P domains that 
mediate downstream signalling (Williams and Insogna 2009). Studies in LRP5 and LRP6 deficient 
mouse models have shown that both LRP5 and LRP6 are required in osteoblasts for normal skeletal 
development and homeostasis (Riddle, Diegel et al. 2013). 
As previously described (section ii.xv.i.i page 35) mutations in LRP5 give rise to several conditions 
and can be inherited in either a dominant or recessive manner. Loss of function mutations can result 
in familial exudative vitreoretinopathy (FEVR), Osteoporosis Pseudoglioma (OPPG) and Idiopathic 
Juvenile Osteoporosis (IJO) whereas gain of function mutations are associated with high bone mass 
conditions such as autosomal dominant osteopetrosis type 1 and endosteal hyperostosis. 
To date, heterozygous loss of function mutation in LRP6 have been described in families with 
autosomal dominant oligodontia, a severe form of tooth agenesis, and combined tooth 
agenesis/orofacial clefting (Massink, Créton et al. 2015, Ockeloen, Khandelwal et al. 2016). 
Discussion with the authors (Massink, Créton et al. 2015) confirmed that although none of the 
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reported patients had generalized amelogenesis imperfecta, there were some teeth showing enamel 
defects. Moreover at least one patient showed clear ankylosis of deciduous teeth (without 
successors), and there were also patients who had tooth-shape anomalies. Skeletal assessment was 
not performed on their patients. 
Very low bone mineral density (Z score of –3.4 at the femoral neck), with low-impact fracture, has 
been reported in an individual from a large family with early coronary disease (Mani, Radhakrishnan 
et al. 2007). Affected individuals were found to be homozygous for a putative partial loss of function 
mutation, p.(Arg611Cys) in LRP6. This mutation lies within the EGF-like domain of the LRP6 protein 
and functional studies confirmed reduced LRP6 signalling in NIH3T3 mutated cells. Two further 
affected members of this family also had early hip fracture and low BMD.  
Studies in a mouse model, (ringelschwanz), who carry a homozygous p.(Arg886Trp) missense 
mutation in Lrp6 also exhibit delayed ossification at birth and have a low bone mass phenotype in 
adults (Kokubu, Heinzmann et al. 2004). 
The amelogenesis imperfecta and osteoporosis described in patient 140 is likely to be at least partly 
caused by his de novo loss of function LRP6 variant, either in isolation or in combination with his 
FAM20C mutation. It would be interesting to explore this further as it seems reasonable to 
hypothesise that further skeletal consequences of mutations in LRP6 remain undiscovered at present.  
 
Patient 107 ZEB2 c.1212G>T;p.(Met404Ile); UBASH3B c.371Tdel;p.(Phe124fs) and SULF2  
c.2411A>G;p.(Asn804Ser) 
Patient 107 is described as having abnormality of T cells, bilateral cryptorchidism, eczema, glandular 
hypospadias, hypoplasia of the corpus callosum, intellectual disability, low-set ears, macrocephaly, 
micrognathia, micropenis, microtia, osteopenia, osteoporosis of vertebrae, primary adrenal 
insufficiency, severe short stature, short foot and stenosis of the external auditory canal. 
A heterozygous c.1212G>T;p.(Met404Ile) missense variant in the Zinc finger E-box-binding 
homeobox 2 (ZEB2) gene (also known as SMADIP1, ZFHX1B and SIP1) was reported to the referring 
clinician by the DDD project. This gene is associated with autosomal dominant Mowat-Wilson 
syndrome (MOWS; OMIM 235730), a complex developmental delay disorder with moderate to 
severe intellectual disability, a distinctive facial gestalt, microcephaly, epilepsy, heart defects, 
urogenital malformations and Hirschsprung disease (HSCR).  
Short stature is also a feature of this disorder but osteopenia, osteoporosis of the vertebrae and T cell 
abnormities, as present in our patient, are not described. Also of note is that 70-75% of patients with 
MOWS have seizures, a further clinical feature that is not reported in patient 107. Interestingly a 
recent report of a cohort of 12  individuals suggests that the majority of MOWS patients also have 
features  that resemble  classical Ehlers Danlos syndrome, namely hyperextensible skin, joint 
hypermobility and atrophic scarring (Teraishi, Takaishi et al. 2017), features that are not described in 
patient 107. 
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The exact mechanism of action by which mutations in the ZEB2 gene cause the range of clinical 
symptoms in MOWS patients is still unclear, although it is known that the ZEB2 protein plays a vital 
role in neural crest cell migration during foetal development, most likely through TGFβ signalling and 
interaction with nucleosome remodelling and histone deacetylation complex (NuRD). 
Zeb2 knockout mice have changes in gene expression levels in dermal fibroblasts including many 
genes that are associated with connective tissue disorders, most noticeably the down regulation of 
collagenogenesis genes and up regulation of genes involved in collagenolysis. Electron microscopy of 
skin biopsy from MOWS patients has also shown reduced collagen fibre diameter supporting a role of 
ZEB2 in dermal fibrillogenesis (Teraishi, Takaishi et al. 2017). 
However, the majority of reported mutations in ZEB2 (HGMD) are either truncating or larger gene 
deletions or rearrangements that result in haploinsufficiency. Missense mutations are rare (only 3 
reported) and there are limited data available for the associated phenotype in these individuals. 
Severity of symptoms is described as mild (Ghoumid, Drevillon et al. 2013).  
The c.1212G>T;p.(Met404Ile) has not been reported in association with disease or in the normal 
population. It affects a highly conserved nucleotide and amino acid, up to tetraodon (considering 12 
species), and in-silico conservation prediction supports a deleterious effect. Another variant at this 
position, c.1211T>C;p.(Met404Thr), is reported in 1 in 246,072 normal alleles (gnomAD). It is 
therefore unclear whether the c.1212G>T;p.(Met404Ile) missense variant is pathogenic and could 
therefore be responsible for the clinical symptoms in patient 107. 
In addition to the ZEB2 variant above, patient 107 is also heterozygous for a c.371Tdel;p.(Phe124fs) 
frameshift variant in the UBASH3B gene and a c.2411A>G;p.(Asn804Ser) missense variant in the 
SULF2 gene, neither of which were reported by DDD to the clinician. 
UBASH3B (Ubiquitin Associated And SH3 Domain Containing B), also known as KIAA1959, STS-1 or 
TULA2, is not associated with any known disorder in the OMIM database.  The GO biological process 
for the protein includes participation in the collagen-activated tyrosine kinase receptor signalling 
pathway, negative regulation of bone resorption and negative osteoclast differentiation. The gene is 
highly expressed in bone, the immune system, reproductive organs and platelets.  
In particular, UBASH3B is highly expressed in osteoclasts and is thought to be required for normal 
bone resorption. Knock-out mouse models have shown that osteoclast precursor numbers are 
increased by reduction in UBASH3B protein and exhibit an enhanced ability to resorb bone. Knock 
out mice also have  an associated decrease in BMD (Back, Adapala et al. 2013). UBASH3B is also 
known to be a critical negative regulator of TCR signalling, regulating T-cell activation (Mikhailik, Ford 
et al. 2007, Newman, Liverani et al. 2014) and to influence receptor signalling in platelets 
(Reppschläger, Gosselin et al. 2016). Many of these functions would fit with the clinical presentation 
of our patient.  
UBASH3B is described as being a loss of function intolerant gene with a pLI=0.99 in gnomAD. The 
c.371Tdel;p.(Phe124fs) variant is predicted to result in a premature termination codon 53 positions 
downstream and to result in nonsense-mediated mRNA decay. It has not been reported previously 
either in association with disease or in the general population.  
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However, this gene is located at 11q24.1, a region of chromosome 11 that is deleted in 8 patients in 
the Decipher database. Review of the supplied clinical features in these 8 patients did not identify any 
patient with either osteoporosis, osteopenia or increased susceptibility to fracture. It would be 
interesting to further explore the phenotype of these DDD patients and perhaps undertake platelet 
function analysis in patient 107 to further investigate the potential role of the UBASH3B gene. Another 
option would be to see how the development of osteoclasts from the patient’s circulating mononuclear 
cells compares to that of normal controls (Fujikawa, Quinn et al. 1996). 
The SULF2 gene encodes a heparin sulphate 6-O-endosulfatase that regulates the release of growth 
factors from extracellular storage sites, activating multiple signalling pathways during growth, 
differentiation and repair of many tissues. It is vital for pathways that require heparin sulphate 
proteoglycan as a co-factor for ligand-receptor binding, including the TGFβ1/SMAD (Chen, Nakamura 
et al. 2017) and WNT-GLI1-CYCLIN D1 pathways (Nakamura, Fernandez-Barrena et al. 2013).  
Of particular interest is that high levels of both SULF1 and SULF2 are expressed in osteoblasts 
actively forming bone (Zaman, Staines et al. 2016). Data suggesting a role of SULFs in Hedgehog 
signalling and within the extracellular matrix during fracture healing has also been presented, with the 
SULFs being proposed as a possible target for future treatment development to aid fracture healing 
(Zaman, Staines et al. 2016). 
The c.2411A>G;p.(Asn804Ser) SULF2 variant has been reported in only 1 in 240358 alleles in 
gnomAD. It lies within the highly conserved extracellular sulfatase domain of the protein and affects a 
highly conserved nucleotide and amino acid. However, in-silico conservation analysis is inconclusive 
and therefore this variant is of uncertain significance.  Interestingly patient 117 also has a 
heterozygous missense variant in SULF2, a c.587T>C;p.(Ile196Thr) within the extracellular sulfatase 
domain. 
Sequence data from both parents of this patient may clarify the inheritance pattern of these three 
variants and help to direct further investigation of their potential role in this patient’s clinical symptoms.  
 
Patient 117 NBAS c.3776C>T;p.(Ser1259Phe), SULF2 c.587T>C;p.(Ile196Thr) and UGGT1 
c.371Tdel;p.(Phe124fs). 
The clinical features of patient 117 are described as abnormal facial shape, constipation, global 
developmental delay, increased susceptibility to fractures, microcephaly, polyhydramnios, sleep 
disturbance and unilateral deafness. His developmental delay features are explained by a reported 
heterozygous CTCF (a chromatin binding factor gene) c.612_615delAAAG;p.(Lys206fs) mutation, a 
gene known to be associated with mental retardation, autosomal dominant 21. However, his 
symptoms of bone fragility are not explained by this finding.  
Three heterozygous variants warranting further exploration were identified in patient 117: NBAS 
c.3776C>T;p.(Ser1259Phe), SULF2 c.587T>C;p.(Ile196Thr) and UGGT1 c.371Tdel;p.(Phe124fs). 
As previously discussed we have identified the NBAS gene as causative of bone fragility in individuals 
with a complex OI/SOPH/Liver failure syndrome (Balasubramanian, Hurst et al. 2017). The 
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c.3776C>T; p.(Ser1259Phe) missense variant lies within the sec39 secretory domain, a region of the 
protein where causative missense mutations have now been described (Li, Qiu et al. 2017). However, 
interrogation of the complete VCF for this patient identified that this variant call is of very low quality 
and likely represents a false positive.  No second candidate NBAS variant was identified in this patient 
and in addition the clinical features of the patient are not consistent with this gene being causative. 
The second variant in patient 117 is a heterozygous c.371Tdel;p.(Phe124fs) variant in the UGGT1 
gene. UGGT is a glycan processing enzyme that acts as a folding sensor within the ER as part of the 
unfolded protein response (UPR). It acts by recognising unfolded glycoproteins, reglucosylating a 
single N-glycan near the misfolded part of the protein. This acts as a marker for sending the protein 
back for further folding attempts or for degradation (Figure 78), (Määttänen, Gehring et al. 2010, 
Izumi, Kuruma et al. 2017).  
Proteoglycans are a known key component of bone tissue and have a broad function, organizing the 
extracellular matrix and participating in collagen fibrillogenesis (Lamoureux, Baud'huin et al. 2007). It 
could be speculated that pathogenic mutations in UGGT1 could therefore affect bone structure and 
function, without a direct role in collagen I processing/trafficking being identified for the UGGT protein 
(Maiers, Kostallari et al. 2017). 
The UGGT1 gene is located at chromosome position 2q14.2 and contains 41 exons comprising 1555 
amino acids, with the first 42 amino acids forming the signal peptide. The c.372del variant, in exon 4, 
is predicted to cause a frameshift, p.(Phe124fs), leading to a premature termination codon 13 
positions downstream. It is likely to result in nonsense mediated decay of the mRNA. This variant has 
not been reported in the general population (gnomAD dataset) and the gene has not so far been 
associated with any human phenotype (OMIM).  
 
Figure 78 Discrimination of folding status of glycoprotein by folding sensor UDP-
glucose:glycoprotein glucosyltransferase (UGGT) in the glycoprotein quality control system.  
UGGT transfers a glucose residue only to the M9 oligosaccharide on a glycoprotein having non-native conformation. 
Figure adapted from Izumi et al (Izumi, Kuruma et al. 2017). 
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Interrogation of the gnomAD dataset identified a further 8 ‘frameshift’ variants in the gene. The 
majority of these have been identified in a single allele with the exceptions of 
c.1040_1041del;p.Lys347Argfs*3 (rs755827151) which is reported in 2/245270 alleles), 
c.1828dupT;p.(Ser610Phefs*4) identified in 4/276846 alleles (rs767476081) and 
c.4303_4304del;p.Arg1435Glyfs*11 present in 3/246254 alleles (rs75447246). As none of these are 
at a particularly high frequency in the general population it is difficult to assign significance to the 
UGGT1 variant identified in this patient. 
A further variant of interest was identified in patient 117, a heterozygous c.587T>C;p.(Ile196Thr) in 
SULF2. This is the second variant in SULF2 identified in this cohort (patient 117, discussed 
previously). The c.587T>C;p.(Ile196Thr) variant has not been reported in the gnomAD database and 
in silico conservation analysis is inconclusive. However, it affects a highly conserved nucleotide and 
amino acid (up to fruitfly, considering 12 species) that, similarly to patient 117, lies within the sulfatase 
extracellular domain. 
A next step in the investigation of the significance of the UGGT1 and SULF2 variants identified in this 
patient would be to test parental samples to ascertain if they are inherited or if they appear de-novo. 
This would give support to which, if either, are worth exploring further. 
Patient 141: BMP6 c.334G>A;p.(Glu112Lys) and POSTN c.1108+2T>C 
Patient 141 is described as having an abnormality of mast cells, autonomic dysregulation, joint 
hypermobility, orthostatic hypotension, osteopenia, seizures and joint dislocations as a young adult. 
Many of these symptoms (autonomic dysregulation, joint hypermobility, orthostatic hypotension and 
joint dislocations) are commonly associated with hypermobile Ehlers Danlos Syndrome, a common 
connective tissue disorder with no identified genetic cause at present. 
A heterozygous maternally-inherited c.334G>A;p.(Glu112Lys) variant in bone morphogenetic protein 
6 (BMP6) was identified in this individual. BMP6 is a major activator of the BMP-SMAD signalling 
pathway (Beederman, Lamplot et al. 2013) and has the ability to induce bone and cartilage bone 
mineralization and influence osteoblast differentiation (Lavery, Swain et al. 2008). It is also known to 
have a major role in iron metabolism and lack of BMP6 results in massive iron overload (Meynard, 
Kautz et al. 2009).  
The c.334G>A;p.(Glu112Lys) variant has not been previously reported but lies in the propeptide 
domain of the protein known to be crucial for BMP6 processing and secretion. A similar variant 
affecting the same amino acid, c.334G>C,p.(Glu112Gln), has been proposed to cause iron overload 
(hereditary haemochromatosis) when in the heterozygous state (Piubelli, Castagna et al. 2017). A 
note of caution is that it is also reported in 0.30% of the Japanese population (HGVD).  
In silico conservation analysis of c.334G>A;p.(Glu122Lys) does not support a pathogenic role and no 
symptoms of iron overload are reported in this individual. It seems likely therefore that the 
c.334G>A;p.(Glu112Lys) is a rare benign variant, although a role in bone metabolism in this patient 
cannot be completely excluded, particularly as it is maternally inherited and there is maternal 
hypermobility, osteopenia and autonomic dysregulation.  
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A second maternally inherited variant, c.1108+2T>C affecting the splice donor site of intron 8 of the 
POSTN gene, was also identified in patient 141. This variant is predicted to result in complete loss of 
the wildtype donor site (Figure 79) and potentially result in a skip of exon 8.  Population frequency 
data shows it is present at very low level in the general population (3/243624 alleles in geNOMAD) 
Splice prediction was undertaken using Alamut Visual 2.9 (Interactive Biosoftware, Rouen, France). 
All five prediction packages support complete loss of intron 8 wildtype donor site. POSTN encodes 
periostin, a multi-functional extracellular matrix protein with a role in tissue repair, inflammatory 
response,  cardiovascular and respiratory systems as well as bone metabolism (Conway, Izuhara et 
al. 2014). Key to its function in connective tissue is that it forms an ECM assembly ‘scaffold’, 
contributing to tissue mechanical strength (Kudo and Kii 2018).  
Periostin binds to type I collagen, tenascin C, lamin γ2 and fibronectin and enhances BMP1 
incorporation into the fibronectin matrix, thereby influencing downstream activation of lysyl oxidase 
(LOX) and subsequent collagen crosslinking (Trackman 2016). The formation of the periostin-BMP1-
LOX complex is thought to underlie collagen fibre mechanical strength (Kudo and Kii 2018). A role in 
secretion of fibronectin from the ER has also been demonstrated (Kii, Nishiyama et al. 2016). 
 
 
Figure 79 In-silico splice prediction of heterozygous POSTN c.1108+2T>C variant identified in 
patient 141. 
Animal model studies have shown that collagen fibrillogenesis is disrupted in osteoblasts in periostin 
null mice although bone mineral density of cortical bone was indistinguishable from that of wildtype 
mice (Kii, Nishiyama et al. 2010). Increased serum periostin levels have also been observed in older 
women with osteoporotic hip fracture when compared to age matched controls (Yan, Liu et al. 2017), 
a finding that suggests periostin plays a role in fracture repair.  Higher serum periostin levels were 
140 
 
also shown to be an independent risk factor for femoral neck BMD, suggesting that periostin plays a 
role in maintaining bone mass. 
Of note is that periostin has been shown to be a key downstream target for SULF2-induced 
angiogenesis in hepatocellur carcinoma cells with upregulation of SULF2 resulting in both increased 
expression and secretion of periostin via the TGFβ1/SMAD signalling pathway  (Chen, Nakamura et 
al. 2017).  
It seems reasonable to consider POSTN as a candidate gene for at least some of the symptoms in 
this family. Further exploration of POSTN and SULF2 variants within this cohort of patient would also 
be worth considering particularly as SULF2-POSTN has been proposed as a potential target for 
treatment to increase BMD and/or aid fracture healing. A first step could be to look at secretion of 
fibronectin from fibroblast ER in patient 141 and her mother in order to assess the functional effect of 
the POSTN variant. 
 
NOTE: All genes of interest identified in the DDD study were subsequently analysed for all exome 
patients (IDs A-H). No additional candidate variants were identified in these genes. 
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ix DISCUSSION 
This research aimed to contribute to the understanding of the molecular basis of Osteogenesis 
Imperfecta, a rare inherited condition characterised by low bone mass, increased bone tissue mineral 
density and an increased risk of fracture.  
Genetic characterisation of families affected with OI has shown that autosomal dominant mutations in 
the genes that encode the alpha chains of type I collagen can be identified in ~85% of affected 
individuals (Rohrbach and Giunta 2012). Research to identify additional genes has largely focused on 
individuals with lethal or severe OI, often from large consanguineous families and has identified a 
further fifteen genes to date (Marini, Forlino et al. 2017).  
It is clear that there are families with mild/moderate OI without an identified causative mutation in the 
type I collagen genes. We wanted to explore the genetic cause of OI in these individuals. 
The first objective of this study was to identify a cohort of families with mild/moderate OI without a 
mutation in the type I collagen genes. We recruited eighteen families for targeted exome analysis and 
eight families for whole exome sequencing. An additional three patients were identified during the 
course of this study following introduction of BMP1 gene analysis into the diagnostic pathway as a 
result of the targeted exome analysis findings. 
The second objective was to elucidate the genetic aetiology of bone fragility in this cohort. We used 
a number of different sequencing strategies: NGS targeted exome sequencing looking at genes 
previously described in severe OI, single gene Sanger sequencing and NGS whole exome 
sequencing. 
We identified the likely cause of OI in two patients using our targeted exome sequencing. The first 
patient is heterozygous for a c.4070T>C;p.(Leu1357Pro) COL1A1 likely pathogenic mutation within 
the C-propeptide domain of the protein. This mutation is within the chain-chain recognition sequence, 
potentially disrupting chain alignment and assembly. Previously described mutations in this region of 
the gene have been associated with both mild OI and a high bone mass phenotypic variant. We did 
not identify any features of high bone mass in the three affected members of this family. In fact the 
symptoms in an adult member of this family were mild enough for him to be unaware that he is 
affected. This is concordant with the mild clinical severity as described by Pace et al (Pace, Kuslich et 
al. 2001). Originally the COL1A1 mutation was thought not to be causative due to apparent non 
segregation. On clinical review of the family, including evaluation of additional individuals and revision 
of affected/unaffected status, it became apparent that this mutation does segregate with the features 
of OI in this family and is highly likely causative. This result highlights the importance of phenotypic 
data in the interpretation of genetic findings. 
The second patient identified by targeted exome sequencing is compound heterozygous for two 
pathogenic mutations affecting the BMP1 gene: a c.1293C>G;p.(Tyr431*) and a 
c.1148C>G;p.(Arg383Gln). At the time of this study less than 20 individuals with OI had been 
identified with mutations in the BMP1 gene. The majority of these, but not all, have presented with 
bone fragility associated with an increase in bone mineral density (BMD). Our patient also presented 
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with increased BMD that become more evident following anti-resorptive treatment. We concluded that 
the c.1293C>G;p.(Tyr431*) and c.1148C>G;p.(Arg383Gln) changes were highly likely to be the cause 
of OI in this patient.  
This result prompted the inclusion of BMP1 in the OI diagnostic testing panel within SDGS. This led to 
the subsequent identification of two patients (siblings) who are homozygous for a 
c.2188dupC;p.(Gln730fs) highly likely pathogenic mutation in the BMP1 gene. The clinical features of 
these siblings contrasts with the severe progressive form of OI described in patients who are 
compound heterozygous for this mutation and the recurring p.(Gly12Arg) signal peptide mutation 
(Syx, Guillemyn et al. 2015). We presented the phenotypic and BMD data for these three patients in 
our American Journal of Medical Genetics manuscript (Pollitt, Saraff et al. 2016). Following 
publication of the manuscript, a further patient with a high bone mass phenotype and a novel 
homozygous c.355C>T;p.(Arg119Trp) mutation in the pro-domain of the BMP1 gene was identified.  
One possible explanation for the variable phenotype in this small cohort of BMP1 OI patients is that 
the degree of mineralization is a direct result of the ‘severity’ of the mutation.  However, we were 
unable to demonstrate any difference in collagen C-propeptide cleavage activity by biochemical 
analysis in dermal fibroblasts, although accumulation of pCα1(I) procollagen species confirmed 
pathogenicity. Characterisation of collagen fibril and fibroblast ultra structural features also gave no 
clues as to the mechanism responsible for the variable phenotypic severity in this cohort.  
Based on these results, it seems reasonable to suggest that mechanisms other than collagen 
processing play a part in determining the degree of mineralization in these patients. It would be 
interesting to measure decorin processing in order to confirm the previous observations by Syx et al 
who reported defective proteolytic prodecorin processing in BMP1 OI patients (Syx, Guillemyn et al. 
2015). As decorin mediates TGF-β signalling, we can speculate that reduced decorin prodomain 
removal is contributing to the increased mineralization in these patients by influencing downstream 
TGF-β signalling. Assessment of TGF-β signalling in our cohort would help to determine the validity of 
this hypothesis.  
An important conclusion from this part of the study is that caution is required for anti-resorptive 
therapy in BMP1-related OI due to the potential risk of delayed healing, increased bone stiffness, 
atypical fractures and iatrogenic osteopetrosis. In our manuscript we have stated that careful 
monitoring of response to bisphosphonate therapy is indicated in these patients.  
Our data also clearly demonstrates the value of genetic diagnosis to inform treatment decisions in OI 
and the importance of inclusion of BMP1 analysis in any diagnostic screening strategy. We also show 
that this analysis should not be confined to patients with a noticeable high bone mass phenotype as 
bone mass in BMP1-related OI can be highly variable. 
It is worth noting that targeted exome sequencing, as used here, can only identify certain types of 
mutations, such as single base substitutions and small deletion/insertions. Larger changes and 
rearrangements are not detected. In addition, as probes are designed to capture specific regions of 
known genes and are usually focused on protein coding sequence, deeply intronic variants and those 
in regulatory regions will be missed. There is also very limited potential for novel gene discovery. 
However, an advantage of this strategy is that the identification of significant incidental findings is 
avoided. 
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A second strategy to identify the genetic cause of OI in this cohort was to screen all participants 
without an identified pathogenic mutation for mutations in the TRAM2 gene using Sanger sequencing. 
Phenotypic data from a knockout mouse model suggested this to be a good candidate gene for OI. 
Only variants present at relatively high frequency in general population datasets were identified and 
we concluded that the diagnostic yield from this approach is likely to be extremely low and did not 
pursue this strategy further. 
In the third strategy, we performed whole exome sequencing on eight patients who had screened 
negative for all known OI genes and TRAM2. Three of these patients, two singletons and a trio, were 
commercially sequenced by Personalis. Their complete datasets, along with a candidate gene report, 
were returned to our centre for confirmation and further analysis. The remaining five patients, four 
trios and one duo, were sequenced in-house using SureSelect Human All Exon V6 baits for target 
enrichment and an Illumina HiSeq platform. We identified likely causative mutations in three 
individuals and a further two that have variants that are currently of uncertain significance.    
Causative mutations include compound heterozygous c.1224-80G>A and c.1080+1G>T in P3H1, a 
heterozygous c.1178A>G;p.(Tyr393Cys) P4HB mutation previously described in Cole Carpenter 
syndrome (CCS), and compound heterozygous c.5741G>A;p.(Arg1914His) and 
c.3010C>T;p.(Arg1004*) in the NBAS gene. The variants of uncertain significance are compound 
heterozygous c.6971G>A;p.(Arg2324His) and c.4358G>A;p.(Cys1453Tyr) in NBAS in one patient and 
de-novo c.9029C>A;p.(Pro3010His) SRCAP and c.1169C>T;p.(Pro390Leu) TAPBP variants in 
another patient.   
Several observations can be made from these mutation data. The first is the advantage of extending 
sequence analysis to include non-coding regions of the gene. The P3H1 c.1224-80G>A was identified 
as a result of exon/intron architecture in this region of the gene, in that the intron in which the 
mutation lies is relatively small (174bp). Therefore, targeting sequence capture to surrounding exons 
has captured intronic sequence by default. It follows that more deeply intronic variants, that may be 
pathogenic, are being missed using current exome sequencing strategies. 
A further observation is that the diagnostic yield from our whole exome sequencing is 38%; this would 
increase to 63% if we can demonstrate causality in our two patients with variants of uncertain 
significance. This is concordant with reported diagnostic yield in larger exome sequencing projects 
such as UK10K and Decipher, and supports the clinical utility of this sequencing strategy in patients 
where the routine diagnostic testing is negative. Additional analysis for the patients where we have 
not identified causal mutations could include whole genome sequencing (WGS), array CGH, or 
multiplex ligation-dependent probe amplification (MLPA).  
Our identification of the c.1178A>G;p.(Tyr393Cys) mutation represents only the third case of Cole 
Carpenter Syndrome caused by a defect in P4HB and suggests the possibility of this recurrent P4HB 
mutation being the cause of this syndrome. No other P4HB variants have been reported in 
association with any clinical phenotype. In addition, detailed phenotyping in our patient with the 
c.1178A>G;p.(Tyr393Cys) P4HB mutation highlights what appears to be an emerging, distinctive 
radiological phenotype for these CCS patients:  meta-diaphyseal fractures with metaphyseal 
sclerosis, a feature that is uncommon in patients with classical OI. We have also identified that early 
treatment with anti-resorptive therapy in patients with a proven P4HB mutation can be beneficial in 
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reducing fracture incidence and vertebral compression fracture frequency (Balasubramanian, 
Padidela et al. 2017). 
 
 
Figure 80 Electron microscopic ultra structure of dermal collagen in an OI patient with a c.838G>A, 
p.(Gly280Ser) COL1A2 mutation. 
A small collection of individual collagen fibrils surrounded by proteoglycans were observed. The significance of this is 
unclear. Magnification: A=9200X, B=20000X. 
 
It has previously been proposed that increased ER stress is the mechanism by which the P4HB  
mutation leads to CCS (Rauch, Fahiminiya et al. 2015). However, using morphological examination of 
reticular dermis by EM and protein expression analysis, we observed no major difference in 
extracellular type I collagen deposition by immunofluorescence studies, little effect on collagen fibril 
assembly and no sign of significant fibroblast ER stress. Our data therefore does not support this 
hypothesis. However, it is possible that the P4HB mutation may cause osteoblast ER stress and not 
fibroblast ER stress. It would be interesting to see if we could reproduce the altered distribution of the 
PDI protein in our patient’s fibroblasts or increased HSP47 protein, in support of ER stress, as 
previously reported (Rauch, Fahiminiya et al. 2015). Additional analysis to look for upregulation of BiP 
(UPR marker) or autophagy, supporting an ER stress mechanism, may also be informative. 
Our data allows us to speculate that it is the assembly, composition or architecture of the extracellular 
matrix that is disorganised in patients with this P4HB mutation rather than collagen secretion itself. An 
observation in our patient that may support this idea is the presence of four small collections of 
individual collagen fibrils surrounded by proteoglycans (Balasubramanian, Padidela et al. 2017). 
Functional analysis will be required to explore this further; a potential starting point could be to 
examine other collagen and proteoglycan function in these patients.  
Interestingly, since publication of our manuscript describing this feature (Balasubramanian, Padidela 
et al. 2017), we have identified an OI patient with a c.838G>A;p.(Gly280Ser) pathogenic mutation in 
exon 17 of the COL1A2 mutation that also has an area where proteoglycan is wrapping around 
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collagen fibrils (Figure 80). We have also identified this feature in our patient with a de-novo SRCAP 
variant (Figure 54, page 97). This raises the question as to whether this is an indication of disturbed 
extracellular matrix in OI or whether this is in fact a rare normal feature of dermal breakdown and 
repair. Further work on a broader range of dermal biopsies, that includes non-OI patients, is ongoing 
to try to clarify the significance of this finding. A note of caution here is that we cannot discount that 
this is a tissue specific finding and may not be reflected in other tissues, such as bone. 
Our study has confirmed the potential of whole exome sequencing to identify novel causes of bone 
fragility by the identification of compound heterozygous c.5741G>A;p.(Arg1914His) and 
c.3010C>T;p.(Arg1004*) mutations in the NBAS gene. We were able to demonstrate reduced levels 
of the NBAS protein by Western blot analysis in patient cultured fibroblasts (performed in another 
laboratory) and the presence of Pelger Huët anomaly in the patient’s neutrophils, confirming 
pathogenicity of the mutations.  
The NBAS gene is known to cause short stature, optic nerve atrophy and Pelger-Huet anomaly 
syndrome (SOPH), and acute onset liver failure. More recently NBAS has been described as causing 
a multisystem disorder with a skeletal phenotype that can include early onset osteoporosis (Capo-
Chichi, Mehawej et al. 2015, Segarra, Ballhausen et al. 2015, Staufner, Haack et al. 2016). Our data 
adds an important extension to the phenotype associated with this gene to include a presentation 
resembling ‘atypical’ OI (Balasubramanian, Hurst et al. 2017). It is worth noting that, although Segarra 
et al report a ‘skeletal dysplasia suggesting a disturbance in bone mineralization’ (Segarra, 
Ballhausen et al. 2015), bone data is currently not available from NBAS patients to support this 
observation. 
The NBAS protein is a component of a soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) complex that is involved in golgi to ER retrograde transport (Aoki, Ichimura et al. 
2009). We observed grossly expanded protein-filled ER by EM examination of patient fibroblasts, 
some of which had formed ‘aggregates’ within the ER. This strongly supports that golgi-ER transport 
is compromised in our patient.  
NBAS is also involved in nonsense mediated decay (NMD) regulation of gene expression including 
genes associated with bone mineralisation, osteoblast differentiation and bone development. It has 
already been proposed that NBAS dysfunction in the NMD processes may explain the short stature 
and growth retardation described in SOPH syndrome. In particular, upregulation of matrix Gla protein 
(MGP), that acts as an inhibitor of cartilage calcification, has been confirmed in NBAS deficient 
zebrafish and C. Elegans (Longman, Hug et al. 2013)  
We suggest that it is possibly a combination of Golgi-ER transport and NMD dysfunction that 
ultimately result in bone fragility in NBAS deficient patients (Balasubramanian, Hurst et al. 2017). We 
could also speculate that altered golgi-ER transport may indirectly affect NMD. To explore the role of 
the NMD pathway, we aim to perform RNA expression analysis in our patients, with a particular focus 
on genes associated with bone mineralisation, osteoblast differentiation and bone development. 
We concluded that mutations in NBAS are a novel cause of heritable bone fragility and that this gene 
should be included in the diagnostic testing strategy for OI. The development of a gene dossier that 
includes testing criteria, and its acceptance and publication by UKGTN, is a significant advancement 
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in equitable access to NBAS testing for patients in the UK with associated implications for diagnosis, 
prognosis and to inform discussions around recurrence risk for these patients. 
Using exome sequencing, we also identified a further patient with short stature, osteopenia and 
fractures who is compound heterozygous for a c.6971G>A;p.(Arg2324His) and a 
c.4358G>A;p.(Cys1453Tyr) in the NBAS gene. These two variants are of unclear significance at 
present. The patient and his family have been invited for further investigation; initially this would 
involve detailed phenotyping, an FBC to look for PHA and liver function tests. Follow on studies of 
NBAS expression in dermal fibroblasts and morphological examination may then be appropriate. To 
date, the family have declined our invitation. 
In a further patient we identified two de-novo variants, c.9029C>A;p.(Pro3010His) in SRCAP and 
c.1169C>T;p.(Pro390Leu) in TAPBP. Truncating mutations in SRCAP are associated with Floating 
Harbour Syndrome (FHS), a condition characterized by short stature, delayed bone age and delayed 
speech (Messina, Atterrato et al. 2016). To date, no missense variants in SRCAP have been reported 
in association with a clinical phenotype.  
The SRCAP protein is the catalytic component of a complex that mediates the ATP-dependent 
exchange of histone H2AZ/H2B dimers for nucleosomal H2A/H2B leading to transcriptional regulation 
of genes by chromatin remodelling. Independently SRCAP is a coactivator for the CREB-binding 
protein (CREBBP, also known as CBP). CREBBP acts with EP300 to regulate the transcription of a 
number of bone-related genes. We considered the c.9029C>A;p.(Pro3010His) variant to be a good 
candidate for a potential role in bone fragility. 
One mechanism for the potential pathogenicity of this variant could be via changes in chromatin 
remodelling and subsequent changes in DNA methylation status. We analysed the DNA methylation 
status of our patient against normal and FHS control populations. The patient did not have the 
characteristic methylation status of FHS, confirming that he does not have a phenotypic variant of this 
disorder. A total of 171 regions with altered methylation status were identified when compared to 
normal controls. These regions contained two genes associated with bone metabolism, POLCE and 
LOXL3, both of which are hypomethylated. It is not clear whether the hypomethylation status of these 
genes is a response to, rather than being the primary cause of, altered bone metabolism. A note of 
caution is that methylation is often tissue specific and we have only examined status in peripheral 
blood. Further analysis in other tissues, particularly bone if available, may be helpful. However, it may 
still be difficult to distinguish causative changes to methylation status and, hence gene expression, 
from compensatory changes in response to other unidentified mechanisms. 
We considered the interaction of SRCAP with CREBBP/EP300 and activation of CREB-mediated 
transcription as a further potential mechanism for this variant to cause bone fragility.  Potential 
pathways include cAMP/CREB signalling pathways in osteoblasts such as mediation of PTH and/or 
BMP2 signalling. However, our patient has no radiographic features of the cleidocranial dysplasia 
associated with RUNX2, a downstream target of BMP2.  Evidence is therefore lacking to support this 
as a pathogenic mechanism. 
The de novo c.1169C>T;p.(Pro390Leu) in TAPBP highlights the dilemma of heterozygous findings in 
autosomal recessive genes that are potentially relevant to a patient’s phenotype. The gene is 
described in Type I Bare Lymphocyte Syndrome, a condition characterised by chronic bacterial 
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infection, and our patient has mild gammaglobulinaemia and non response to pneumococcal 
vaccination. It is possible that either there is a second unidentified mutation elsewhere in the gene, 
that this represents a milder dominant form of the syndrome or that it is not relevant to the patient’s 
clinical symptoms. Trying to reach a conclusion in these circumstances is challenging, particularly 
where the variant is de-novo. There is a reported frequency of de-novo point mutations per generation 
in the region of 70-175, of which approximately 3 would be expected to cause changes in protein 
coding sequence (Nachman and Crowell 2000, Conrad, Keebler et al. 2011). It therefore follows that 
a de-novo missense variant may not necessarily be associated with a deleterious clinical phenotype. 
Serological or flow cytometric analysis of HLA status, specifically the expressions of class I MHC 
molecules, would provide evidence to inform the clinical significance of this variant. 
The third objective of this study was to explore a broader dataset of variants from additional patients 
by establishing a collaborative complementary analysis project with the ‘Deciphering Developmental 
Disorders’ (DDD) project. The required subset of patient data was identified by searching the DDD 
database using Human Phenotype Ontology (HPO) terms relating to reduced bone mass and 
potential bone fragility. 
Forty nine patients were selected and a total of 939 candidate variants were assessed. Nine patients 
were reported to have a clinical diagnosis of OI and we identified causative variants in four of these. 
Our discovery of two mutations, COL1A2 c.280-2A>C and IFITM5 c.-14C>T, that were not reported 
by Decipher to the referring clinician, highlights a number of issues with current pipelines for large 
dataset analysis.  
The first is that, even where a variant is of high sequence quality, causative mutations may not be 
reported as being relevant to the patient’s clinical phenotype. In the case of COL1A2 c.280-2A>C, the 
patient is stated as having a clinical diagnosis of OI and a known COL1A2 mutation. This information 
is provided in the ‘additional notes’ data field rather than being in the HPO field. The HPO terms do 
however state ‘bowing of limbs due to multiple fractures’ and ‘multiple prenatal fractures’, both of 
which should have highlighted the COL1A2 mutation. It is therefore unclear why this was not thought 
relevant to the patient’s symptoms and leads us to suggest that caution is required in the 
interpretation of any negative results provided by automated pipelines. 
The second issue is that, as discussed previously, intronic sequence may not be reliably captured by 
whole exome sequencing. In the case of the IFITM5 c.-14C>T mutation, the sequence data had fallen 
below the acceptable quality threshold and was therefore disregarded. We could also speculate that, 
as this an intronic variant, it is unlikely to have been highlighted as potentially causative even if it was 
of good quality due to the limitations of splicing variant analysis in current analysis pipelines. It is 
worth stating that, for these two patients at least, standard diagnostic targeted panel analysis would 
have had an advantage over whole exome analysis as this includes specific probes to capture the 
IFITM5 c.-14C>T mutation and all variants are manually assessed for likely causality. 
For patients without a stated clinical diagnosis of Osteogenesis Imperfecta a total of 19 candidate 
variants for bone fragility were identified in 12 patients.  Two patients without a stated clinical 
diagnosis of OI were found to have a pathogenic mutation in the type I collagen genes, COL1A1 
c.2644C>T;p.(Arg882*) and COL1A1 c.1299+1G>A. This could suggest that milder forms of OI are 
under diagnosed.  
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Our data also highlighted the potential phenotypic overlap between OI and Ehlers Danlos syndrome. 
We identified compound heterozygous mutations in the B4GALT7, the gene associated with 
spondylodysplastic EDS (spEDS). The patient is reported as having mild short stature and 
generalized hypotonia, both of which are within the diagnostic criteria for spEDS. The additional 
clinical features of osteopenia, bowing of the long bones and vertebral compression fractures are 
more suggestive of OI. In our centre we have also identified patients with OI type I collagen mutations 
previously clinically diagnosed with classical EDS. We concluded that a broader OI/EDS testing 
strategy is clearly indicated in a diagnostic setting. This is further supported by the identification of a 
heterozygous PLOD1 mutation, associated with kyphoscoliotic EDS, in our data. 
As with the TAPBP de novo variant described earlier, the heterozygous PLOD1 mutation in our data 
illustrates the difficulty with assessing the significance of these findings. Generally heterozygous 
variants, even if likely pathogenic, are not reported for autosomal recessive genes by exome analysis 
pipelines. Clearly important findings relevant to a patient’s phenotype may therefore be missed and 
manual review of variants would be advantageous. Our data also illustrates the difficulty in 
distinguishing heterozygous carriers from patients with a 2nd mutation that is unidentified by current 
exome sequencing analysis and would confirm a diagnosis. A recurrent PLOD1 mutation, a 
duplication of exons 10 to 16, would not be detected by the Decipher bioinformatics analysis pipeline 
and therefore the diagnosis in this patient is currently unresolved. We have contacted the patient’s 
clinician and recommended that a urine sample for deoxypyridinoline to pyridinoline ratio analysis is 
obtained. 
We identified a number of pathways that may be important for the bone fragility in our DDD cohort. 
The first is voltage-gated sodium channels, where three patients with variants in the SCN8A or 
SCN9A suggest a potential pathway between pain sensation, epilepsy/seizures and bone parameters. 
This is supported by a recent report of a clinical phenotype “consistent with OI type IV” in association 
with a homozygous c.570G>A;p.(Trp190*) in SCN9A (Caparros-Martin, Aglan et al. 2017).  
Data is also available that shows increased osteoclast numbers and bone resorption in Scn8a-
deficient mouse along with disorganized collagen structure and increased mineralization 
heterogeneity. A patient with SCN8A-related epileptic encephalopathy and multiple fractures is 
reported with low bone mineral density (DXA Z score -2.9) and a decreased bone volume per tissue 
volume (BV/TV), as assessed by high-resolution peripheral quantitative computed tomography (HR-
pQRT) in the tibia. Improvement in BV/TV (+46% at 25 months post treatment initiation) and no 
further fractures following anti-resorptive therapy (Neridronate) is described, supporting a bone 
remodelling/resorption pathology (Rolvien, Butscheidt et al. 2017).  
We conclude that further clinical evaluation of our SCN8A/SCN9A patients, in particular their bone 
parameters, is warranted. However, a note of caution is that anti-convulsion medication and reduced 
mobility, which may be associated with epilepsy/seizures and developmental delay respectively, can 
both contribute to osteopenia. 
A second candidate pathway is highlighted by the c.1A>G;p.(Met1?) variant in the glutamine, 
glutamate, and aspartate transporter gene, SLC38A10 (Hellsten, Hägglund et al. 2017). Glutamine 
has emerged as an important regulator of osteoblasts, being actively metabolised and essential for 
matrix mineralization (Brown, Hutchison et al. 2011). Glutamine signalling, alongside Wnt signalling 
via Frizzled (Fz) and Lrp5/6 and activation of mTORC1, increases levels of key enzymes involved in 
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glucose and glutamine metabolism, notably glutamine anaplerosis into the citric acid cycle (TCA) 
(Figure 81).  
Energy metabolism in osteoblasts has been proposed as a key mechanism in the osteoporosis 
associated with diabetes mellitus and anorexia nervosa (Lee, Guntur et al. 2017) and Slc38a10 
knockout mice have weak and brittle bones (Bassett, Gogakos et al. 2012). Anabolic treatment for 
osteoporosis is known to increase bone mass and reduce fracture risk possibly by stimulating 
osteoblastogenesis and/or altering osteoblast metabolic processes (Lee, Guntur et al. 2017). We 
propose that SLC38A10 is therefore a good candidate gene for osteoporosis and increased fracture 
risk in man. 
 
 
Figure 81 Energy Metabolism of Osteoblasts 
Wnt signalling increases both gglutamine anaplerosis into the citric acid cycle (TCA) and fatty acid oxidation. 
Through Frizzled (Fz) and Lrp5/6, Wnt signalling activates mTORC1, increasing levels of key enzymes involved in 
glucose and glutamine metabolism. Wnt signaling through β-catenin also increases expression of genes important for 
fatty acid oxidation. Figure modified from Lee et al  (Lee, Guntur et al. 2017) 
The clinical features of our patient include generalized osteoporosis with pathologic fractures, 
otosclerosis and severe generalized osteoporosis. The patient’s mother, who is also heterozygous for 
the c.1A>G;p.(Met1?) variant is also reported to have osteoporosis and otosclerosis. This supports a 
potential role for this variant in the bone phenotype in this family but is not conclusive.  The patient 
and their family have been invited for further clinical review. 
With the identification of a de-novo loss of function LRP6 variant in a patient who has a homozygous 
c.1225C>T;p.(Arg409Cys) mutation in the FAM20C gene, we have demonstrated that there is a risk 
of incorrectly attributing all phenotypic features to a single gene. It seems likely that both the 
amelogenesis imperfecta and osteoporosis described in our patient is likely to be at least partly 
caused by his LRP6 variant, either in isolation or in combination with his FAM20C mutation. However, 
as the LRP6 variant was not reported back to the clinician, it has been assumed that FAM20C fully 
explains the patient's whole phenotype.  
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Novel candidate genes identified in our cohort are UBASH3B, UGGT1, SULF2 and POSTN. The 
inheritance of the variants in these genes is unknown, with the exception of POSTN which is 
maternally inherited. It will be important to confirm inheritance, and clinically assess any carrier 
parents, before embarking on any functional studies to clarify the role of these genes in bone fragility, 
particularly where patients have variants in more than one candidate gene. 
UBASH3B is a loss of function intolerant gene (pLI=0.99 in gnomAD) that is highly expressed in 
osteoclasts, the immune system, reproductive organs and platelets, and is thought to be a 
requirement for normal bone resorption. In particular the UBASH3B protein negatively regulates 
osteoclast precursor numbers and in its absence osteoclasts exhibit an enhanced ability to resorb 
bone. This is supported by increased osteoclast precursors and decreased BMD in knock-out mice 
(Back, Adapala et al. 2013). UBASH3B is also known to be a critical negative regulator of TCR 
signalling, regulating T-cell activation. We identified a c.371Tdel;p.Phe124fs likely loss of function 
variant in a patient with, among other features, abnormality of T cells, osteopenia, osteoporosis of 
vertebrae and severe short stature. We concluded that these symptoms would fit with the reported 
function of UBASH3B.  
However, the UBASH3B gene is located at 11q24.1, a region of chromosome 11 that is deleted in 8 
patients in the Decipher database none of whom have reported osteoporosis, osteopenia or 
increased susceptibility to fracture. To explore the potential role of UBASH3B we plan to investigate 
the phenotype of these Decipher patients further. We would also like to undertake platelet function 
analysis and examine the development of osteoclasts from circulating mononuclear cells in our 
patient. 
UGGT1, an ER resident enzyme, acts as a folding sensor reglucosylating unfolded glycoproteins as 
part of the unfolded protein response (UPR). The c.371Tdel;p.(Phe124fs) loss of function variant 
identified in our patient may have an effect either by causing ER stress or by release of misfolded 
proteoglycans that could disrupt extracellular matrix organization. There are several options available 
to explore the function of the variant in our patient: we could undertake enzymatic activity assays 
(Trombetta, Bosch et al. 1989); undertake gene and protein expression assays;  examine a dermal 
biopsy for evidence of ER stress and matrix disorganisation; or measure markers of ER stress such 
as  upregulation of BiP. We plan to obtain a dermal biopsy from our patient and assess collagen and 
fibroblast ultrastructure by EM as a first step. 
Of particular interest is that we identified SULF2 missense variants in both the UBASH3B and UGGT1 
patients discussed above (c.2411A>G;p.(Asn804Ser) and c.587T>C;p.(Ile196Thr) respectively). The 
SULF2 protein regulates growth factor release from extracellular storage sites, activating multiple 
signalling pathways including TGFβ1/SMAD (Chen, Nakamura et al. 2017), WNT-GLI1-CYCLIN D1 
pathways (Nakamura, Fernandez-Barrena et al. 2013) and Hedgehog/GLI1 (Zheng, Gai et al. 2013).  
It has been shown to be highly expressed in active osteoblasts, particularly during healing, and has 
been proposed as a possible future treatment target to aid fracture healing (Zaman, Staines et al. 
2016). 
We have also identified a c.1108+2T>C splicing variant within the POSTN gene, a key downstream 
target for SULF2, with upregulation of SULF2 resulting in both increased expression and secretion of 
POSTN via the TGFβ1/SMAD signalling pathway (Chen, Nakamura et al. 2017). Periostin binds to 
type I collagen, tenascin C, lamin γ2 and fibronectin and enhances BMP1 incorporation into the 
151 
 
fibronectin matrix. This in turn influences downstream activation of lysyl oxidase (LOX) and 
subsequent collagen crosslinking (Trackman 2016). In a similar manner to SULF2, increased serum 
periostin levels have been observed in older women with osteoporotic hip fracture (Yan, Liu et al. 
2017), a finding that suggests periostin may play a role in fracture repair.  More recently periostin has 
been shown to play a protective role against mechanical stretch-induced apoptosis in osteoblast-like 
MG-63 cells (Yu, Yao et al. 2018). 
It seems reasonable to consider POSTN-SULF2 as a candidate pathway for at least some of the 
findings in these individuals. As periostin has a role in secretion of fibronectin from the ER (Kii, 
Nishiyama et al. 2016), a first step to investigate this further could be to assess secretion from 
fibroblast ER, using immunohistochemistry. Alternatively, we could measure the expression levels of 
both POSTN and SULF2 in osteoblasts. We are currently exploring what material is available from 
these patients. 
 
In conclusion, we were able to address all research objectives formulated in this thesis and have 
identified novel genetic mechanisms leading to bone fragility and OI. We have also identified a 
number of novel genes and pathways that warrant further investigation as outlined above, namely 
SLC38A10, SRCAP, UGGT1, UBASH3B, SULF2-POSTN, and voltage-gated sodium channel genes.  
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x FUTURE PERSPECTIVE 
During the course of this project there have been considerable advances in genetic technology. We 
have moved from sequential Sanger sequencing of individual genes, to routine NGS targeted exome 
panels through to whole exome and genome sequencing.  
The launch of the Genomics England 100,000 Genomes Project, with the aim of sequencing patients 
with rare diseases and cancer, means there will be an ongoing expansion of phenotypic and genetic 
data available. This has the potential to improve identification of novel disease genes, phenotypic 
modifiers, factors influencing disease progression, and optimize development of novel therapies and 
treatment regimes. 
 
 
Human Phenotypic Ontology (HPO) Term 
Abnormal heart morphology Kyphosis 
Abnormality of cardiac morphology Low-set ears 
Abnormality of the hip bone Multiple prenatal fractures 
Abnormality of the respiratory system Multiple rib fractures 
Abnormality of the teeth Multiple small vertebral fractures 
Abnormality of the vertebral column Nephrolithiasis 
Autistic behaviour Osteoarthritis 
Basilar impression Osteopenia 
Basilar invagination Periosteal new bone (humeral diaphysis) 
Blue sclerae Periosteal new bone (humeral) 
Bruising susceptibility Periosteal new bone of humeral diaphysis 
Calcification of the interosseus membrane of the 
forearm 
Periosteal new bone of humerus 
Coarse humeral trabeculae Platybasia 
Coarse trabeculae (humeral) Platyspondyly 
Contractures of the joints of the lower limbs Pointed chin 
Contractures of the joints of the upper limbs Protrusio acetabuli 
Corneal perforation Scoliosis 
Craniosynostosis Sensorineural hearing impairment 
Cutis laxa Spondylolisthesis 
Dentinogenesis imperfecta Spondylolysis 
Fractures of the long bones Turricephaly 
Gastric ulcer Wormian bones 
Gastroesophageal reflux Global developmental delay 
Joint dislocation Joint hypermobility 
Table 25 HPO data model developed by the 100,000 Genomes Project Musculoskeletal GeCIP, 
Bone Fragility SubDomain 
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Our study has highlighted some potential obstacles to gaining maximum benefit from the 100,000 
Genomes Project data likely to become available for OI patients. The first is the need for a robust 
clinical dataset that allows deeper phenotyping, reducing the need for immediate clinical re-evaluation 
of the patient and their family if a variant is identified. The second is the need for improved annotation 
and filtering of sequencing data particularly splice site variants and non-coding regions, including 
regulatory elements, of the genome. Thirdly, analysis is currently focused on monogenic disease; 
there are significant interpretation challenges to identify polygenic associations and development of 
more sophisticated bioinformatics tools is indicated. Finally, even with the relatively small patient 
numbers in our study, we have identified a number of potential genes/pathways that warrant further 
analysis. As the number of candidate variants increases, during the 100,000 Genomes Project and 
beyond, there will be a growing need for more complex and functional analysis to inform variant 
causality. 
 
 
Figure 82 Flow chart showing the OBCD bone phenotyping platform. 
The aim of this workflow is to identify significant abnormal skeletal phenotypes in mouse models, in conjunction with 
the IMPC standardised phenotyping project (Freudenthal, Logan et al. 2016) 
To address some of these issues, a bone fragility sub-domain of the Musculoskeletal (MSK) 
Genomics England Clinical Interpretation (GeCIP) research group has been formed. I am the lead 
scientist for the MSK GeCIP. We have instigated a minimum data model for patient recruitment that 
provides more detailed skeletal phenotyping information than provided for the Decipher patients in 
this study (Table 25). 
We have developed an initial research investigation pipeline using BAM and VCF files and summary 
data on SNVs, small indels and copy-number variant analyses. We will use a web-based utility 
(vcf2hgvs) to convert VCF variant calls into HGVS nomenclature-compliant variant descriptions. 
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These will first be interrogated using an inheritance based approach (Strategy iii.ix.i, page 57). Genes 
showing de novo variants and other very rare variant combinations will be analysed against other OI 
patients from our existing cohort and those of our GeCIP collaborators. 
Data will be compared with candidates identified from our in-house exome studies and these 
candidates will be further explored by cell based studies through ongoing collaborations with 
colleagues in the Centre for Membrane Interaction and Dynamics (University of Sheffield). We plan to 
use zebra fish animal modelling as a screening tool for pathways/activity in both embryonic and adult 
developmental stages by collaboration with the Sheffield Zebrafish Screening Facility at the Bateson 
Centre.  
Collaboration with the extended effort to phenotype mouse models by the Origins of Bone and 
Cartilage Disease (OBCD) project, part of the International Mouse Phenotyping Consortium, will be 
ongoing. They have a comprehensive rapid throughput phenotyping platform (Figure 82) designed to 
identify the monogenic cause of bone and cartilage disease; we will focus on those genes that may 
be important to skeletal fragility. 
The data from our project has established that this approach to sequence analysis can identify novel 
causes of OI and bone fragility. An accurate genetic diagnosis can inform treatment decisions, lead to 
appropriate family counselling, improve our understanding of disease pathways and facilitate 
development of novel therapies. It also supports research into the assessment of response to therapy 
and our understanding of genotype/phenotype correlations. 
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xiii ABBREVIATIONS  
5’UTR – 5’ Untranslated Region  
AD – Autosomal-Dominant  
ADAMTS – A Disintegrin and Metalloproteinase with Thrombospondin Motifs  
ALF – Acute liver failure 
ALP – Alkaline Phosphatase 
ALPL – Alkaline Phosphatase, Liver/Bone/Kidney 
Annol – A Personalis bioinformatics tool for variant annotation 
AR – Autosomal-Recessive  
ARG – Arginine 
ARID1A –.Gene encoding the AT-rich interactive domain-containing protein 1A 
ARID1B – Gene encoding the AT-rich interactive domain-containing protein 1B 
Array CGH – Array comparative genomic hybridization 
ASP – Aspartic Acid or Aspartate  
ATF6 – Activating transcription factor 6 
B3GALT3 – Beta-1,3-N-Acetylgalactosaminyltransferase 
B3GALT6 – Beta-1,3-Galactosyltransferase 6; 
B4GALT7 – Beta-1,4-Galactosyltransferase 7 
BGN – Biglycan 
BiP – Binding Immunoglobulin Protein, also known as GRP78 and HSPA5. 
BMD – Bone Mineral Density   
BMP – Bone Morphogenetic Protein  
BMP1 – Bone morphogenic protein 1 
BMP2 – Bone morphogenic protein 2 
BMP6 – Bone morphogenic protein 6 
BRIL – Bone-Restricted Ifitm-Like Protein  
BS – Bruck Syndrome  
BSP – Bone sialoprotein 
BWA - Burrows-Wheeler Aligner 
BWA-MEM  - a BWA algorithm recommended for high quality sequence queries 
C – Carboxy  
CCD – Cleidocranial dysplasia 
CCS – Cole Carpenter Syndrome 
cDNA – Complementary DNA  
CHOP – CCAAT/enhancer binding protein 
CHST14 – Carbohydrate Sulfotransferase 14 
CNV – Copy Number Variation  
COL1A1 – Type 1 collagen, alpha 1 chain gene  
COL1A2 – Type 1 collagen, alpha 2 chain gene  
COL6A3 – Alpha-3 chain of type VI collagen 
COMP – Cartilage Oligomeric Matrix Protein  
CREB – cAMP response element-binding protein 
CREB3L1 – CAMP Responsive Element Binding Protein 3 Like 1 
CREBBP – Creb-binding protein 
CRTAP – Cartilage-Associated Protein  
CSR – Calcium sensing receptor 
CUB domain - An evolutionarily conserved protein domain of approximately 110 residues 
CyPB – Cyclophilin B  
DCN – Decorin  
DDD – Deciphering Developmental Disorders 
DECIPHER – DatabasE of genomiC variation and Phenotype in Humans using Ensembl Resources 
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DEL – Deletion  
DEXA – Dual-energy X-ray absorptiometry 
DI – Dentinogenesis Imperfecta  
DLX5 – Distal-less homeobox 5 
DMP1 – Dentine matrix protein 
DNA – Deoxyribonucleic Acid  
ECM – Extracellular Matrix  
EDS – Ehlers-Danlos Syndrome  
EDTA – Ethylenediaminetetraacetic acid 
EM – Electron Microscopy 
EP300 – Histone acetyltransferase p300 
ER – Endoplasmic Reticulum  
ERAD – ER associated degradation 
FAM20C – Family With Sequence Similarity 20, Member C 
FEVR – Familial exudative vitreoretinpathy 
FGF – Fibroblast growth factor 
FGFR – FGF/Fibroblast growth factor receptor 
FHS – Floating Harbour Syndrome 
FKBP10 – FK506-binding protein 10 
FKBP14 – FK506 binding protein 14 
FKBP65 – 65 kDa FK506 Binding Protein 10  
FZD – Frizzled transmembrane receptor family 
GAG – Glycosaminoglycan  
GATK – Genome Analysis Tool Kit 
GC-RICH – Guanine-Cytosine Rich  
gDNA – Genomic DNA  
GI – Gastrointestinal 
Gly – Glycine 
gnomAD – Genome Aggregation Database 
GO – Gene Ontology 
HGMD – Human Gene Mutation Database 
HGVS – Human Genome Variation Society 
HPO – Human Phenotype Ontology 
HSP47 – Heat Shock Protein 47  
IFITM5 – Interferon Induced Transmembrane Protein 5 
IGF – Insulin-like growth factor 
IGV – Integrative Genomics Viewer  
IMPC – International Mouse Phenotyping Consortium,  www.mousephenotype.org 
Indel – Insertion-Deletion variant  
IRE1 – Inositol-requiring enzyme 1 
LAP – Latency Associated Protein 
LH2 – Lysyl Hydroxylase 2  
LOD – Logarithmic Odds Score   
LOF – Loss of Function 
LOVD – Leiden Open Variation Database 
LOX – Lysyl Oxidase  
LOXL3 – Lysyl Oxidase Like 3 
LRP4 – Low-density lipoprotein receptor-related protein 4 
LRP5 – Lipoprotein Receptor-Related Protein 5  
LRP6 – Low-density lipoprotein receptor-related protein 6 
MAF – Minor Allele Frequency  
MBTPS1 – Membrane-Bound Transcription Factor Protease, Site 1, known as S1P 
MBTPS2 – Membrane-Bound Transcription Factor Protease, Site 2, known as S2P 
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M-CSF – Macrophage Colony Stimulation Factor   
MGP – Maritx Gla Protein 
MINT - Molecular INTeraction database 
MLBR – Major Ligand Binding Region  
MMP – Matrix Metalloproteinase   
MOWS – Mowat Wilson Syndrome 
mRNA – Messenger RNA  
MSC – Mesenchymal Stem Cell  
mTORC1 – Mammalian Target Of Rapamycin Complex 1 
MYH6 – Myosin, Heavy Chain 6, Cardiac Muscle, Alpha 
N – Amino  
NBAS – Neuroblastoma Amplified Sequence gene 
NCBI – National Centre for Biotechnology Information 
NGS – Next Generation Sequencing  
NMD – mRNA Nonsense Mediated Decay  
OASIS – Old Astrocyte Specifically Induced Substance Protein encoded by CREB3L1 
OCN – Osteocalcin 
OI – Osteogenesis Imperfecta  
OMIM – Online Mendelian Inheritance in Man 
OPG – Osteoprotegerin  
OPPG – Osteoporosis Pseudoglioma Syndrome 
OSX – Osterix  
P3H1 – Prolyl 3-Hydroxylase 1  
P4HB – Procollagen-Proline, 2-Oxoglutarate-4-Dioxygenase, Beta Subunit 
PCOLCE – Procollagen C-endopeptidase enhancer 1 
PCR – Polymerase Chain Reaction  
PDI – Protein Disulfide Isomerase 
PEDF – Pigment Epithelium-Derived Factor  
PERK – Protein Kinase R(PKR)-like ER kinase 
PHA – Pelger Huet Anomaly 
PLOD1 – Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1 
PLOD2 – Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2 
PLS3 – Plastin 3 
POSTN – Gene encoding the Periostin protein. 
PPIase – Peptidyl-Prolyl Isomerase  
PPIB – Peptidyl-Prolyl Cis-Trans Isomerase B 
PTC – Premature Termination codon 
PTH1 – Parathyroid hormone 1 
PTH1R – Parathyroid Hormone 1 Receptor 
RANKL – Receptor Activator of NF-κβ Ligand  
Reactome - (a database of reactions, pathways and biological processes 
rER – Rough Endoplasmic Reticulum  
RIDD – Regulated IRE1-dependent decay 
RNA – Ribonucleic Acid  
RUNX2 – Run-related Transcription Factor 2  
Sanger MGP – Sanger Mouse Genetics Project 
SCN11A Sodium Voltage-Gated Channel Alpha Subunit 11 
SCN8A – Sodium Voltage-Gated Channel Alpha Subunit 8 
SCN9A – Sodium voltage-gated channel alpha subunit 9 
SDGS – Sheffield Diagnostic Genetics Service 
SDS-PAGE – Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis  
SEC24D – Sec24-Related Gene Family, Member D 
SERPINF1 – Serpin Peptidase Inhibitor, Clade F, Member 1 
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SERPINH1 – Serpin Peptidase Inhibitor, Clade H, Member 1 
SKIV2L – Superkiller Viralicidic Activity 2, S. Cerevisiae, Homolog-Like 
SLC38A10 – Sodium-Coupled Neutral Amino Acid Transporter 10 also known as Solute Carrier 
Family 38, Member 10 
SLRP – Small Leucine Rich Proteoglycans  
SMAD – SMA and MAD Related Protein  
SNARE – Soluble N-Ethylmaleimide-Sensitive Factor Activating Protein Receptor Protein 
SNP – Single Nucleotide Polymorphism  
SNV – Single Nucleotide Variant 
SOPH – Short Stature, Optic Nerve And Pelguer Huet Anomaly Syndrome 
SOST – Gene Encoding The Sclerostin Protein 
SP7 – Gene encoding the Osterix protein  
SPARC – Secreted Proteins Acidic Rich in Cysteine, also known as osteonectin 
SRCAP – Snf2-Related Cbp Activator Protein 
SREBP – Sterol Regulatory Element Binding Protein 
SULF1 – Sulfatase 1 
SULF2 – Sulfatase 2 
TAPBP – Transporter Associated With Antigen Processing (TAP) Binding Protein 
TAPT1 – Transmembrane Anterior Posterior Transformation 1 protein 
TCA – The Citric Acid Cycle 
TGF-β1 – Transforming Growth Factor-Beta1  
TMEM38B – Trimeric Intracellular Cation Channel Type B 
TRAM2 – Translocation Associated Membrane Protein 2 
TRIC – Monovalent Cation-Specific Transmembrane Channel  
UGGT1 – UDP-Glucose Glycoprotein Glucosyltransferase 1 
UKGTN – UK Genetic Testing Network 
UPR – Unfolded Protein Response  
VCF – Variant Call Format, text file  
VQSR - Variant Quality Score Recalibration 
WES – Whole Exome Sequencing 
WGS – Whole Genome Sequencing 
Wnt – Wingless 
XYLT1 – Xylosyltransferase 1 
XYLT2 – Xylosyltransferase 2 
ZEB2 – Zinc Finger E-Box Binding Homeobox 2 
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A. SRCAP c.9029C>A,p.(Pro3010His) pathogenicity evaluation form 
Unclassified Variant Evaluation  
 
 Checklist to help document lines of evidence in classifying a sequence variant 
Disease Floating-Harbor 
syndrome 
Ref Seq No  Variant 
Gene SRCAP cDNA NM_006662.2 DNA c.9029C>A 
Exon 34   Protein p.Pro3010His 
 
Classification 
 
Class 1 - Neutral polymorphism   
Class 2 - Probably neutral polymorphism  
Class 3 - Unclassified variant  
Class 4 - Probably pathogenic mutation  
Class 5 - Pathogenic mutation  
CONCLUSION 
Truncating mutations in this gene are associated with Floating-Harbor syndrome (FHS), inherited in 
an autosomal dominant manner. FHS clinical features = proportionate short stature, delayed bone 
age, delayed speech development, and dysmorphic facial features: triangular face with deep-set 
eyes, long eyelashes, bulbous nose, wide columella, short philtrum, and thin lips. 
All the pathogenic FHS mutations reported to date are in the last 2 exons; exons 33 and 34.  
The variant is not listed on dbSNP and is de-novo in the proband. 
The variant is in a moderately conserved nucleotide and protein position and is within a functional 
domain of the protein. 
In silico analysis - conflicting predictions. 
This variant is of uncertain significance.  
 
 
3 
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SUMMARY 
  
Support 
pathogenicity 
 Extent of Analysis N/I 
 Population Frequency YES 
 Web-based Literature Search N/I 
 Frameshift Mutation N/A 
 In-frame Deletion or Insertion N/A 
 Nonsense Mutation N/A 
 Evolutionary Conservation NO 
 Severity of Amino Acid Substitution YES 
 Splice Site Prediction NO 
 De-Novo Variant YES 
FINAL CLASSIFICATION    1 = Neutral polymorphism  
3 
 
 2 = Probably neutral polymorphism 
 3 = Unclassified variant 
 4 = Probably pathogenic mutation 
 5 = Pathogenic mutation 
 
Extent of Analysis  
Has the entire coding sequence been analysed? blank 
Methodology (sequencing or [which] mutation scanning method) Sanger 
MLPA for deletions/duplications No 
Have other unclassified variants been characterised in this gene in this patient? No 
Classification of any other variants blank 
Is there genetic heterogeneity? Yes 
What other gene(s) has/have been analysed? All Exomes 
Have any variants been characterised in this/these gene(s)? No 
List any other variants identified N/A 
Classification of variants in these other genes N/A 
Comments – Variant identified from exome data as de-novo. 
Patient's clinical features are suggestive of Osteogenesis Imperfecta but are atypical. He has 
rhizomelia and mild immunodeficiency as well as multiple fractures. No likely causative mutation has 
been identified in genes known to be associated with OI. 
Heterozygous truncating variants in SRCAP gene are assocaited with Floating Harbor syndrome 
(autosomal dominant)  which has a skeletal phenotype of short stature. 
Does the extent of analysis support pathogenicity? N/I 
Population Frequency 
Has the UV been tested in normal controls? no 
If yes, how many?  
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Has the UV been tested in other screened patients? no 
If yes how many?  
Is the UV on NCBI dbSNP http://www.ncbi.nlm.nih.gov/pubmed  No 
Is the UV on ENSEMBL www.ensembl.org gene variation report No 
Is the UV on the ALlele FREquency Database 
http://alfred.med.yale.edu/alfred/index.asp gene variation report? 
No 
RefSNP accession number (rs#)  
Allele frequency recorded on dbSNP  
Minor Allele Count  
Population studied : 
There is no report of either this variant or any other variant at this amino acid position 
Comments   
Does population frequency support pathogenicity? YES 
 
Web-based Literature Search 
 
Search tool  Search Terms 
PubMed http://www.ncbi.nlm.nih.gov/pubmed  "SRCAP" ("9029C>A" | 
"9029C->A" | "9029C-->A" 
| "9029C/A" | 
"Pro3010His" | "P3010H") 
Google Scholar http://scholar.google.co.uk/  As above 
Google http://www.google.co.uk   As above 
Locus specific database (specify)   
DMuDB 
http://www.ngrl.org.uk/Manchester/projects/informatics/dmudb 
  
HGMD http://www.biobase-international.com/product/hgmd  SRCAP mutations 
OMIM http://www.omim.org/   
Other - specify   
 
References and comments   
This mutation not listed in the HGMD database. There are 2 missense mutation that are listed as 
?disease causing mutation and reported with an association with atrial septal defect but these are not 
in the same region as the p.Pro3010His. Other mutations in the gene are nonsense mutations 
reported in association with Floating-Harbor Syndrome and tightly clustered around the last 2 exons 
of the gene (Hood et al., 2012 Mutations in SRCAP, Encoding SNF2-Related CREBBP Activator 
Protein, Cause Floating-Harbor Syndrome. Am J Hum Genet). The p.Pro3010His is located in this 
region. 
Does review of the literature support pathogenicity? N/I 
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 Frameshift Mutation  
Does the mutation result in a shift in the reading frame? no 
Comments   
Does this support pathogenicity? N/A 
In-frame Deletion or Insertion Mutation  
Does the mutation result in an altered protein that maintains the reading frame? no 
Comments   
Does this support pathogenicity? N/A 
 
Nonsense Mutation  
Does the change result in a stop mutation? no 
Comments   
Does this support pathogenicity? N/A 
Evolutionary Conservation 
Analysis of a variant should be performed using at least three different programmes to achieve a 
consensus 
Context   http://pfam.xfam.org/ & http://www.uniprot.org/ 
Is the UV in a conserved domain?     
Nucleotide yes Amino acid yes 
Is this a functional domain?. yes 
What function?   AT hook, DNA binding domain and AT hook like  
Is the residue predicted to affect post-translational modification, disulphide bonding etc? No 
Comments      Moderately conserved nucleotide and amino acid (considering 11 species)  
 
The following programs are grouped dependent on type of tool- please use at least one from each section 
(these are in order of NGRL recommendation) 
Machine-learning (SVM) 
SNPs&GO http://snps.biofold.org/snps-and-go/ 
Method Prediction RI Probability 
PhD-SNP Neutral 5 0.249 
PANTHER Disease 3 0.672 
SNPs&GO Neutral 4 0.311 
Comments conflicitng results and low reliability  
 
Supervised-learning 
MutPred http://mutpred.mutdb.org/ 
Probability of being deleterious 0.481 
Hypotheses none 
Comment  
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Loss of catalytic residue at P3010 (P = 0.0081) 
Loss of glycosylation at P3010 (P = 0.014) 
Gain of MoRF binding (P = 0.0526) 
Loss of ubiquitination at K3012 (P = 0.1881) 
Loss of methylation at R3009 (P = 0.1902)  
Note : Only one supervised learning has returned a result.  
 
Sequence/evolutionary conservation 
PROVEAN http://provean.jcvi.org/genome_submit_2.php?species=human 
 - N.B. this tool makes PROVEAN and SIFT predictions simultaneously 
Score -2.53 
PREDICTION Deleterious 
Number of Sequences used 82 
Comments  
SIFT Analysis http://provean.jcvi.org/genome_submit_2.php?species=human 
- N.B. this tool makes PROVEAN and SIFT predictions simultaneously and gives a more confident 
prediction than SIFT through Alamut. 
SIFT score   0.000 
SIFT median conservation score 4.32 
Number of Sequences used 33 
SIFT prediction  Damaging 
Comments   
MutationAssessor http://mutationassessor.org/ 
Functional Impact Neutral 
FI score 0.695 
Comments 2/3 Sequence/evolutionary conservation tools suggest that this is a deleterious variant 
 
Protein sequence and structure based  
PolyPhen2 Analysis  http://genetics.bwh.harvard.edu/pph2/ 
HumDiv (For evaluating rare alleles)  Probably 
damaging 
HumDiv Score 0.997 
HumDiv Sensitivity and Specificity:  0.41 0.98 
HumVar (For Mendelian disease)  Probably 
damaging 
HumVar Score 0.781 
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HumVar Sensitivity and Specificity:  0.76 0.87 
Alignment checked for validity yes 
3D Visualization present? no 
Comments   
 
Does evolutionary conservation analysis support pathogenicity?  
Comments   NO 
 
Severity of amino Acid Substitution 
Russell Analysis  
Effect according to Russell http://www.russelllab.org/aas/ Disfavoured 
Degree of effect (numerical value) -2 
Amino acid comparison (Alamut) 
BLOSUM45 -2 
BLOSUM62 -2 
BLOSUM80 -4 
Grantham distance 77 
Comments : The function of the SRCAP protein is not fully characterised, Russel score has been 
taken from the 'all protein' type. 
Does severity of amino acid substitution support pathogenicity? YES 
 
Splice Site Prediction  
 
Predicted to affect splicing by SpliceSiteFinder (like) Accessed through Alamut  no 
Predicted to affect splicing by MaxEntScan; Accessed through Alamut  
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html 
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html 
no 
Predicted to affect splicing by NNSplice (FruitFly); Accessed through Alamut  
http://www.fruitfly.org/seq_tools/splice.html 
no 
Predicted to affect splicing by GeneSplicer; Accessed through Alamut 
http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml 
no 
Predicted to affect splicing by Human Splicing Finder; Accessed through Alamut 
http://www.umd.be/HSF3/ 
no 
Comments:  No significant effect on splicing predicted 
Do predicted splicing effects support pathogenicity? NO 
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  De-Novo Variant 
Is father unaffected? Yes 
Does father carry UV? No 
Has paternity been confirmed ?(PowerPlex 16 assay) No 
Is mother unaffected?  Yes 
Does mother carry UV? No 
Has germline mosaicism been reported for this disorder? No 
Comments – Likely de-novo 
Do parental studies support pathogenicity  YES 
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B. Patient phenotypes and variants evaluated in the DDD CAP12 study 
Highlighted variants (Pink) were reported by Decipher (DDD) to the patients referring clinician as potentially causative of the patient’s symptoms. 
 
 
Patient Phenotype 
S
tudy  
ID
 
D
ecipher 
 ID
 
C
hr Location Gene Notes Consequence ref/alt 
alleles 
trio_ 
genotype 
Bowing of limbs due to multiple 
fractures, Fractured hand bones, 
Pathologic fracture 
101 258358 1 109271328 FNDC7 c.1451_1453del;p.(Asp484del). Also 
heterozygous for GLI3 
c.2179G>A;p.(Gly727Arg)  variants reported as 
pathogenic and associated with Postaxial 
polydactyly A/B but  present in up to 1% of 
population and described as benign. 
In frame 
deletion 
AATG/A 1/0/0 
Abnormality of the radius, Blue sclerae, 
Multiple rib fractures, Pathologic 
fracture, Plagiocephaly, Thoracic 
kyphosis, Vertebral compression 
fractures 
102 259467 2 86285812 86509436 CNV reported Ratio 0.504374. DUPLICATION. 
Genes in region: IMMT - mitochondrial protein" 
"REEP1 - AD HSP" 
"PTCD3 - mitochondrial protein" 
"SNORD94 - small nuclear RNA" 
"POLR1A - AD Acrofacial dysostosis, 
Cincinnati type. A ribosomopathy characterized 
by a spectrum of mandibulofacial dysostosis 
phenotypes, with or without extra facial skeletal 
defects (Weaver et al 2015) including severe 
conductive hearing loss, short stature. 
congenital short, bowed femurs with 
metaphyseal flaring, dysplastic acetabula, and 
delayed or absent ossification of the capital 
Large 
duplication 
  1/0/1 
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femoral epiphyses" 
"MIR4779 - micro RNA" 
"MRPL35 - mitochondrial ribosomal RNA" 
3 38739788 SCN10A c.4923G>T;p.(Met164Ile). Gene associated 
with Brugada syndrome. Polymorphisms assoc 
with atrial fibrillation. 
Missense 
variant 
C/A 1/0/1 
Abnormality of the helix, Joint laxity, 
Low-set ears, Narrow foot, Narrow 
mouth, Plagiocephaly, Recurrent 
fractures, Scoliosis, Seizures, Slanting 
of the palpebral fissure 
103 260858 16 89350233 ANKRD11 Reported by DDD. Gene associated with KBG 
syndrome= devdel, short stature and skeletal 
abnormalities. BUT not associated with 
recurrent fractures. LIKELY BENIGN, 
maternally inherited. 
Missense 
variant 
C/A 1/NA/NA 
7 40039066 CDK13 Reported by DDD. PATHOGENIC mutation 
reported in association with congenital heart 
disease, devdel, clinodactyl and hyper mobility. 
Sifrim et al Nat Genet 2016 – DDD publication. 
DE-NOVO 
Missense 
variant 
G/A 1/NA/NA 
15 51834626 DMXL2 0.003% in gnomAD. ? Associated with AD 
deafness. Not consistent with reported patient 
phenotype. 
Missense 
variant 
C/T 1/NA/NA 
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7 154672650 DPP6 c.2131A>T; p.(Lys711*).Not reported. Disease 
- Mental retardation, autosomal dominant 33 - 
microcephaly and variable mental retardation. 
Loss of function mutations cause this (Liao, C., 
Fu, F., Li, R., Yang, W., Liao, H., Yan, J., Li, J., 
Li, S., Yang, X., Li, D. Loss-of-function variation 
in the DPP6 gene is associated with autosomal 
dominant microcephaly and mental retardation. 
Europ. J. Med. Genet. 56: 484-489, 2013). 
Stop gained A/T 1/NA/NA 
15 101566237 LRRK1 c.2300G>T;p.(Arg767Leu). GO biological 
processes included: bone resorption, 
intracellular signal transduction, negative 
regulation of peptidyl-tyrosine phosphorylation, 
osteoclast development, positive regulation of 
canonical Wnt signalling pathway, positive 
regulation of intracellular signal transduction. 
BUT present in 2/120712 alleles in gnomAD  
Missense 
variant 
G/T 1/NA/NA 
16 81213294 PKD1L2 PKD gene Missense 
variant 
G/C 1/NA/NA 
15 67457239 SMAD3 Reported by DDD, stop_gained. Loeys Dietz 3 
syndrome. May get early onset osteoarthritis. 
BENIGN as alternate transcript. 
Stop gained G/A 1/NA/NA 
Disproportionate short stature, 
Hypoplasia of dental enamel, Limited 
elbow extension, Moderate generalized 
osteoporosis, Skeletal dysplasia 
104 262876 17 27963096 SSH2 De novo c.2152G>A;p.(Val718Met). Protein 
tyrosine phosphatase that play a key role in the 
regulation of actin filaments. SSH2=exomizer 
gene. 
Missense 
variant 
C/T 1/0/0 
2-3 toe syndactyly, Abnormality of male 
external genitalia, Bilateral single 
105 263310 5 177031401 B4GALT7 Reported by DDD, c.277dupC;p.(His93fs). 
Paternally inherited 
frameshift G/GC 1/0/1 
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transverse palmar creases, Cleft 
palate, Gastroesophageal reflux, 
Generalized hypotonia, 
Hemimegalencephaly, Hypermetropia, 
Lumbar hemivertebrae, Micrognathia, 
Mild short stature, Optic nerve 
hypoplasia, Osteopenia, Radioulnar 
synostosis, Ventriculomegaly, 
Vertebral compression fractures 
5 177035541 B4GALT7 Reported by DDD, c.641G>A;p.(Cys214Tyr). 
Maternally inherited 
Missense 
variant 
G/A 1/1/0 
Abnormality of taste sensation, 
Constipation, Hyperhidrosis, Impaired 
pain sensation, Lacrimation 
abnormality, Muscle weakness, 
Painless fractures due to injury, 
Urticaria 
106 263659 X 70360588 MED12 Reported by DDD, c.736_741del; 
p.(Gln249_Gln250del) inframe_deletion. Gene 
associated with Opitz-Kaveggia syndrome 
(305450), also known as FG syndrome, is an 
X-linked disorder characterized by mental 
retardation, relative macrocephaly, hypotonia, 
and constipation. ClinVar likely benign - in poly 
Gln tract. 
In frame 
deletion 
G/GAG
CAGC 
1/1/0 
2 167056281 SCN9A c.4835T>G; p.(Leu1612Arg). SCN9A=HPO 
gene congenital insensitivity to pain - 
autosomal recessive, no other likely deleterious 
variants identified  (p.Leu1612Pro reported in 
Paroxysmal extreme pain disorder). Mutation at 
this codon associated with paroxysmal extreme 
pain disorder. Gene also associated with 
congenital insensitivity to pain. 
Missense 
variant 
A/C 1/0/0 
Abnormality of T cells, Bilateral 
cryptorchidism, Eczema, Glandular 
hypospadias, Hypoplasia of the corpus 
callosum, Intellectual disability, 
moderate, Low-set ears, Microcephaly, 
107 264065 2 233399868 CHRND Associated with lethal multiple pterguim 
syndrome characterised by arthrogryposis, fetal 
akenesis and hydrops 
Missense 
variant 
G/A 2/NA/NA 
21 47532415 COL6A2 Bethlem myopathy : patient does not have and 
present in 0.013% AA popn. 
Missense 
variant 
G/A 1/NA/NA 
201 
 
Micrognathia, Micropenis, Microtia, 
Osteopenia, Osteoporosis of vertebrae, 
Primary adrenal insufficiency, Severe 
short stature, Short foot, Stenosis of 
the external auditory canal 
20 46290600 SULF2 c.2411A>G;p.(Asn804Ser). GO biological 
process include: bone development, embryonic 
skeletal development, heparan sulphate 
proteoglycan metabolic process. Geneatlas 
basic functions include:SULF1, SULF2 plays 
an important role in the development of the 
inner ear. gnomAD freq 1 in 240358 alleles. 
SUF2 variant also in patient 265826 
Missense 
variant 
T/C 1/NA/NA 
11 122647887 UBASH3B c.371Tdel;p.(Phe124fs). GO biological process: 
collagen-activated tyrosine kinase receptor 
signalling pathway, negative regulation of bone 
resorption, negative osteoclast differentiation. 
Expressed in bone, immune system, 
reproductive and platelets. Gene atlas - 
suppression of T-cell receptor signalling. 
Critical regulator of the signalling pathways that 
regulate T-cell activation. pLI=0.99.We 
consider pLI >= 0.9 as an extremely LoF 
intolerant set of genes. 
Frameshift 
variant 
TC/T 1/NA/NA 
2 145157542 ZEB2 c.1212G>T;p.(Met404Ile). Reported by DDD, 
missense_variant. Associated with Mowat-
Wilson syndrome. Complex dev del disorder, 
not assoc with bone fragility 
Missense 
variant 
C/A 1/NA/NA 
Ataxia, Blue sclerae, Delayed speech 
and language development, Global 
developmental delay, Horizontal 
nystagmus, Joint hypermobility, Poor 
coordination, Recurrent fractures 
108 264081 17 48267063 COL1A1 Reported by DDD- pathogenic mutation, stop 
gained. Inherited from mother. 
c.2644C>T;p.(Arg882*) 
Stop gained G/A 1/1/0 
2 166797557 TTC21B AR Short-rib thoracic dysplasia 4 with or 
without polydactyly  
Missense 
variant 
C/G 1/1/0 
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Microcephaly, Osteopenia, Ovarian 
cyst, Specific learning disability, 
Tetralogy of Fallot 
109 264182 X 41205786 DDX3X c.1526A>T;p.(Asn509Ile). Reported de-novo 
missense-variant. XLD mental retardation s-
linked type 102. Below average general 
intellectual functioning associated with 
impairments in adaptive behaviour and 
manifested during the developmental period. 
Additionally, patients manifest variable non-
neurologic features such as joint hyperlaxity, 
skin pigmentary abnormalities, cleft lip and/or 
palate, hearing and visual impairment, and 
precocious puberty. Previously reported 
pathogenic (Snijders Blok (2015) Am J Hum 
Genet 97: 343)  
Missense 
variant 
A/T 1/0/0 
Abnormality of the face, Asymmetry of 
spinal facet joints, Increased 
susceptibility to fractures, Joint 
hypermobility, Pes planus, Specific 
learning disability 
110 264424 17 48263382 COL1A1 Reported by DDD, splice _variant. C.4006-
1G>T 
Splice variant C/A 1/NA/NA 
17 80789837 ZNF750 c.494T>C;p.(Val165Ala). Reported by DDD, 
missense_variant. Seborrhea-like dermatitis 
with psoriasiform elements - inheritance not 
stated in OMIM. No skeletal phenotype 
reported. One frameshift mutation described in 
HGMD.  
Missense 
variant 
A/G 1/NA/NA 
Abnormality of upper lip, Drooling, 
Generalized seizures, Global 
developmental delay, Intellectual 
disability, severe, Involuntary 
movements, Microcephaly, Nystagmus, 
Osteopenia, Postnatal microcephaly, 
Reduced bone mineral density, Thick 
upper lip vermilion 
111 264568        
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Decreased antibody level in blood, 
Elevated hepatic transaminases, 
Hypoglycaemia, IgA deficiency, IgG 
deficiency, Increased susceptibility to 
fractures, Ligamentous laxity, 
Nystagmus, Osteopenia, Progeroid 
facial appearance, Progressive cone 
degeneration, Recurrent fractures, 
Wide anterior fontanel 
112 264693 2 15378794 NBAS Reported, c.5741G>A;p.(Arg1914His) Missense 
variant 
C/T 1/1/0 
2 15607518 NBAS Reported stop_gained, c.2032C>T;p.(Gln678*) Stop gained G/A 1/0/1 
Blue sclerae, Ligamentous laxity, 
Recurrent fractures 
113 264830 11 67258406 AIP Gene causes a benign hormone-secreting 
adenoma - Clinical manifestations of Cushing 
syndrome include facial and obesity, abdominal 
striae, muscular weakness, osteoporosis, 
arterial hypertension, diabetes 
Missense 
variant 
G/A 1/NA/NA 
8 27657118 ESCO2 Gene associated with AR Roberts syndrome. 
Rare autosomal recessive disorder 
characterized by pre- and postnatal growth 
retardation, microcephaly, bilateral cleft lip and 
palate, and mesomelic symmetric limb 
reduction. 
Missense 
variant 
A/G 1/NA/NA 
1 22168854 HSPG2 Gene associated with Autosomal recessive: 
Dysegmental dysplasia, Silverman-Handmaker 
type and Schwartz-Jampel syndrome, type 
1(lethal forms of neonatal short-limbed 
dwarfism) 
Missense 
variant 
C/T 1/NA/NA 
9 140347297 NSMF Variant is intronic in major transcript with no 
predicted affect on splicing. 
Missense 
variant 
G/A 1/NA/NA 
16 30732293 SRCAP Reported missense_variant. 
c.3247C>T;p.(Pro1083Ser). 12/28456 South 
Asian alleles, not in mutation hotspot region. 
Missense 
variant 
C/T 1/NA/NA 
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Cafe-au-lait spot, Generalized 
dystonia, Global developmental delay, 
Osteopenia, Reduced bone mineral 
density, Seizures, Status epilepticus 
  
114 265503 5 156920055 ADAM19 Uni-Prot May be involved in osteoblast 
differentiation and/or osteoblast activity in 
bone. 4/126710 alleles in Europeans. pLI 0.00. 
Decipher has 12 individuals with loss of one 
copy of this gene, none with skeletal.   
Stop gained G/A 1/NA/NA 
6 75862094 COL12A1 c.3670C>T;p.(Arg1224Cys) Gene - 
Ullrich/Bethlem -AD, missense mutations 
reported as pathogenic. This variant present in 
7/276644 alleles therefore unlikely pathogenic. 
Missense 
variant 
G/A 1/NA/NA 
6 70962012 COL9A1 c.1771A>G; p.(Thr591Ala). Present in 1 in 
33552 Latino. Gene assoc with stickler 
syndrome (AR) - Bones are affected by slight 
platyspondylisis and large, often defective 
epiphyses. Also gene may be assoc with MED6 
(AD) -Joint pain, joint deformity, waddling gait, 
and short stature are the main clinical signs 
and symptoms. Radiological examination of the 
skeleton shows delayed, irregular 
mineralization of the epiphyseal ossification 
centers and of the centers of the carpal and 
tarsal bones. NO second likely pathogenic 
mutation identified. 
Missense 
variant 
A/G 1/NA/NA 
3 33155582 CRTAP Not reported. c.13C>A;p.(Arg5Ser). 
Monoallelic. Mainly LOF mutations described - 
unlikely to be causative in this individual. No 
likely 2nd mutation in VCF. 
Missense 
variant 
C/A 1/NA/NA 
X 48652207 GATA1 Disease - X-linked dyserythropoietic anaemia 
and thrombocytopenia 
Missense 
variant 
G/A 1/NA/NA 
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12 52200885 SCN8A Reported missense_variant. Disease=Epileptic 
encephalopathy, early infantile, 13 (EIEE13) a 
disorder characterized by markedly delayed 
cognitive and motor development, attention 
deficit disorder, and cerebella ataxia. 
 c.5615G>A;p.(Arg1872Gln) reported 
pathogenic mutation in assoc with AD epileptic 
encephalopathy 
Missense 
variant 
G/A 1/NA/NA 
Few cafe-au-lait spots, Gait ataxia, 
Generalized hypotonia, Global 
developmental delay, Pectus 
excavatum, Preaxial hand polydactyly, 
Recurrent fractures 
115 265512 X 118975168 UPF3B Reported de novo frameshift_variant. Assoc 
with X-linked recessive mental retardation 
Frameshift 
variant 
TTTTC/
T 
2/0/0 
Abnormality of eye movement, 
Agammaglobulinemia, Feeding 
difficulties in infancy, 
Gastroesophageal reflux, Generalized 
myoclonic seizures, Global 
developmental delay, Infantile axial 
hypotonia, Inguinal hernia, Multiple rib 
fractures, Optic disc pallor, Recurrent 
respiratory infections, Vertebral 
compression fractures, Wormian bones 
116 265802 22 41573186 COL10A1 COL10A1 c.880G>A;p.(Gly294Arg) - in triple 
helix but this is not where mutations are 
reported in MED. Also other glycine 
substitutions reported in gnomAD data = 
doesn't support pathogenicity. 
COL10A1=skeletal dysplasia gene (panel app) 
Missense 
variant 
G/A 1/0/0 
Abnormal facial shape, Constipation, 
Global developmental delay, Increased 
susceptibility to fractures, 
Microcephaly, Polyhydramnios, Sleep 
disturbance, Unilateral deafness 
  
117 265826 17 80403807 C17orf62 c.231G>A, synonymous change in major 
transcript, no splice effect predicted. V low 
frequency 0.0048%. 
Missense 
variant 
C/T 1/NA/NA 
12 75698578 CAPS2 c.794_795del;p.(Met265Asnfs*6) - candidate 
gene for intellectual disability.  
Frameshift 
variant 
CA/C 1/NA/NA 
2 238285643 COL6A3 AD/AR Bethlem myopathy 
c.2842G>T;p.(Val948Phe). Only 0.0015% in 
Missense 
variant 
C/A 1/NA/NA 
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Eur pop (1 allele). 
16 67645346 CTCF c.612_615del;p.(Lys206fs). Reported 
frameshift_variant, Mental retardation, 
autosomal dominant 21 
frameshift CAAAG/
C 
1/NA/NA 
12 49422934 KMT2D c.1416C>T;p.(Arg4721Cys) Reported 
missense_variant. Gene associated with AD 
Kabuki syndrome = congenital mental 
retardation syndrome with additional features, 
including postnatal dwarfism, a peculiar facies 
characterized by long palpebral fissures with 
eversion of the lateral third of the lower eyelids,  
a broad and depressed nasal tip, large 
prominent earlobes, a cleft or high-arched 
palate, scoliosis, short fifth finger, persistence 
of finger pads, radiographic abnormalities of 
the vertebrae, hands, and hip joints, and 
recurrent otitis media in infancy 
Missense 
variant 
G/A 1/NA/NA 
2 15506745 NBAS c.3776C>T; p.(Ser1259Phe), low quality score 
in VCF. ? False positive. No other likely 2nd 
mutation in VCF. Clinical features not 
suggestive of this gene being causative 
Missense 
variant 
G/A 1/NA/NA 
11 70798909 SHANK2 c.64G>T;p.(Ala22Ser). Reported 
missense_variant. Gene associated with 
autism susceptibility 
Missense 
variant 
    
20 46319020 SULF2 c.587T>C;p.(Ile196Thr). No frequency data. 
GO biological processes include: bone 
development, heparan sulfate proteoglycan 
metabolic process, positive regulation of WNT 
signalling. Look at GeneAtlas function info. 
Gene also in another patient. 
Missense 
variant 
A/G 1/NA/NA 
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PolyPhen=possibly damaging(0.809), 
SIFT=deleterious(0.03) 
2 128910450 UGGT1 c.371Tdel;p.(Phe124fs) From UniProt: 
Recognizes glycoproteins with minor folding 
defects. Reglucosylates single N-glycans near 
the misfolded part of the protein, thus providing 
quality control for protein folding in the 
endoplasmic reticulum 
Frameshift 
variant 
A/AC 1/NA/NA 
Bilateral sensor neural hearing 
impairment, Bruising susceptibility, 
Cavernous hemangioma, Deeply set 
eye, Highly arched eyebrow, 
Intellectual disability, Mandibular 
prognathia, Mild postnatal growth 
retardation, Osteopenia, Petechiae, 
Short lingual frenulum 
118 265937 22 41573186 EP300 c.5471A>C;p.(Gln1824Pro). Reported De-novo 
AD Rubinstein-Taybi syndrome 2 (RSTS2) 
craniofacial abnormalities, postnatal growth 
deficiency, broad thumbs, broad big toes, 
mental retardation and a propensity for 
development of malignancies. Decipher = likely 
pathogenic and partially explains clinical 
phenotype.  
Missense 
variant 
A/C 1/0/0 
Absence seizures, Absent speech, 
Camptodactyly of finger, Episodic 
hypoventilation, Generalized tonic-
clonic seizures, Global developmental 
delay, Hyperacusis, Intellectual 
disability, profound, Knee flexion 
contracture, Kyphosis, Motor delay, 
Narrow foot, Osteoporosis, Short foot 
119 269622        
Cerebellar hypoplasia, Cortical visual 
impairment, Hip dislocation, 
Microcephaly, Recurrent pneumonia, 
Scoliosis, Seizures, Severe 
generalized osteoporosis, Severe 
global developmental delay 
120 270466 X 41674114 41788517 CNV reported Ratio -1.783055. Loss. Gene is 
CASK, associated with XLD Mental retardation 
and microcephaly with pontine and cerebellar 
hypoplasia. 
Large deletion  1/0/0 
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Adducted thumb, Cubitus valgus, 
Dysarthria, Gait ataxia, Gait 
disturbance, High palate, 
Hypocalcemia, Increased susceptibility 
to fractures, Long face, Long fingers, 
Long foot, Osteoporosis, Pes planus, 
Reduced bone mineral density, 
Scoliosis, Slender finger, Tall stature 
121 270572 X 153999050 DKC1 c.932A>T:p.(Tyr311Phe). Reported - 
missense_variant, brother of DDDP107936. 
Dyskeratosis congenica, X-linked (DKCX). A 
rare, progressive bone marrow failure 
syndrome characterized by the triad of 
reticulated skin hyperpigmentation, nail 
dystrophy, and mucosal leukoplakia. Early 
mortality is often associated with bone marrow 
failure, infections, fatal pulmonary 
complications, or malignancy. Symptoms can 
include osteoporosis - HPO:0002659 -
susceptibility to fractures. 
Missense 
variant 
A/T 2/1/0 
21 44486410 CBS Also heterozygous for CBS 
c.394C>T;(p.Arg132Cys). ClinVar submission - 
likely pathogenic (updated 2nd May 2016 - now 
uncertain significance). Very low frequency 
data. AR homcysteineurea. Affected individuals 
are often tall and slender and have Marfanoid 
habitus. Prone to osteoporosis.  Some 
controversy about whether carriers have an 
increased risk of cardiovascular disease. 
Missense 
variant 
C/T 1/0/1 
1 43213881 P3H11 Also heterozygous for P3H1 
c.1828C>T;p.(Arg610Cys). Only found in 2 
alleles in 119078. Polyphen pathogenic. 
Brother does not have this variant. 
Missense 
variant 
C/T 1/1/0 
20 60892813 LAMA5 c.7261C>T;p.(Arg2421Trp). Present in 
97/269372 alleles but no homozygotes. 
GeneAtlas: function includes: stimulates 
osteogenic gene expression in mesenchymal 
stem cells, in the absence of any other 
osteogenic stimulus (Klees 2007) • activates 
Missense 
variant 
G/A 1/0/1 
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extracellular matrix production and osteogenic 
gene focusing in human mesenchymal stem 
cells (Klees 2007) 
20 60901773 LAMA5 c.5258C>T;p.(Thr1753Met). Present in 
52/276498 allele and one homozygote 
Missense 
variant 
G/A 1/1/0 
Athetoid cerebral palsy, Gait 
disturbance, High palate, Increased 
susceptibility to fractures, Long foot, 
Macrotia, Moderate global 
developmental delay, Osteoarthritis, 
Osteopenia, Relative macrocephaly, 
Slender finger, Tall stature 
  
122 270575 5 14751270 ANKH Reported De-novo initiator_codon_variant UV 
c.595A>G;p.(Met199Val) Autosomal dominant 
inheritance of Craniometaphyseal dysplasia 
and chondrocalcinosis 
Missense 
variant 
T/C 1/0/0 
X 153999050 DKC1 missense_variant, brother of DDDP100275 Missense 
variant 
A/T 2/1/0 
20 60892813 LAMA5 See brother's results above (patient 121). Missense 
variant 
G/A 1/0/1 
20 60901773 LAMA5 See brother's results above (patient 121). Missense 
variant 
G/A 1/1/0 
Abnormality of the pinna, Alopecia of 
scalp, Congenital sensorineural 
hearing impairment, Fractures of the 
long bones, Premature ovarian failure, 
Short stature 
123 271487 21 47783795 PCNT Mutations in this gene cause Seckel syndrome-
4 and microcephalic osteodysplastic primordial 
dwarfism type II.  
In frame 
insertion 
C/CCTT 1/1/0 
21 47783796 PCNT AR inheritance - this region of gene has 
deletions reported in GnomAD, these changes 
both 0.028%. These two changes are called 
next to each other and probably represent one 
change that is miss called. Both in-frame. 
Unlikely pathogenic. 
I nframe 
deletion 
TGCG/T 1/1/1 
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Generalized seizures, Growth hormone 
deficiency, Hip dislocation, Moderate 
generalized osteoporosis, Severe 
global developmental delay, Short 
stature, Thoracolumbar scoliosis 
124 274096 1 27835713 28494006 CNV reported. Ratio -0.764081 LOSS. Genes 
in region include AHDC1 associated with Xia-
Gibbs syndrome - hypotonia, and delayed 
psychomotor development with absent or poor 
expressive language. Mild dysmorphic features 
were present, including low-set or protuberant 
ears, flat nasal bridge, hypertelorism, up- or 
down slanting palpebral fissures, and 
micrognathia. Also sleep apnoea. 
Large deletion   
Astigmatism, Deeply set eye, Delayed 
speech and language development, 
Gastroesophageal reflux, Global 
developmental delay, High anterior 
hairline, Increased susceptibility to 
fractures, Large for gestational age, 
Narrow chest, Poor gross motor 
coordination, Seizures, Triangular face 
125 274310 1 153800509 GATAD2B c.314_315insA;p.(Asp106fs). Reported 
frameshift_variant. AD mental retardation with 
dysmorphic features including hypertelorism 
and narrow palpebral fissures. LoF mutations 
Frameshift 
variant 
C/CT 1/0/0 
3 168834157 MECOM AD Radioulnar synostosis with 
amegakaryocytic thrombocytopenia 2 
Missense 
variant 
G/C 1/1/0 
3 168840462 MECOM AD Radioulnar synostosis with 
amegakaryocytic thrombocytopenia 2 
Missense 
variant 
T/C 1/0/1 
Autistic behaviour, Easy fatigability, 
Hemihypotrophy of lower limb, Narrow 
chest, Osteopenia, Rocker bottom foot, 
Short lower limbs, Tapered finger 
126 274716        
Campodactyly of finger, Dislocated 
wrist, Osteoporosis, Pes cavus, 
Scoliosis, Severe Myopia 
127 276443   PLOD1 Osteoporosis, scoliosis, pes cavus, severe 
myopia. No fractures.  Heterozygous for the 
c.153dup;p.(Asn52fs). Known mutation 
associated with kyphoscoliotic EDS. Can we 
test for common duplication in this patient or do 
urine cross-links? 
frameshift, G/A 1/0/0 
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Abnormality of blood circulation, Aortic 
regurgitation, Asthma, Bronchiectasis, 
Fine, reticulate skin pigmentation, 
Generalized osteoporosis with 
pathologic fractures, Genu valgum, 
Glaucoma, Migraine, Myopia, 
Otosclerosis, Severe generalized 
osteoporosis, Short foot, Slender build, 
Slender finger, Slender toe, Thin skin 
128 276614 9 123808662 C5 Splice donor variant c.66-1 G>T NM_001735.2 
inherited from mother. Complement component 
5 deficiency (C5D) autosomal dominant. A rare 
defect of the complement classical pathway 
associated with susceptibility to severe 
recurrent infections, predominantly by 
Neisseria gonorrhoea or Neisseria meningitidis. 
NO report of any bone phenotype - probably 
incidental finding. 
splice_variant C/A 1/1/0 
16 89259925 CDH15 c.1904del;p.(Gly636fs) Reported by DDD 
missense_variant. AD autism gene.  
Frameshift CG/C 1/1/0 
14 21896152 CHD8 Gene associated with Mental Retardation, 
Autosomal Dominant 3; MRD3 
Missense 
variant 
G/T 1/1/0 
11 103026129 DYNC2H1 AR inheritance - short-rib thoracic dysplasia-3 
with or without polydactyly (SRTD3; 613091). 
Missense 
variant 
C/T 1/0/1 
21 46021438 KRTAP10-
7 
Gene known as TSPEAR. Involvement in 
disease 
Deafness, autosomal recessive, 98 (DFNB98)1 
Publication 
A form of non-syndromic sensorineural hearing 
loss with prelingual onset. Sensorineural 
deafness results from damage to the neural 
receptors of the inner ear, the nerve pathways 
to the brain, or the area of the brain that 
receives sound information. NOT listed as 
associated with bone phenotype.  
Missense 
variant 
C/T 1/1/0 
17 79268721 SLC38A10 ? Candidate gene UniProt Go biological 
process: bone development.c.1A>G;p.(Met1?) 
SLC38A10=Mice weak + brittle gene. GnomAD 
allele frequency 4 in 118,638 but pLI= 0.00 The 
Initiator codon 
variant 
T/C 1/1/0 
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closer pLI is to one, the more LoF intolerant the 
gene. Maternally inherited, mum has 
osteoporosis, otosclerosis, abnormal kidney 
2 96955598 SNRNP20
0 
c.2879C>T;p.(Ala960Val). UniProt GO 
biological process=osteoblast differentiation. 
Gene associated with Retinitis Pigmentas 33 
(autosomal dominant). This gene 1-2%of AD 
RP. Missense mutations in HGMD - this variant 
listed as unknown significance (Ellingford et al 
J Med Genet. 2016 Nov; 53(11): 761–767). Our 
patient has some optic clinical features but 
variant inherited from mum who doesn't have 
any optical features. 
Missense 
variant 
G/A 1/1/0 
Dilation of lateral ventricles, 
Generalized joint laxity, Intellectual 
disability, moderate, Postnatal 
macrocephaly, Recurrent fractures 
129 277040 19 50436333 ATF5 c.833G>A;p.(Arg278Lys). UniProt: Function: 
May be involved in osteogenic differentiation 
(PubMed:22442021). Inherited from mum who 
has no symptoms. 
Missense 
variant 
G/A 1/0/1 
1 9804609 CLSTN1 Induces KLC1 association with vesicles and 
functions as a cargo in axonal transport 
Missense 
variant 
C/T 1/0/1 
22 41546158 EP300 Freq data =benign Missense 
variant 
C/A 1/0/1 
22 41574510 EP300 Freq data =benign Intron variant TCAG/T 1/1/0 
7 50514031 FIGNL1 c.954del;p.(Ser319fs). UniProt function: May 
regulate osteoblast proliferation and 
differentiation. Inherited pLI=0.00 
Frameshift 
variant 
AC/A 1/1/0 
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11 102707247 MMP3 GO function: Can degrade fibronectin, laminin, 
gelatins of type I, III, IV, and V; collagens III, IV, 
X, and IX, and cartilage proteoglycans. 
Activates procollagenase. Polymorphism in 
gene associated with increased risk of coronary 
artery disease. BUT this a deeply intronic 
change with allele frequency 0.0038% 
Regulatory 
region variant 
G/A 1/1/0 
2 167055749 SCN9A c.5367_5368insGAGAACTCTAT;p.(Lys1790fs)
.Pain disorders (AR); epilepsy with febrile 
seizures (AD); primary erythermalgia (AD). 
Inherited from mum - ? LOF mutations not 
pathogenic. No 2nd likely mutation identified. 
Frameshift 
variant 
A/AGAG
AACTC
TAT 
1/1/0 
16 3642722 SLX4 c.2305C>G. Fanconi anaemia (P) Some 
individuals affected by Fanconi anaemia of 
complementation group P have skeletal 
anomalies. Clinical features of patient don't 
indicate Fanconi's phenotype. 267/276130 
alleles, one homozygotes. 
Missense 
variant 
C/G 1/0/1 
16 3645688 SLX4 c.1931A>C;p.(Asp644Ala) no frequency data. Missense 
variant 
T/G 1/1/0 
Aplasia/Hypoplasia of the patella, 
Fractures of the long bones, Limited 
elbow flexion/extension, Proximal 
placement of thumb, Radial head 
subluxation 
  
  
130 277078   MYO7  c.731G>A; p.(Arg244His) associated with non-
syndromal  deafness and retinosa pigmentosa 
(RP). None of these symptoms reported in this 
patient.  
Missense 
variant 
C/T 2/1/1 
8 145740620 RECQL4 c.1379C>T;p.(Pro466Leu). Reported 
missense_variant. Rothmund–Thomson (RTS), 
RAPADILINO and Baller–Gerold (BGS), are 
characterized by growth retardation and radial 
defects, but RAPADILINO syndrome lacks the 
main dermal manifestation, poikiloderma that is 
Missense 
variant 
G/A 1/0/1 
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a hallmark feature in both RTS and BGS 
8 145741453 RECQL4 c.1048_1049del;p.(Arg350fs). Reported 
frameshift_variant. Compound heterozygote - 
considered to fully explain patients phenotype 
in Decipher. 
Frameshift CCT/C 1/1/0 
Broad-based gait, Cone/cone-rod 
dystrophy, Global developmental 
delay, Horizontal pendular nystagmus, 
Open mouth, Osteoporosis, Reduced 
visual acuity, Seizures, Short philtrum, 
Ventriculomegaly, Wide nose 
  
131 277867 15 89382022 ACAN c.199G>A;p.(Ala67Thr). Reported probable 
SNP 0.19% AD Osteochondritis dissecans, 
short stature, and early-onset osteoarthritis. 
Clinical phenotype doesn't fit. 
Missense 
variant 
G/A 1/0/1 
15 89386826 ACAN c.998A>G;p.(Asn333Ser) AD 
Spondyloepimetaphyseal dysplasia, aggrecan 
type and Kimberley type. Inherited from 
unaffected parent. 0.0056% in European. 
Skeletal dysplasia characterized by shortening 
of the trunk and limbs 
Missense 
variant 
A/G 1/1/0 
Anteverted nares, Aplasia/Hypoplasia 
of fingers, Aplasia/Hypoplasia of the 
distal phalanges of the toes, 
Atrioventricular canal defect, Cone-
shaped epiphysis, Delayed speech and 
language development, Gastrostomy 
tube feeding in infancy, Global 
developmental delay, Growth 
abnormality, High anterior hairline, 
Intrauterine growth retardation, Long 
philtrum, Nasogastric tube feeding in 
132 278587 20 57478742 GNAS c.2257A>G;p.(Met753Val). Reported 
missense_variant. McCune-Albright syndrome 
= symptoms include: Pathologic fracture or 
bone deformity may be presenting 
manifestations and pseudarthrosis occurs 
frequently. Deafness and blindness can result 
from impingement of the bony process on the 
cranial foramina.  
Missense 
variant 
A/G 1/0/0 
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infancy, Osteopenia, Prenatal 
movement abnormality, Recurrent 
respiratory infections, Short stature, 
Synophrys 
Abnormal emotion/affect behaviour, 
Autistic behaviour, Blue sclerae, 
Fractures of the long bones, Muscular 
hypotonia, Short stature, Sleep 
disturbance 
  
133 281522 19 18893921 COMP c.2170G>A;p.(Val724Ile0. Reported 
missense_variant. Gene associated with 
MED1. COMP protein is a pentameric 
extracellular matrix protein that catalyzes the 
assembly of collagens and promotes formation 
of well-defined fibrils. Present in 0.006% of AA 
population in gnomAD. Phenotype includes: 
skeletal dysplasias pseudoachondroplasia and 
multiple epiphyseal dysplasia 
Missense 
variant 
C/T 1/1/0 
22 41573804 EP300 c.6089A>G;p.(Gln2030Arg). Reported 
missense_variant. No frequency data. 
Missense 
variant 
A/G 1/1/0 
4 5720973 EVC c.175-2A>G. Reported as disease causing 
mutation ins Ellis-van Creveld syndrome 
(EVC)(Valencia (2009) Hum Mutat 30: 1667 ). 
An autosomal recessive condition 
characterized by the clinical tetrad of 
chondrodystrophy, polydactyly, ectodermal 
dysplasia and cardiac anomalies. Patients 
manifest short-limb dwarfism, short ribs, 
postaxial polydactyly, and dysplastic nails and 
teeth. Congenital heart defects, most 
commonly an atrioventricular septal defect, are 
observed in 60% of affected individuals. None 
of these features lists in patient phenotype. No 
Splice variant A/G 1/1/0 
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2nd likely mutation in VCF. 
17 36891739 PCGF2 c.770_771del;p.(Glu57fs). Reported 
frameshift_variant. The Deciphering 
Developmental Disorders Study (2015) 
identified 2 unrelated patients with intellectual 
disability who shared the same heterozygous 
missense mutation in the PCGF2 gene (this 
patient and a second). No indication of skeletal 
phenotype in the second patient 
Frameshift ACT/A 1/1/0 
9 2039799 SMARCA2 Reported missense_variant. AD Nicolaides-
Baraitser syndrome. A rare disorder 
characterized by severe mental retardation with 
absent or limited speech, seizures, short 
stature, sparse hair, typical facial 
characteristics, brachydactyly, prominent finger 
joints and broad distal phalanges 
Missense 
variant 
AGC/C
GC 
1/1/0 
Abnormal renal morphology, 
Abnormality of the liver, Bladder 
diverticulum, Congenital hip 
dislocation, Hydronephrosis, Motor 
delay, Osteopenia, Pulmonic stenosis, 
Short stature 
134 282638        
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Abnormality of dentin, Absent speech, 
Autistic behavior, Cognitive 
impairment, Drooling, Fractures of the 
long bones, Microcephaly, Myopathic 
facies, Neonatal hypotonia, Open 
mouth, Osteopenia, Reduced bone 
mineral density, Seizures, Strabismus 
135 283516        
Bowing of limbs due to multiple 
fractures, Congenital contracture, 
Decreased antibody level in blood, 
Multiple prenatal fractures 
136 283921 16 30750390 SRCAP Reported missense_variant. 
C.9029C>A;p.(Pro3010His) 
Missense 
variant 
C/A 1/0/0 
6 33272115 TAPBP Bi-allelic loss of function mutations in TAPBP 
are associated with Type I Bare Lymphocyte 
Syndrome, a condition characterised by chronic 
bacterial infection. 
Missense 
variant 
G/A 1/0/0 
Bowing of limbs due to multiple 
fractures, Congenital contracture, 
Decreased antibody level in blood, 
Multiple prenatal fractures 
  
  
137 285317 7 94033866 COL1A2 Not reported by DDD c.280-2A>C. Not reported 
in Decipher database. Inherited from mum who 
is clinically affected. 
Splice  variant A/C 1/1/0 
7 31011710 GHRHR c.597T>C;p.(Thr199Thr), synonymous change. 
Gene associated with isolated growth hormone 
deficiency. 
Missense 
variant 
T/C 1/1/0 
2 220434949 OBSL1 3m syndrome - recessive. Missense 
variant 
C/A 1/0/0 
14 57269042 OTX2 c.305G>A;p.(Arg102His). Reported 
missense_variant. Retinal Dystrophy with or 
without Pituitary Dysfunction. Gene probably 
reported due to 'blue sclerae' being listed under 
'eye abnormality' in DDD. 
Missense 
variant 
G/A 1/1/0 
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5 86564716 RASA1 c.448C>T;p.(Leu150Phe). Reported 
missense_variant. Capillary malformation-
arteriovenous malformation. Parkes Weber 
syndrome is characterized by a cutaneous 
flush with underlying multiple micro-AVFs 
(arteriovenous fistulas), in association with soft 
tissue and skeletal hypertrophy of the affected 
limb. Low level frequency data in gnomAD. 
Missense 
variant 
C/T 1/1/0 
Abnormal aggressive, impulsive or 
violent behaviour, Fractures of the long 
bones, Severe expressive language 
delay, Smooth philtrum, Tetralogy of 
Fallot, Thin vermilion border 
138 286790        
Macroglossia, Moderate global 
developmental delay, Multiple 
exostoses, Neonatal respiratory 
distress, Osteopenia, Postnatal 
macrocephaly, Seizures, Sparse scalp 
hair 
  
139 287325 X 39934294 BCOR c.305G>A;p.(Arg102Gln) Reported 
missense_variant. X-linked Microphthalmia, 
syndromic 2. Multiple congenital anomaly 
syndrome characterized by eye anomalies, 
facial abnormalities, cardiac anomalies and 
dental abnormalities.  
Missense 
variant 
G/A 1/1/0 
10 28824551 WAC c.139C>T;p.(Arg47*) Reported stop_gained. 
Previously reported ?cause of DD  
Stop gained C/T 1/0/0 
Phenotype: Abnormality of the 
odontoid process, Amelogenesis 
imperfecta, Cerebral calcification, 
Depressed nasal bridge, Down slanted 
palpebral fissures, Elevated circulating 
parathyroid hormone (PTH) level, 
Hypophosphatemia, Malar flattening, 
Narrow mouth, Osteoporosis, Sagittal 
craniosynostosis, Subglottic stenosis 
140 294005 7 295967 FAM20C c.1225C>T;p.(Arg409Cys). Reported 
missense_variant. Protein = plays a key role in 
biomineralization of bones and teeth. Raine 
syndrome (RNS)= Autosomal recessive 
osteosclerotic bone dysplasia with neonatal 
lethal outcome. Clinical features include 
generalized osteosclerosis, craniofacial 
dysplasia and microcephaly. Reported 
pathogenic mutation in Alazami et al 2015 but 
Missense 
variant 
C/T 2/1/1 
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this is an exome sequencing project and no 
functional evidence provided. Full explanation 
of phenotype reported in Decipher. 
16 86602355 FOXC2 Disorder characterized by primary limb 
lymphedema associated with distichiasis 
(double rows of eyelashes, with extra 
eyelashes growing from the Meibomian gland 
orifices) 
Upstream 
variant 
A/G 2/1/1 
14 58934462 KIAA0586 Reported missense_variant. Gene associated 
with Joubert syndrome 23 (phenotype was 
relatively mild and homogeneous, consisting 
mainly of neurologic features, such as delayed 
development, abnormal eye movements, and 
the molar tooth sign on brain imaging) and 
short rib-polydactyly syndrome, type IX (severe 
hydrocephaly, polydactyly, and skeletal 
abnormalities) which is usually lethal due to 
thoracic insufficiency. Likely benign in 
Decipher. 
Missense 
variant 
A/G 2/1/1 
12 12277566 LRP6 c.4481dup;p.(Arg1495fs).Cell-surface 
coreceptor of Wnt/beta-catenin signalling, 
which plays a pivotal role in bone formation. 
Gene associated with tooth agenesis, selective, 
7 (STHAG7), autosomal dominant form of 
selective tooth agenesis, a common anomaly 
characterized by the congenital absence of one 
or more teeth. 
Frameshift 
variant 
C/CT 1/0/0 
Abnormality of mast cells, Autonomic 
dysregulation, Joint hypermobility, 
Orthostatic hypotension, Osteopenia, 
Seizures, obsolete Joint dislocations in 
141 294027 6 7727522 BMP6 c.334G>A;p.(Glu112Lys) .Go biological 
processes - bone mineralization, osteoblast 
differentiation. Likely polymorphic variant as in 
del/ins in dbSNP 
Missense 
variant 
GAGCA
GCAGC
/AAGCA
GCAGC 
1/1/0 
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young adult 
  
5 60224690 ERCC8 AR Cockayne syndrome = rare disorder 
characterized by cutaneous sensitivity to 
sunlight, abnormal and slow growth, cachectic 
dwarfism, progeroid appearance, progressive 
pigmentary retinopathy and sensorineural 
deafness 
Splice variant C/G 1/1/0 
12 49418641 KMT2D c.1587G>C;p.(Glu5291Asp). Reported - 
missense_variant. Kabuki syndrome = 
congenital mental retardation syndrome with 
additional features, including postnatal 
dwarfism, a peculiar facies characterized by 
long palpebral fissures with eversion of the 
lateral third of the lower eyelids, a broad and 
depressed nasal tip, large prominent earlobes, 
a cleft or high-arched palate, scoliosis, short 
fifth finger, persistence of fingerpads, 
radiographic abnormalities of the vertebrae, 
hands, and hip joints, and recurrent otitis media 
in infancy. Likely benign in Decipher. 
Missense 
variant 
G/C 1/1/0 
13 38158851 POSTN  Variant c.1108+2T> C. Gene = periostin, 
osteoblast specific factor. Involved in bone 
metabolism. Good candidate gene. UniProt - 
Enhances incorporation of BMP1 in the 
fibronectin matrix of connective tissues, and 
subsequent proteolytic activation of lysyl 
oxidase LOX. Variant c.1108+2T> C, 0.0027% 
in gnomAD. Inherited from mum who has Joint 
hypermobility, Osteopenia, Autonomic 
dysregulation 
Splice variant A/G 1/1/0 
Bowing of limbs due to multiple 
fractures, Fractures of the long bones, 
142 294357        
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Increased susceptibility to fractures, 
Osteopenia 
Aplasia/Hypoplasia involving the 
musculature of the upper limbs, 
Aplasia/Hypoplasia of the thumb, 
Delayed gross motor development, 
Pathologic fracture, Protruding ear, 
Recurrent bacterial infections 
143 295131        
High palate, Multiple small vertebral 
fractures, Osteoporosis, Proportionate 
tall stature 
144 295328        
Flexion contracture of toe, Fractures of 
the long bones, High pitched voice, 
Increased hepatic glycogen content, 
Intellectual disability, moderate, Low-
set ears, Moderately short stature, 
Patellar dislocation, Pelvic kidney, 
Prominent epicanthal folds, Scoliosis, 
Short foot, Upslanted palpebral fissure, 
Vesicoureteral reflux 
145 301078 2 216226780 FN1 c.7274G>A;p.(Arg2452His). GeneAtlas Basic 
function, multiple but includes: upregulates 
osteoclast activity despite inhibiting osteoclast 
formation and these effects involve nitric oxide 
and IL1B signalling. Present in 0.2% of GoNL 
pop. No homozygotes. Gene associated with 
AD plasma fibronectin deficiency.  
Missense 
variant 
C/T 1/0/1 
2 216240047 FN1 c.6047C>T; p.(Pro2016Leu). 0.06% in 
gnomAD, no homozygotes 
Missense 
variant 
G/A 1/1/0 
Apnea, Autistic behavior, Clinodactyly 
of the 5th finger, Feeding difficulties, 
Focal seizures, Gait imbalance, 
Generalized tonic-clonic seizures, 
Impaired pain sensation, Increased 
susceptibility to fractures, Intellectual 
disability, severe, Long philtrum, 
Micrognathia, Moderate global 
146 301415 15 93467724 CHD2 c.236T>C;p.(Leu79Pro). Reported by DDD 
missense_variant. A severe form of epilepsy 
characterized by onset of multiple seizure types 
in the first few years of life and associated with 
poor prognosis. Affected individuals have 
cognitive regression and intellectual disability 
Missense 
variant 
T/C 1/NA/NA 
21 38877655 DYRK1A c.1309C>T;p.(Arg437Ter). Reported 
stop_gained. AD mental retardation type 7. 
Missense 
variant 
C/T 1/NA/NA 
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developmental delay, Optic nerve 
hypoplasia, Painless fractures due to 
injury, Posteriorly rotated ears, 
Sensorineural hearing impairment, 
Severe expressive language delay, 
Short nose, Stereotypic behaviour, 
Typical absence seizures 
  
6 85446617 TBX18 c.1610C>G;p.(Ser537Cys). Reported 
missense_variant. Gene associated with AD 
congenital anomalies of the kidney and urinary 
tract. No skeletal phenotype listed associated 
with this condition. Likely benign in Decipher. 
Missense 
variant 
C/G 1/NA/NA 
21 38877655 DYRK1A c.1309C>T;p.(Arg437Ter). Reported 
stop_gained. AD mental retardation type 7. 
Stop gained C/T 1/NA/NA 
11 76868371 MYO7A c.782G>A; p.(Gly261Asp). AR Usher 
syndrome. profound congenital hearing 
impairment with unintelligible speech, early 
retinitis pigmentosa (usually evident within the 
first decade), and constant vestibular 
dysfunction 
Missense 
variant 
G/A 1/NA/NA 
Abnormality of the temporomandibular 
joint, Absent distal interphalangeal 
creases, Camptodactyly of finger, 
Hashimoto thyroiditis, Increased 
susceptibility to fractures, Lateral 
displacement of patellae, Myopia, 
Short neck 
147 301797        
Abnormality of the teeth, Bone pain, 
Delayed eruption of teeth, Fractures of 
the long bones, High palate, Joint 
hypermobility, Large posterior 
fontanelle, Narrow chest, Wide anterior 
fontanel 
148 304402 3 176756186 TBL1XR1 c.962C>G;p.(Thr321Ser). Reported 
missense_variant. AD mental retardation type 
41. A form of mental retardation, a disorder 
characterized by significantly below average 
general intellectual functioning associated with 
impairments in adaptive behaviour and 
manifested during the developmental period. 
No skeletal manifestations. 
Missense 
variant 
G/C 1/0/0 
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2-3 toe syndactyly, Abnormality of 
dental enamel, Blue sclerae, Bruising 
susceptibility, Constipation, Delayed 
gross motor development, Delayed 
speech and language development, 
Down slanted palpebral fissures, 
Increased muscle fatigability, 
Intellectual disability, severe, Joint 
hypermobility, Malar flattening, 
Recurrent fractures 
149 304572 17 48272592 COL1A1 Reported splice_variant c.1299+1G>A Splice variant G/A 1/0/0 
 
  Trio Genotype column indicates the presence of the variant in the proband/mother/ father, where: 
1 = present on one allele 
2 = present on both alleles 
0 = not present.  
NA indicates that the parent was not available for analysis 
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C. Poster: International Skeletal Dysplasia Society (2017)  
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D. Poster: International Conference on Childrens Bone Health (2017) 
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E. Manuscript: Phenotypic Variability in Patients with Osteogenesis Imperfecta caused by 
BMP1 Mutations  
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F. Manuscript: P4HB recurrent missense mutation causing Cole-Carpenter syndrome  
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G. Manuscript: Compound Heterozygous Vairants in NBAS as a cause of atypical osteogenesis 
imperfecta 
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H. List of Genes in Targeted Panel for Exome analysis 
Source Key : 
A = Skeletal dysplasia monogenic disease F = TGFB signalling 
B = HPO susceptibility to fractures G = Participates in osteoblastogenic processes 
C = Mouse model abnormal mineralization H = Genome wide association studies (GWAS) 
D = Mouse model decreased bone mineral density I = Personal communication 
E= Collagen prolyl hydroxylase family  
 
Gene symbol Sourc
e 
OMIM/HGN
C Number 
Chromoso
me 
Location 
Gene name 
MARCH9 C 613336 12q14.1 MEMBRANE ASSOCIATED RING-CH-TYPE FINGER 9 
ACAN A 155760 15q26  AGGRECAN 
ACP2 C,D 171650 11p11.2 ACID PHOSPHATASE 2, LYSOSOMAL 
ACP5  A 171640 19p13.2  TARTRATE-RESISTANT ACID PHOSPHATASE (TRAP) 
ACSBG2 C 614363 19p13.3 ACYL-COA SYNTHETASE, BUBBLEGUM FAMILY MEMBER 2 
ADAR D 146920 1q21.3 ADENOSINE DEAMINASE, RNA-SPECIFIC 
ADGRD1 D  613639 12q24.33 ADHESION G PROTEIN-COUPLED RECEPTOR D1 
ADGRF5 D H:19030 6p12.3 ADHESION G PROTEIN-COUPLED RECEPTOR F5 
AGA B 613228 4q34.3 ASPARTYL-GLUCOSAMINIDASE 
AGPAT2  B 603100 9q34.3 1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 2 
AGPAT3 D 614794 21q22.3 1-ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 3 
AGXT  B 604285 2q37.3 ALANINE-GLYOXYLATE AMINOTRANSFERASE 
AIP  B 605555 11q13.2 ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN 
AJAP1 D 610972 1p36.32 ADHERENS JUNCTION-ASSOCIATED PROTEIN 1 
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AKR1A1 D 103830 1p34.1 ALDO-KETO REDUCTASE FAMILY 1, MEMBER A1 
AKT2 C,D 164731 19q13.2 V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 2 
AKTIP D 608483 16q12.2 AKT-INTERACTING PROTEIN 
ALDH18A1 A 138250 10q24.1 ALDEHYDE DEHYDROGENASE 18 FAMILY, MEMBER A1 
ALDH2 C,D 100650 12q24.12 ALDEHYDE DEHYDROGENASE 2 FAMILY 
ALDH3A1 D 100660 17p11.2 ALDEHYDE DEHYDROGENASE, FAMILY 3, SUBFAMILY A, MEMBER 1 
ALOX15 G,H 152392 17p13.2 ARACHIDONATE 15-LIPOXYGENASE 
ALPL A,D 171760 1p36.1–p34 ALKALINE PHOSPHATASE, TISSUE NON-SPECIFIC (TNSALP) 
ANKH A 605145 5p15.2–14.2 HOMOLOG OF MOUSE ANK (ANKYLOSIS) GENE 
ANKRD11 C,D 611192 16q24.3 ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 11 
ANO5 A. 608662 11p14.3  ANOCTAMIN 5 
ANOS1 (KAL1) B 300836 Xp22.31 ANOSMIN 1 
ANTXR2 B 608041 4q21 ANTHRAX TOXIN RECEPTOR 2 
AP4E1 D 607244 15q21.2 ADAPTOR-RELATED PROTEIN COMPLEX 4, EPSILON-1 SUBUNIT 
AQP3 D 600170 9p13.3 AQUAPORIN 3 
ARHGAP31 A 610911 3q13.33  RHO GTPASE-ACTIVATING PROTEIN 31 
ARHGEF4 D 605216 2q21.1 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR 4 
ARL4D D 600732 17q21.31 ADP-RIBOSYLATION FACTOR-LIKE 4D 
ARRDC1 D H:28633 9q34.3 ARRESTIN DOMAIN CONTAINING 1 
ASXL1 D 612990 20q11.21 ADDITIONAL SEX COMBS-LIKE 1 
ATF3 D 603148 1q32.2 ACTIVATING TRANSCRIPTION FACTOR 3; 
ATP6V0A2 A 611716 12q24.3 ATPASE, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A2 
ATP7A  B 300011 Xq21.1 ATPASE, CU(2+)-TRANSPORTING, ALPHA POLYPEPTIDE 
ATRX A 300032 Xq21.1 ATR-X  
AXIN1 H 603816 16p13.3 AXIS INHIBITOR 1 
B3GALT6 A 615291 1p36.33   UDP-GAL:BETA-GAL BETA-1,3-GALACTOSYLTRANSFERASE POLYPEPTIDE 6 
252 
 
B3GAT3 A 606374 11q12.3 BETA-1,3-GLUCURONYLTRANSFERASE 3 
B4GALT7 A 604327 5q35 XYLOSYLPROTEIN 4-BETA-GALACTOSYLTRANSFERASE DEFICIENCY 
BACH2 D 605394 6q15 BTB AND CNC HOMOLOGY 2 
BBS5 D 603650 2q31.1 BBS5 GENE 
BBX D H:14422 3q13.12 BBX, HMG-BOX CONTAINING 
BLM A 604610 15q26.1  RECQ PROTEIN-LIKE 3 
BMP1 A 112264 8p21.3 BONE MORPHOGENETIC PROTEIN 1 
BMP2 D 112261 20p12.3 BONE MORPHOGENETIC PROTEIN TYPE 2 
BMP4 G 112262 14q22.2 BONE MORPHOGENETIC PROTEIN 4 
BMP7 G 112267 20q13.31 BONE MORPHOGENETIC PROTEIN 7 
BMPR1B A 603248 4q23 BONE MORPHOGENETIC PROTEIN RECEPTOR 1B 
BOC D 608708 3q13.2 BOC CELL ADHESION ASSOCIATED, ONCOGENE REGULATED 
BRPF1 D 602410 3p25.3 BROMODOMAIN- AND PHD FINGER-CONTAINING PROTEIN 
BSCL2  B 606158 11q12.3 BSCL2 GENE 
BTK A 300300 X22.1 BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE 
BTRC D 603482 10q24.32 BETA-TRANSDUCIN REPEAT-CONTAINING PROTEIN 
C17ORF53 H H:28460 17q21.31 CHROMOSOME 17 OPEN READING FRAME 53 
C17ORF62 D  H:28672 17q25.3 CHROMOSOME 17 OPEN READING FRAME 62 
C1ORF112 C H:25565 1q24.2 CHROMOSOME 1 OPEN READING FRAME 112 
C6ORF97 
(CCDC170) 
H H:21177 6q25.1 COILED-COIL DOMAIN CONTAINING 170 
CA2 B 611492 8q22 CARBONIC ANHYDRASE 2 
CANT1 A 613165 17q25.3 CALCIUM-ACTIVATED NUCLEOTIDASE 1  
CASR A,D 601199 3q13.3–21 CALCIUM-SENSING RECEPTOR 
CAST D 114090 5q15 CALPASTATIN 
CAV1  B 601047 7q31.2 CAVEOLIN 1 
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CBS  B 613381 21q22.3 CYSTATHIONINE BETA-SYNTHASE 
CC2D2A A 612013 4p15 COILED-COIL AND C2 DOMAINS-CONTAINING PROTEIN 2A 
CCDC8 A 614145 19q13.32 COILED-COIL DOMAIN CONTAINING 8 
CDC6 A 602627 17q21.2 CELL DIVISION CYCLE 6, S. CEREVISIAE, HOMOLOG OF 
CDH3 A 114021 16q22 CADHERIN 3 
CDK5RAP2 D 608201 9q33.2 CDK5 REGULATORY SUBUNIT-ASSOCIATED PROTEIN 2 
CDKN1C A 600856 11p15.4  CYCLIN-DEPENDENT KINASE INHIBITOR 1C 
CDT1 A 605525 16q24.3 CHROMATIN LICENSING AND DNA REPLICATION FACTOR 1 
CENPJ D 609279 13q12.12-
q12.13 
CENTROMERIC PROTEIN J 
CEP290 A 610142 12q21.32 CENTROSOMAL PROTEIN 
CHD2 D 602119 15q26.1  CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 2 
CHD7  B 608892 8q12.2 CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 7 
CHRNA1  B 100690 2q31.1 CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1 
CHRND  B 100720 2q37.1 CHOLINERGIC RECEPTOR, NICOTINIC, DELTA POLYPEPTIDE 
CHRNG  B 100730 2q37.1 CHOLINERGIC RECEPTOR, NICOTINIC, GAMMA POLYPEPTIDE 
CHST14 A 608429 15q14  CARBOHYDRATE SULFOTRANSFERASE 14; ERMATAN 4-SULFOTRANSFERASE 
CHST3 A 603799 10q22.1  CARBOHYDRATE SULFOTRANSFERASE 3; CHONDROITIN 6-
SULFOTRANSFERASE 
CHSY1 A 608183 15q26.3  CHONDROITIN SULFATE SYNTHASE 1 
CIDEC D 612120 3p25.3 CELL DEATH-INDUCING DFFA-LIKE EFFECTOR C 
CISD2 C 611507 4q24 CDGSH IRON SULFUR DOMAIN PROTEIN 2 
CLCN5 A 300008 Xp11.22 CHLORIDE CHANNEL 5 
CLCN7 A,H 602727 16p13 CHLORIDE CHANNEL 7 
CLDN14 H 605608 21q22.13 CLAUDIN 14 
CLK1 C 601951 2q33.1 CDC-LIKE KINASE 1 
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CLSTN1 D 611321 1p36.22 CALSYNTENIN 1 
CLSTN3 D 611324 12p13.31 CALSYNTENIN 3 
CLVS1 D 611292 8q12.2-
q12.3 
CLAVESIN 1 
COL10A1 A 120110 6q21–22.3  COLLAGEN 10 ALPHA-1 CHAIN 
COL11A1 A 120280 1p21  TYPE 11 COLLAGEN ALPHA-1 CHAIN 
COL11A2 A 120290 6p21.3  TYPE 11 COLLAGEN ALPHA-2 CHAIN 
COL12A1 A 120320 6q13-q14 COLLAGEN, TYPE XII, ALPHA-1 
COL14A1 D 120324 8q24.12 COLLAGEN TYPE XIV ALPHA 1 CHAIN 
COL1A1 A 120150 17q21–22 COLLAGEN 1, ALPHA-1 CHAIN 
COL1A2 A 120160 7q21.3   COLLAGEN 1, ALPHA-2 CHAIN 
COL2A1 A 120140 12q13.1 TYPE 2 COLLAGEN 
COL5A1 A 120215 9q34.3 COLLAGEN 5 ALPHA-1 CHAIN 
COL9A1 A 120210 6q13  COLLAGEN 9 ALPHA-1 CHAIN 
COL9A2 A 120260 1p32.2–33  COLLAGEN 9 ALPHA-2 CHAIN 
COL9A3 A 120270 20q13.3  COLLAGEN 9 ALPHA-3 CHAIN 
COMP A 600310 19p13.1 COMP 
CREB3L1 D 616215 11p11.2 CAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 1 
CREBBP A 600140 16p13.3 CREB-BINDING PROTEIN 
CRTAP A 605497 3p22.3   CARTILAGE-ASSOCIATED PROTEIN 
CSF1 D 120420 1p13.3 COLONY-STIMULATING FACTOR, MACROPHAGE-SPECIFIC 
CSF1R D 164770 5q32 COLONY-STIMULATING FACTOR 1 RECEPTOR 
CSRP2BP(KAT14) D 617501 20p11.23 LYSINE ACETYLTRANSFERASE 14 
CTC1  B 613129 17p13.1 CONSERVED TELOMERE MAINTENANCE COMPONENT 1 
CTNNB1 C,H 116806 3p22.1 CADHERIN-ASSOCIATED PROTEIN, BETA 
CTNND2 B 604275 5p15.2 CATENIN, DELTA-2 
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CTSK A,D 601105 1q21 CATHEPSIN K 
CUL7 A,D 609577 6p21.1 CULLIN 7 
CYB561 D 600019 19q23.3 CYTOCHROME B561 
CYLD H 605018 16q12.1 CYLD GENE 
CYP26B1 A 605207 2p13.2 CYTOCHROME P450, SUBFAMILY XXVIB, POLYPEPTIDE 1 
CYP27B1  B,D 609506 12q14.1 CYTOCHROME P450, SUBFAMILY XXVIIB, POLYPEPTIDE 1 
CYP2R1  B 608713 11p15.2 CYTOCHROME P450, SUBFAMILY IIR, POLYPEPTIDE 1 
DAGLA D 614015 11q12.2 DIACYLGLYCEROL LIPASE, ALPHA 
DCDC5 H 612321 11p14.1 DOUBLECORTIN DOMAIN-CONTAINING PROTEIN 5 
DDR2 A 191311 1q23  DISCOIDIN DOMAIN RECEPTOR FAMILY, MEMBER 2 
DDX52 C 612500 17q12 DEAD BOX POLYPEPTIDE 52 
DDX58 H 609631 9p21.1 DEAD BOX POLYPEPTIDE 58 
DEF6 D 610094 6p21.1 DEF6, MOUSE, HOMOLOG OF 
DHCR24 A 606418 1p33–31.1 3-BETA-HYDROXYSTEROL DELTA-24-REDUCTASE 
DHCR7 A 602858 11q13.4    7-DEHYDROCHOLESTEROL REDUCTASE 
DHX40 C 607570 17q23.1 DEAH BOX POLYPEPTIDE 40 
DKC1  B 300126 Xq28 DYSKERIN 
DKK1 H 605189 10q21.1 DICKKOPF, XENOPUS, HOMOLOG OF, 1 
DLG4 D 602887 17p13.1 DISCS LARGE, DROSOPHILA, HOMOLOG OF, 4 
DLL3 A 602768 19q13 DELTA-LIKE 3 
DLX3 A 600525 17q21 DISTAL-LESS HOMEOBOX 3 
DMP1 A 600980 4q21 DENTIN MATRIX ACIDIC PHOSPHOPROTEIN 1 
DMXL2 D 612186 15q21.2 DMX-LIKE 2 
DNAJB3 D H:32397 2q37.1 DNAJ HEAT SHOCK PROTEIN FAMILY (HSP40) MEMBER B3 
DNASE1L2 D 602622 16p13.3 DEOXYRIBONUCLEASE I-LIKE 2 
DNASE2B D 608057 1p31.1- DEOXYRIBONUCLEASE II BETA 
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p22.3 
DSPP A 125485 4q22.1 DENTIN SIALOPHOSPHOPROTEIN 
DUSP6  B 602748 12121.33 DUAL-SPECIFICITY PHOSPHATASE 6 
DYM A 607461 18q12–21.1  DYMECLIN  
DYNC2H1 A 603297 11q22.3  DYNEIN, CYTOPLASMIC 2, HEAVY CHAIN 1 
EBP A 300205 Xp11.23 EMOPAMIL-BINDING PROTEIN 
EFEMP2 B 604633 11q13.1 EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 2 
EFNB1 A 300035 Xq13.1 EPHRIN B1 
EFTUD2 A 603892 17q21.31 ELONGATION FACTOR TU GTP-BINDING DOMAIN-CONTAINING 2 
EIF2AK3 A 604032 2p12  TRANSLATION INITIATION FACTOR 2-ALPHA KINASE-3 
ELMO1 D 606420 7p14.2-
p14.1 
ENGULFMENT AND CELL MOTILITY GENE 1 
ENPP1 A 173335 6q23 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 
ENTPD6 D 603160 20p11.21 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 6 
EOMES D 604615 3p24.1 EOMESODERMIN, XENOPUS, HOMOLOG OF 
EP300 A 602700 22q13 E1A-BINDING PROTEIN, 300-KDA 
EPC1 C 610999 10p11.2 ENHANCER OF POLYCOMB, DROSOPHILA, HOMOLOG OF, 1 
ERCC6 A 609413 10q11.23 EXCISION REPAIR CROSS-COMPLEMENTING, GROUP 6 
ERCC8 A 609412 5q12.1 EXCISION REPAIR CROSS-COMPLEMENTING, GROUP 8 
ERLIN2 D 611605 8p11.23 ENDOPLASMIC RETICULUM LIPID RAFT-ASSOCIATED PROTEIN 2 
ESCO2 A 609353 8p21.1 HOMOLOG OF ESTABLISHMENT OF COHESION—2 
ESR1 H 133430 6q25.1-
q25.2 
ESTROGEN RECEPTOR 1 
EVC A 604831 4p16 ELLIS–VAN CREVELD 1 PROTEIN 
EVC2 A 607261 4p16  EVC GENE 2 
EXT1 A 608177 8q23–24.1 EXOSTOSIN-1 
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EXT2 A 608210 11p12–11 EXOSTOSIN-2 
FADD D 602457 11q13.3 FAS-ASSOCIATED VIA DEATH DOMAIN 
FAM111A A 615292 11q12.1     FAMILY WITH SEQUENCE SIMILARITY 111, MEMBER A 
FAM134B  B 613114 5p15.1 FAMILY WITH SEQUENCE SIMILARITY 134, MEMBER B 
FAM134C D 616498 17q21.2 FAMILY WITH SEQUENCE SIMILARITY 134 
FAM20C A,D  611061 7p22 FAMILY WITH SEQUENCE SIMILARITY 20, MEMBER C 
FAM210A H H:28346 18p11.21 FAMILY WITH SEQUENCE SIMILARITY 210 MEMBER A 
FAM73B D 616774 9q34.11 FAMILY WITH SEQUENCE SIMILARITY 73, MEMBER B 
FAM83G D 615886 17p11.2 FAMILY WITH SEQUENCE SIMILARITY 83, MEMBER G 
FARSA D 602918 19p13.2  PHENYLALANINE-TRNA SYNTHETASE, ALPHA SUBUNIT 
FBLN1 A 135820 22q13.3 FIBULIN 1 
FBLN5 B 604580 14q32.12 FIBULIN 5 
FBN1 A 134797 15q21.1  FIBRILLIN 1 
FBXO11 C,D 607871 2p16.3 F-BOX ONLY PROTEIN 11 
FBXW4 A 608071 10q24 DACTYLIN 
FERMT3 (KIND3) A 607901 11q12 FERMITIN 3 (KINDLIN 3) 
FEZF1 B 613301 7q31.32 FEZ FAMILY ZINC FINGER PROTEIN 1 
FGD1 A 300546 Xp11.22 FYVE, RHOGEF, AND PH DOMAIN-CONTAINING PROTEIN 1 
FGF10 A 602115 5p13–p12 FIBROBLAST GROWTH FACTOR 10 
FGF17  B 603725 8p21.3 FIBROBLAST GROWTH FACTOR 17 
FGF23 A,D 605380 12p13.3 FIBROBLAST GROWTH FACTOR 23 
FGF7 D 148180 15q21.2 FIBROBLAST GROWTH FACTOR 7 
FGF8  B 600483 10q24.32 FIBROBLAST GROWTH FACTOR 8 
FGF9 A 600921 13q11–q12 FIBROBLAST GROWTH FACTOR 9 
FGFR1 A,D 136350 8p11.23-
p11.22 
FIBROBLAST GROWTH FACTOR RECEPTOR 1 
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FGFR2 A 176943 10q26.12 FIBROBLAST GROWTH FACTOR RECEPTOR 2 
FGFR3 A 134934 4p16.3 FIBROBLAST GROWTH FACTOR RECEPTOR 3 
FGFR4 D 134935 5q35.2 FIBROBLAST GROWTH FACTOR RECEPTOR 4 
FGFRL1 H 605830 4p16.3 FIBROBLAST GROWTH FACTOR RECEPTOR-LIKE 1 
FGL1 C 605776 8p22 FIBRINOGEN-LIKE 1 
FIG4 B 609390 6q21  FIG4, S. CEREVISIAE, HOMOLOG OF 
FKBP10 A 607063 17q21.2 FK506-BINDING PROTEIN 10 
FLJ42280 (SEM1) H 601285 7q21.3 SEM1, 26S PROTEASOME COMPLEX SUBUNIT 
FLNA A 300017 Xq28  FILAMIN A 
FLNB A,D 603381 3p14.3  FILAMIN B  
FLRT3  B 604808 20p12.1 FIBRONECTIN-LIKE DOMAIN-CONTAINING LEUCINE-RICH TRANSMEMBRANE 
PROTEIN 3 
FOS B 164810 14q24.3 V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG 
FOSB G 164772 19q13.32 V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG B 
FOSL1 G 136515 11q13.1 FOS-LIKE ANTIGEN 1 
FOSL2 G 601575 2p23.2 FOS-LIKE ANTIGEN 2 
FOXC1 A 601090 6p25.3 FORKHEAD BOX C1 
FOXC2 H 602402 16q24.1 FORKHEAD BOX C2 
FOXL1 H 603252 16q24.1 FORKHEAD BOX L1 
FOXO3 D 602681 6q21 FORKHEAD BOX O3A 
FRS2 D 607743 12q15 FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2 
FSHR D 136435 2p16.3 FOLLICLE-STIMULATING HORMONE RECEPTOR 
FUBP3 H 603536 9pq34.11-
q34.12 
FAR UPSTREAM ELEMENT-BINDING PROTEIN 3 
FZD4  B 604579 11q14.2 FRIZZLED, DROSOPHILA, HOMOLOG OF, 4 
GALNT3 A 601756 2q24–q31 UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-
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ACETYLGALACTOSAMINYLTRANSFERASE 3 
GATA1  B 305371 Xp11.23 GATA-BINDING PROTEIN 1 
GBA A 606463 1q22 GLUCOSIDASE, BETA, ACID 
GDF5 A 601146 20q11.2 GROWTH AND DIFFERENTIATION FACTOR 5 
GH1 A 139250 17q23.3 GROWTH HORMONE 1 
GHR A 600946 5p13-p12 GROWTH HORMONE RECEPTOR 
GHRHR A,D 139191 7p14.3 GROWTH HORMONE-RELEASING HORMONE RECEPTOR 
GHSR A 601898 3q26.31 GROWTH HORMONE SECRETAGOGUE RECEPTOR 
GK  B 300474 Xp21.2 GLYCEROL KINASE 
GLE1  B 603371 9q34.11 GLE1, RNA EXPORT MEDIATOR 
GLI2 A 165230 2q14.2 GLI-KRUPPEL FAMILY MEMBER 2 
GLI3 A 165240 7p13 GLI-KRUPPEL FAMILY MEMBER 3 
GLRB D 138492 4q32.1 GLYCINE RECEPTOR, BETA SUBUNIT 
GNA11 C 139313 19p13.3 GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-11 
GNAS A,C 139320 20q13 GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-STIMULATING ACTIVITY 
SUBUNIT 1 
GNPTAB A 607840 4q21–23 N-ACETYLGLUCOSAMINE 1-PHOSPHOTRANSFERASE, ALPHA/BETA SUBUNITS 
GORAB A  607983 1q24.2 SCYL1-BINDING PROTEIN 1 
GPATCH1 H H:24658 19q13.12 G PATCH DOMAIN CONTAINING 1 
GPC6 A 604404 13q31–q32 GLYPICAN 6 
GPR116 (ADGRF5) D H:19030 6p12.3 ADHESION G PROTEIN-COUPLED RECEPTOR F5 
GPR133 H 613639 12q24.33 ADHESION G PROTEIN-COUPLED RECEPTOR D1 
GPR152 D H:23622 11q13.2 G PROTEIN-COUPLED RECEPTOR 152 
GPR177 H 611514 1p31.3 WNTLESS, DROSOPHILA, HOMOLOG OF 
GPX4 A 138322 19p13.3 GLUTATHIONE PEROXIDASE 4 
GREM1 A 603054 15q13–q14 GREMLIN 1, FORMIN 1 
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GRIN2D D 602717 19q13.33 GLUTAMATE RECEPTOR, IONOTROPIC, N-METHYL-D-ASPARTATE, SUBUNIT 2D 
GSC A 138890 14q32.13 GOOSECOID HOMEOBOX 
GSE1 C 616886 16q24.1 GSE1 COILED-COIL PROTEIN 
GULOP D 240400 8p21.1 HYPOASCORBEMIA 
HACE1 D 610876 6q16.3 HECT DOMAIN- AND ANKYRIN REPEAT-CONTAINING E3 UBIQUITIN PROTEIN 
LIGASE 1 
HAX1 D 605998 1q21.3 HCLS1-ASSOCIATED PROTEIN X1 
HBS1L D 612450 6q23.3 HBS1-LIKE PROTEIN 
HDAC4 A 605314 2q37.3 HISTONE DEACETYLASE 4 
HDAC5 H 605315 17q21.3 HISTONE DEACETYLASE 5 
HDAC8 D 300269 Xq13.1 HISTONE DEACETYLASE 8 
HECTD2 D H:26736 10q23.32 HECT DOMAIN CONTAINING 2 
HERC4 D 609248 10q22 HECT DOMAIN AND RCC1-LIKE DOMAIN 4 
HESX1 A 601802 3p14.3  HOMEOBOX GENE EXPRESSED IN ES CELLS 
HOOK3 D 607825 8p11.21 HOOK, DROSOPHILA, HOMOLOG OF, 3 
HOXA11 A 142958 7p15–14.2 HOMEOBOX A11 
HOXD13 A 142989 2q31 HOMEOBOX D13 
HPGD A 601688 4q34–35 15-ALPHA-HYDROXYPROSTAGLANDIN DEHYDROGENASE 
HRAS B 190020 11p15.5     V-HA-RAS HARVEY RAT SARCOMA VIRAL ONCOGENE HOMOLOG 
HS6ST1  B 604846 2q14.3 HEPARAN SULFATE 6-O-SULFOTRANSFERASE 1 
HSPG2 A 142461 1q36–34  PERLECAN  
HTR3B D 604654 11q23.2 5-HYDROXYTRYPTAMINE RECEPTOR 3B 
IBSP H 147563 4q22.1 INTEGRIN-BINDING SIALOPROTEIN 
ICK A 612325 6p12.3 INTESTINAL CELL KINASE 
ID1 D 600349 20q11.21 INHIBITOR OF DIFFERENTIATION 1 
IDH1  B 147700 2q34 ISOCITRATE DEHYDROGENASE 1 
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IDH2  B 147650 15q26.1  ISOCITRATE DEHYDROGENASE 2 
IFIH1 H 606951 2q24.2 INTERFERON-INDUCED HELICASE C DOMAIN-CONTAINING PROTEIN 1 
IFITM5 A 614757 11p15.5     INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 5 
IFT122 A 606045 3q21 INTRAFLAGELLAR TRANSPORT 122 (CHLAMYDOMONAS, HOMOLOG OF) 
IFT140 A 614620 16p13.3  INTRAFLAGELLAR TRANSPORT 140, CHLAMYDOMONAS, HOMOLOG OF 
IFT172 A 607386 2p23.3 INTRAFLAGELLAR TRANSPORT 172, CHLAMYDOMONAS, HOMOLOG OF 
IFT43 A 614068 14q24.3 INTRAFLAGELLAR TRANSPORT 43, CHLAMYDOMONAS, HOMOLOG OF 
IFT80 A 611177 3q25.33 INTRAFLAGELLAR TRANSPORT 80, CHLAMYDOMONAS, HOMOLOG OF 
IGF1 A 147440 12q23.2 INSULIN-LIKE GROWTH FACTOR I 
IGF1R A 147370 15q26.3  INSULIN-LIKE GROWTH FACTOR I RECEPTOR 
IHH A 600726 2q35 INDIAN HEDGEHOG 
IKBKAP B 603722 9q31.3 INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELLS, 
KINASE COMPLEX-ASSOCIATED PROTEIN 
IKBKG (NEMO) A 300248 Xq28 INHIBITOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER, KINASE OF 
IL17RD  B 606807 3p14.3  INTERLEUKIN 17 RECEPTOR D 
IL1RN A 147679 2q14.2 INTERLEUKIN 1 RECEPTOR ANTAGONIST 
INPPL1 D 600829 11q13.4    INOSITOL POLYPHOSPHATE PHOSPHATASE-LIKE 1 
INSR A 147670 19p13.2  INSULIN RECEPTOR 
IQSEC3 D 612118 12p13.33 IQ MOTIF- AND SEC7 DOMAIN-CONTAINING PROTEIN 3 
ITGA5 F  135620 12q13.13 INTEGRIN SUBUNIT ALPHA 5 
JAG1 H 601920 20p12.2 JAGGED 1 
JUN G 165160 1p32.1 V-JUN AVIAN SARCOMA VIRUS 17 ONCOGENE HOMOLOG 
KAT6B A 605880 10q22.2  LYSINE ACETYLTRANSFERASE 6B 
KCNJ16 C 605722 17q24.3 POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 16 
KCNMA1 H 600150 10q22.3 POTASSIUM CHANNEL, CALCIUM-ACTIVATED, LARGE CONDUCTANCE, 
SUBFAMILY M, ALPHA MEMBER 1 
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KDM6A A 300128 Xp11.3 LYSINE-SPECIFIC DEMETHYLASE 6A 
KIF1A B 601255 2q37.3 KINESIN FAMILY MEMBER 1A 
KIF22 A 603213 16p11.2   KINESIN FAMILY MEMBER 22 
KIF3B D 603754 20q11.21 KINESIN FAMILY MEMBER 3B 
KIF7 A 611254 15q26.1  KINESIN FAMILY MEMBER 7 
KISS1R  B,D 604161 19p13.3 KISS1 RECEPTOR 
KIT  B 164920 4q12 V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG 
KMT2D A 602113 12q13.12 LYSINE-SPECIFIC METHYLTRANSFERASE 2D 
KRAS A 190070 12p12.1 V-KI-RAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG 
L3MBTL2 D 611865 22q13.2 L3MBT-LIKE 2 
LACTB2 H H:18512 8q13.3 LACTAMASE, BETA 2 
LBR B 600024 1q42.1 LAMIN B RECEPTOR, 3-BETA-HYDROXYSTEROL DELTA (14)-REDUCTASE 
LEMD3 A,B 607844 12q14 LEM DOMAIN-CONTAINING 3 
LEPRE1(P3H1) A 610339 1p34.2 LEUCINE- AND PROLINE-ENRICHED PROTEOGLYCAN 1 
LFNG A 602576 7p22 LUNATIC FRINGE 
LHX3 A 600577 9q34.3 LIM HOMEOBOX GENE 3 
LIFR A  151443 5p13.1 LEUKEMIA INHIBITORY FACTOR RECEPTOR 
LMBR1 A 605522 7q36 PUTATIVE RECEPTOR PROTEIN 
LMNA A 150330 1q21.2 LAMIN A/C 
LMX1B A 602575 9q34.1 LIM HOMEOBOX TRANSCRIPTION FACTOR 1 
LPIN2 B 605519 18p11.3 LIPIN 2 
LRP4 H 604270 11p11.2 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 4 
LRP5 A 603506 11q13.2 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 5 
LRP6 H 603507 12p13.2 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6 
LTBP1 D 150390 2p22.3 LATENT TRANSFORMING GROWTH FACTOR-BETA-BINDING PROTEIN 1 
MAFB A 608968 20q12   V-MAF MUSCULOAPONEUROTIC FIBROSARCOMA ONCOGENE FAMILY, PROTEIN 
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B 
MAMSTR D 610349 19q13.33 MEF2-ACTIVATING SAP TRANSCRIPTIONAL REGULATOR 
MAP3K10 D 600137 19q13.2 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 10 
MAP3K7 F 602614 6q15 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7 
MAPKAPK2 D 602006 1q32.1 MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE 2 
MAPKBP1 B,D 616786 15q15.1 MITOGEN-ACTIVATED PROTEIN KINASE-BINDING PROTEIN 1 
MARHC09 A 613336 12q14.1 MEMBRANE-ASSOCIATED RING-CH FINGER PROTEIN 9 
MATN3 (MBL1) H 602109 2p23–24  MATRILIN 3 
MBL2 H 154545 10q21.1 LECTIN, MANNOSE-BINDING, SOLUBLE, 2 
MBTPS1 G 603355 16q23.3-
q24.1 
MEMBRANE-BOUND TRANSCRIPTION FACTOR PROTEASE, SITE 1 
MBTPS2 A 300294 Xp22.12 MEMBRANE-BOUND TRANSCRIPTION FACTOR PROTEASE, SITE 2 
MCPH1 D 607117 8p23.1 MICROCEPHALIN 
MDK D 162096 11p11.2 MIDKINE 
MECOM C 165215 3q26.2 MDS1 AND EVI1 COMPLEX LOCUS 
MEF2C H 600662 5q14.3 MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE C 
MEPE H 605912 4q22.1 MATRIX, EXTRACELLULAR, PHOSPHOGLYCOPROTEIN 
MESP2 A 605195 15q26 MESODERM POSTERIOR (EXPRESSED IN) 2 
MGP A 154870 12p13.1–
12.3 
MATRIX GLA PROTEIN 
MIR96 C  611606 7q32.2 MICRO RNA 96 
MKS1 A 609883 17q23 MKS1 GENE 
MMP13 A 600108 11q22.2  MATRIX METALLOPROTEINASE 13 
MMP2 A,F 120360 16q13 MATRIX METALLOPROTEINASE 2 
MMP9 A,F  120361 20q13.12  MATRIX METALLOPROTEINASE 9 
MOGS  B 601336 2p13.1 MANNOSYL-OLIGOSACCHARIDE GLYCOSIDASE 
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MPI C 154550 15q24.1 MANNOSEPHOSPHATE ISOMERASE 
MPP7 H 610973 10p12.1 MEMBRANE PROTEIN, PALMITOYLATED 7 
MPV17  B 137960 2p23.3 MPV17, MOUSE, HOMOLOG OF 
MRAP2 D 615410 6q14.2 MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN 2 
MRPS35 C 611995 12p11.22 MITOCHONDRIAL RIBOSOMAL PROTEIN S35 
MSX2 A 123101 5q35.2 MUSCLE SEGMENT HOMEOBOX 2 
MTA1 C 603526 14q32.33 METASTASIS-ASSOCIATED GENE 1 
MTAP  B 156540 9p21.3 METHYLTHIOADENOSINE PHOSPHORYLASE 
MYCN A 164840 2p24.3 V-MYC AVIAN MYELOCYTOMATOSIS VIRAL-RELATED ONCOGENE, 
NEUROBLASTOMA-DERIVED 
MYO7A C 276903 11q13.5 MYOSIN VIIA 
MYOG D 159980 1q32.1 MYOGENIN 
MYSM1 C 612176 1p32.1 MYB-LIKE, SWIRM, AND MPN DOMAINS-CONTAINING PROTEIN 1 
NAB2 D 602381 12q13.3 NGFIA-BINDING PROTEIN 2 
NBAS A 608025 2p24.3 NEUROBLASTOMA-AMPLIFIED SEQUENCE 
NBEAL2 D 614169 3p21.31 NEUROBEACHIN-LIKE 2 
NBN A 602667 8q21.3 NIBRIN 
NBR1 D 166945 17q21.31 NEIGHBOR OF BRCA1 GENE 1 
NCALD D 606722 8q22.3 NEUROCALCIN, DELTA 
NDP  B 300658 Xp11.3 NORRIN 
NEK1 A 604588 4q33   NIMA RELATED KINASE 1 
NF1 D 162200 17q11.2 NEUROFIBROMIN 
NFIX B 164005 19p13.3 NUCLEAR FACTOR I/X 
NGF  B 162030 1p13.2 NERVE GROWTH FACTOR 
NGFR D 162010 17q21.33 NERVE GROWTH FACTOR RECEPTOR 
NHLH2 D 162361 1p13.1 NESCIENT HELIX LOOP HELIX 2 
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NHP2 (NOLA2) B  606470 5q35.3 NUCLEOLAR PROTEIN FAMILY A, MEMBER 2; NOLA2  
NIPBL A 608667 5p13.1 NIPPED-B-LIKE 
NKX3-2 A 602183 4p16.1  NK3 HOMEOBOX 2  
NLRP3 A 606416 1q44 NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 
NMNAT1 C 608700 1p36.22 NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 1 
NOG A 602991 17q22 NOGGIN 
NOP10  B 606471 15q14 NUCLEOLAR PROTEIN FAMILY A, MEMBER 3; NOLA3  
NOTCH2 A  600275 1p12-p11  NOTCH, DROSOPHILA, HOMOLOG OF, 2 
NPR2 A 108961 9p13–12 NATRIURETIC PEPTIDE RECEPTOR 2 
NRAS  B 164790 1p13.2 NEUROBLASTOMA RAS VIRAL ONCOGENE HOMOLOG 
NSDHL A 300275 Xp11 NAD(P)H STEROID DEHYDROGENASE-LIKE PROTEIN 
NSMF  B 608137 9q34.3 NMDA RECEPTOR SYNAPTONUCLEAR SIGNALING AND NEURONAL MIGRATION 
FACTOR 
NTRK1 A 191315 1q23.1 NEUROTROPHIC TYROSINE KINASE, RECEPTOR, TYPE 1 
NXN D 612895 17p13.3  NUCLEOREDOXIN 
OBSL1 A 610991 2q35 OBSCURIN-LIKE 1 
OCRL  B 300535 Xq26.1 OCRL GENE 
OFD1 A 300170 Xp22.2  CHR. X OPEN READING FRAME 5 
ORC1 A 601902 1p32.3  ORIGIN RECOGNITION COMPLEX, SUBUNIT 1, S. CEREVISIAE, HOMOLOG OF 
ORC4 A 603056 2q23.1 ORIGIN RECOGNITION COMPLEX, SUBUNIT 4, S. CEREVISIAE, HOMOLOG OF 
ORC6 A 607213 16q11.2 ORIGIN RECOGNITION COMPLEX, SUBUNIT 6, S. CEREVISIAE, HOMOLOG OF 
OSTM1 A 607649 6q21 GRAY LETHAL/OSTEOPETROSIS ASSOCIATED TRANSMEMBRANE PROTEIN 
P3H1/LEPRE1 A 610339 1p34.2 PROLYL 3-HYDROXYLASE 1 
P4HA1 E 176710 10q22.1 PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, ALPHA SUBUNIT, 
ISOFORM 1 
P4HA2 E 600608 5q31.1 PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, ALPHA SUBUNIT, 
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ISOFORM 2 
P4HA3 E 608987 11q13.4 PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, ALPHA SUBUNIT, 
ISOFORM 3 
P4HB A 176790 17q25.3 PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE-4-DIOXYGENASE, BETA SUBUNIT 
PAK1 D 602590 11q13.5-
q14.1 
P21 PROTEIN-ACTIVATED KINASE 1 
PAPSS2 A 603005 10q23–q24  PAPS-SYNTHETASE 2  
PARL D 607858 3q27.1 PRESENILIN-ASSOCIATED RHOMBOID-LIKE PROTEIN 
PARN  B 604212 16p13.12 POLYADENYLATE-SPECIFIC RIBONUCLEASE 
PARVB C 608121 22q13.31 PARVIN, BETA 
PAX3 A 606597 2q36.1 PAIRED BOX GENE 3 
PCNT A 605925 21q22.3 PERICENTRIN 
PDE11A  B 604961 2q31.2 PHOSPHODIESTERASE 11A 
PDE8B  B 603390 5q13.3 PHOSPHODIESTERASE 8B 
PER2 C 603426 2q37.3 PERIOD, DROSOPHILA, HOMOLOG OF, 2 
PEX7 A 601757 6q22–24 PEROXISOMAL PTS2 RECEPTOR 
PFN1 D 176610 17p13.2 PROFILIN 1 
PGD C 172200 1p36.22 6-PHOSPHOGLUCONATE DEHYDROGENASE, ERYTHROCYTE 
PHEX A,C 300550 Xp22 X-LINKED HYPOPHOSPHATEMIA MEMBRANE PROTEASE 
PHOSPHO1 D H:16815 17q21.32 PHOSPHATASE, ORPHAN 1 
PIAS2 D 603567 18q12.1-
q12.3 
PROTEIN INHIBITOR OF ACTIVATED STAT2 
PIGV A 610274 1p36.11 PHOSPHATIDYLINOSITOL-GLYCAN BIOSYNTHESIS CLASS V PROTEIN (GPI 
MANNOSYLTRANSFERASE 2) 
PITX1 A 602149 5q31.1  PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 1 (PITUITARY 
HOMEOBOX 1) 
PITX2 A 601542 4q25 PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 2 
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PITX3 D 602669 10q24.32 PAIRED-LIKE HOMEODOMAIN TRANSCRIPTION FACTOR 3 
PJA2 D H:17481 5q21.3 PRAJA 2 
PLCG2 C 600220 16q23.3 PHOSPHOLIPASE C, GAMMA-2 
PLD5 D H:17481 1q43 PHOSPHOLIPASE D FAMILY, MEMBER 5 
PLEKHM1 A 611466 17q21.3 PLECKSTRIN HOMOLOGY DOMAIN-CONTAINING PROTEIN, FAMILY M, MEMBER 1 
PLOD1 D 153454 1p36.22 PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 
PLOD2 A 601865 3q24    PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 
PLOD3  B 603066 7q22.1 PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 3 
PLS3 A 300161 Xq23 PLASTIN 3 
POC1A A 614783 3p21.2 POC1 CENTRIOLAR PROTEIN, CHLAMYDOMONAS, HOMOLOG OF, A 
POLR1C A 610060 6p21.1 POLYMERASE (RNA) I POLYPEPTIDE C 
POR A 124015 7q11.23 CYTOCHROME P450 OXIDOREDUCTASE 
POU1F1 A 173110 3p11.2 POU DOMAIN, CLASS 1, TRANSCRIPTION FACTOR 1 
PPARG  B 601487 3p25.2 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA 
PPIB A 123841 15q22.31 PEPTIDYL-PROLYL ISOMERASE B 
PPM1A D 606108 14q23.1 PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1A 
PPP2R3A D 604944 3q22.2-
q22.3 
PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B-DOUBLE PRIME, ALPHA 
PRDM14 D 611781 8q13.3 PR DOMAIN-CONTAINING PROTEIN 14 
PRDM4 D 605780 12q23.3 PR DOMAIN-CONTAINING PROTEIN 4 
PRDM5  B 614161 4q27 PR DOMAIN-CONTAINING PROTEIN 5 
PRKAR1A A 188830 17q24.2  PROTEIN KINASE, CAMP-DEPENDENT, REGULATORY, TYPE I, ALPHA 
PROK2  B 607002 3p13 PROKINETICIN 2 
PROKR2  B 607123 20p12.3 PROKINETICIN RECEPTOR 2 
PROP1 A 601538 5q35.3 PROP PAIRED-LIKE HOMEOBOX 1 
PRPSAP2 D 603762 17p11.2 PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE-ASSOCIATED PROTEIN 2 
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PRSS50 C,D 607950 3p21.31 TESTIS-SPECIFIC PROTEASE 50  
PSPH D 172480 7p11.2 PHOSPHOSERINE PHOSPHATASE 
PTDSS1 A 612792 8q22.1 PHOSPHATIDYLSERINE SYNTHASE 1 
PTEN  B 601728 10q23.31 PHOSPHATASE AND TENSIN HOMOLOG 
PTH H 168450 11p15.3 PARATHYROID HORMONE 
PTH1R A, D 168468 3p22–21.1 PTH/PTHRP RECEPTOR 1 
PTHLH H 168470 12p11.22 PARATHYROID HORMONE-LIKE HORMONE (PARATHYROID HORMONE RELATED 
PEPTIDE, PTHRP) 
PTPN11 A 176876 12q24 PROTEIN-TYROSINE PHOSPHATASE NONRECEPTOR-TYPE 11 
PTPRQ A 603317 12q21.31 PROTEIN-TYROSINE PHOSPHATASE, RECEPTOR-TYPE, Q 
PXYLP1 D H:26303 3q23 2-PHOSPHOXYLOSE PHOSPHATASE 1 
PYCR1 A  179035 17q25.3 PYRROLINE-5-CARBOXYLATE REDUCTASE 1 
RAB23 A 606144 6p11.2  RAS-ASSOCIATED PROTEIN RAB23 
RAB24 D 612415 5q35.3 RAS-ASSOCIATED PROTEIN 24 
RAB3IP D 608686 12q13-q14 RAB3A-INTERACTING PROTEIN 
RAF1 A 164760 3p25.2 V-RAF-1 MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 
RAPSN B 601592 11p11.2 RECEPTOR-ASSOCIATED PROTEIN OF THE SYNAPSE, 43-KD 
RASGRP2  A 605577 11q13 RAS GUANYL NUCLEOTIDE-RELEASING PROTEIN 2 
RECQL4 A 603780 8q24.3 RECQ PROTEIN-LIKE 4 
RGN D 300212 Xp11.3 REGUCALCIN 
RHBDD1 C 617515 2q36.3 RHOMBOID DOMAIN CONTAINING 1 
RHBDF2 C 614404 17q25.1 RHOMBOID 5, DROSOPHILA, HOMOLOG OF, 2 
RHOBTB3 D 607353 5q15 RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 3 
RHOT2 D 613889 16p13.3  RAS HOMOLOG GENE FAMILY, MEMBER T2 
RIC1 C 610354 9p24.1 CONNEXIN 43-INTERACTING PROTEIN 
RIC8B D 609147 12q23.3 RIC8, C. ELEGANS, HOMOLOG OF, B 
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RLN3 D 606855 19p13.12 RELAXIN 3 
RNASE10 D H:19275 14q11.1 RIBONUCLEASE A FAMILY MEMBER 10 
RNF169 C H:26961 11q13.4 RING FINGER PROTEIN 169  
ROR2 A 602337 9q22 RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTOR 2 
RPGRIP1L A 610937 16q12.1 RPGRIP1-LIKE 
RPS6KA3 A 300075 Xp22.12 RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 3 
RPS6KA5 H 603607 14q32.11 RIBOSOMAL PROTEIN S6 KINASE, 90-KD, 5 
RSPO3 H 610574 6q22.33 R-SPONDIN 3 
RTEL1  B 608833 20q13.33 REGULATOR OF TELOMERE ELONGATION HELICASE 1 
RUNX2 A, D,H 600211 6p21 RUNT RELATED TRANSCRIPTION FACTOR 2 
RXRG C 180247 1q23.3 RETINOID X RECEPTOR, GAMMA 
SALL1 A 602218 16q12.1 SAL-LIKE 1 
SALL4 A 607343 20q13 SAL-LIKE 4 
SBDS A 607444 7q11 SBDS PROTEIN 
SC5D  B 602286 11q23.3-
q24.1 
STEROL C5-DESATURASE-LIKE 
SCARB2  B 602257 4q21.1 SCAVENGER RECEPTOR CLASS B, MEMBER 2 
SCN10A  B 604427 3p22.2 SODIUM CHANNEL, VOLTAGE-GATED, TYPE X, ALPHA SUBUNIT 
SCN11A B 604385 3p22.2 SODIUM CHANNEL, VOLTAGE-GATED, TYPE XI, ALPHA SUBUNIT 
SCN3B D 608214 11q24.1 SODIUM CHANNEL, VOLTAGE-GATED, TYPE III, BETA SUBUNIT 
SCN9A B 603415 2q24.3 SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT 
SDHC D 602413 1q23.3 SUCCINATE DEHYDROGENASE COMPLEX, SUBUNIT C, INTEGRAL MEMBRANE 
PROTEIN, 15-KD 
SEC24D A 607186 4q24 SEC24-RELATED GENE FAMILY, MEMBER D 
SELE  I 131210 1q24.2 SELECTIN E 
SEMA3A  B 603961 7q21.11 SEMAPHORIN 3A 
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SEMA3F D 601124 3p21.31 SEMAPHORIN 3F 
SEMA5A  B 609297 5p15.31 SEMAPHORIN 5A 
SERPINF1 A 172860 17p13.3  SERPIN PEPTIDASE INHIBITOR, CLADE F, MEMBER 1 
SERPINH1 A 600943 11q13.5 SERPIN PEPTIDASE INHIBITOR, CLADE H, MEMBER 1 
SETD2 D 612778 3p21.31 SET DOMAIN-CONTAINING PROTEIN 2 
SETDB1 D 604396 1q21.3 SET DOMAIN PROTEIN, BIFURCATED, 1 
SFRP1 C 604156 8p11.21 SECRETED FRIZZLED-RELATED PROTEIN 1 
SFRP2 C 604157 4q31.3 SECRETED FRIZZLED-RELATED PROTEIN 2 
SH3BP2 A 602104 4p16 SH3 DOMAIN-BINDING PROTEIN 2 
SH3GL2 D 604465 9p22.2 SH3 DOMAIN, GRB2-LIKE, 2 
SH3PXD2B A 613293 5q35.1  TKS4 
SHH D 600725 7q36 SONIC HEDGEHOG 
SHOX A 312865 Xp22.33 SHORT STATURE—HOMEOBOX GENE 
SHOX2 A 602504 3q25.32 SHORT STATURE HOMEOBOX 2 
SLC20A2 D 158378 8p11.21 SOLUTE CARRIER FAMILY 20 (PHOSPHATE TRANSPORTER), MEMBER 2 
SLC25A12 A 603667 2q31.1 SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER, ARALAR), MEMBER 12 
SLC25A13 H 603859 7q21.3 SOLUTE CARRIER FAMILY 25 (CITRIN), MEMBER 13 
SLC25A21 D 607574 14q13.3 SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL OXODICARBOXYLATE CARRIER), 
MEMBER 21 
SLC26A2 A 606718 5q32–q33  SOLUTE CARRIER FAMILY 26 (SULFATE TRANSPORTER), MEMBER 2 
SLC29A1 D 602193 6p21.1 SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 1 
SLC29A3 B 612373 10q22.1 SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTER), MEMBER 3 
SLC34A1  B 182309 5q35.3 SOLUTE CARRIER FAMILY 34 (TYPE II SODIUM/PHOSPHATE COTRANSPORTER), 
MEMBER 1 
SLC34A3 A 609826 9q34 SODIUM-PHOSPHATE COTRANSPORTER 
SLC35D1 A 610804 1p31.3  SOLUTE CARRIER FAMILY 35 MEMBER D1; UDP-GLUCURONIC ACID/ UDP-N-
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ACETYLGALACTOSAMINE DUAL TRANSPORTER 
SLC38A10 D 616525 17q25.3 SOLUTE CARRIER FAMILY 38 (AMINO ACID TRANSPORTER), MEMBER 10 
SLC39A13 A 608735 11p11.2  SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 13 
SLC40A1 D 604653 2q32.2 SOLUTE CARRIER FAMILY 40 (IRON-REGULATED TRANSPORTER), MEMBER 1 
SLC4A1  B 109270 17q21.31 SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1 
SLC7A1 A 104615 13q12.3 SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, Y+ 
SYSTEM), MEMBER 1 
SLC9A3R1  B 604990 17q25.1 SOLUTE CARRIER FAMILY 9, MEMBER 3, REGULATOR 1 
SLC9A4 D 600531 2q12.1 SOLUTE CARRIER FAMILY 9, MEMBER 4 
SMAD1 F  601595 4q31.21 MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 1 
SMAD4 F  600993 18q21.2     MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 4 
SMAD7 F  602932 18q21.1   MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 7 
SMARCAL1 A 606622 2q34–q36  SWI/SNF-RELATED REGULATOR OF CHROMATIN SUBFAMILY A-LIKE PROTEIN 1 
SMC1A A 300040 Xp11.22 STRUCTURAL MAINTENANCE OF CHROMOSOMES 1A 
SMC3 A,D 606062 10q25.2 STRUCTURAL MAINTENANCE OF CHROMOSOMES 3 
SMOC1 H 608488 14q24.2 SPARC-RELATED MODULAR CALCIUM-BINDING 1 
SMS B,D 607642 17p11.2 RETINOIC ACID-INDUCED GENE 1 
SNX10  B 614780 7p15.2 SORTING NEXIN 10 
SOS1 A 182530 2p22.1 SON OF SEVENLESS, DROSOPHILA, HOMOLOG 1 
SOST H 605740 17q21.31   SCLEROSTIN 
SOX10 B 602229 22q13.1 SRY-BOX 10 
SOX2 A 184429 3q26.33 SRY-BOX 2 
SOX3 A 313430 Xq27.1 SRY-BOX 3 
SOX6 H 607257 11p15.2 SRY-BOX 6 
SOX9 A 608160 17q24.3 SRY-BOX 9 
SP7 A 606633 12q13.13   TRANSCRIPTION FACTOR SP7 
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SPARC D 182120 5q33.1 SECRETED PROTEIN, ACIDIC, CYSTEINE-RICH 
SPNS2 D 612584 17p13.2 SPINSTER, DROSOPHILA, HOMOLOG OF, 2 
SPP1 (OPN) H 166490 4q22.1 SECRETED PHOSPHOPROTEIN 1 
SPRY4  B 607984 5q31.3 SPROUTY, DROSOPHILA, HOMOLOG OF, 4 
SPTBN1 H 182790 2p16.2 SPECTRIN, BETA, NONERYTHROCYTIC, 1 
SQSTM1  B 601530 5q35.3 SEQUESTOSOME 1 
SRCAP A 611421 16p11.2   SNF2-RELATED CBP ACTIVATOR PROTEIN 
SSBP2 D 607389 5q14.1 SINGLE-STRANDED DNA-BINDING PROTEIN 2 
SST D 182450 3q28 SOMATOSTATIN 
STAG3 D 608489 7q22.1 STROMAL ANTIGEN 3 
STARD3NL H 611759 7p14.1 STARD3 N-TERMINAL-LIKE 
STAT3  B 102582 17q21.2 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 
STAT5B A 604260 17q21.2 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5B 
SUCO D H:1240 1q24.3 SUN DOMAIN CONTAINING OSSIFICATION FACTOR 
SULF1 A 610012 8q13.2-
q13.3 
SULFATASE 1 
SYN3 D 602705 22q12.3 SYNAPSIN III 
TACR3  B 162332 4q24 TACHYKININ RECEPTOR 3 
TBCE A 604934 1q42–q43 TUBULIN-SPECIFIC CHAPERONE E 
TBX15 A 604127 1p13 T-BOX GENE 15 
TBX3 A 601621 12q24.21  T-BOX GENE 3 
TBX4 A 601719 17q21–q22 T-BOX GENE 4 
TBX5 A 601620 12q24.1 T-BOX GENE 5 
TBXAS1 A 274180 7q34 THROMBOXANE A SYNTHASE 1 
TCIRG1 B 604592 11q13 SUBUNIT OF ATPASE PROTON PUMP 
TCOF1 A 606847 5q32 TREACHER COLLINS-FRANCESCHETTI SYNDROME 1 
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TCTN3 A 613847 10q24.1  TECTONIC FAMILY, MEMBER 3  
TDP2 A 605764 6p22.3 TYROSYL-DNA PHOSPHODIESTERASE 2 
TERC  B 602322 3q26.2 TELOMERASE RNA COMPONENT 
TERT  B 187270 5p15.33 TELOMERASE REVERSE TRANSCRIPTASE 
TFEB D 600744 6p21.1 T-CELL TRANSCRIPTION FACTOR EB 
TGFB1 A 190180 19q13 TRANSFORMING GROWTH FACTOR BETA 1 
TGFBR1 F  190181 9q22.33     TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE I 
TGFBR2 F  190182 3p24.1 TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE II 
THBS1 F 188060 15q14 THROMBOSPONDIN I 
THPO A 600044 3q27 THROMBOPOIETIN 
THRB A 190160 3p24.2 THYROID HORMONE RECEPTOR, BETA 
TIMM50 D 607381 19q13.2 TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 50, YEAST, HOMOLOG 
OF 
TIMM8A  B 300356 Xq22.1 TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 8, YEAST, HOMOLOG 
OF, A 
TINF2  B 604319 14q12 TRF1-INTERACTING NUCLEAR FACTOR 2 
TMCO1 A 614123 1q24.1 TRANSMEMBRANE AND COILED-COIL DOMAINS PROTEIN 1 
TMEM132A D 617363 11q12.2 TRANSMEMBRANE PROTEIN 132A  
TMEM135 H 616360 11q14.2 TRANSMEMBRANE PROTEIN 135 
TMEM136 D H:28280 11q23.3 TRANSMEMBRANE PROTEIN 136 
TMEM189 D 610994 20q13.13 TRANSMEMBRANE PROTEIN 189 
TMEM216 A 613277 11q12.2  TRANSMEMBRANE PROTEIN 216 
TMEM38B (TRIC-B) A 611236 9q31.2 TRANSMEMBRANE PROTEIN 38B 
TNFAIP1 D 191161 17q11.2 TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 1 
TNFRSF11A A,H 603499 18q21.33 RECEPTOR ACTIVATOR OF NF-KAPPA-B 
TNFRSF11B D,H 602643 8q24 OSTEOPROTEGERIN 
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TNFSF11 (RANK) B,H 602642 13q14.11 RECEPTOR ACTIVATOR OF NF-KAPPA-B LIGAND (TUMOR NECROSIS FACTOR 
LIGAND SUPERFAMILY, MEMBER 11) 
TNIK D 610005 3q26.2-
q26.3 
TRAF2- AND NCK-INTERACTING KINASE 
TP63 A 603273 3q28 TUMOR PROTEIN P63 
TPGS2 D H:24561 18q12.2 TUBULIN POLYGLUTAMYLASE COMPLEX SUBUNIT 2 
TPPP D 608773 5p15.33 TUBULIN POLYMERIZATION-PROMOTING PROTEIN 
TRAM2 D 608485 6p12.2 TRANSLOCATION-ASSOCIATED MEMBRANE PROTEIN 2 
TRAPPC2 A 300202 Xp22  TRACKING PROTEIN PARTICLE COMPLEX, SUBUNIT 2 
TREM2 A 605086 6p21.2 TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 
TRIM37 A 605073 17q22 TRIPARTITE MOTIF-CONTAINING PROTEIN 37 
TRIM45 D 609318 1p13.1 TRIPARTITE MOTIF-CONTAINING PROTEIN 45 
TRIP11 A 604505 14q32.12  GOLGI-MICROTUBULE-ASSOCIATED PROTEIN, 210-KDA; MAP210 
TRMT10A A 616013 4q23 TRNA METHYLTRANSFERASE 10, S. CEREVISIAE, HOMOLOG OF, A 
TRPC3 D 602345 4q27 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY C, MEMBER 3 
TRPS1 A 604386 8q24 ZINC FINGER TRANSCRIPTION FACTOR 
TRPV4 A 605427 12q24.1  TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 4 
TSPAN12  B 613138 7q31.31 TETRASPANIN 12 
TTC21B A 612014 2q24.3   TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 21B 
TTC28 D 615098 22q12.1 TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 28 
TWIST1 A 601622 7p21.1 TWIST, DROSOPHILA, HOMOLOG OF, 1  
TWIST2 A 607556 2q37.3 TWIST, DROSOPHILA, HOMOLOG OF, 2  
TXNIP D 606599 1q21.1 THIOREDOXIN-INTERACTING PROTEIN 
TYROBP A 604142 19q13.1 TYRO PROTEIN TYROSINE KINASE-BINDING PROTEIN 
UBE2J1 D 616175 6q15 UBIQUITIN-CONJUGATING ENZYME E2J 1 
UBE3C D 614454 7q36.3 UBIQUITIN PROTEIN LIGASE E3C 
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UMOD D 191845 16p12.3 UROMODULIN 
UROS D 606938 10q26.2 UROPORPHYRINOGEN III SYNTHASE 
USB1 B 613276 16q21 CHROMOSOME 16 OPEN READING FRAME 57; C16ORF57  
USP8  B 603158 15q21.2 UBIQUITIN-SPECIFIC PROTEASE 8 
VANGL2 C 600533 1q23.3 VANG-LIKE 2 
VDR H 601769 12q13.11 VITAMIN D RECEPTOR 
VIPAS39  B 613401 14q24.3 VPS33B-INTERACTING PROTEIN, APICAL-BASOLATERAL POLARITY REGULATOR, 
SPE39 HOMOLOG 
VPS13A D 605978 9q21.2 VACUOLAR PROTEIN SORTING 13, YEAST, HOMOLOG OF, A 
VPS33B  B 610034 12q24.31 VACUOLAR PROTEIN SORTING 33, YEAST, HOMOLOG OF, A 
WBP2 D 606962 17q25.1 WW DOMAIN-BINDING PROTEIN 2 
WDR11  B 606417 10q26.12 WD REPEAT-CONTAINING PROTEIN 11 
WDR35 A 613602 2p24.1 WD REPEAT-CONTAINING PROTEIN 35 
WDR60 A 615462 7q36.3 WD REPEAT-CONTAINING PROTEIN 60 
WISP3 A 603400 6q22–23 WNT1-INDUCIBLE SIGNALING PATHWAY PROTEIN 3 
WLS H 611514 1p31.3  WNTLESS, DROSOPHILA, HOMOLOG OF 
WNT1 A,B 164820 12q13.12 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 1 
WNT16 H 606267 7q31.31 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 16 
WNT3 H 165330 17q21.31  WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 3 
WNT3A  B 606359 1q42.13 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 3A 
WNT4 H 603490 1p36.12 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 4 
WNT5A A 164975 3p14.3  WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5A 
WNT5B H 606361 12p13.33 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5B 
WNT7A A 601570 3p25 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 7A 
WNT9B H 602864 17q21.32 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 9B 
WRAP53  B 612661 17p13.1 WD REPEAT-CONTAINING PROTEIN ANTISENSE TO TP53 
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WRN/RECQL2 A 604611 8p12 RECQ PROTEIN-LIKE 2 
XBP1 C 194355 22q12.1 X BOX-BINDING PROTEIN 1 
XYLT1 A 608124 16p12.3 XYLOSYLTRANSFERASE 1 
XYLT2 A 608125 17q21.33 XYLOSYLTRANSFERASE 2 
ZBTB40 H 612106 1p36.12 ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 40 
ZBTB45 D H:23715 19q13.43 ZINC FINGER AND BTB DOMAIN-CONTAINING PROTEIN 45 
ZFYVE28 D 614176 4p16.3 ZINC FINGER FYVE DOMAIN-CONTAINING PROTEIN 28 
ZMPSTE24 A,D 606480 1p34 ZINC METALLOPROTEINASE 
ZNF408  B 616454 11p11.2 ZINC FINGER PROTEIN 408 
ZNF469  B 612078 16q24.2 ZINC FINGER PROTEIN 469 
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I. Patient information sheet for young people 
  
 
PARTICIPANT INFORMATION SHEET 
FOR YOUNG PEOPLE 
Study title 
Novel molecular mechanisms leading to Osteogenesis Imperfecta 
(DNA studies to find new causes of Brittle Bone Disease)   
Part 1 – to give you first thoughts about the project 
 
1. Invitation paragraph 
We would like you to help us with our research study.  Please read this 
information carefully and talk to your mum, dad or carer about the study.  Ask 
us if there is anything that is not clear or if you want to know more.  Take time 
to decide if you want to take part.  It is up to you if you want to do this.  If you 
don’t then that’s fine, you’ll be looked after at the hospital just the same. 
 
2. Why are we doing this research? 
We want to try and find out if mistakes in inherited factors 
called genes can cause fractures and a condition called 
Brittle Bone Disease.  Genes are carried on genetic material 
called DNA. We inherit genes from our parents. Each gene 
is made up of thousands of individual genetic letters known 
as the gene sequence. A mistake in the gene sequence (a 
mutation) can disrupt the genetic message and in some 
instances cause bones to not receive the correct 
instructions for growth and development.  
 
If you have brittle bones, they’re not as strong as other peoples and you’re 
more likely to fracture them. Some people have an inherited condition called 
brittle bone disease (also called osteogenesis imperfecta) where their bones 
are much more likely to fracture and in some severe cases may not form 
properly. 
 
Although some genes have already been studied in people with fractures and 
brittle bone disease, it is likely that more genes exist. We hope that by studying 
some new genes in families who have fractures that this study will help us to 
identify currently unknown causes of fractures and brittle bone disease. If we 
can discover more about the genes that cause fractures and brittle bone 
disease it may lead to important advances in the management of children and 
their families with fractures and we may be able to develop new treatments to 
combat the condition. 
 
The study is being conducted as part of a research degree. 
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3. Why have I been asked to take part? 
You have been chosen because you and some of your family have had 
fractures and a previous gene test did not find the cause of these fractures. 
 
4. Do I have to take part? 
No! It is entirely up to you.  If you do decide to take part: 
- you will be asked to sign a form to say that you agree to take part (an assent 
form) 
- you will be given this information sheet and a copy of your signed assent form 
to keep. 
You are free to stop taking part at any time during the research without giving a 
reason.  If you decide to stop, this will not affect the care you receive whilst in 
hospital. 
 
 
5. What will happen to me if I take part? 
We would like to do some tests for some new genes by using a sample of your 
DNA.  which we hope may explain the cause of the fractures in your family.  
For most people we have a DNA sample stored in our laboratory. This DNA is 
left over from when you had your previous gene test.  
If there is not enough DNA leftover for us to finish our tests we would like to 
take a small blood sample from you, so we can extract more DNA for analysis. 
We would need to take about 1 teaspoon of blood (5mls), which can be taken 
at your next Genetics clinin, if you have one, of at your local surgery by your 
GP or Practice Nurse. Taking blood samples may take up to 10 minutes, and 
will be very similar to having blood samples taken at a routine clinic visit. Local 
anaesthetic cream can be used to help numb any pain and your parent/carer 
can stay with you while you give your blood sample.  
 
We may ask you questions about: 
 How many brothers & sisters you have 
 Do your Mum and Dad have brothers and sisters, uncles & 
aunts and what other family members are there? 
 If any of them have fractures or other problems 
 
Our testing of your DNA is difficult and may take some years.  We will only use 
your DNA to look at genes which may be involved in brittle bones. 
 
279 
 
6. What will I be asked to do? 
For most people, taking part in the study will only mean consenting to use of 
their stored DNA sample. 
Some people may be asked of give a small sample of blood. 
You may have to give your Genetics clinician/nurse more information on your 
family tree. This should take about 10 minutes. 
 
7. Is there anything else to be worried about if I take part? 
Your normal medical care will continue unchanged.  
ou would not need to attend any extra clinic appointments or have any extras 
tests to participate in this study. The study does not involve any treatment, or 
follow up clinic visits. You will not have to miss any meals to take part. 
If we find out something that we think is important about the cause of your 
fractures we will talk to your mum, dad or carer and ask them if they want to 
come back and have you checked again at the hospital. 
 
8. Will the study help me? 
No, but the information we get might help treat young people with fractures and 
brittle bones better in the future. 
 
9. What happens when the research study stops? 
We will collect all the information together and decide if it is useful in telling us 
if we can manage fractures and brittle bone disease better in the future. 
 
10. Contact for further information 
If you would like any further information about this study you could contact: 
Dr M Balasubramanian 
Consultant Clinical Geneticist 
Sheffield Clinical Genetics Service 
Sheffield Children's NHS Foundation Trust 
Western Bank 
Sheffield S10 2TH 
Phone: 0114 2717025 
 
Thank you for reading so far - if you are still interested, please go to Part 2: 
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Part 2 - more detail – information you need to know if you still want to take part. 
 
11. What if new information comes along? 
Sometimes during research, new things are found out about your condition.  If 
this happens, someone from the research team will tell you all about it and 
discuss whether you want to continue in the study.  If you change your mind 
this will not affect any care you will receive whilst in hospital.  If you decide to 
continue in the study you will be asked to sign an updated assent form. 
 
12. What if I don’t want to do the research anymore? 
Just tell your mum, dad, carer, doctor or nurse at any time.  They will not be 
cross with you.  You will still have the same care whilst you are at hospital. 
 
13. What if there is a problem or something goes wrong? 
Tell us if there is a problem and we will try and sort it out straight away.  You 
and your mum, dad or carer can either contact the 
project co-ordinator: 
 
Dr M Balasubramanian 
Consultant Clinical Geneticist 
Sheffield Clinical Genetics Service 
Sheffield Children's NHS Foundation Trust 
Western Bank 
Sheffield S10 2TH 
Phone: 0114 2717025 
or the hospital complaints co-ordinator: 
Mrs Linda Towers 
Patient Advice & Liaison Co-ordinator 
Sheffield Children’s NHS Foundation Trust 
Tel: 0114 271 7594 
 
14. Will anyone else know I’m doing this? 
The people in our research team will know you are taking part.  The Genetics 
doctor looking after you will also know. 
Your medical notes may also be looked at by other people who work at the 
hospital to check that the study is being carried out correctly. 
All information that is collected about you during the research will be kept 
strictly confidential.  You will be given a number which will be used instead. 
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Once the study is complete all information will be kept by the research team for 
30 years. This will include results of the work that we undertake whilst looking 
for a mistake in genes which may cause brittle bones.  
15. What will happen to any samples I give? 
Your DNA sample will be held in special fridges/freezers at Sheffield Diagnostic 
Genetics Service for 30 years. At the end of this period, your sample will be 
destroyed. 
Your DNA sample will be used only for studying genes which may be a cause 
of brittle bones. This may involve looking for possible causes of brittle bones 
that cannot yet be specified. Only researchers involved in this work will have 
access to your sample.  
Any significant findings during/after the study will be fed back to you by your 
Genetics doctor.  
 
16. What will happen to the results of the research study? 
When the study has finished we will present our findings to other doctors, and 
we will put the results in medical magazines and websites that doctors read.  
We would also like to put a brief summary on the hospital research website so 
that you will be able to read about our results too.  This will be available at the 
end of the study, in <insert date>, on www.sheffieldchildrenscrf.nhs.uk.  The 
results will also be included as part of the chief investigator’s educational 
qualification.  They will be anonymous, which means that you will not be able to 
be identified from them. 
 
17. Who is organising and funding the research? 
The research is being organised by Sheffield Children’s NHS Foundation Trust 
and paid for by the Childrens Hospital Charity Research Fund 
 
18. Who has checked the study? 
Before any research goes ahead it has to be checked by a Research Ethics 
Committee.  This is a group of people who make sure that the research is OK 
to do.   
It has also been checked by the Research Department at this hospital. 
 
19. How can I find out more about research? 
The Clinical Research Facility at this hospital has an Information for families 
section on its website www.sheffieldchildrenscrf.nhs.uk or you could contact 
the hospital Clinical Research Facility: 
Mrs Wendy Swann 
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R&D Manager 
Clinical Research Facility 
Sheffield Children’s NHS Foundation Trust 
Tel: 0114 2717417 
Thank you for taking the time to read this – please ask any questions if you 
need to. 
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J. Approved funding application for Targeted Exome Sequencing Project  
FULL STUDY TITLE  
Investigation of the SERPINH1, SERPINF1, FKBP10 and SP7 genes to determine novel mutational 
mechanism responsible for Osteogenesis Imperfecta in families lacking a mutation in the type I collagen 
genes. 
SHORT STUDY TITLE  
Novel molecular mechanisms leading to Osteogenesis Imperfecta. 
 
STUDY NUMBER  
 
DATE AND VERSION NUMBER  
09th March 2011 Version 1 
 
LAY SUMMARY 
Osteogenesis imperfecta (OI) is a group of inherited disorders characterized by increased bone fragility and is often 
referred to as brittle bone disease. The severity of OI can range from very mild, with few fractures, to lethal. At present it can 
be difficult to exclude OI in children with recurrent fractures, particularly where there is a family history of bone fragility. A 
genetic test can help to establish the diagnosis of OI in some children. 
The majority, but not all, of OI is caused by a genetic mistake (mutation) in one of the two genes which code for a protein 
called type I collagen, which is a major component of bone. If a mutation is found in the type I collagen genes, it will help to 
confirm a diagnosis of OI. However ~10% of families with OI do not have a mutation and therefore a negative test does not 
completely exclude OI. 
 Research to identify the cause of OI in individuals without mutations in the type I collagen genes has focused on 
individuals with lethal forms of the disease. Recently it has been found that some severely affected individuals may have 
mutations in new genes called FKBP1, SERPINF1, SERPINH1 and SP7.  
We want to find out if children and their families with moderate or mild OI also have mutations in these new genes. We 
will collect a group of 20 patients with moderate/mild OI without mutations in the type I collagen genes and use them to 
study the new genes. If a mutation can be found in any of these patients then this would influence how we investigate 
unexplained and recurrent fractures in infancy and childhood, improve the diagnosis and possible treatment of future OI 
patients and allow family members to find out if they carry the OI mutation.  
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GENERAL INFORMATION 
Sponsor: Sponsor’s Representative/Contact: 
Sheffield Children’s NHS Foundation Trust 
Western Bank 
Sheffield  
S10 2TH 
United Kingdom 
  
Dr Jim Bonham 
Director of Research & Development 
 
Phone:  0114 2717404 
Fax:      0114 2717417 
Email:   jim.bonham@sch.nhs.uk 
  
Chief Investigator: Principal Investigator 
Name – Rebecca Pollitt 
Address –  
Sheffield Diagnostic Genetics Department 
Sheffield Children’s NHS Foundation Trust 
Western Bank 
Sheffield  
S10 2TH 
United Kingdom 
Telephone –  +441142717016 
Fax +441142750629 
Email – rebecca.pollitt@sch.nhs.uk 
Name –  
Address –  
Telephone –  
Fax –  
Email - 
  
Co-Investigator: Co-Investigator: 
Name – Dr A Dalton 
Address –  
Sheffield Diagnostic Genetics Department 
Sheffield Children’s NHS Foundation Trust 
Name – Prof N J Bishop 
Address – 
Academic Unit of Child Health, University of 
Sheffield 
Stephenson Wing 
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Western Bank 
Sheffield  
S10 2TH 
United Kingdom 
Telephone – +441142717004 
Fax +441142750629 
Email – ann.dalton@sch.nhs.uk 
Sheffield Children's Hospital 
Western Bank 
Sheffield S10 2TH 
 
Telephone – Tel +441142717303 
Fax +441142755364 
 
Email – N.J.Bishop@scheffeild.nhs.uk 
  
Statistician: Other: 
Name –  
Address –  
Telephone –  
Fax –  
Email - 
Name –  
Address –  
Telephone –  
Fax –  
Email - 
  
GLOSSARY 
A list of abbreviations and definitions 
Osteogenesis Imperfecta (OI)  – inherited bone disease resulting in bone fragility and fractures. 
Mutation – a genetic mistake responsible for an inherited disease such as OI 
Collagen –  the fibrous protein constituent of bone, cartilage, tendon and other connective tissue.  
COL1A1 and COL1A2 –  human genes that encode for the type I collagen protein. 
FKBP10 – the gene that encodes the FK506-binding protein that acts as a molecular chaperone. 
Chaperones are proteins that assist in the folding, unfolding, assembly and disassembly of other larger 
molecules. 
SERPINH1 –  the gene that encodes for the HSP47 protein that is a collagen specific chaperone 
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SERPINF1 -   this gene encodes pigment epithelium-derived factor (PEDF),  a multifunctional protein and 
one of the strongest inhibitors of angiogenesis currently known in humans 
Osterix/SP7 – a putative master regulator of bone cell differentiation 
Osteoblast – a cell that contributes to the formation of bone 
CRAP, LEPRE1 and  PPIB – genes which encode for the cartilage associated protein, leprecan and 
cyclophilin B proteins. These proteins form a complex that helps process certain forms of collagen 
UKNEQAS – United Kingdom National External Quality Assessment Service 
EMQN – European Molecular Quality Network 
 
1.0 BACKGROUND  
Osteogenesis imperfecta (OI), also know as brittle bone disease, is an inherited connective tissue disorder characterized 
by low bone mass and increased bone fragility estimated to affect 1:15,000 to 1:20,000 individuals1-3. Clinical severity can 
be highly variable ranging from mild, with few or no fractures, to lethal. Recurrent fractures in children, affects approximately 
1 in 5 of those with a previous fracture, and is often accompanied by a reported family history of bone fragility. The scientific 
basis for excluding Osteogenesis Imperfecta (OI) in these children is poorly defined and relies heavily on clinical expertise.  
 In the majority of OI patients the disorder is caused by an autosomal dominant mutation in one of the two genes that 
encode the alpha chains of type I collagen, COL1A1 and COL1A2. Research to identify the cause of OI in families without a 
mutation in these two genes (~ 10% of families) has focused on individuals with lethal forms of the disease. The discovery of 
an intracellular collagen-modifying complex, which is encoded by the CRTAP, LEPRE1 and PPIB genes, led to the 
identification of severe autosomal recessive OI, with a proposed frequency of  ~ 5% in lethal OI4. However, these genes 
have not been reported to be associated with mild or moderate OI phenotypes. 
Recent evidence has shown that mutations in the osteoblast-specific transcription factor Osterix (Osx), encoded by the 
SP7 gene8-9, can also be associated with severe OI, with homozygous (Knock-out) mutations in this gene being reported7. 
Mutations in genes involved in the regulation of bone formation are known to be associated with a variety of bone diseases, 
for example homozygous mutations in LRP5 are associated with the severe osteoporotic disorder Osteoporosis 
Pseudoglioma (OPPG) whereas heterozygous mutations have a variable phenotype including Idiopathic Juvenile 
Osteoporosis (IJO) and reduced bone mass10. Heterozygous loss of function mutations in the CBFA1 gene (Runx2), another 
transcription factor which acts upstream of Osx, are associated with Cleidocranial Dyspasia11.  Autosomal recessive 
mutations in the type I collagen chaperone genes, FKBP1012--13 and SERPINH114 have also recently been reported to be 
associated with severe OI, as have mutations in SEPINF117.  
The prevalence and range of phenotypes associated with mutations in FKBP10, SERPINH1, SERPINF1 and SP7 is 
unknown and the phenotype of carriers of these mutations is not well documented.  However these findings identify a 
previously unrecognized molecular mechanism in the pathogenesis of OI. 
Hypothesis: Mutations in FKBP10, SERPINH1, SERPINF1 and SP7 are associated with mild/moderate OI phenotypes. 
This is a pilot study to identify genes associated with mild/moderate OI by investigating families with multiple affected 
individuals, previously shown to lack a mutation in the type I collagen genes, for mutations in FKBP10, SERPINH1, 
SERPINF1 and SP7.  Identification of mutations in any of these genes in this cohort would have implications for the 
strategies by which individuals thought to have OI are evaluated at a genetic level as well as influence the investigation of 
recurrent fractures in infancy and childhood. The identification of causative mutations provides information to patients and 
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their families about their condition and its inheritance as well as improving the diagnosis and possible treatment of future OI 
patients. 
Sheffield Diagnostic Genetics Service (SDGS) has been providing a national and international service for OI in 
collaboration with Professor Bishop, Professor of Paediatric Metabolic Bone disease, since 2002 based on analysis of the 
type I collagen genes with results published 5,15-16. A service for severe autosomal recessive OI by analysis of CRTAP, 
LEPRE1 and PPIB was developed and introduced in 2009.  The Laboratory has recently developed a comprehensive NCG 
funded service for Ehlers Danlos Syndrome as part of a portfolio of connective tissue disorders.  
 
2.0 STUDY OBJECTIVES AND PURPOSE 
The primary objective is to identify and recruit 20 individuals and their family members from Sheffield and 
around the UK who have been referred to the SDGS for investigation of a clinical diagnosis of 
mild/moderate OI and who are known from previous genetic analysis to lack a mutation in the type I 
collagen genes. This patient cohort will form the basis for analysis of the SERPINH1, SERPINF1, FKBP10 
and SP7 genes. 
By analysis of these genes we aim to identify novel mutations causing mild/moderate OI and improve the 
strategies by which children with recurrent fractures should be evaluated. A better understanding of the 
pathways and molecular mechanisms of OI has implications for treatment, genetic counselling and family 
studies.  At present these families cannot receive the same standard of genetics counselling or make 
informed reproductive decisions without knowledge of the mutation responsible for their disease.  
If the research is productive we plan to undertake further studies to ascertain the incidence of mutations in 
these genes more generally in the OI population and a possible role for these genes in influencing the 
phenotype of individuals with an identified type I collagen mutation would be investigated. Children with low 
bone mass and recurrent fractures could also be studied for mutations and polymorphisms in these genes. 
It is not envisaged that a mutation will be identified in these new genes in all patients recruited, but a well 
characterised group of families will have been compiled which would be suitable for further studies to 
identify novel genetic causes of OI. 
 
3.0 STUDY DESIGN 
The study design is represented in figure 1. Clinical data supplied with the initial referral for type I collagen 
gene analysis will be retrospectively reviewed by the chief investigator for all mutation negative individuals. 
Any available pedigree information detailing further affected family members will also be reviewed. Those 
with a clear phenotype and strong family history will be identified and invited to participate in the study 
through their local referring Clinical Genetics Service. 
Consent for genetic investigation for OI and storage of a DNA sample will have been obtained prior to 
previous analysis of the type I collagen genes. Recruitment will involve obtaining informed consent for 
further genetic analysis of the stored DNA sample for the SP7, FKBP10, SERPINF1 and SERPINHI genes 
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in this study. If there is insufficient DNA or the DNA is of poor quality it may be necessary to obtain a blood 
sample (2-5mls EDTA) that would be obtained through the referring Clinical Genetics Service at a routine 
clinic appointment. 
An extensive pedigree identifying index cases and affected plus unaffected family members should already 
be available in the patient’s records but may require further clarification by the referring clinician, and will be 
used to provide information about possible modes of inheritance of the clinical phenotype in the family.  
Analysis of DNA by sequencing the coding region and intron/exon boundaries of the candidate genes will be 
performed at the SDGS for each index case. Changes identified will be sought on locus specific database 
and dbSNP to identify previously reported variants. In silico analysis using amino acid conservation and 
splice prediction tools to indicate possible pathogenicity and to aid in prioritising further analysis will be 
performed. Family members will be investigated for any putative mutations identified to determine 
inheritance/penetrance. 
At the end of the study findings will be returned to the local Clinical Genetics Services for dissemination to 
the participants.  
There are no therapeutic interventions in this study and it is not envisaged that participants will withdraw 
from the study following initial recruitment. However, if for any reason patients decide to withdraw a 
discussion will be held regarding retaining/destroying samples and records already collected.  
Primary and Secondary Endpoints 
The primary end point will be recruitment of 20 index cases with mild/moderate OI without a mutation in the 
type I collagen genes.  
The secondary endpoint will be completion of analysis of SP7, SERPINH1, SERPINF1 and FKBP10 for 
index patients and their families.  
General Information 
The risk to patients and their families is limited to one standard venepuncture, if required 
The referring Clinical Geneticist, or their nominated genetic counsellor, will discuss the study with patients 
and their family and take consent. Participation in this study will not influence patient treatment. 
 
4.0 SELECTION OF PARTICIPANTS  
Individuals will be identified for the study if they have previously been referred to the Sheffield Diagnostic 
Genetics Service for diagnostic analysis of the type I collagen genes. 
Inclusion Criteria 
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Individuals with a clinical diagnosis of mild/moderate OI and a strong family history but without a previously 
identified type one collagen gene mutation will be invited to participate. 
Exclusion Criteria 
Individuals without a clear clinical phenotype will be excluded as will those where analysis has been 
performed to exclude a diagnosis of OI in cases of suspected non-accidental injury (medico-legal testing).  
 
5.0 PARTICIPANT RECRUITMENT 
Consultant Clinical Geneticists who have referred individuals eligible for the studied will be contacted with 
information on the study. Consultants will be asked to discuss the study with relevant patients and carers 
who are interested in participation either directly or through their Genetic councelling team. Patients who are 
interested in participation will be sent an invitation letter and age appropriate patient information sheet 
describing the study and its objective. After the patient (and/or carer) has had the opportunity to discuss the 
study with the referring clinician they will be given up to 6 weeks to decide if they wish to participate. 
Consent for diagnostic genetic testing for OI and storage of DNA samples will have previously been 
obtained by the referring Clinical Genetics department prior to analysis of the type I collagen genes. 
Recruitment will involve obtaining consent for genetic analysis for the purpose of research and will be 
obtained by the clinician responsible for their care. 
Where non-English speakers are invited to participate, standard arrangements used by Clinical Genetics to 
communicate with individuals and their families will be followed.  
There will be no payment made for participating in this study. 
Withdrawal of participants 
It is not envisaged that withdrawal from the study will happen frequently. However, if a patient decides to 
withdraw from the study, all analysis will be halted. Clarification will be sort from the patient about 
information and samples to be retained/destroyed. A further eligible patient would be invited to participate in 
the study. Clinical care of any participant would not be affected by withdrawal from the study.   
Data collection 
A list of data to be collected and its source is shown in table 1.  
The Chief Investigator will collate data into the research specific StarLims database.  
 
6.0 DATA HANDLING AND RECORD KEEPING 
290 
 
The chief investigator will be responsible for the data collection, recording and quality. 
Data will primarily consist of paper copies of referral forms, clinical and pedigree data. These will be stored 
in swipe card access controlled offices in the SDGS. All data will be scanned into the research specific 
Starlims Genetics database in accordance with standard operating procedures. Paper copies will then be 
destroyed in accordance with standard operating procedures.  The Starlims database is secure and 
password protected and will be accessed by the research team only. The database is stored on a network 
computer drive which is password protected. 
Laboratory worksheets, which record details of genetic analysis undertaken for the study, will be retained 
and stored as per standard operation procedures.  Electronic records of DNA sequence will be generated 
during the course of the study.. 
 
STANDARD STATEMENT ON DATA PROTECTION 
Data will be collected and retained in accordance with the Data Protection Act 1998. 
 
 
STANDARD STATEMENT ON STORAGE OF RECORDS 
Study documents (paper and electronic) will be retained in a secure location during and after the 
study has finished.  All source documents will be retained for a period of 5 years following the end 
of the study.  Where study related information is documented in the medical records – those 
records will be identified by a “Do not destroy before dd/mm/yyyy” label where date is 5 years after 
the last patient last visit. 
 
 
7.0 ACCESS TO SOURCE DATA  
The chief investigator will be the custodian of the data. Access to all data will be restricted to members of 
the research team.  
The sponsor will permit monitoring and audits by the relevant authorities, including the Research Ethics 
Committee and the Medicines and Healthcare products Regulatory Agency (MHRA).  The investigator will 
also allow monitoring and audits by these bodies and the sponsor, and they will provide direct access to 
source data and documents.   
 
8.0 STATISTICAL ANALYSIS 
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This study is focused on finding changes in the SP7, SERPINH1, SERPINF1 and FKBP10 genes. No 
statistical analysis is required.  
 
9.0 SAFETY ASSESSMENTS 
 
A few participants may have a venous blood sample drawn. This may result in pain/discomfort at the site of 
venupunture. Some participants may have subsequent bruising. These events will not require reporting. 
Monitoring 
The study will be monitored and audited in accordance with the Monitoring Standard Operating Procedures 
of the Clinical Research Support Unit.  All study related documents will be made available on request for 
monitoring and audits by the Sponsor, the relevant Research Ethics Committee and for inspection by the 
MHRA or other licensing bodies. 
The SDGS participates in UKNEQAS and EMQN quality assessment schemes. 
 
10.0 ETHICAL CONSIDERATIONS 
The study will be conducted in compliance with a Research Ethics Committee favourable opinion, including 
any provisions for Site Specific Assessment, and local Research and Development approval.  The study will 
also be conducted in accordance with the International Conference for Harmonisation of Good Clinical 
Practice (ICH GCP), and the Research Governance Framework for Health and Social Care (2nd Edition). 
Index cases recruited will already have had genetic analysis undertaken, but without the identification of a 
type I collagen gene mutation, so may be disappointed. Participants may be pleased to have the opportunity 
to possibly find out the cause of the OI in their family. 
Each participant will be bled, the venepuncture may cause transient discomfort and bruising in a small 
number of cases. Where appropriate paediatric blood sampling equipment will be used to minimise this. 
The patient and their family members will be asked about family relationships to establish or confirm a 
previously ascertained pedigree. Where relationships have broken down, this may represent unwelcome 
intrusion into the family. 
DNA will be prepared and stored for several years. Samples will be securely stored and used only to seek 
mutations responsible for OI in the patients and their families. This study is expected to produce a cohort of 
well characterised patients and their family members, and novel mutations responsible for their OI will be 
identified in only a proportion, therefore a further application for funding is expected to follow. Participants 
will be asked for permission to store and use samples over several years and not just for this initial study, 
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however if patients do not consent to have their samples stored, then samples will be destroyed after the 
initial testing in this study.  
Information on the patients and their family members will be held on computer. To ensure confidentiality, 
access to this information will be restricted to the study team.   
Results of the study will be presented at relevant scientific meetings and in peer-reviewed scientific journals. 
Participants will be consented for publication at recruitment. The data will be anonymised prior to any 
publication.  
 
11.0 FINANCE AND INDEMNITY 
 
This is an NHS sponsored study.  For NHS sponsored research HSG (96) 48 reference no. 2 refers.  If there 
is negligent harm during the study when the NHS body owes a duty of care to the person harmed, NHS 
Indemnity will cover NHS staff, medical academic staff with honorary contracts and those conducting the 
study.  NHS Indemnity does not offer no-fault compensation and is unable to agree in advance to pay 
compensation for non-negligent harm.  Ex-gratia payments may be considered in the case of a claim. 
 
12.0 REPORTING AND DISSEMINATION  
Throughout the project, where significant findings are made, they will be presented at relevant national and 
international meetings (eg British Society for Human Genetics, International Conference on Osteogenesis 
Imperfecta). Manuscripts on the study findings will be submitted to relevant international journals. Mutations 
identified will be submitted to the international OI mutation database16, the most relevant means of 
communicating genetic analysis results with other laboratories undertaking OI genetic analysis.  
For any mutations identified, laboratory analysis will be established and validated to NHS diagnostic 
standards (if not already) and the mutation reported to the patient’s Clinician, thus any novel mutations will 
be added to the laboratories’ diagnostic repertoire shortly after having been identified.  
The results of the study will also be disseminated on the Trust R&D website and in the R&D newsletter. 
 
 
 
 
 
293 
 
TABLES, FIGURES AND REFERENCES 
Table 1 Data items to be collected (section 5.0). 
Data item Comment Source of data 
 
Full Name Allows results of previous genetic analysis for OI to be 
traced and confirmed 
Recruiting centre 
Date of birth Part of unique patient identifier Recruiting centre 
Genetic 
Councelling 
Family code 
Numeric code, used to identify index case and family 
members 
Recruiting centre 
Clinical 
examination 
findings 
Presence or absence of extra-skeletal manifestation of 
OI 
Obtained from patient records by 
treating clinician 
Fracture 
history 
Number, age range for fractures and type of fractures 
sustained. 
Obtained from patient records by 
treating clinician 
Extent of 
previous OI 
analysis 
Extent of previous OI analysis including; gene tested 
and methodology eg MLPA, DNA, RNA, collagen 
species analysis. 
 
Copies of reports sent to 
referring clinician 
Pedigree Hand drawn or transferred to computer using Cyrillic 
software during previous interview prior to investigation 
of type I collagen genes. 
Obtained from patient records by 
treating clinician. 
Results of 
FKBP10, 
SERPINH1, 
SERPINF1, 
and SP7 
gene analysis 
Results for sequence analysis of each gene. SDGS data generated during the 
study.  
Result of in-
silico analysis 
Extent and results of all in-silico analysis performed for 
any unclassified variant identified. 
Data generated during the study. 
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APPENDICES 
 
Figure 1 Schematic diagram of study design 
 
 
Retrospective review of patients referred to 
SDGS for COL1A1 and COL1A2 analysis
Report findings
Identify eligible patients and 
contact referring clinician
Invite patient to participate
In-silico analysis
Extract DNA. 
Analysis of FKBP10, SERPINH1,SERPINF1 and SP7
Obtain consent and samples from 
appropriate family members
Obtain consent.Collect blood sample
Segregation/penetrance analysis
Variant identified
NO
YES
Putative mutation
YES
NO
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K. DDD complementary research proposal submission form 
DDD COMPLEMENTARY RESEARCH PROPOSAL SUBMISSION FORM 
Proposal # [to be filled in by central office] 
Proposed by  Rebecca Pollitt/ Meena Balasubramanian 
Research Group Sheffield Diagnostic Genetics Service/ Sheffield Clinical Genetics Service 
Sheffield Childrens NHS Foundation Trust 
Western Bank 
Sheffield 
S10 2TH 
Contact details Rebecca.pollitt@sch.nhs.uk/ Meena.balasubramanian@sch.nhs.uk 
Date 30.1.13 
Title of project Novel molecular mechanisms leading to Osteogenesis Imperfecta 
Brief description of project 
 
 
 
 
We aim to identify novel candidate genes for mild/moderate OI in 
patients without mutations in the type I collagen genes. 
 
How required subset of samples will be identified (e.g. specific 
HPO terms or codes) 
We will search the DDD database for phenotypes using the 
following HPO terms: 
 Abnormal susceptibility to fractures 
 Fractures of the long bones 
 Fractures of vertebral bodies 
 Generalised osteoporosis with pathologic fractures 
 Increased fracture rate 
 Increased susceptibility to fractures 
 Recurrent fractures 
 Pathologic fractures 
 Vertebral compression fractures 
 Generalized osteopenia 
 Generalized osteopenia with pathologic fractures 
 Moderate generalised osteoporosis 
 Severe osteoporosis 
 Osteopenia 
 Spontaneous fractures 
 
 
The type of genetic data required (e.g CNVs, exome variants) 
 
We will assess the phenotype in each case and review the copy number 
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and exome data. Any variants identified will be assessed against the list 
of genes known to be involved in susceptibility fractures and those in 
pathways involved in skeletal development and bone homeostasis. 
 
The level of data required (e.g. variant files, raw data files) 
Variant files with array CGH and exome sequence results 
 
 
Will the project require 
additional local ethical 
approval? (e.g. will additional 
investigations be required that 
are outside standard clinical 
care) 
No 
Will data be shared with 
investigators outside DDD? 
(i.e. investigators outside of the 
group of a DDD researcher) 
Yes, possibly 
If yes, what type of data and with 
whom? 
Nationally-commissioned OI service via Dr Balasubramanian 
 
 
Other DDD researchers who 
might be interested in this 
proposal 
Not at this moment 
Additional comments [any additional information you feel is relevant] 
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L. Confirmation of Ethical Approval for Target Exomes 
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302 
 
 
 
303 
 
M. NBAS Gene Dossier Approved by UKGTN 
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305 
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